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 2
1 Introduction 
 
A lot of publicity has been rightly accorded to the Human Genome Project, which has 
now been completed.1 The success of this work has been hailed as a breakthrough that 
will lead to a new era in medicinal research. However, it is important to appreciate that 
this knowledge forms only the tip of the iceberg. As proteins ‘speak’ for DNA and 
phenotypes of all living organism on earth, the study of the proteins has become the more 
significant task in this post genomic era. This is far more challenging than understanding 
the genome, because of the complexity of interactions that can take place between 
proteins. Moreover, the structure and function of proteins present in a cell depend on the 
type of cell. In the diseased state, the structure and hence the function of the proteins can 
be altered. Currently and even in the future, drugs that interact with proteins will remain 
the most important target in medicine and provide treatment for ailments such as cancer, 
pain, depression, asthma and many other problems. 
  
The race is now on to analyze the structure and function of proteins, many of which are 
completely new to science, and to see whether they can act as novel drug targets for the 
future. This is not an easy task, and it is made all the more difficult by the fact that it is 
simply not possible to derive the structure of proteins based on the known gene sequences 
alone. This is because different proteins can be derived from a single gene, and proteins 
are often modified following their synthesis (post-translational modification).  
 
The analysis of secondary and tertiary structure of proteins is painstaking work. If the 
protein can be crystallized, it is then possible to determine its structure by X-ray 
crystallography. However, not all proteins can be crystallized, and even if they are, it is 
possible that the conformation in the crystal form is different from that in solution. In this 
aspect, NMR spectroscopy has become an important complementary tool to X-ray 
crystallography in identifying the structure of proteins, especially in the study of 
membrane proteins that cannot be crystallized easily.2    
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2 Background 
 
2.1.1 Cancer and oncogenes 
 
Cancer is a class of diseases or disorders characterized by uncontrolled division of cells 
and the ability of these cells to spread, either by direct growth into adjacent tissue through 
invasion, or by implantation into distant sites by metastasis (where cancer cells are 
transported through the bloodstream or lymphatic system). Cancer may affect people of 
all ages, but risk tends to increase with age. It is one of the principal causes of death in 
developed countries. In the USA and other developed countries, cancer is presently 
responsible for about 25% of all deaths. On a yearly basis, 0.5% of the population is 
diagnosed with cancer.3  
 
Cell division or cell proliferation is a physiological process that occurs in almost all 
tissues. Normally the balance between proliferation and apoptosis (programmed cell 
death) is tightly regulated to ensure the integrity of organs and tissues (Figure 1A). 
Cancer cells avoid apoptosis and continue to multiply in an unregulated manner. One of 
the most profound features of cancer cell is the growth properties in laboratory culture 
dish. Tumor cells grow in multilayers, with higher cell densities, and they continue to 
grow even when the surface of the culture dish is completely covered (Figure 1B). The 
reason of this uncontrolled cell growth is normally attributed to the mutation or damage 
of genes. Cancer is, ultimately, a disease of genes.  
 
                    
 
 
Figure 1. A) Normal cell division and apoptosis of damage cells 2 leading to cell death 1; B) 
Non-stop division of cancer cells4  
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Cancer formation is initiated via the conversion of normal cellular genes, called proto-
oncogenes, into oncogenes. This results in the alteration of growth properties that is 
characterized as oncogenic transformation. The biological function of proto-oncogenes is 
not to cause cancer. Rather these genes encode proteins that are part of the regular 
process of signal transduction pathways, which control normal cellular growth and 
differentiation.5  
 
Cellular growth, division and differentiation are all controlled by signal transduction 
pathways triggered mainly by proteins called growth factors. Many growth factor 
receptors are membrane spanning proteins with protein tyrosine kinase activity. Binding 
of the ligand (growth factor) to its receptor leads to activation of the tyrosine kinase 
activity and the subsequent activation of a number of cytoplasmic proteins. These 
proteins form a cascade in which the activation of one molecule causes activation of its 
downstream effector until the final target is reached. 
                   
Oncogenic transformation of cells can be caused by constitutive activation of these 
pathways in a number of ways. For example, over- or inappropriate expression of a 
growth factor can result in inappropriate activation of a signal transduction pathway 
causing cells to grow and divide under conditions where they would not otherwise divide. 
Mutation of an intermediate component in the cascade, which results in the protein 
getting accumulated in its activated form results in a pathway whose output is always 
"on" and is independent of the original extracellular signal. This also leads to 
uncontrolled growth of cells. 
 
One component of the signal transduction cascade involved in growth regulation is the 
protein encoded for by the Ras (rat sarcoma) gene.6 
 
2.1.2 Ras proteins and cancers 
 
 
Ras proteins are the prototype members of a large family of ~ 21 kDa GTP-regulated 
molecular switches for signaling pathways that modulate many aspects of cell behavior, 
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including proliferation,7 differentiation,8 motility9 and death.10 The Ras superfamily of 
GTPases can be subdivided into the Ras, Rho, Rab, ARF, and Ran subfamilies. The 
tumor oncoproteins H-Ras, K-Ras, and N-Ras are the founding members of a larger 
family of at least 35 related human proteins.11  
 
Ras genes were first identified and characterized as transduced oncogenes in the Harvey 
and Kirsten strains of acutely transforming retroviruses.12 Mutationally activated forms of 
H-Ras, K-Ras, and N-Ras were subsequently isolated from human tumor cells using 
transfection-based assays. 
 
The H-, N-, and K-Ras proteins are ubiquitously expressed in mammalian cells. About 
30% of human tumors exhibit activating mutations in one or more of the Ras genes, and 
of these, K-Ras is most frequently found to be mutated (about 85% of the total), followed 
by N-Ras (15%) and H-Ras (less than 1%).13 High rates of K-Ras-activating mutations 
have been detected in non–small cell lung cancer (15 to 20% of tumors)14, colon 
adenomas (40%)15, and pancreatic adenocarcinomas (95%)16. More than half of the most 
malignant thyroid tumors, characterized as poorly differentiated or undifferentiated, 
harbor a mutation in K-Ras, H-Ras, or N-Ras. In addition to mutational activation, Ras 
genes are amplified or over-expressed in some tumors. In contrast, Ras mutations are 
rarely seen in some neoplasms, such as breast cancer (< 5%). Despite this low frequency, 
there is considerable experimental evidence that aberrant Ras activation and signaling 
may promote breast cancer formation.17 
 
2.1.3 Upstream ligands and downstream effectors of Ras proteins 
 
Ras proteins require binding of GTP to develop functional activity. Switching between 
the active GTP-bound and the inactive GDP-bound state is regulated by binding to the 
guanine nucleotide.18 Although Ras proteins possess intrinsic GTPase and GDP/GTP 
exchange activities, they are too low to account for the rapid and transient GDP/GTP 
cycling that occurs during mitogenic stimulation. Instead, a complete model for Ras 
function includes regulatory proteins that control the GTP/GDP cycling rate. These 
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regulatory proteins include GTPase activating proteins (GAPs), which stimulate 
hydrolysis of bound GTP to GDP, and guanine nucleotide exchange factor proteins 
(GEFs), which promote the replacement of bound GDP with GTP (Figure 2). 
 
 
 
 
 
Figure 2. Activation and deactivation of Ras by GAP and GEF19. Ras GTP is deactivated by 
GAP and Ras GDP is activated by GEF.  
 
Active Ras-GTP induces a wide variety of cellular processes, such as transcription, 
translation, cell-cycle progression, apoptosis or cell survival, through direct interaction 
with various effectors (Figure 3). One of the best characterized Ras signaling pathways is 
the Raf/MEK/ERK pathway.20 The outcome of this signaling pathway can be either anti- 
or proapoptotic depending on the circumstances, thus determine the life or death of the 
cell. As shown in Figure 3, through interaction with Raf, Ras activates the MEK kinases 
and, in turn, the ERK kinases. ERKs phosphorylate cytoplasmic targets such as Rsk, 
Mnk, and phospholipase A2 which are then translocated to the nucleus, where they 
stimulate the activity of various transcription factors and cell-cycle progression. 
 
It has recently been found that Ras homologues vary in their ability to activate the key 
effectors Raf and PI3K, with K-Ras being more effective as a recruiter and activator of 
Raf to the plasma membrane than does H-Ras, and H-Ras being more effective as an 
activator of PI3K.21 This indicates that activation of different Ras isoforms can have 
distinct biochemical consequences for the cell. Furthermore, it has been suggested that 
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the subcellular distribution of Ras proteins could be related to differential participation of 
various Ras homologues in signaling process.22  
 
 
 
 
Figure 3. Ras signal transduction cascade of different downstream effectors23. Ras proteins 
regulate many biological processes such as transcription, cell-cycle progression and etc.  
 
 
2.1.4 CAAX modification and membrane targeting of Ras proteins  
 
 
An important question for the studies of Ras is whether the ubiquitously expressed, 
almost identical Ras homologues have distinct functions. It has long been assumed that 
due to the high degree of sequence homology (>90%) shared by the three main expressed 
isoforms H-Ras, N-Ras and K-Ras, the identical sequences are functionally redundant. 
This view is reinforced by observations that all Ras homologues share common sets of 
downstream effectors, upstream GEFs and GAPs.  
 
It was until recently that the biological differences in the cellular requirements of these 
Ras homologues which have identical sequences covering the effectors, exchange factors 
and guanine-nucleotide-binding domains were detected, where signaling through each 
Ras homologue can result in distinct biochemical outcomes.24  
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The only region of the Ras homologues that exhibits significant sequence divergence is 
the final 24 residues of the protein, known as the hypervariable region (HVR), which 
exhibits approximately 10-15% conservation as compared with > 90% similarity over the 
N-terminal of 165 residues. HVR can be divided into two domains: the membrane-
targeting domain and the linker domain. The membrane-targeting domain comprises the 
C-terminal CAAX motif, common to all Ras proteins plus a second signal sequence. The 
CAAX box (C = cysteine, A = aliphatic amino acids, X = serine or methionine) is 
sequentially modified after translation to render it more hydrophobic. The second signal 
sequence consists of a polybasic stretch of six lysine residues (175-180) in K-Ras, or 
palmitoylation of cysteine 181 and farnesylation of cysteine 186 in N-Ras, palmitoylation 
of cysteine 181 and 184, and farnesylation of cysteine 186 in H-Ras (Figure 4).25   
 
 
 
Figure 4. Amino acid sequences and lipid modification of the C-termini of different Ras 
homologues.26 
 
The post-translational modification of the CAAX motif is common to all Ras proteins. 
Figure 5 shows the schematic processing of post-translational modification of the CAAX 
motif after the biosynthesis of Ras proteins. First, protein farnesyltransferase (FTase), a 
cytosolic enzyme, attaches a farnesyl group to the cysteine residue of the CAAX motif. 
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Following that, an endopeptidase, Rce1 (Ras and a-factor converting enzyme) located on 
the cytosolic surface of the ER, removes the AAX tripeptide.27 The α-carboxyl group on 
the carboxy-terminus of the farnesyl cysteine is then methylated by isoprenylcysteine 
carboxyl methyltransferase (Icmt).28 K-Ras is more efficiently methylated than H-Ras or 
N-Ras.29 Finally, after methylation, Ras proteins take one of two routes to the cell 
surface, which is dictated by a second targeting signal that is located immediately after 
the amino-terminal of the farnesylated cysteine.30 H-Ras and N-Ras undergo 
palmitoylation on cysteine residues in their HVRs and enter the exocytic pathway, 
trafficking through the Golgi to the plasma membrane. In contrast, K-Ras, which has a 
polylysine sequence instead of cysteine residues, bypasses the Golgi and reaches the 
plasma membrane by an as-yet-unknown mechanism.31 The correct processing of the 
CAAX motif is essential for the efficient forward transport of Ras, because deletion of 
Rce1 or Icmt impairs the ability of Ras to engage both trafficking pathways, which 
results in mislocalization to the cytosol.32, 33   
 
 
 
Figure 5. Schematic processing of post-translational modification of the CAAX motif after the 
biosynthesis of Ras proteins. 6b 
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Farnesylation is an irreversible process and stable modification of Ras. However 
palmitoylation, which results in the formation of a labile thioester bond is reversible in 
cells. At present, three palmitoyltransferase Akr1, Erf2 and Ykt6 have been identified to 
palmitoylate Ras proteins in yeast Saccharomyces cerevisiae.34  
 
2.1.5 Microlocalization of Ras proteins at the plasma membrane 
 
Once Ras proteins have been delivered to the plasma membrane, their spatial 
microlocalization is dictated by a complex interplay between the Ras protein and the 
plasma membrane. Critical determinants of Ras microlocalization include the lipid 
anchor, the adjacent hypervariable region, and properties of the plasma membrane such 
as phospholipids/cholesterol composition of the membrane.  
 
The plasma membrane comprises a complex mosaic of microdomains.35 The best 
characterized of these are lipid rafts and caveolae, although it has been proposed that 
there are other lipid-based microdomains. For the lipid anchor, palmitoylated peripheral 
membrane proteins can associate with lipid rafts because the saturated palmitoyl chain 
packs well into the liquid order raft structure, whereas unsaturated, branched chain prenyl 
groups stays mostly in non-raft domains. This division of the plasma membrane into raft 
and non-raft compartments clearly presents a framework for differential lateral 
segregation of the Ras isoforms. As shown in Figure 6, K-Ras is associated 
predominantly with non-raft plasma membrane, irrespective of its activation state. H-Ras 
is distributed approximately equally between raft and non-raft plasma membrane, but 
GTP loading increases the fraction of H-Ras in non-raft membrane. It is important to 
stress that H-Ras and K-Ras are highly mobile in the plasma membrane, so the 
localizations shown need to be thought of more in terms of residence time. 
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Figure 6. Microlocalization of Ras proteins in different phospholipids domains. 33  
 
2.1.6 Dynamic regulation of Ras microlocalization and activity 
 
Mature, fully processed Ras proteins that reached the plasma membrane were believed to 
remain on this compartment until degraded. However, two recent studies have uncovered 
a dynamic palmitoylation pathway that regulates H- and N-Ras trafficking. This pathway 
operates constitutively and is essential for maintaining the correct Ras localization.36 
 
This dynamic palmitoylation of Ras proteins results in a constant flux of the proteins 
between endomembranes and the plasma membrane. Palmitoylation at Golgi membranes 
directs Ras to the plasma membrane, whereas depalmitoylation at the plasma membrane 
releases the protein into the cytosol, allowing it to rebind to Golgi membranes, where it is 
once again palmitoylated and traffics to the plasma membrane (Figure 7). 
 
This mechanism confers high accuracy in protein localization, because any 
mislocalization into other membrane compartments is prevented by the de-/re-
palmitoylation cycle that continuously resets the systems. The precise localization is lost 
when the palmitate thioester is replaced by a thioether bond which cannot undergo 
dynamic palmitoylation. This finding suggests that the reversible cycle of de-/re- 
palmitoylation is crucial for allowing Ras proteins (H-Ras and N-Ras) to be properly 
localized in the cell.  
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Figure 7. Dynamic palmitoylation of Ras proteins. Ras proteins are depalmitoylated at plasma 
membrane and palmitoylated at Golgi.  
 
The discovery of the highly dynamic nature of Ras membrane interaction has changed the 
perception of compartmentalized Ras signaling. In addition to the existence of different 
signaling and regulatory environments in a cell, continuous shuttling of Ras between 
plasma membrane and Golgi has provided yet another additional regulatory mechanism. 
Its signaling activity from a particular membrane system is therefore not simply regulated 
by the timing of local GAP/GEF recruitment but also by the dynamics of its inter-
membrane trafficking. 
 
Different membrane compartments, such as the plasma membrane and Golgi, supply 
unique sets of GAPs and GEFs and downstream effector pathways. The three Ras 
homologues have similar preferences for effector proteins or regulators. In a given 
compartment, all Ras homologues are thus subject to the same regulation and encounter 
the same effectors. What makes Ras signaling distinct between various homologues is the 
differential access to and residence time in a particular membrane compartments. The 
stability of palmitoylation (H-Ras and N-Ras) or controlled membrane desorption (K-
Ras) allows fine-tuning of the onset, duration and amplitude of signaling from specific 
compartments.  
SO
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2.2.1 Solid-state nuclear magnetic resonance (NMR) spectroscopy 
 
Determining three-dimensional structures and gaining information on the dynamics of 
membrane-associated proteins are fundamental to the understanding of many biological 
functions. Approximately 30% of all genes in a genome code for integral membrane-
associated proteins, such as ion channel and receptor proteins, which are involved in a 
wide range of functional activities essential for the cell. Hence, knowledge of their 
structural and dynamical information is therefore an essential in deciphering the 
information from the various genome projects.  
 
The two principal experimental methods, X-ray crystallography and solution NMR 
spectroscopy, are complementary to each other for the study of proteins structure and 
dynamics, and have contributed more than 98% of protein structures to the Protein Data 
Bank (85% and 13% of structures are determined by X-ray and NMR spectroscopy, 
mostly solution NMR spectroscopy, respectively). However, the fact that only around 1% 
of the protein structures in the Protein Data Bank correspond to membrane-associated 
proteins reflects the significant challenge posed by this class of proteins.    
 
The structure determination of membrane-bound proteins remains difficult even with 
advanced methodologies. X-ray crystallography analysis is hampered by the difficulty in 
preparing high-quality crystals. Solution NMR analysis of membrane-associated proteins 
is very difficult due to the slow tumbling motion of the large membrane complexes 
causing the severe resonance line broadening effect. Thus solution NMR analyses of 
membrane proteins have been largely conducted under membrane-mimicking 
environments of micelles, and less in water condition. The information obtained under 
these conditions, however, may not reflect the real structures in the membrane-bound 
states.  
 
In contrast to the solution NMR, solid-state NMR has several advantages in determining 
the structures and dynamics of membrane-bound proteins. Application of solid-state 
NMR is not limited by slow molecular motions of these large protein complexes. 
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Structures of numerous membrane-associated proteins have been determined by magic-
angle spinning (MAS) method. Solid-state MAS NMR has been used for structural 
analysis of a small uniformly isotope-labeled membrane protein and for signal 
assignments of semi-selectively labeled membrane proteins. Further, solid-state NMR 
techniques provide the unique possibility to study molecular dynamics in a broad window 
of correlation times.  
 
2.2.2 Solid state magic-angle spinning   
  
Magic-angle spinning is used routinely in the vast majority of solid-state NMR 
experiments, where its primary task is to remove the effects of chemical shift anisotropy 
(chemical shifts due to different orientations of a nucleus and its electron cloud with 
respect to the external magnetic field B0) and to assist in the removal of heteronuclear 
dipolar coupling effects. It is also used to narrow lines from quadrupolar nuclei (nuclei 
with spin quantum number ≥ 1, such as deuterium), and is increasingly the method of 
choice for removing the effects of homonuclear dipolar coupling from NMR spectra.   
 
In solution NMR spectra, effects of chemical shift anisotropy, dipolar coupling, and etc., 
are rarely observed. This is because the rapid isotropic tumbling of the molecules in a 
solution averages the molecular orientation dependence of the transition frequencies to 
zero on the NMR timescale, i.e. the rate of change of molecular orientation is fast relative 
to the magnitude of the chemical shift anisotropy, dipole-dipole coupling, and etc., in 
frequency units. 
 
Spinning of a sample in the magnetic field during an NMR experiment leads to a 
reduction (scaling) of the anisotropic interaction tensor. The interaction is scaled by the 
second Legendré polynomial ½(3cos2θ-1), where θ is the angle between the spinning axis 
and the external magnetic field. If this angle is 54.7°, the second Legendré polynomioal 
equals zero and the anisotropic interaction vanishes, the result is a narrow NMR line and 
a set of spinning sidebands occurring at integer multiples of the spinning frequency. 
Magic-angle spinning removes the effects of chemical shielding anisotropy. In 
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combination with high power decoupling heteronuclear, dipolar couplings are averaged 
out, which provides spectra with better resolution. In addition to the magic-angle, another 
factor which determines the resolution of spectra is the spinning speed. In order for 
magic-angle spinning to reduce a powder pattern to a single line at the isotropic chemical 
shift, the rate of the sample spinning must be around a factor of 3 or 4 greater in 
comparison to the anisotropy. Figure 8a shows the broad NMR resonance of 13C at a 
static sample. Figure 8b and 8c illustrate the effect of magic-angle spinning at 5 kHz and 
10 kHz respectively. At higher spinning rate, the spectrum consist of fewer spinning 
sidebands, which further increases the resolution of the spectrum and provides a better 
resolution-to-noise ratio. At present, spinning rates of up to 50 kHz are achievable, with 
30 kHz being routine on a modern spectrometer.37  
 
 
 
Figure 8. Effect of magic-angle spinning on the 13C NMR spectrum of powdered Gly; a) The 
static NMR spectrum of Gly is characterized by two broad anisotropic line shapes, Magic angle 
spinning at b) 5 kHz and; c) 10 kHz removes the anisotropic line shapes and yields narrow lines 
plus a set of spinning side bands.38 
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2.2.3 2H quadrupole coupling 
 
 
An interaction that is never directly seen in liquid spectra but can dominate solid-state 
spectra is the quadrupole interaction. Figure 9A shows the energy level scheme for a spin 
quantum number I = 1 nuclei, such as deuterium, 2H. Nuclei with I > ½ behave as if their 
electric charge distribution is nonspherical. This uneven distribution of electric charge 
produces two different energy states under magnetic field B0. In 2H powder NMR spectra 
of static samples, the doublet arising from the two possible transitions: +1↔ 0 and 0 ↔ -
1 (Figure 9B). Because in a powdered sample, a spherical distribution of the spins with 
respect to the laboratory frame occurs, so called Pake patterns are observed, because the 
position of an NMR line in the spectrum depends on the orientation of the respective 
crystallite. Magic-angle spinning can also be used to narrow the line broadening effect 
arising from quadrupolar coupling.   
 
νο
νο
νο+ ∆ν/2
νο− ∆ν/2
No quadrupole
interaction
With quadrupole
interaction
B0
+1
0
-1
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B
 
 
Figure 9. Nuclear spin/electric quadrupolar coupling. A) Energy levels of nuclei with spin 
quantum number I =1; B) Splitting pattern in the absence and in the presence of the quadrupolar 
interaction. 
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It has been realized that quadrupolar splitting features arising from nuclei with spin 
quantum number I > ½, especially deuterium, is a powerful nucleus for studies of 
molecular dynamics in solids, polymers, lipids and liquid crystals. The moderate 
quadrupole-coupling constant, in the range 140-220 kHz in organic compounds, and 
moderate width of Pake patterns, in the range 105-165 kHz make this nucleus relatively 
easy to deal with experimentally. Moreover, the lineshapes are sensitive to molecular 
motions with correlation times of the order of ~100 ps to ~100 µs. Furthermore, 2H 
exchange experiments can also provide information about millisecond correlation time 
motions. Because of this, 2H has been extensively used in motional studies, primarily via 
lineshape analyses, but also through relaxation time measurement. Normally in 2H 
quadrupolar measurement, the larger coupling constant always indicates the presence of 
atoms in more rigid condition and vice versa.  
 
2.2.4 Relaxation measurement 
 
NMR possesses another facet, the nuclear relaxation times (T1, spin lattice relaxation and 
spin-spin relaxation T2, respectively), which allow measurement of dynamic parameters 
such as correlation times, activation energies, and etc. All nuclear relaxation processes 
are induced by fluctuating nuclear spin interactions, with the fluctuations arising from 
molecular motion. Relaxation describes the return of the magnetization vector into 
equilibrium from some non-equilibrium state imposed, for instance prepared by a 
sequence of radiofrequency (rf) pulses.39  
 
At equilibrium, the net magnetization vector lies along the direction of the applied 
magnetic field Bo and is called the equilibrium magnetization M0 (Figure 10). In this 
configuration, the Z component of magnetization MZ equals M0. The time constant which 
describes how MZ returns to its equilibrium value M0 is called the spin lattice relaxation 
time (T1). In general, T1 is inversely proportional to the spectral density of molecular 
motions at the Larmor frequency. The rotation frequency distribution depends on the 
temperature and viscosity of the surrounding environment. Therefore T1 will vary as a 
function of temperature. 
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Figure 10. The cartoon describes T1 relaxation. A 180° pulse inverts the magnetization vector 
along the –z direction. T1 relaxation describes the flipping back of the magnetization vector into 
the equilibrium state. 
 
Another parameter which can be used to measure dynamic properties of corresponding 
molecules is spin-spin relaxation T2. T2 is the time constant that describes the diphasing 
of the magnetization in the XY plane completely before growing back up to Z axis 
(Figure 11). Actually, both processes T1 and T2 occur simultaneously with the only 
restriction being that T2 is smaller than or equal to T1. Two factors contribute to the decay 
of spin-spin magnetization: 1) molecular interactions (due to a pure T2 molecular effect) 
and 2) variations in B0 (due to an inhomogeneous T2 effect). The combination of these 
two factors is what actually results in the decay of spin-spin magnetization. 
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Figure 11. T2 relaxation describes the dephasing of the magnetization vector in the xy-plane. 
 
By measuring the relaxation times of T1 and T2, a detailed analysis of intramolecular, 
molecular and collective motions that occur in a membrane with temperature change may 
be observed. Normally, correlation times are plotted in a log scale as a function of the 
reciprocal of temperature in order to have a direct reading of activation energies from the 
slopes of the lines; the steeper the slope, the higher the activation energy.  
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3 Aim of the Dissertation 
 
It is worth noting that while the structure of the soluble part of N-Ras proteins (residues 
1-166) has been solved by both X-ray diffraction and solution NMR spectroscopy in the 
absence of a membrane,40 there are no structural data for the C-terminal membrane 
binding region (residues 180-186). The difficulties of crystallizing membrane attached 
Ras protein and the line broadening effect in solution NMR due to slow molecular motion 
of protein while associated with lipid bilayer have resulted in the lack of full structural 
data of this protein. It is therefore of general significance that the structural information 
of residues 180-186 can be obtained in the membrane-associated form, in order not only 
to understand the biological important domain (membrane-associated region) but also to 
establish the full N-Ras protein structure.  
 
While structure data on N-Ras protein is scarce, the information about their mobility is 
even more limited. Though several studies have addressed the dynamics of the soluble N-
teminus of Ras protein,41 little is known about the dynamic aspects of the membrane 
anchor of membrane-associated Ras protein. This part of the molecule not only attaches 
to the membrane bilayer but also determines the sorting of Ras into rafts or liquid 
crystalline domains. Recent work unveiled a dynamic pathway that is based on dynamic 
de-/re-palmitoylation of H-Ras protein to regulate Ras trafficking and has significantly 
raised the level of understanding of the dynamic information for the membrane anchor 
domain to another important level.36     
 
Recent advancement in solid-state NMR has prompted us to consider using this technique 
to investigate the structural and dynamic information for the C-terminal membrane 
binding region of the N-Ras protein. In addition to providing the sophisticated 
methodology required for measuring structural parameters, solid-state NMR spectroscopy 
has unique capabilities for studying the molecular dynamics of membrane proteins in 
their natural environment in a broad time window.  
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The aim of this dissertation is to study the dynamic and structural information of the 
membrane-bound domain (residues 180-186) of the N-Ras protein in a lipid bilayer.42 
Lipidated N-Ras proteins can be produced by ligating the expressed water-soluble N-
terminal Ras protein with lipophilic chemically synthesized C-terminal peptides (residues 
180-186) to obtain a fully functional hybrid protein. In this way, isotopically labeled 
amino acids (13C, 15N) should be introduced into specific positions of the lipidated C-
terminus. The N-terminus of chemically synthesized lipopeptides should be incorporated 
with a thiol accepting group such as maleimidocaproyl (MIC) to facilitate protein 
ligation. In order to maintain the stability of the protein, the labile thioester palmitoyl 
lipid chain at cysteine should be displaced by more stable thioether hexadecyl chain 
which should be labeled by deuterium 2H to study the dynamic information of lipid chain 
in lipid bilayer (Scheme 1).  
 
Cys-CO2H
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O
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Solid Phase Peptide SynthesisMolecular BIology Approch  
 
Scheme 1. General synthetic scheme to yield the 2H, 13C and 15N labeled lipidated N-Ras protein. 
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For the solid-state NMR study, three chemically modified N-Ras proteins 1, 2 and 3 with 
different 13C- and 15N- labeling patterns containing one S-hexadecylated (HD) and one S-
farnesylated (Far) cysteine should be synthesized (Figure 12). The hexadecyl lipid chain 
of Cys 181 should be fully labeled with deuterium. The alternating labeling pattern 
should preclude most of the signal superposition and enabled well-resolved peaks to be 
observed. The chemically modified N-Ras proteins should be subjected to different solid-
state NMR measurements all conducted under magic angle spinning (for instance 13C-13C 
and 13C-1H correlation experiments) and static 2H measurements to probe the structural 
and dynamic information of the N-Ras C-terminus.  
 
-Mic-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
S-(HD-D33) S-(Far)
3
-Mic-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
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O
O
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Figure 12. Three chemically modified N-Ras proteins. Bold: fully 13C, 15N labeled amino acids; 
HD: hexadecyl.  
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4 Results and Discussion  
 
4.1 Synthesis of Isotope Labeled N-Ras Proteins 
 
4.1.1 Synthetic plan   
 
 
The biochemical generation of fully functionalized and modified lipidated protein 
conjugates is difficult, time consuming, and limited to only certain protein conjugates. 
Enzymatic lipidation of entire Ras proteins can be achieved by means of 
farnesyltransferase (FTase) together with the corresponding farnesyl pyrophosphate. 
FTase was successfully used to synthesize a Ras protein and peptides carrying analogues 
of the farnesyl group.43 Although these methods can be used to generate Ras proteins 
embodying farnesyl groups and analogues, they do not allow for the synthesis of fully 
processed and correctly lipidated Ras proteins.  
 
The biosynthesis of Ras proteins proceeds through farnesylation of a precursor protein 
carrying the C-terminal CAAX sequence, followed by proteolytic removal of the AAX 
tripeptide and methyl esterification of the resulting C-terminal cysteine residue. Only 
then is the palmitic acid thioesters introduced. Despite numerous and intense attempts, 
the mammalian Ras palmitoyltransferase has not yet been identified. Thus the enzymatic 
synthesis of fully processed and correctly lipidated Ras protein is currently not feasible. 
The attachment of hexadecyl lipid to form the thioether to afford a more stable adduct 
instead of chemically unstable palmitoyl lipid chain has rendered the used of an 
enzymatic approach not possible. Furthermore, in our case, 13C and 15N could not be 
incorporated specifically into the residues 180-186 at the C-terminus of N-Ras protein by 
using the molecular biology approach alone 
 
The synthesis of fully chemically decorated N-Ras proteins therefore has to be achieved 
by combining the techniques of organic synthesis and methods of molecular biology.44 
Normally, this approach involves the expression of suitable Ras mutants lacking the 
lipidatable C-terminus and their subsequent coupling with different corresponding 
lipidated peptides to the C-terminus of Ras by means of a protein ligation strategy.     
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C-terminally truncated N-Ras proteins 5 were generated by introducing stop codons at 
position 182 of wild-type human N-Ras. These mutants carried a cysteine at the C-
terminal position 181, which lies on the surface of the protein and is therefore accessible 
to external reagents and peptides. The N-Ras mutant protein 5 was then allowed to react 
with the maleimido modified peptides 6 in stoichiometric amounts. The 
maleimidocaproyl (MIC) group is a well-established functionality for the covalent 
modification of proteins. It is known to react specifically with mercapto groups of 
proteins by conjugate addition of the thiol to the α, β-unsaturated carbonyl compound to 
form the desired protein conjugate 4 (Scheme 2).45  
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Scheme 2. Ligation of truncated N-Ras protein 5 and Mic-containing lipidated peptide 6 via 
Michael reaction. 
 
As compared to wild type N-Ras protein, the synthesized protein conjugate 4 consists of 
an extra glycine residue, maleimidocapropyl and hexadecyl chain instead of palmitoyl 
group. The analogues of this semi-synthetic Ras protein 4 have been verified to be 
biologically active in PC12 cells.44 Although the thioether hexadecyl lipid chain behaves 
differently from the thioester palmitoyl chain in vivo, the structural and dynamic 
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information should be similar to each other in NMR studies with the thioether hexadecyl 
chain conferring higher stability. The chemical stability of these three protein conjugates 
is critical to the structural and dynamical studies by NMR spectroscopy, as in general, 
NMR measurement requires very long measuring time (one day to a week). The easily 
hydrolyzed thioester makes the palmitoyl lipid unsuitable for NMR experiment.  
 
Three lipidated peptides 7, 8 and 9 with different sites of isotope incorporated amino 
acids were prepared for the coupling to the truncated N-Ras protein 5 (Figure 13).  
Lipidated 13C, 15N and 2H labeled peptides carrying a MIC group at the N-terminus were 
synthesized by means of Solid Phase Peptide Synthesis (SPPS) employing Fmoc-
protection strategy. In this synthesis, a building block strategy will be conducted to obtain 
the three desired products. The lipidated chains, farnesyl and deuterium-labeled 
hexadecyl, will be attached to the cysteine side chain before the beginning of solid-phase 
synthesis.       
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Figure 13. Three chemically synthesized isotopically labeled lipidated peptides. Fully 13C and 
15N labeled amino acids are highlighted in bold. 
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4.1.2 Selection of linker for the preparation of peptides 
 
The major challenge to be met in the synthesis of lipidated peptides is the selection of a 
set of suitable orthogonally stable protecting groups and a linker, which allows for the 
selective introduction of different lipids and other functional groups. Typical solid-phase 
linkers such as the Wang linker and Rink amide linker are not compatible with these 
requirements, as the strong acid required for release of peptide from the solid support will 
destroy the acid sensitive farnesyl group. Other linkers such as those based on the trityl 
group or the Sasrin resin that allow release of product under very mild acid conditions are 
compatible with the farnesyl group, but do not meet the requirements for introduction the 
of methyl ester at the C-terminus. In addition, the nucleophilic release of peptide from 
resin under strong basic conditions such as sodium methoxide to form methyl ester at the 
C- terminus will cause the hydrolysis of maleimidocapropyl group.  
 
The oxidation sensitive aryl hydrazine group 10 has been known for more than 30 years. 
Although used previously for peptide synthesis, the special utility of the hydrazine linker 
really came to light when applied to the synthesis of lipidated peptides.46 The linker is 
cleaved by oxidation to an acyldiazene, which is then displaced by a suitable nucleophile 
(Scheme 3). The oxidation method which is suitable for the preparation of lipidated 
peptide is carried out in situ, employing catalytic Cu(OAc)2, pyridine and methanol in 
CH2Cl2. Methanol serves as a nucleophile to give the desired lipidated peptide with 
methyl ester at the C-terminus 13.   
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Scheme 3. General scheme for the synthesis of peptide methyl ester using the hydrazine linker. 
 
The linker is orthogonal to classical urethane protecting groups such as Boc, Fmoc and 
Aloc. Moreover, racemization does not occur upon release of peptides from the resin. In 
this work, the aryl hydrazine linker will be used for the construction of three isotope 
labeled lipidated peptides 7, 8 and 9. The Fmoc protecting group was chosen as a 
standard protecting group strategy in the preparation of lipidated peptides. 
 
4.1.3 Preparation of building blocks    
 
To prepare labeled lipidated peptides 7, 8 and 9, different building blocks containing the  
Fmoc protecting group must be first synthesized. Commercially available and fully 13C 
and 15N decorated amino acids, leucine, proline, glycine, methionine, were protected with 
the Fmoc group using Fmoc-Cl and Na2CO3 in H2O/dioxane as a solvent at room 
temperature overnight (Scheme 4). In general, the yields of the Fmoc protection on the 
four above mentioned amino acids ranged from 70% to 85% after purification. The 
unlabeled Fmoc protected amino acids were obtained from commercial sources and used 
without further purification. 
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Scheme 4. Synthesis of Fmoc-protected fully 13C and 15N labeled building blocks. 
 
Though the introduction of the Fmoc group on glycine, methionine, proline and leucine is 
straight forward, the synthesis of Fmoc protected lipidated cysteine is relatively 
challenging. The thiol group presents on the cysteine side chain made the Fmoc 
protection of the amine group followed by alkylation impossible. The better 
nucleophilicity of sulfur compared to oxygen and nitrogen means that the Fmoc group 
will be loaded on cysteine side chain instead of amine group. The synthesis of Fmoc 
protected lipidated cysteine therefore must start prior to the introduction of lipid group to 
the cysteine side chain followed by Fmoc protection.  
 
For the synthesis of 13C and 15N labeled Fmoc-Cys(Far)-OH 24, the isotope decorated 
cysteine 22 was reacted with farnesyl bromide in 7N NH3 in methanol from 0°C to room 
temperature overnight. The resulting NH2-Cys(Far)-OH 23 was proceeded to next step 
without purification and subjected to Fmoc protection using Fmoc-OSu and Et3N in 
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CH2Cl2 for 2 hours to afford the desired product 24 in 63% yield as a colorless liquid 
after purification (Scheme 5). The synthesis of unlabeled Fmoc-Cys(Far)-OH 35 
followed the same protocol.   
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S
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24  
 
Scheme 5. Synthesis of 13C and 15N labeled lipidated Fmoc-Cys(Far)-OH 24 building block. 
   
The synthesis of 13C, 15N and 2H labeled Fmoc-Cys(HD-D33)-OH 29 can not be 
performed using the same protocol as for the preparation of compound 24. The unreactive 
hexadecyl halide can not be linked to the sulfur atom of cysteine in 7N NH3 in methanol. 
Therefore an alternative method was developed to obtain the desired product Fmoc-
Cys(HD-D33)-OH 29. The synthesis of underlying compound 29 started from 
commercially available labeled cysteine hydrochloride and D33-hexadecyl alcohol 25. 
Starting material 25 was transformed to D33-hexadecyl iodide 26 employing I2, PPh3 and 
imidazole in CH2Cl2 at 0°C to room temperature overnight to afford the desired product 
26 in quantitative yield (Scheme 6).  
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Scheme 6. Synthesis of deuterium labeled hexadecyl iodide 26. 
 
Initial attempts to introduce compound 26 to labeled cysteine followed by Fmoc 
protection failed to yield any product 29, although a trial reaction using unlabeled 
cysteine hydrochloride gave the desired product in 30% yield. This was quite surprising 
as the conditions and reagents used for the synthesis of Fmoc protected hexadecylated 
cysteine were the same, with the only exception being that the isotope decorated cysteine 
was not used as a hydrochloride salt. In order to perform the reaction under identical 
conditions, the labeled cysteine was pretreated with 1M HCl in water and ether 
respectively, before alkylation and protection. The alkylation of compound 26 to isotope 
labeled cysteine hydrochloride 27 was achieved by using Na2CO3 in DMF at room 
temperature for 48 hours to yield 28. Protection of resulted unpurified hexadecylated 
cysteine 28 was performed by using Fmoc-OSu and Na2CO3 in H2O/dioxane overnight to 
afford the desired product 29 in 28% yield (Scheme 7). The synthesis of unlabeled Fmoc-
Cys(HD-D33)-OH 36 followed the same protocol.   
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Scheme 7. Synthesis of 13C, 15N and 2H labeled lipidated Fmoc-Cys(HD-D33) 29 building block. 
 
4.1.4 Synthesis of isotopically labeled lipidated peptides  
 
The synthesis of isotope labeled lipidated peptide 7 was carried out on hydrazine resin 
using commercially available Fmoc hydrazine linker 30. Fmoc group of resin 30 was 
deprotected using 20% piperidine in DMF to give free amino group 31 which can be used 
later for the coupling of the first amino acid. The loading of the first building block, 13C 
and 15N decorated Fmoc-Cys(Far)-OH 24, was achieved using the coupling reagent DIC 
and HOBT in CH2Cl2/DMF at room temperature overnight to afford 32. The addition of 
CH2Cl2 as a co-solvent was necessary as compound 24 exhibits poor solubility in DMF. 
A longer coupling time was required for the coupling of the first amino acid 24 to the 
resin due to the bulky farnesyl side chain.  
 
The subsequent elongation of the peptide chain and deprotection of the Fmoc group were 
achieved by employing standard coupling reagents DIC and HOBT in DMF for two 
hours and 20% piperidine in DMF respectively to give 33. Compound 33 was deprotected 
and coupled to MIC carboxylic acid using the coupling reagent HOAT, HBTU and 
DIPEA in DMF overnight to obtain 34. Peptide 34 on resin was released from the solid 
support by oxidation using Cu(OAc)2, pyridine and excess methanol in CH2Cl2 for 3 
hours to afford the desired isotope incorporated lipidated peptide 7 in 23% yield after 
purification (Scheme 8).  
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In general, the synthesis of MIC-modified isotope labeled lipidated peptides 7 on 
hydrazine resin gave reasonable amounts of products (11 mg) for the subsequent coupling 
to truncated N-Ras protein. The generally low yield (23% in this case) of employing 
hydrazine linker was not attributed to the inefficient coupling of amino acid building 
blocks to the resin or formation of side products. Instead, it was believed that during the 
oxidative release of peptide from the solid support, the formation of radical species in situ 
by Cu(OAc)2 caused a radical derived from the hydrazide to be trapped by the 
polystyrene polymer. Upon formation of hydrazine and polystyrene bond, the peptides 
therefore would not be released from the solid support.  
 
N
H
O
N
H
H
N
Fmoc
20% pyridine/DMF N
H
O
N
H
H2N
DIC, HOBT, 24
CH2Cl2/DMF (1:1)
  r.t. overnight
1. 20% piperidine/DMF
2. Fmoc-AA-OH, DIC
    HOBT, DMF, 2hours
Fmoc-Cys-NH-NH
S-(HD-D33)S-(Far)
Fmoc-Gly-Cys-Met-Gly-Leu-Pro-Cys-NH-NH
S-(Far)
1. 20% piperidine/DMF
2. Mic-CO2H, HOAT
    HATU, DIPEA
    DMF, overnight
S-(HD-D33)
Mic-Gly-Cys-Met-Gly-Leu-Pro-Cys-NH-NH
S-(Far)
Cu(OAc)2, pyridine
MeOH/CH2Cl2
    3 hours
S-(HD-D33)
Mic-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
S-(Far)
30 31
32 33
34
7  
 
Scheme 8. Synthesis of MIC-incorporated isotope labeled lipidated peptide 7. Bold = fully 13C 
and 15N labeled amino acids. 
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Figure 14 shows the LC-MS trace for peptide 7. The HPLC peak at 10.69 minute 
corresponds to the correct peptide 1 mass peak of 1367 [M+H]+. 
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Figure 14. HPLC_MS trace of isotope decorated lipidated peptide 7 after purification.     
 
MIC-incorporated peptide 8 and 9 were prepared by means of the same procedure as 
peptide 7 in 10% and 17% yield respectively.  
 
4.1.5 Coupling of MIC-incorporated isotope labeled lipidated peptides to 
truncated N-Ras protein 
 
The protein ligation between cysteine side chain of the truncated Ras mutant and the 
maleimidocaproyl (MIC) group at the N-terminus of lipopeptide was developed in 
2002.44 This ligation technique allows the presence of base and acid sensitive lipid groups 
in peptide. Under suitable reaction conditions, the thiol group of cysteine side chain 
reacts specifically with the maleimido group to form a thioether bond.  
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The ligation reaction was conducted by Christine Nowak in the group of Jürgen 
Kuhlmann, Max-Plank Institute of Molecular Physiology. The coupling was performed 
with stoichiometric amounts of isotope labeled lipidated peptide 7 and truncated N-Ras 
protein 5. The coupling mixture was incubated in Triton X114 containing Tris buffer at 
4°C overnight under argon to give product 1 (Scheme 9). The addition of nonionic 
detergent enables to dissolve the lipophilic peptide 7 and hydrophilic truncated N-Ras 
mutant 5. The purification of the reaction mixture can be assisted by this detergent. The 
hydrophobic coupling product and lipidated peptide 7 was extracted to Triton X114 
phase, and unreacted protein 5 remained in the water phase.  
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Scheme 9. Synthesis of chemical modified N-Ras protein 1 by protein ligation of truncated N-
Ras protein 5 and isotope labeled lipidated peptide 7. Bold : fully 13C and 15N labeled amino 
acids. 
  
The protein extract was diluted to 2% Triton and applied on a DEAE-sepharose column 
to give semi-synthetic protein 1 in 37% yield. Figure 15 shows the SDS-page 
characterization of protein 1. 
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Figure 15. SDS-PAGE gel of semi-synthetic N-Ras protein 1. The bands represented as the 
following, 1: truncated N-Ras protein 5, 12: Marker, 2-11: Product fraction after purification.   
 
The resulting semi-synthetic lipidated protein 1 was further characterized by MALDI-
TOF measurement.  Figure 16 shows the MALDI-TOF spectrum of semi-synthetic 
protein 1.  
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Figure 16. MALDI-TOF spectrum of semi-synthetic protein 1. The mass peak at 10880 and 
21759 corresponds to the mass of coupling protein 1.    
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Isotope labeled lipidated proteins 2 and 3 were prepared under the same ligation 
condition as protein 1 to give 15% and 30% yield respectively (Scheme 9). The isotope 
labeled pattern of protein 2 is complementary to protein 1. 
 
In summary, three 13C, 15N and 2H labeled lipidated semi-synthetic proteins 1, 2, and 3 
have been synthesized by combining techniques of organic synthesis and molecular 
biology. In general, the amount of the proteins obtained from the ligation reaction (5 to 
10 mg) was sufficient to carry out the NMR measurement. The NMR experiments of the 
three semi-synthetic proteins were performed in collaboration with the group of PD Dr. 
Daniel Huster at the University of Leipzig to study the structural and dynamical 
information of the membrane associated C-terminus of the underlying N-Ras proteins 1, 
2 and 3. 
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4.2 Structural Studies of Membrane-Associated C-terminus of Lipid-Modified 
Human N-Ras Protein by Solid-State NMR Spectroscopy 
 
4.2.1 Solid-state NMR spectroscopy study of phospholipid phases 
 
The key to NMR studies of membrane proteins is the preparation of the phospoholipid 
membrane. Phospholipids can form numerous self-assembled superstructures,47 like 
micellar, bilayer, hexagonal, and other phases. Figure (17a, b) displays the molecular 
arrangements of phospholipids in micelle and bilayer structure. Each micelle typically 
formed from lysolipids, contains approximately 50-60 single chain lipid molecules and a 
single polypeptide. In contrast, lipid bilayers are very large supramolecular structures 
with many phospholipids and polypeptide molecules in extended two-dimensional arrays.  
 
(a) (b)
 
 
Figure 17. Typical self-assembled phospholipids structures with incorporated membrane protein. 
a) micelle, b) bilayer.  
 
Proteins in micelles re-orientate relatively slowly, while those in bilayers are immobile 
on the relevant NMR timescales, enabling them to be treated spectroscopically as solids. 
The association of membrane proteins with these two phospholipids configuration gives 
rise to different results and conclusions. The existence of different phospholipid phases 
can be identified by phosphorous 31P NMR. Depending on the phase state of the 
phospholipids, 31P NMR spectra display different peak patterns, as shown in Figure 18. In 
bilayers, rapid axial diffusion leads to a partial motional averaging of the 31P chemical 
shift tensor. Hence, an axially symmetric powder pattern is observed, characteristic of 
phospholipids bilayers. 
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Figure 18. 31P NMR spectra of different phospholipids phases. 48 
 
In this dissertation, the dynamical and structural information of membrane-bound N-Ras 
proteins were studied in phospholipids bilayers, which reflect the basic structural motive 
of a cellular membrane. Figure 19 shows the 31P NMR spectra of phospholipid bilayers of 
DMPC-D54 and DMPC-D54 with N-Ras protein prepared using the described protocol.62 
The 31P NMR spectrum of DMPC-d54 with or without N-Ras proteins corresponds well 
with the 31P NMR peak pattern of lipid bilayer shown in Figure 18. Protein binding does 
not interfere with the bilyer structure of DMPC.   
 
 
 
Figure 19. 31P NMR spectra of DMPC-D54 and DMPC-D54 in the presence of N-Ras protein at a 
molar ratio of 1:150.  
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4.2.2 Measurement of proton and carbon NMR for N-Ras proteins 1 and 2 
 
The structural analysis of the membrane-bound N-Ras protein was conducted together 
with Dr. Daniel Huster and Guido Reuther at the University of Leipzig. From empirical 
analysis it is known that the secondary chemical shift, in other words, the difference 
between the measured isotropic chemical shift and the corresponding value in the random 
coil, strongly correlate with protein secondary structure.49 Thus the secondary structure of 
a protein can be deduced by determination of 13C and 1H chemical shift of the given 
protein. For example, the chemical shifts of valine show distinctive chemical shifts 
changes in different secondary structures (Figure 20). The chemical shift of valine Cα in 
a β-sheet shifts downfield, while chemical shift of α-helix moves upfield when compared 
with the value of the random coil.       
 
 
 
Figure 20. Simulated 13C NMR spectra of of valine in different secondary structures.50 
Noticeable shifts in the isotropic peak positions depending on secondary structures are observed. 
 
By using this characteristic feature of chemical shifts for different protein secondary 
structures, two isotopically labeled lipid-modified N-Ras proteins 1 and 2 were subjected 
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to NMR spectroscopy measurement to determine their chemical shifts. Different MAS 
NMR experiments such as 13C experiment, 13C-13C and 13C-1H correlation experiments 
were performed to establish the 13Cα, 13Cβ, 13CO and 1Hα chemical shifts for the C-
terminus of the membrane-bound N-Ras protein. There are two possible approaches to 
obtain the 13C NMR of the underlying lipidated N-Ras proteins 1 and 2.      
 
The first of the two approaches involves the investigation of 13C chemical shifts of N-Ras 
proteins using a Bloch-decay experiment. In this NMR experiment, the 13C nucleus is 
directly irradiated. Since isotopic enrichment in the C-terminus of the Ras protein was 
prepared, the delivery of well-resolved spectra and identification of chemical shifts of 
each carbon from the lipidated N-Ras C-terminus are possible. The mixing ratio of 150 
equivalents of phospholipids DMPC to the protein would affect the NMR spectra of the 
N-Ras C-terminal region due to the relatively high intensity of DMPC peaks at natural 
abundance in 13C (1.1%). Furthermore the chemical shifts of DMPC might lie in the same 
region as the N-Ras C-terminus, which would pose a serious problem in the identification 
of N-Ras C-terminus 13C peaks. Another obvious disadvantage of using the Bloch-decay 
measurement will be the low sensitivity of 13C due to the small gyromagnetic ratio of 13C 
compared to 1H. This shortcoming may reduce the intensity of 13C signal of the N-Ras 
proteins. 
 
Figure 21 shows the 13C NMR spectrum of semi-synthetic N-Ras protein 1 determined by 
the Bloch-decay method. From the 13C spectra, each chemical shift of the N-Ras C-
terminus can be identified and characterized easily by comparing with the literature 
values. Fortunately, the 13C chemical shifts of DMPC do not overlap with the N-Ras 
protein 1 as shown by the spectra and the intensity of Ras 1 peaks are at an acceptable 
range. However, the line widths of each 13C peak are quite broad showing that the 13C 
chemical shifts obtained from this method might not be very accurate. In addition, the 
methionine β and γ 13C chemical shifts overlap with a prominent lipid natural abundance 
peak, which makes this method alone not very accurate for getting the 13C chemical shifts 
of both N-Ras proteins 1 and 2. A complementary method called cross-polarization was 
therefore applied to compare the 13C chemicals shift with Bloch-decay measurement.       
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Figure 21. 13C NMR spectrum of semi-synthetic N-Ras protein 1 in a DMPC matrix (1:150, 
mol/mol) at 30°C using direct polarization (Bloch-decay method). 
 
Cross polarization (CP) measurement makes use of the high gyromagnetic ratio of 1H. In 
the 13C CP experiments, 1H was irradiated instead of 13C. Through a special pulse 
sequence, the magnetizations are transferred to its adjacent carbon atoms using dipolar 
couplings thus obtaining the 13C NMR spectrum. By using this method, the intensity of a 
13C signal can be enhanced up to 4 times as compared to the Bloch-decay experiment. CP 
is one of the most widely used techniques in solid-state NMR. Figure 22 shows the 
spectrum of a 13C CP experiment51 of the semi-synthetic N-Ras protein 1.  
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Figure 22 13C NMR spectrum of semi-synthetic N-Ras protein 1 in a DMPC lipid matrix using 
cross polarization. 
 
The intensity and resolution of the peaks have increased significantly as compared to the 
Bloch-decay measurement. Due to the small dipolar couplings in the highly mobile lipid 
matrix, the methionine peaks can be identified in the spectra. The disadvantage of this 
measurement is that the chemical shifts of 13CO can not be detected due to the absence of 
adjacent 1H. Bloch-decay and cross polarization measurement of 13C chemical shifts of 
membrane-bound lipid modified N-Ras C-terminus were therefore used complementary 
to each other. 
 
The peaks in the Bloch-decay and cross polarization experiment were assigned with 
reference to literature values.52 However, the assignment can be ambiguous due to the 
overlay of several signals from different 13CO and 13C α of protein. Therefore, 
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measurement of 2D NMR spectroscopy is essential to establish the correct assignment of 
each peak. This is very important for the subsequent determination of torsion angles.  
 
4.2.3 Two dimensional (2D) NMR 
 
The 2D NMR technique is a very powerful method to identify signals and characterize 
the relationship between two atoms. Signals arise in the 2D NMR spectrum only if a 
coupling between two atoms exists. In solid-state NMR spectroscopy, the correlation 
between atoms is produced by dipolar couplings instead of, J coupling as in solution 
NMR spectroscopy. In 2D NMR, the x and y axis correspond to the frequency of two 
investigated nuclei. A cross peak will be observed only if the dipole couplings between 
two nuclei occur. Towards the analysis of membrane-bound N-Ras proteins, several 2D 
NMR experiments have been carried out such as 13C-13C proton-driven spin diffusion and 
1H-13C HetCor measurements.53  
 
In Figure 23 relevant regions of the 1H-13C of two isotopic labeled N-Ras proteins 1, 2 
correlation spectra are shown. The alternating labeling pattern precludes most of the 
signal superposition, and well-resolved peaks are observed. In the spectra all correlation 
peaks for directly bonded 1H-13C pairs are present. Typical line widths for the Cα and Hα 
signals are ≈ 1 ppm and ≈ 0.15-0.25 ppm, respectively. This suggests that dipolar 
couplings are reduced by molecular motion but still sufficiently large to allow for 
polarization transfer by cross-polarization and proton-driven spin diffusion.54  
 
The 1H-13C correlation spectra also provide different crosspeak patterns depending on the 
labeling scheme of the protein investigated. 13C and 15N labeled amino acids are shown in 
bold italics. In addition to the protein signals, crosspeaks of the non-deuterated glycerol 
(G) and lipid chain signals (C-2, CH2) from the membrane are detected. 
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N-Ras-Mic-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
S-(HD-D33) S-(Far)
N-Ras-Mic-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
S-(HD-D33) S-(Far)
1 2  
 
 
Figure 23. Contour plots of 13C-1H MAS NMR spectra of the lipidated membrane-bound Ras 
proteins. a) N-Ras 1, b) N-Ras 2, Bold and italic: 13C and 15N labeled amino acids.  
 
The 13C-13C correlation spectra show all correlations within the labeled amino acid 
between Cα and CO (Figure 24). In the carbonyl region of the 13C-13C correlation spectra 
six out of seven Cα-CO crosspeaks are resolved. Thus, the complete assignment was 
possible from this set of MAS NMR experiments. A table containing the assignments and 
chemical-shift values is given in Table 1. 
 
 
 
Figure 24. Contour plots of 13C-13C MAS NMR spectra of the lipidated membrane-bound Ras 
proteins. a) N-Ras 1, b) N-Ras 2.  
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Table 1. 1H and 13C chemicals shifts, signal assignment, and deviation from 
random coil values for the C-terminus of membrane-associated N-Ras. 
 
Residue Signal δ [ppm] δ random coil-δexperiment [ppm] 
Gly 180 Cα 45.4 -0.3 
 CO 173.8 1.1 
 Hα 4.02 -0.06 
Cys 181 Cα 56.5 1.9 
 CO 174.6 0.1 
 Cβ 35.5 -7.1 
 Hα 4.53 0.03 
 Hβ 2.87 n.r. 
Met 182 Cα 56.0 -0.7 
 CO 174.4 1.9 
 Cβ 30.9 1.7 
 Cγ 31.4 n.r. 
 Cδ 17.3 n.r. 
 Hα 4.42 0.06 
 Hβ 2.20 n.r. 
 Hγ 2.32 n.r. 
 Hδ 2.10 n.r. 
Gly 183 Cα 45.4 -0.3 
 CO 173.6 1.3 
 Hα 3.73 0.23 
Leu 184 Cα 52.3 2.6 
 CO 174.7 2.4 
 Cβ 42.6 -0.3 
 Cγ 27.1 n.r. 
 Cδ 25.6 n.r. 
 Hα 4.65 -0.31 
 Hβ 1.99 n.r. 
 Hγ 1.84 n.r. 
 Hδ 0.96 n.r. 
Pro 185 Cα 62.7 0.5 
 CO 174.4 2.9 
 Cβ 33.1 -1.4 
 Cγ 27.3 n.r. 
 Cδ 49.9 n.r. 
 Hα 4.65 -0.23 
 Hβ 2.65 n.r. 
 Hγ 2.07 n.r. 
 Hδ 3.57 n.r. 
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Residue Signal δ [ppm] δ random coil-δexperiment [ppm] 
Cys 186 Cα 54.6 3.8 
 Cβ 35.6 -7.2 
 Hα 4.68 -0.13 
 Hβ 2.82 n.r. 
  
 n.r. : not relevant for structural analysis. 
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4.2.4 Torsion angle prediction by TALOS 
 
The 13Cα, 13Cβ, 13CO, and 1Hα chemical shifts for the C-terminus of the membrane-
bound N-Ras proteins 1 and 2 determined in the MAS NMR experiments provided the 
input parameters for the structural calculations. The program package TALOS was used 
to determine a model for the backbone structure of the membrane-binding domain of Ras 
from the isotopic chemical shifts. The deviations of the observed chemical shifts from 
those of the random coil increase towards the C-terminus of Ras, indicating that the 
TALOS prediction is also better for the C-terminal amino acids. 
 
TALOS55 is a database system used for the empirical prediction of Φ and Ψ backbone 
torsion angles by using the input of five isotropic chemical shifts (Hα, Cα, Cβ, CO, N). 
The goal of TALOS is to use secondary chemical shift and sequence information in order 
to make quantitative predictions for the protein backbone angles Φ and Ψ, and to provide 
a measure of the uncertainties in these predictions.  
 
This program searches a database containing 78 proteins of known X-ray structure for 
chemical-shift and sequence homology. The TALOS database, while small, was 
constructed using the most well-defined parts of high resolution (2.2 Å or better) X-ray 
crystal structures to define the Φ and Ψ angles. TALOS finds chemical-shift identities for 
triplets of amino acids and yields the backbone torsion angles as output. The idea behind 
TALOS is that if one can find some triplet of residues in a protein of known structure 
with similar secondary shifts and sequence to a triplet in a target protein, then the Φ and 
Ψ angles in the known structure will be useful predictors for the angles in the target. The 
information obtained from TALOS calculation will provide a basis for calculating a 
structural model of the molecule in question.56   
 
In practice, TALOS searches a database for the 10 best matches to a given triplet in the 
target protein. If these 10 matches indicate consistent values for Φ and Ψ angles, then 
their average and standard deviations are used as a prediction. However, if the 10 best 
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matches have mutually inconsistent value of Φ and Ψ angels, the matches are declared 
ambiguous and not prediction is made for the central residue.  
 
The output of TALOS database is given in a Ramachandran plot. The Ramachandran plot 
shows the Φ/Ψ distributions of the 10 best database matches for the selected residue. The 
graph is shaded to show the most populated regions of the TALOS database. In the graph, 
each match from the database is drawn as a small square at a particular Φ/Ψ coordinate. 
The squares are colored according to this scheme: Green ⁪, this match is good and 
included in the prediction. Red ⁪, outlier; not included in the prediction. Blue ⁪, 
reference (Φ/Ψ taken from “–ref” structure). The Ramachandran plot of TALOS 
calculation was given in Figure 25. 
 
          
   Cys 181       Met 182         Gly 183 
     
  Leu 184     Pro 185 
 
Figure 25. TALOS results for membrane bound Ras-protein as a Ramachandran plot of the 5 
amino acids in the C-terminus of the molecule. 
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No torsion angles for glycine 180 and cysteine 186 could be predicted by TALOS 
because glycine 180 and cysteine 186 are, respectively, the first and the terminal labeled 
amino acids in the sequence of interest. TALOS requires the input of chemical-shift data 
for three consecutive residues. With the exception of methionine 182, the torsion angles 
for the backbone geometry determined were conclusive. For this residue, three equally 
populated subsets of backbone torsion angles were found. From the Ramachandran plot, 
one can immediately conclude that cysteine 181, leucine 184 and proline 185 lies in the 
β-sheet region, while glycine 183 stays in a left handed helix.  
 
The TALOS program also gave the average and standard deviation of Φ and Ψ angles for 
the selected residue matched. The average backbone torsion angles and standard 
deviation for the amino acids 181-185 of the C terminus of N-Ras are given in Table 2. 
The standard deviation for the predicted torsion angles is approximately 15%. This is 
reasonable given that TALOS is just a small database containing NMR chemical shifts 
correlation of only 78 proteins structures. 
 
Table 2. Backbone torsions angles of the membrane-binding domain of the 
lipidated human N-Ras protein. 
 
Residue Φ Ψ 
Cys 181 -135°± 20° 151°±17° 
-67°±11° -22°±25° 
-79°±23° 121°±10° Met 182 
51°±5° 45°±7° 
Gly 183 84°±11° -12°±13° 
Leu 184 -83°±14° 141°±22° 
Pro 185 -63°±8 147°±9° 
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4.2.5 Structural model of membrane-associated C-terminus of N-Ras protein 
 
A simulated annealing protocol was used for structural calculations of the C-terminus of 
the membrane-bound lipidated Ras protein. Because of the ambiguity in the TALOS 
result for methionine 182, three families of structural models were calculated. Figure 26 
shows the structural model for the lipidated C-terminus of the membrane-bound N-Ras 
protein derived from solid-state NMR data.  
 
Figure 26. Possible structural model for the lipidated C-terminus of the membrane-bound N-Ras 
protein.  
 
The superposition of the 10 lowest energy backbone models are displayed for the three 
sets of methionine 182 torsion angles in the left column shown in Figure 26 a-c. The Cα 
coordinates of the five amino acid stretch, for which the torsion angles have been 
predicted, show a root mean square deviation (rmsd) of a) 0.56, b) 0.51 and c) 0.63 Å 
(calculated from 200 structural models). Figure 26 d-f show different views of the 
averaged structural model with the backbone in blue and proline in green. The Cβ atoms 
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for the cysteine, leucine and methionine are shown in red, yellow, and magenta, 
respectively.   
 
The global fold of the C-terminus of the N-Ras protein in the membrane resembles a 
horseshoe. The membrane anchor of Ras protein has no regular α-helical or β-sheet 
motifs. This is not surprising because the sequence investigated here contains two glycine 
residues and one proline residue, which are well-known turn promoters and helix 
breakers.57 As a result of the lack of structural information for glycine 180 and 
cysteine 186, the ends of the sequence appear disordered in the images. 
 
The TALOS results for methionine 182 show that the relationship between torsion angles 
and chemical shift is not unique. Therefore, additional spectroscopic information is 
required to determine the most likely structural model of membrane-bound Ras protein, 
perhaps through torsion angle measurement.58 Studies of membrane binding of the 
lipidated Ras heptapeptide (residues 180-186) by 1H MAS NOESY and neutron 
diffraction spectroscopy have been reported.59 Strong intermolecular crosspeaks indicated 
that the hydrophobic side chains (cysteine, leucine, and methionine) insert into the 
membrane interior. The polar five-membered ring of proline points towards the aqueous 
phase. These results provide additional information for the selection of the most likely 
structural models of the three possible for the membrane-binding domain of N-Ras. 
 
It should be noted that the torsion angle predictions by TALOS do not provide 
information about the side chains of the protein. However, the tetrahedral geometry of the 
Cα atom in the backbone determines the direction of the side chain with respect to the 
protein backbone. In the middle and right columns of Figure 26, two views of the average 
backbone conformational model of the Ras membrane-binding domain are shown for 
each set of methionine torsion angles. These structural models also include the Cβ sites. 
For two of the three models, the hydrophobic side chains point in different directions, 
which appears to be a rather unlikely conformation based on thermodynamic 
considerations and is not in line with the NOEs between Ras peptide side chains and the 
membrane. Thus one structural model remains, in which the lipidated and hydrophobic 
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side chains point in the same direction, suggesting the orientation of the membrane-
binding domain of the protein (Figure 26 c and f). In agreement with the hydrophobicity 
scale60 in this model, proline would point away from the membrane into the aqueous 
phase. Therefore, the interaction of the protein with the membrane stabilizes its 
conformation. 
 
From these results, a model of the structure of the membrane-bound lipidated N-Ras 
protein was constructed (Figure 27). The membrane topology of the protein is determined 
by hydrophobic interactions between the lipidated cysteine and hydrophobic side chains. 
Further, hydrogen bonds between the peptide backbone and the phospholipids in the 
interface region of the membrane are likely to occur. The lipid-binding domain is linked 
to the GTP-binding N-terminal region of the protein by a linker domain, which is 
putatively flexible.61 In contrast to H-Ras, there is currently no structure available for the 
N-terminus of N-Ras. However, considering that there is 92 % sequence homology 
between H-Ras and N-Ras it can be assumed that these structures are very similar.  
 
Figure 27. Structural model for membrane-associated C-terminus of N-Ras protein. 
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4.3 Dynamical Studies of Membrane-Associated C-Terminus of Lipid-Modified 
Human N-Ras Protein by Solid-State NMR Spectroscopy 
4.3.1 Lipid chain dynamics of membrane bound Ras protein 
Deuterium labeled hexadecyl lipid chain at cysteine 181 of N-Ras protein 3, was used to 
obtain the dynamical information of the N-Ras lipid chain’s interaction with phospholipid 
membranes. This provides the essential key to study the dynamical information of lipid 
chain, where deuterium in a C-2H bond has quadrupolar coupling constant of 167 kHz. 
This moderate interaction strength makes this nucleus very valuable for dynamical 
studies of lipid chains in the membrane. Moreover, the lineshapes are sensitive to 
molecular motions with correlation times between approximately 100 ps and 100 µs, 
which coincidentally corresponds well with the motion of membrane-bound proteins.   
The dynamical data of the membrane-bound N-Ras proteins was analyzed together with 
Dr. Daniel Huster and Guido Reuther at Leipzig University. The Ras proteins 3 were 
reconstituted into DMPC or chain perdeuterated DMPC-D54 membranes and investigated 
by static 2H NMR methods.62 To gain insights into the molecular dynamics of the lipid 
modifications of membrane-associated N-Ras, the properties of the lipid chains were 
compared in three different samples: (i) pure DMPC-D54, (ii) DMPC-D54/N-Ras (non-
deuterium labeled) at a 150:1 molar ratio, and (iii) DMPC/N-Ras 3 at a 150:1 molar ratio. 
Thus, structural and dynamical information about the Ras hexadecyl chain attached to 
cysteine 181 in comparison to the phospholipid chains can be extracted. Furthermore, the 
effect of the Ras protein on the bilayer properties of the host DMPC matrix was 
determined using the same combination of samples. 
Figure 28 shows the 2H NMR powder spectrum of the three samples. The blue DMPC/N-
Ras 3 spectrum shows the quadrupole splitting of N-Ras lipid chain, which provides 
dynamical information of the protein lipid chain in lipid bilayer. Further dynamic 
information of the lipid bilayer under the influence of Ras proteins can be obtained from 
the measurement of DMPC-D54/N-Ras (Red line). The final black line DMPC-D54 
spectrum was measured without N-Ras.  
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From the raw 2H NMR powder spectra, it is very difficult to obtain any useful 
information due to the poorly resolved deuterium peaks. A mathematical algorithm called 
de-Paking63 was employed to convert the 2H raw spectra to the spectra which can be read 
and calculated. 
 
Figure 28. 2H NMR powder spectra of Ras/membrane preparations. Blue: N-Ras protein 3 in 
DMPC, Red: N-Ras protein in DMPC-D54, Black: DMPC-D54. 
The spectra shown in Figure 29 are symmetric and well resolved after de-Paking 
procedure was conducted. The quadrupole splitting of each deuterium atom is assigned 
such that the smallest splitting belongs to the deuterium attached at C16, and the next 
splitting is the deuterium at C15. The following splitting corresponds to C14, C13 and so 
on.  
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Figure 29. Depaked spectra from Figure 29. Blue: N-Ras protein 3 in DMPC, Red: N-Ras protein 
in DMPC-D54, Black: DMPC-D54. 
Dynamical information of the lipid chain can be extracted from the value of 2H 
quadrupolar splitting. A smaller quadrupolar splitting represents a more flexible carbon in 
a CH2 bond while a bigger quadrupolar splitting means a more rigid bond. In order to 
compare the flexibility of each carbon chain easily, the quadrupolar splitting of each Pake 
doublet was converted into an order parameter according to Eq. (1).64  
The order parameter, S, provides information about the amplitude of motion of the 
corresponding C-2H bond and varies between 1 to 0. When S is 1, it means that the 
respective C-H bond is completely rigid. If S is 0, it means that the bond is isotropically 
mobile. The value of the order parameter can be calculated from the experimental 
quadrupolar splitting based on the equation (1).  
( )nS
h
qQe
4
3 2
Q =ν∆                       (1) 
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Where, S(n) is order parameter of the corresponding atom, and ∆νQ is the quadrupolar 
splitting of that particular deuterium and e2qQ/h is the quadrupolar coupling constant 
(167 kHz in a C-2H bond).   
Smoothed order parameter profiles showing the dependence of the order parameter on the 
position of the carbon segment in the acyl chain are presented in Figure 30. The segments 
are numbered consecutively starting from the carbonyl group of the lipid or the carbon 
directly connected to the sulfur atom of cysteine 181 of N-Ras, respectively. The red and 
black lines in the graph correspond to DMPC-D54 in the presence and in the absence of 
N-Ras protein, respectively. The blue line corresponds to N-Ras 3 in DMPC.  
 
Figure 30. Comparison of order parameter of N-Ras hexadecyl lipid chain Blue: N-Ras protein 3 
in DMPC, Red: non isotope labeled N-Ras protein in DMPC-D54, Black: DMPC-D54. 
Striking differences between the chain order parameters of DMPC-D54 and N-Ras are 
observed. The dramatically narrower 2H NMR spectrum of the N-Ras 3 chains illustrates 
that the order parameter of N-Ras 3 is significantly lower than DMPC. This indicates that 
the hydrocarbon chains of the Ras protein occupy a substantially greater conformational 
space than the DMPC hydrocarbon chains and the lipid chain of the protein is less orderly 
packed in the DMPC lipid bilayer. It can therefore be deduced that the Ras protein lipid 
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chain is very mobile inside the DMPC phospholipid membrane. In contrast, the order 
parameter profiles for DMPC-D54 in the presence and in the absence of Ras are very 
similar. This shows clearly that the addition of N-Ras protein 3 does not affect the 
mobility and structure of DMPC lipid bilayer. 
The order parameter of N-Ras protein 3 lipid chain was compared with the previously 
studied C-terminal N-Ras heptapeptide (residues 180-186)59, 65 to understand the 
influence of the globular part of N-Ras protein on the dynamics of the lipid chain. The 
results of the comparison are summarized and shown in Figure 31. 
 
 
Figure 31. Comparison of N-Ras protein 3 lipid chain and N-Ras C-terminal heptapeptide lipid 
chain. 
 
Interestingly, the order parameters for C-terminal N-Ras heptapeptide and N-Ras protein 
3 were found to be highly similar. These similar dynamical features of the lipid chain of 
the peptide and protein indicate that the lipid chain modifications of Ras protein may 
move relatively independent to the rest of the protein. 
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From the 2H NMR data, the average area per hydrocarbon chain <A> and the chain length 
of the hydrocarbon region DC can be calculated.65 Figure 32 shows the length of each 
lipid chain (for the phospholipids as well as for the Ras lipid chain modifications). Table 
3 reports the values of the average area per hydrocarbon chain <A> and the summary of 
the length of lipid chain.  
 
 
Figure 32. Comparison of chain extension of N-Ras protein 3. Blue: N-Ras protein 3 in DMPC, 
Red: N-Ras protein in DMPC-D54, Black: DMPC-D54.  
 
Table 3. Summary of the chain length and average area results for DMPC-D54, 
DMPC-D54/Ras, and DMPC/N-Ras 3 at 30°C. 
 
 <A> /Å2 Dc/ Å 
DMPC-D54 29.7 ± 0.4 12.9 ± 0.2 
DMPC-D54/Ras 29.5 ± 0.4 13.0 ± 0.2 
DMPC/N-Ras 3 33.8 ± 0.8 13.0 ± 0.4 
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The hydrocarbon thickness for DMPC-D54 is in good agreement with X-ray results.66 The 
slightly higher absolute magnitudes of the order parameters for DMPC-D54 in the 
presence of N-Ras protein indicate a slightly thicker hydrocarbon core, so that the 
interfacial area per chain is somewhat smaller compared to pure DMPC-D54. It is very 
interesting to note that N-Ras protein lipid chain has 16 carbon atoms and DMPC-D54 has 
only 14 carbon atoms but they share similar chain extension value, which are 13.0 Å and 
12.9 Å long respectively. This is in good agreement with previously reported studies on a 
lipidated Ras heptapeptide (residues 180-186), which also showed the C-terminal Ras 
peptide and DMPC lipid chains to match in their lengths.59, 65 In contrast, the average area 
per hydrocarbon chain for N-Ras 3 is more than 4 Å2 larger. The large cross-sectional 
area of the Ras chain provides space for the peptide backbone, which takes up a 
substantial area in the lipid-water interface of the membrane. In the space beneath the 
peptide backbone in the membrane core, lies the hydrophobic peptide side chains (leucine 
and methionine) and the Ras lipid chains, which undergo large amplitude motion. Thus, 
the polar protein backbone forms an "umbrella" shielding the hydrophobic side chains 
and lipid modifications of Ras from the water medium.67 
 
To provide dynamics information of the lipid at chemically modified N-Ras protein in 
DMPC constructed lipid bilayer, 2H NMR spin-lattice relaxation time (T1Z) or 
longitudinal relaxation time measurements were performed for the various samples 
studied. The inverse of T1Z defines the spin-lattice relaxation rate R1Z. While order 
parameters provide information about the motional amplitude of a C-H bond vector, the 
correlation time of motion can be deduced from relaxation times. 
 
Figure 33 shows the inversion recovery of the magnetization vector that is used to 
measure the spin-lattice relaxation time T1Z. At equilibrium state, most of the nuclei spin 
point towards the direction of Z axis, which is parallel to the direction of magnetic field 
B0. When a 180° pulse is applied to the magnetization vector, it is inverted to the –Z axis. 
The loss of energy to the surrounding environment renders the nuclear spins to return to 
their equilibrium state where the direction of the magnetization is parallel to magnetic 
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field B0. By simple definition, the relaxation time T1z of nuclei is the time by which 
nuclei spin requires to return to its equilibrium state from excited state. 
 
 
 
Figure 33. The principle of inversion recovery to measure the spin-lattice relaxation time T1. 
 
The relaxation Time T1z is dependant on the mobility of the nucleus in the sample. As 
mobility increases, the vibrational and rotational frequencies increase, making it more 
likely for a component of the sample to be able to interact with excited nuclei. However, 
at extremely high mobility, the probability of a component of the surrounding 
environment being able to interact with excited nuclei decreases, therefore lengthening 
the relaxation time. From the study of the relaxation time for N-Ras 3, the dynamical 
information about the amplitude motion of lipid chain can be understood.    
 
The relaxation study for DMPC-D54 in the presence and in the absence of the Ras as well 
as for N-Ras 3 in a DMPC matrix is shown in Figure 34. For DMPC-D54 in the presence 
as well as in the absence of Ras protein, the dependence is linear. However, the relaxation 
rate R1Z(i) versus order parameter  SCD(i) 2 plot for the N-Ras 3 hexadecyl chain departs 
from the linear dependence and shows a bent shape with a steeper slope. The relaxation 
rates for the N-Ras 3 hexadecyl chain are generally higher than for DMPC-D54. The 
steeper slope of N-Ras 3 implies that the Ras lipid chain is much more flexible and 
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mobile than that of DMPC-D54. In previous analyses of pure phospholipid membranes, it 
has been found that the relaxation rate often exhibits a linear dependence on the square of 
the order parameter.68 While the physical reason for this interesting behavior is still under 
discussion, it has been shown to be a common feature for non-saturated phospholipids.  
 
 
 
Figure 34. Dependence of the R1Z(i) relaxation rates on the corresponding order parameter 
squared for DMPC-D54 (♦), DMPC-D54/N-Ras (150:1 mol/mol) (▲), and DMPC/N-Ras 3 (150:1 
mol/mol) (■) at 115.1 MHz (17.6 T). 
 
These R1Z versus SCD 2 plots report the elastic properties of the lipid chains in a 
membrane.69 In softer materials, the lipid chains are undergoing large amplitude motions, 
which are expressed in a steeper slope in the square-law plots with a nonlinear 
dependence. This is exactly the behavior observed for the Ras hexadecyl chain 
modification at cysteine 181. This Ras lipid modification is not only more loosely packed 
as expressed by low order parameters, it also appears to be highly flexible and dynamic, 
undergoing motions with large angular amplitudes. A material made of such highly 
mobile chains would be soft and very elastic. Interestingly, the lipid chains of the host 
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matrix show a somewhat shallower slope in the square-law plots, which means, that the 
elasticity of the host membrane is actually slightly reduced. This again underlines that the 
changes in the membrane caused by the insertion of the Ras protein are mostly 
compensated for by the mobility of the Ras chains rather than by the host matrix. 
 
The relaxation time T1z of N-Ras protein 3 was also compared with the C-terminal N-Ras 
heptapeptide. A plot of quadrupolar relaxation time T1 of each carbon atom was shown in 
Figure 35.  
 
 
Figure 35. Comparison of the relaxation time for N-Ras protein 3 and C-terminal N-Ras-D33 
heptapeptide. 
 
The relaxation time of N-Ras protein 3 and C-terminal N-Ras-D33 heptapeptide shows 
similar trend with increasing relaxation time from carbon close to protein/peptide back to 
carbon far away from the backbone. The absolute value of relaxation time ranges from 
around 25 ms to 300 ms for N-Ras-D33 heptapeptide and 200 ms for N-Ras-protein 3. The 
relaxation time determined for the hexadecyl chain of the Ras protein are about 100ms 
longer, which can be understood by considering the molecular mass difference between 
peptide and protein, which results in somewhat slower motions of the later.  
 
________________________________________________________________________ 
 62
4.3.2 Molecular dynamics of the C-terminus of membrane-associated Ras protein.  
 
In addition to the dynamics information for the Ras protein lipid modification at cysteine 
181, the backbone and side chain molecular mobility of the seven isotopic labeled C-
terminal amino acids of Ras were studied by 13C MAS NMR spectroscopy. The order 
parameter of backbone and side chain can be determined by 2D dipolar coupling 
chemical-shift correlation experiment (DIPSHIFT).70  
 
In DIPSHIFT measurement, the motional averaged dipolar coupling strength between 1H 
and its directly bonded 13C is measured. Similar to the motional averaged quadrupolar 
interaction, the actually measured dipolar coupling can be used to determine the 
molecular order parameter of the 13C-1H bond vector. The order parameter of the 
backbone can thus be calculated from the motionally averaged dipolar coupling. Large 
dipolar coupling of 1H and its neighboring 13C implies that the 13C and 1H bond has a 
small motional amplitude angle θ and large order parameter and vice versa. Figure 36 
shows the 13C-1H bond motional amplitude angle.  
 
θ
13C
1H
 
 
Figure 36. 13C-1H bond motional amplitude angle.  
 
To avoid overlapping of the NMR signals, two complementary 13C labeled Ras proteins, 
N-Ras proteins 1 and 2, were subjected to DIPSHIFT measurements. The good resolution 
of the 1D 13C NMR spectra performed in the structure investigation of C-terminal N-Ras 
protein allows determining the strength of the 1H-13C dipolar couplings in a DIPSHIFT 
experiment. Fast anisotropic molecular motions partially average these couplings. 
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Therefore, the amplitude of the motion of the bond vectors can be assessed from the order 
parameter defined by the ratio of the motionally averaged and full dipolar coupling. 
Figure 37A shows order parameters for the protein backbone and side chains of the seven 
isotopic labeled terminal amino acids residues. Filled bars correspond to the order 
parameters of Cα sites, open bars to the Cβ, hatched bars to the Cγ, and crossed bars to 
the Cδ sites. Figure 37B shows the combined plot of the order parameters of cysteine 181 
starting at the Cα site and continuing into the lipid chain of the membrane anchor.  
 
 
 
Figure 37. 1H-13C order parameters of the membrane bound C-terminus of Ras. (A) Order 
parameters for the protein backbone and side chains are given for the seven terminal residues. (B) 
Combined plot of the order parameters of cysteine 181 starting at the Cα site and continuing into 
the lipid chain membrane anchor. The hexadecyl chain order parameters were taken from Figure 
30 
 
The absolute values for these order parameters are relatively low indicating large 
amplitude motions in the C-terminus of membrane bound Ras. A monotonic decrease of 
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the order parameters along the side and lipid chains is observed indicating that the 
amplitude of motions increases along the chain. Only for Pro 185, order parameters 
decrease for Cβ and increase again for Cγ and Cδ as expected for the five-membered ring 
that folds back to the main chain. In general, lipid chain attached cysteine 181 and 
cysteine 186 show higher order parameter. This can be recognized by the anchor of lipid 
chain to the phospholipids in which render higher rigidity of these two amino acids 
residues in the study. There is no conclusive trend in the amplitude of the backbone 
motions of the membrane bound Ras protein. It is interesting that the two lipid modified 
cysteine residues exhibit very different order parameters suggesting that the farnesylated 
Cys 186 is more rigid than the hexadecylated Cys 181. 
 
Finally, it is important to know the correlation times of the molecular motions studied. To 
this end, 13C MAS NMR T1 and T2 relaxation times as a function of temperature was 
measured for membrane-bound N-Ras protein 3, shown in Figure 38.  
 
 
 
Figure 38. Experimental and simulated relaxation times vs inverse temperature data for the 13Cα 
signal of Gly 183 of membrane-bound Ras protein. The symbols refer to the experimental T1 (■) 
and T2 (♦) relaxation times, and the lines are the best fit simulation using a modified Lipari-
Szabo approach. 
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With increasing temperature, T1 relaxation times decrease while T2 relaxation times 
increase as typical for samples exhibiting molecular motions that are not in the extreme 
narrowing limit. To calculate correlation times for the backbone motions of membrane 
bound Ras, a modified Lipari-Szabo formalism71 was used with an Arrhenius temperature 
dependence of the correlation time with τ0 = 10-15 s.72 It was further considered that two 
directly bonded hydrogens relax the 13Cα spin of glycine 183. Since membrane binding 
restricts the mobility of the Ras protein, the spectral density functions contained one 
anisotropic term for the overall and one for the internal protein motions. The anisotropy 
is represented in an order parameter for the fast internal (Sf) and slower (Ss) overall 
motions of membrane-associated Ras. The spectral density functions of the modified 
Lipari-Szabo equation are given in equation (2). 
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The product S of Sf and Ss represents the order parameter measured in the DIPSHIFT 
experiments. For the temperature dependence of the correlation times, an Arrhenius 
behavior was assumed. These parameters could be determined from the experimentally 
measured temperature dependence of the relaxation times. The results of the analysis are 
shown in Table 4.  
 
Table 4. Correlation times for the slow and fast motions of glycine 183 in 
membrane-associated lipidated Ras protein 
 
Temperature/K τs/ns τf/ns 
283   864.0 ± 22.2 7.4 ± 0.3  
298 306.7 ± 7.9 3.3 ± 0.1 
310 143.9 ± 3.7 1.9 ± 0.1 
323              67.6 ± 1.6   1.0 ± 0.05 
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Depending on temperature, the correlation times are between ~70 and 900 ns for the 
overall and between ~1 and 7 ns for the internal motions. The order parameters for these 
dynamic processes are 0.445 and 0.70, respectively, and SDIPSHIFT = Ss x Sf = 0.312. 
 
4.3.3 Summary of the dynamic study for the membrane-associated N-Ras protein 
C-Terminus 
The dynamical results calculated from the 2H NMR indicates that the lipid modification 
at cysteine 181 adjusts its length to that of the host membrane. Instead of the membrane 
adjusting to the longer protein chain by local curvature, which costs free energy, the 
chain inserts into the hydrophobic membrane interior with almost no energy cost, thereby 
largely retaining its configurational entropy and leaving the host matrix relatively 
unchanged. This requires the protein chain to be flexible in order to insert into a fluid 
membrane that is characterized by a large amount of molecular disorder.  
This may indicate that the matching between the Ras and the DMPC chain lengths 
happened by chance and the low order parameter of the Ras lipid modifications result 
from the insertion of the protein backbone and side chains into the lipid water interface of 
the membrane. Thereby, the phospholipids molecules are spaced apart, which decreases 
the lateral pressure in the membrane underneath.  
The lipid chain modifications of Ras can fill the volume below the protein backbone by 
assuming very low order parameters, which means high amplitude motions for these 
chains. Therefore, the matching of the length of the Ras hydrocarbon chains with those of 
the phospholipid matrix is a result of energetically favorable hydrophobic contacts 
between the Ras and the DMPC chains as well as the accommodation of the interfacial 
area of the Ras chains to the area that the peptide backbone occupies in the membrane 
interface.  
The dynamic properties of this lipid chain completely differ from that of the phospholipid 
membrane. Interestingly, the dynamic properties of the Ras lipid chain at cysteine 181 
resemble those of phospholipid chains in very soft membranes. Such bilayers are 
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characterized by very flexible and mobile hexadecyl chains described by low order 
parameters and large amplitude motions. In other words, the lipid chain of cysteine 181 is 
characterized by a high amount of flexibility.  
Although an immobile lipid chain would provide maximal hydrophobic interactions with 
the membrane, the entropic contribution to the free energy of protein binding would be 
unfavorable. For stable membrane insertion, two lipid modifications are necessary.73 
While the farnesyl moiety appears to be more rigid as inferred from the higher order 
parameter of cysteine 186, the highly flexible and mobile Ras hexadecyl chain 
modification contributes sufficient hydrophobic binding energy but also configurational 
entropy, which both reduces the free energy of the membrane bound Ras protein and 
contributes to stable membrane insertion. According to this model, the branched farnesyl 
chain provides the more rigid membrane anchor while the second flexible chain 
modification can contribute both hydrophobic energy but also favorable configurational 
entropy and therefore reduce the free energy of the membrane ensemble.  
The motional amplitudes of the seven terminal amino acids of the membrane-associated 
Ras protein were determined using 13C CP MAS NMR experiments. It is particularly 
noteworthy that the order parameter of farnesylated cysteine 186 is about 60% higher 
than that of hexadecylated cysteine 181. Considering the high degree of flexibility of the 
chain of cysteine 181, this would suggest that the farnesyl modification of cysteine 186 is 
relatively rigid. Currently, very little is known about the mobility of farnesyl moieties in 
membranes; however, molecular dynamics and NMR results suggest that they exist 
primarily in an extended conformation74 and have no effect on the lipid chain order in 
phospholipids membranes.75 The higher order of cysteine 186 compared to cysteine 181 
suggests that the farnesyl chain may not show the high degree of flexibility that was 
observed for the hexadecyl chain. From its branched structure, the farnesyl chain 
represents a barbed hook that may more stably insert into the membrane than the very 
flexible hexadecyl chain.  
The protein order parameters are relatively low compared to other membrane proteins.76 
However, it should be recalled that the membrane anchor of Ras is not folded into a 
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regular secondary structure. Further, the order parameters need to be related to the time 
scale on which they are measured. Correlation times from the analysis of 13C relaxation 
rates of glycine 183 in membrane-associated Ras 3 were studied by relaxation 
measurement. According to the modified Liparid-Szabo model, the molecular mobility of 
the membrane-associated Ras protein 3 can be separated into a fast segmental and a 
slower overall process. The order parameter for the fast motion of the glycine 183 Cα-Hα 
bond vector is 0.70 and for the slow motions of the membrane anchor it is 0.445.   
At 37 °C the fast bond vector fluctuations of glycine 183 occur with a correlation time of 
1.9 ns and a motional amplitude angle of ~40°. Such segmental fluctuations are quite 
common for amino acids in somewhat flexible loop structures of soluble proteins. This 
agrees with the structural model of membrane-associated Ras protein that showed no 
regular secondary structure.77 On the other hand, the membrane anchor of Ras inserts into 
the lipid water interface of the membrane where it experiences a highly dynamic 
structural assembly of lipids and water molecules.78 This suggests that membrane binding 
of Ras stabilizes the structure of its membrane anchor presumably by hydrogen bonds 
between the protein backbone and phospholipids segments in the membrane interface. In 
addition to the segmental mobility, the membrane anchor of Ras undergoes slower 
motions with large amplitudes (order parameter of 0.445). The correlation time for this 
motion is ~140 ns at 37 °C.  
In summary, the C-terminus of membrane-associated full length Ras protein shows a 
versatile dynamics (Figure 39).  
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Figure 39. Cartoon illustrates the results of dynamical studies of N-Ras proteins.42   
The protein backbone is shown as the 200 lowest energy structures (orange). The 
flexibility of the structure is represented by the yellow tube. Fast segmental motions of 
the protein backbone and side chains occur with correlation times in the nanosecond 
range. The entire C-terminus of Ras undergoes axially symmetric motions on the 
membrane surface with correlation times of several 100 ns. The lipid modifications are 
also highly mobile and flexible in the membrane. 
The segmental motions of the protein backbone are similar to those of loop structures of 
soluble proteins. It is suggested that binding to the lipid membrane stabilizes the structure 
of the C-terminus of Ras. Further, the membrane anchor of Ras undergoes slower 
motions with axial symmetry, which may apply to the entire protein. In fact, NMR study 
of full-length farnesylated Ras also indicated that the motions of the N-terminal domain 
are influenced by the lipidated C-terminus in solution.79 The lipid chain modification at 
cysteine 181 is highly mobile in the liquid-crystalline membrane. 
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5 Experimental Part 
 
5.1.1 Materials and Methods 
 
Nuclear Magnetic Resonance Spectroscopy 
 
1H and 13C NMR spectra were recorded on one of the following instruments: Varian Mercury 
400, Bruker DRX 400 and Bruker DRX 500 with tetramethylsilane as the internal reference. The 
chemical shifts are provided in ppm and the coupling constants in Hz. The following 
abbreviations for multiplicities are used: s, singlet; d, doublet; dd, double doublet; dt, doublet 
triplet; t, triplet; q, quadruplet; m, multiplet; br, broad. The 1H and 13C spectra are calibrated to 
the solvent signals of CDCl3 (7.26 ppm and 77.00 ppm) and MeOH (3.31 ppm, 49.05 ppm).  
 
Solid State NMR Spectroscopy 
 
1H, 2H and 13C NMR spectra were acquired with a Bruker Avance 750 widebore NMR 
spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) at a resonance frequency of 749.8 
for 1H, 188.5 MHz for 13C and 115.1 MHz for 2H.  
 
Sample Preparation 
 
Large unilamellar vesicles were prepared by extrusion in buffer (10mM, HEPES, 10mM NaCl, 
1mM MgCl2, pH 7.4). Aliquots of soluble Ras molecules were added to the liposome solution at a 
1:150 protein to lipid molar ratio. After incubation at 37°C for 4 hours, the sample was 
ultracentrifuged at ~90.000 for 10 hours. Subsequently, the pellet was lyophilized and then 
hydrated to 35 wt% water content. After equilibration by several freeze-thaw cycles and gentle 
centrifugation the sample was transferred into 4 mm MAS rotors with Teflon insert.  
 
Mass Spectrometry 
 
Gass chromatography-mass spectrometry (GC-MS) were measured from a Hewlett Packard 6890 
GC system coupled to a Hewlett Packard 5973 Mass Selective Detector. A HP 5TA capillary 
column (0.33 µm x 25 m x 0.2 mm) and helium flow rate of 2 mL/ min were used. High 
resolution mass spectra (HR-MS, 70 eV) were measured on a Jeol SX 102A spectrometer by 
using fast atom bombardment (FAB) techniques. The matrix used for FAB was 3-
nitrobenzylalcohol (3-NBA). The MALDI-TOF spectra were recorded on a Voyager-DE Pro 
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MALDI-TOF and with 2,5-dihydroxybenzoic acid (DHB) as the matrix (20 mg DHB, 900 µl 
H2O, 90 µl ethanol, 10 µl TFA). 
 
Reversed-Phase High-Pressure Liquid Chromatography 
 
Analytical HPLC was recorded on an Agilent HPLC (1100 series machine). The standard 
gradient began at 10% acetonitrile and was raised to 90% over 15 min. After 3 min at 90% 
acetonitrile, the column was washed for 5 min with 100% acetonitrile. The column was then 
equilibrated for 3 min with 10% acetonitrile. TFA (0.1% v/v) was added to the HPLC solvents. 
Analytical HPLC-MS measurements were recorded on an Agilent HPLC (1100 series) coupled to 
a Finnigan LCQ ESI spectrometer. The column used is indicated in parenthesis.  
 
Thin-Layer Chromatography (TLC) 
 
Thin-layer chromatography (TLC) plates were obtained from Merck (Silica gel 60, F254). The 
TLCs were visualized by UV light (λ = 254 nm, 366 nm) or by staining with KMnO4 solution. 
The solvent system and Rf values are noted for the synthesized compounds. 
 
Flash Chromatography 
 
Flash column chromatography was performed using flash silica gel (Merck, Darmstadt, 40-64 
µM) with pressure ranging from 0.5 - 1.0 bar.  
 
Chemicals 
 
Chemicals were obtained from the following suppliers and used without further purification: 
Acros, Aldrich, Fluka, Novabiochem, Senn Chemicals. The solid support was purchased from 
Novabiochem. Uniformly 13C and 15N labeled amino acids were purchased from Euriso-Top 
GmbH (Saarbrücken, Germany).  
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5.2.1 Experimental procedures and analytical data 
 
General procedure (GP 1) for the synthesis of building blocks 15, 17, 19 and 21 
 
To isotope labeled amino acid (0.64 mmol, 1.0 equivalent) in Na2CO3 solution (1.6 mmol, 2.5 
equivalents, 2 mL) and dioxane (4 mL) mixture was added Fmoc-Cl (0.64 mmol, 1.0 equivalent) 
at 0°C. The reaction mixture was stirred at room temperature overnight. The reaction mixture was 
extracted with diethyl ether (10 mL x 2), and the organic layer was discarded. The pH of the 
aqueous layer was adjusted to pH 1 with 1 M HCl. The aqueous solution was extracted with ethyl 
acetate (10 mL x 2). The combined organic layers were washed with brine, dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography.       
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) glycine-13C2, 15N 15   
O
H
N
OH
O
O
15  
 
Yield = 85 %; Rf = 0.1 (CH2Cl2 / MeOH : 9/1); LRMS (FAB, m-NBA) m/z calc. for 
C1513C2H1515NO4 300.1, found 300.0 [M+H]+; 1H NMR (400 MHz, CDCl3): δ = 7.77 (d, J = 7.5 
Hz, 2H), 7.60 (d, J = 7.0 Hz, 2H), 7.41 (t, J = 7.5, 7.5 Hz, 1H), 7.32 (dt, J = 7.5, 1.2 Hz, 2H), 
4.44 (dd, J = 7.0, 0.6 Hz, 2H), 4.24 (t, J = 7.0 Hz, 1H), 3.90-3.86 (m, 1H) ppm; 13C NMR (100 
MHz, CDCl3): δ = 171.9 (d, J = 59.2 Hz, 1C), 156.5, 143.7, 140.6, 127.5, 127.0, 125.0, 120.0, 
65.6, 46.5, 42.5 (dd, J = 59.6, 14.3 Hz, 1C) ppm. 
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) L-Methionine-13C5, 15N 17 
O
H
N
OH
O
O
17
S
 
 
Yield = 75 %; Rf = 0.32 (CH2Cl2 / MeOH : 9/1); LC-MS (C18, ESI_MS) 378.1 [M+H]+; Rt = 
8.82 min; 1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 7.5 Hz, 2H), 7.6 (d, J = 7.6 Hz, 2H), 
7.40 (t, J = 7.4 Hz, 2H), 7.31 (t, J = 7.44 Hz, 2H), 4.72 (br, 1H), 4.44 (d, J = 6.8 Hz, 1H), 4.23 (t, 
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J = 6.8 Hz, 2H), 2.39 (br, 1H), 2.27 (br, 1H), 2.10 (s, 3H), 1.93 (br, 2H) ppm; 13C NMR (100 
MHz, CDCl3): δ = 176.87 (d, J = 58.8 Hz, 1C), 155.9, 143.6, 141.3, 127.7, 127.0, 125.0, 120.0, 
67.1, 52.9 (ddd, J = 58.7, 34.3, 12.9 Hz, 1C), 47.1, 31.5 (t, J = 35.0 Hz, 1C), 29.9 (d, J = 35.7 
Hz, 1C), 15.4 (s, 1C) ppm. 
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) L-Proline-13C5,15N 19  
O N
O
19
OHO
 
 
Yield = 70 %; Rf = 0.38 (CH2Cl2 / MeOH : 9/1); LC-MS (C18, ESI_MS) 343.9 [M+H]+; Rt = 
8.51 min; 1H NMR (400 MHz, CDCl3): δ =  7.77 (d, J = 7.4 Hz, 2H, trans), 7.72 (d, J = 7.4 Hz, 
2H, cis), 7.60 (d, J = 7.4 Hz, 2H, trans), 7.56 (d, J = 8.2 Hz, 2H, cis), 7.45-7.35 (m, 2H), 7.35-
7.27 (m, 2H), 4.60 (br, 1H), 4.54-4.45 (m, 1H), 4.44-4.34 (m, 1H), 4.30-4.20 (m, 2H), 3.75 (br, 
1H), 3.65 (br, 1H), 3.39 (br, 1H), 3.29 (br, 1H), 2.45 (br, 1H), 2.29 (br, 1H), 2.13 (br, 2H), 1.94-
1.63 (m, 2H) ppm (cis-trans isomers); 13C NMR (101 MHz, CDCl3): δ =  176.8 (d, J = 60.4 Hz, 
1C), 174.46 (d, J = 58.7 Hz, 1C), 156.5, 154.1, 143.760, 143.6, 141.3, 127.7, 127.6, 127.0, 125.0, 
124.9, 120.0, 119.9, 60.27-57.55 (m, 1C), 68.0, 67.3, 47.85-45.91 (m, 1C), 30.9 (t, J = 30.6, 30.6 
Hz, 1C), 28.7 (t, J = 31.9, 31.9 Hz, 1C), 24.3 (t, J = 32.0, 32.0 Hz, 1C), 23.3 (t, J = 32.0, 32.0 
Hz, 1C) ppm (cis-trans isomers). 
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) L-Leucine-13C6, 15N 21  
O
H
N
OH
O
O
21  
 
Yield = 85 %; Rf  = 0.45 (CH2Cl2 / MeOH : 9/1); 1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 
7.59 Hz, 2H), 7.64-7.54 (m, 2H), 7.40 (t, J = 7.36 Hz, 2H), 7.31 (t, J = 7.33 Hz, 2H), 4.60 (br, 
1H), 4.51-4.35 (m, 2H), 4.23 (t, J = 7.02 Hz, 1H), 2.03-1.64 (m, 2H), 1.63-1.34 (m, 2H), 1.12 (d, 
J = 5.5 Hz, 3H), 0.81 (d, J = 3.6 Hz, 3H) ppm; 13C NMR (101 MHz, CDCl3): δ = 177.48 (d, J = 
58.8 Hz, 1C), 143.6, 141.3, 127.7, 127.0, 125.0, 119.9, 67.0, 52.29 (ddd, J = 58.7, 34.2, 12.2 Hz, 
1C), 47.1, 41.3 (t, J = 34.4, 34.4 Hz, 1C), 24.76 (q, J = 34.6, 34.6, 34.4 Hz, 1C), 22.81 (d, J = 
34.8 Hz, 1C), 21.67 (d, J = 34.5 Hz, 1C) ppm. 
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General procedure (GP 2) for the synthesis of compound 24, 35 
 
To isotope labeled cysteine 22 (71 mg, 0.57 mmol) in methanol (5 mL) was added 7N NH3 in 
methanol (2 mL) and farnesyl bromide ( 340 mg, 0.60 mmol) respectively at 0°C. The reaction 
mixture was slowly warmed to room temperature and stirred overnight. The reaction mixture was 
evaporated to dryness under reduced pressure. CH2Cl2 (10 mL) and Et3N (115 mg, 1.14 mmol) 
were added to the remained white solid flask followed by Fmoc-OSu (230 mg, 0.68 mmol) at 
0°C. The reaction mixture was slowly warmed to room temperature and stirred for 3 hours. 1M 
HCl (5 mL) was added to the reaction mixture, and extracted twice with CH2Cl2. The combined 
organic phase was washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The 
crude was purified by flash chromatography.      
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) S-Hexadecyl L-Cysteine-13C3, 
15N 24  
O
H
N
OH
O
O
S
24  
 
Yield = 63 %; Rf = 0.7 (CH2Cl2 / MeOH : 9/1); LC-MS (C4, ESI_MS) 552.2 [M+H]+; Rt = 9.15 
min; 1H NMR (400 MHz, CDCl3): δ = 7.76 (d, J = 7.4 Hz, 2H), 7.60 (d, J = 6.8 Hz, 2H), 7.40 (t, 
J = 7.66 Hz, 2H), 7.31 (t, J = 7.45 Hz, 2H), 5.22 (t, J = 7.34 Hz, 1H), 5.13-5.01 (m, 2H), 4.63 ( 
m, 1H), 4.55-4.32 (m, 2H), 4.24 (t, J = 7.00 Hz, 1H), 3.46-2.98 (m, 2H), 2.92-2.66 (m, 2H), 2.18-
2.00 (m, 6H), 2.00-1.91 (m, 2H), 1.67 (s, 3H), 1.65 (s, 3H), 1.59 (s, 6H) ppm; 13C NMR (100 
MHz, CDCl3): δ = 173.0 (d, J = 57.7 Hz, 1C), 156.5, 144.0, 141.5, 140.2, 135.5, 131.4, 127.9, 
127.4, 125.4, 124.7, 124.1, 120.2, 11.9, 67.7, 54.30-52.43 (m, 1C), 47.3, 40.0, 39.9, 33.7, 33.1 (d, 
J = 35.6 Hz, 1C), 30.4, 27.2, 26.7, 26.0, 18.0, 16.4, 16.3 ppm. 
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) S-Farnesyl L-Cysteine 35  
O
H
N
OH
O
O
S
35  
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Yield = 60 %; Rf = 0.7 (CH2Cl2 / MeOH : 9/1); LC-MS (C4, ESI_MS) 548.4 [M+H]+; Rt = 9.69 
min; 1H NMR (400 MHz, CDCl3 ): δ = 7.76 (d, J = 7.4 Hz, 2H), 7.60 (t, J = 6.47 Hz, 2H), 7.40 (t, 
J = 7.42 Hz, 2H), 7.31 (t, J = 7.38 Hz, 2H), 5.61 (d, J = 7.86 Hz, 1H), 5.22 (t, J = 7.46 Hz, 1H), 
5.08 (t, J = 6.80 Hz, 2H), 4.62 (dd, J = 12.50, 5.55 Hz, 1H), 4.41 (t, J = 7.03 Hz, 2H), 4.24 (t, J 
= 7.07 Hz, 1H), 3.45-3.07 (m, 2H), 3.06-2.87 (m, 2H), 2.08-2.00 (m, 6H), 2.00-1.92 (m, 2H), 
1.67 (s, 3H), 1.65 (s, 3H), 1.59 (6, 3H) ppm; 13C NMR (100 MHz, CDCl3 ): δ =173.0, 156.5, 
144.0, 141.5, 140.2, 135.5, 131.4, 127.9, 127.4, 125.4, 124.7, 124.1, 120.2, 11.9, 67.7, 53.0, 47.3, 
40.0, 39.9, 33.7, 33.1, 30.4, 27.2, 26.7, 26.0, 18.0, 16.4, 16.3 ppm. 
 
General procedure (GP 3) for the synthesis of compound 26 
 
To a solution of imidazole (99 mg, 1.45 mmol) and PPh3 (285 mg, 1.09 mmol) in CH2Cl2 (2 mL) 
at 0°C was added I2 (276 mg, 1.09 mmol). Cetyl alcohol 25 (200 mg, 0.72 mmol) in CH2Cl2 (1 
mL) was then added and the reaction mixture was warmed to room temperature after 0.5 hour 
stirring. The reaction flask was covered with aluminum foil and stirred overnight. The reaction 
mixture was quenched with 5 % Na2S2O3 (20 mL). The organic layer was separated and the 
aqueous layer was washed with CH2Cl2. The combined organic phase was washed with brine, 
dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by column 
chromatography. 
 
Analytical data of Hexadecyl-D33 iodide 26 
26
DD
DD
DD
DD
DD
DD
DD
DD
DD
DD
DD
DD
DD
DD
DD
D
DD
I
 
 
Yield = Quantitative; Rf = 0.9 (cyclohexane / ethyl acetate : 4/1); GC-MS: 6.66 min, 385 [M]+, 
258 [M-I]+; 13C NMR (100 MHz, CDCl3): δ = 32.1, 29.8, 29.5, 22.9, 14.3, 8.2 ppm. 
 
General procedure (GP 4) for the synthesis of compound 29 
 
13C and 15N labeled cysteine (42 mg, 0.34 mmol) was treated with 1M HCl (3 mL) for 1 hour and 
dried under reduced pressure, the procedure was repeated once to afford 27. Deuterated 
hexadecyl iodide 26 (132 mg, 0.34) in ether was added to 27 and the ether was evaporated under 
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reduced pressure. DMF (1 mL) and Na2CO3 (76 mg, 0.72 mmol) were added to the reaction flask 
and the reaction mixture was stirred at room temperature for 60 hours. The reaction mixture was 
evaporated to dryness under reduce pressure.  H2O (1 mL) and dioxane (2 mL) were added to the 
reaction mixture, followed by Na2CO3 (36 mg, 0.34 mmol) and Fmoc-OSu (114 mg, 0.34 mmol) 
at 0°C. The reaction mixture was stirred for 3 hours at room temperature. 1M HCl (5 mL) was 
added to the reaction mixture, and extracted twice with CH2Cl2. The combined organic phase was 
washed with brine, dried over MgSO4, filtered and concentrated in vacuo. The crude was purified 
by flash chromatography.  
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) S-Hexadecyl-D33 L-Cysteine-
13C3, 15N 29 
D
DD
D D
DD
D D
DD
D D
DD
D D
DD
D D
DD
D D
DD
D D
D
D D
O
H
N
O
O
S
29
D
OH
 
 
Yield = 35 %; Rf = 0.5 (CH2Cl2 / MeOH : 9/1); 1H NMR (400 MHz, CDCl3): δ = 7.69 (d, J = 
7.6Hz, 2H), 7.53 (d, J = 7.2 Hz, 2H), 7.33 (t, J = 7.4 Hz, 2H), 7.24 (t, J = 7.3 Hz, 2H), 5.68 (d, J 
= 7.9 Hz, 1H), 5.45 (d, J = 7.5 Hz, 1H), 4.73 (br, 1H), 4.34 (d, J = 6.5 Hz, 2H), 4.17 (t, J =7.00 
Hz, 1H), 3.14 (br, 1H), 2.78 (br, 1H) ppm; 13C NMR (100 MHz, CDCl3): δ = 174.57 (d, J = 59.5 
Hz, 1C), 155.92 (dd, J = 26.7, 1.9 Hz, 1C), 143.65, 141.31, 127.75, 127.09, 125.08, 120.00, 
67.40, 53.41 (ddd, J = 50.0, 35.0, 12.8 Hz, 1C), 47.11, 33.99 (d, J = 35.8 Hz, 1C) ppm. 
 
General procedure (GP 5) for the synthesis of compound 36 
 
To Fmoc-Cys(Trt)-OH (200 mg, 0.35 mmol) in CH2Cl2 (15 mL) was added 3% TES (0.45 mL) 
and 5% TFA (0.75 mL). The reaction mixture was stirred for 2 hours at room temperature. The 
solvent was co-evaporated with toluene two times under reduced pressure. To the resulted white 
solid in DMF (5 mL) was added K2CO3 (145 mg, 1.05 mmol) and deuterated hexadecyl iodide 26 
(135 mg, 0.35 mmol) respectively. The reaction mixture was stirred at room temperature for 4 
hours. The solvent was poured into diethyl ether (20 mL) and extracted with 1M HCl (5 mL) 
twice. The collected organic layer was washed with brine, dried over MgSO4, filtered and 
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concentrated in vacuo. The crude product was purified by silica gel chromatography to obtain 50 
mg 36 as white solid (23% yield).     
 
Analytical data of N-(9-Fluorenylmethoxycarbonyl) S-Hexadecyl-D33 L-Cysteine 36 
D
DD
D D
DD
D D
DD
D D
DD
D D
DD
D D
DD
D D
DD
D D
D
D D
O
H
N
O
O
S
36
D
OH
 
 
Yield = 23 %; Rf = 0.5 (CH2Cl2 / MeOH : 9/1); LC-MS (C4, ESI_MS) 601.4 [M+H]+; Rt = 10.53 
min; 1H NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 7.3 Hz, 2H), 7.53 (d, J = 7.1 Hz, 2H), 7.34 (t, 
J = 7.4 Hz, 2H), 7.24 (t, J = 7.3 Hz, 2H), 5.56 (d, J = 7.5 Hz, 1H), 4.64 (br, 1H), 4.37 (d, J = 7.8 
Hz, 2H), 4.17 (t, J = 7.04 Hz, 1H), 3.15-2.91 (m, 2H) ppm; 13C NMR (101 MHz, 
CDCl3): δ =174.5, 155.9, 143.6, 141.2, 127.6, 127.0, 125.1, 119.9, 67.4, 47.0 ppm. 
 
General procedure (GP 5) for the synthesis of isotope labeled lipidated peptides 7, 8 and 9 
 
Coupling using DIC/HOBT activation. The Fmoc-amino acid to be coupled (3 equivalents 
relative to resin loading) was dissolved in dry DMF (For lipidated amino acids, same volume of 
CH2Cl2 was added), followed by addition of HOBt (3 equivalents) and DIC (3 equivalents). The 
mixture was stirred for 1 minute and added to the hydrazine resin 31 at room temperature. The 
mixture was shaken at room temperature for 2 hours (For lipidated amino acids, the mixture was 
shaken overnight). The solvent was filtered off and the resin was washed three times with DMF, 
three times with CH2Cl2, and three times with DMF.  
 
Determination of Fmoc-loading. Resin (1-2 mg) was weighed into a volumetric flask and filled 
with 3 mL 20% piperidine in DMF. After 20 minutes of gentile agitation, 1 mL was transferred to 
a quartz UV cuvette and diltuted to 3 mL with DMF. The absorbance was measured against 
reference at λ = 301 nm. The loading CL is determined according to Beer’s Law, A = εcd, where ε 
= 7800 at 301 nm.  
 
CL = M
VCv ×
 = 
M7800
10009A
×
××
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where CV is the volume concentration, A is the absorbance, d is the path length of the UV cuvette, 
V is the total volume, M is the mass of the resin. 
 
Determination of Theoretical Loading. The theoretical loading of the resin was determined 
according to the following formula: 
 
Loadingnew (mol/g) = )g/mol(loading1
)g/mol(loading
old
old
×∆+  
 
Where loadingold is the previous loading and ∆ is the mass difference of the added compound to 
the resin. 
 
Removal of Fmoc protecting group. The resin was washed 3 times with 3 mL 20% 
piperidine/DMF (5 minutes each time) to remove the Fmoc group from the amino 
acid.Subsequently, the resin was washed again three times with DMF, three times with CH2Cl2, 
three times with DMF (each time 2 to 5 mL). 
 
Coupling of MIC group using HATU/HOAT. The Fmoc-amino acid to be coupled (3 
equivalents relative to resin loading) was dissolved in dry DMF followed by addition of HOAT (3 
equivalents) and HATU (3 equivalents). DIPEA (6 equivalents) was lastly added and the resulting 
solution was was stirred for 1 minute and added to the peptidyl hydrazine resin at room 
temperature. The mixture was shaken at room temperature for 2 hours. The solvent was filtered 
off and the resin was washed three times with DMF, three times with CH2Cl2, and three times 
with DMF. Finally, the resin was dried in vacuo.  
 
Release of Peptides using Cu(OAc)2/pyridine/Methanol. To MIC-containing peptidyl 
hydrazine resin (initial loading 3.4 mmol) in CH2Cl2 (2 mL) was added Cu(OAc)2 (3mg, 1.7 
mmol), pyridine (26 mg, 0.34 mmol) and methanol (0.1mL, 2.4 mmol) mixture in CH2Cl2 (2 mL). 
The reaction mixture was shaken for 3 hours at room temperature under oxygen. The reaction 
solvent was collected and washed with CH2Cl2. The collected solvent was extracted twice with 
1M HCl (5 mL each), washed with brine, dried with MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by silica gel chromatography.   
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Analytical data of MIC-Gly-Cys(HD-D33)-Met-Gly(13C2, 15N)-Leu-Pro-Cys(Far)-
OMe 9 
NH-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
S-(HD-D33) S-(Far)
O
N
O
O
9  
 
Yield = 17 %; Rf = 0.4 (CH2Cl2 / MeOH : 9/1); LC-MS (C4, ESI_MS) 1351.8 [M+H]+, 1374.0 
[M+Na]+; Rt = 11.13 min; 1H NMR (400 MHz, CDCl3): δ = 6.68 (s, 2H), 5.15 (t, J = 7.6 Hz, 
1H), 5.11-5.04 (m, 2H), 4.75 (t, J = 9.5 Hz, 1H), 4.72-4.61 (m, 2H), 4.62-4.52 (m, 2H), 4.30-4.23 
(m, 1H), 3.95 (t, J = 5.0 Hz, 1H), 3.74 (s, 3H), 3.54-3.45 (m, 4H), 3.16 (dd, J = 13.3, 8.2 Hz, 
1H), 3.05 (dd, J = 13.3, 7.1 Hz, 1H), 2.94 (dd, J = 13.8, 4.8 Hz, 1H), 2.84 (dd, J = 11.5, 6.7 Hz, 
1H), 2.71 (dd, J = 13.6, 6.6 Hz, 1H), 2.64-2.52 (m, 3H), 2.29 (t, J = 7.4 Hz, 1H), 2.25-2.17 (m, 
4H), 2.13-1.92 (m, 12H), 1.66 (s, 3H), 1.65 (s, 3H), 1.59 (s, 6H), 0.93 (d, J = 4.7 Hz, 3H), 0.92 
(d, J = 4.4 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ = 170.8, 170.5, 170.0, 169.59 (d, J = 
53.0 Hz, 1C), 169.5, 169.4, 169.3, 169.0, 168.9, 140.0, 135.3, 134.0, 131.2, 124.2, 123.6, 119.4, 
60.0, 53.3, 52.5, 51.9, 49.0, 47.3, 42.98 (dd, J = 53.0, 10.8 Hz, 1C), 39.6, 37.5, 35.8, 30.5, 30.5, 
29.6, 28.1, 26.7, 26.5, 26.2, 25.6, 24.9, 24.8, 24.8, 24.5, 23.2, 21.6, 17.6, 16.1, 15.9, 15.0 ppm. 
 
Analytical data of MIC-Gly(13C2, 15N)-Cys(HD-D33)-Met(13C5, 15N)-Gly-Leu-
Pro(13C5, 15N)-Cys(Far, 13C3, 15N)-OMe 7 
NH-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
S-(HD-D33) S-(Far)
O
N
O
O
7  
 
Yield = 23 %; Rf = 0.4 (CH2Cl2 / MeOH : 9/1); LC-MS (C4, ESI_MS) 1367.6 [M+H]+, 1389.7 
[M+Na]+; Rt = 10.69 min; 13C NMR (100 MHz, CDCl3): δ = 171.83-170.33 (m, 4C), 60.03 (dd, J 
= 54.9, 32.2 Hz, 1C), 53.69-51.29 (m, 2C), 43.99 (dd, J = 52.6, 11.8 Hz, 1C), 47.41 (dd, J = 
31.2, 9.4 Hz, 1C), 33.18 (d, J = 35.8 Hz, 1C), 30.60 (d, J = 35.2 Hz, 2C), 28.05 (td, J = 65.0, 
35.2, Hz, 1C), 24.90 (t, J = 31.7 Hz, 1C), 15.03 (s, 1C) ppm. 
 
Analytical data of MIC-Gly-Cys(HD-D33, 13C3, 15N)-Met-Gly(13C2, 15N)-Leu(13C6, 
15N)-Pro-Cys(Far)-OMe 8 
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NH-Gly-Cys-Met-Gly-Leu-Pro-Cys-OMe
S-(HD-D33) S-(Far)
O
N
O
O
8  
 
Yield = 5.4 mg (10%); Rf = 0.4 (CH2Cl2 / MeOH : 9/1); LC-MS (C4, ESI_MS) 1362.9 [M+H]+, 
1384.8 [M+Na]+; Rt = 10.53 min. 
 
General procedure (GP 6) for the ligation of isotope labeled lipidated peptides with 
truncated N-Ras protein 1, 2 and 3 
 
The coupling of labeled lipidated peptide and truncated N-Ras protein (1-182N-RasG12V) was 
performed by Christine Nowak following the previously reported protocol.44 The product of the 
ligation was analyzed by MALDI-TOF MS and SDS-PAGE.  
 
Analytical Data of N-Ras∆181MIC-Gly-Cys(HD-D33)-Met-Gly-Leu-Pro-Cys(Far)-
OMe 1 
 
Yield = 37%; The mass peak at 21759 corresponds to the ligation product 1 
 
1999.0 7600.2 13201.4 18802.6 24403.8 30005.0
Mass (m/z)
0
1.4E+
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1=>MC[BP = 21755.8, 13509]
21759.06
10880.78
21889.73
21578.98
10940.63 21438.92
21344.37
10690.242452.39 7249.64 21205.79
 
 
 
 
________________________________________________________________________ 
 81
 
 
1: truncated N-Ras protein 1-182N-RasG12V, 12: marker, 2-11: product fraction after purification   
 
Analytical Data of N-Ras∆181MIC-Gly-Cys(HD-D33)-Met-Gly-Leu-Pro-Cys(Far)-
OMe 2 
 
Yield = 15%; The mass peak at 21749 corresponds to the ligation product 2. 
 
1999.0 7600.2 13201.4 18802.6 24403.8 30005.0
Mass (m/z)
0
1.1E+
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1=>MC[BP = 21748.6, 11338]
21749.69
10875.23
21623.71
21198.16
21567.04
21329.0310932.46
20390.0010982.23
10709.56 20924.82
2580.12 7254.45 10468.29 22207.3420271.233028.354554.18
 
 
 
 
8: truncated N-Ras protein 1-182N-RasG12V, 12: marker, 1-7: product fraction after purification, 
9: crude mixture. 
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Analytical Data of N-Ras∆181MIC-Gly-Cys(HD-D33)-Met-Gly-Leu-Pro-Cys(Far)-
OMe 3 
 
Yield = 30 %; The mass peak at 21750 corresponds to the ligation product 3. 
 
1999.0 7600.2 13201.4 18802.6 24403.8 30005.0
Mass (m/z)
0
3.0E+
0
10
20
30
40
50
60
70
80
90
100
%
 In
te
ns
ity
Voyager Spec #1=>MC[BP = 21749.0, 29846]
21750.78
10872.46
21962.04
21848.28
10978.74
10797.212219.27 22186.236416.232336.15 11093.58
4038.61 20395.87
 
 
 
 
7: truncated N-Ras protein 1-182N-RasG12V, 12: marker, 1-6: product fraction after purification, 
8: crude mixture.   
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1 Introduction 
 
Over the past centuries, science and technology have improved the life quality of human 
beings tremendously. From transportation, entertainment, medicine and to every daily 
activity, science and technology have shaped the fate of human beings from the 
beginning of life till the end of the day. The life span of human beings has been 
prolonged because of the advancement of medicine and development of new drugs. 
However, there are still many diseases such as HIV and Alzheimer’s disease that can not 
be cured. To tackle these diseases, chemical biology has come into play from the end of 
the last century.        
 
Chemical biology is a rapidly developing discipline, which attempts to answer biological 
questions by directly probing living systems at the chemical level. In contrast to research 
using biochemistry, genetics, or molecular biology, where mutagenesis can provide a 
modified version of the organism or cell of interest for further studies, chemical 
biological studies probe systems in vitro and in vivo with chemical entities that have been 
designed for a specific purpose or identified on the basis of biochemical or cell-based 
screening. Because of the nearly limitless number of chemicals available, this approach 
has become increasingly popular and useful in basic research, especially so for drug 
discovery and design. 
  
A century of genetics-based interrogations of life has shown that perturbing life processes 
and observing the consequences can provide illuminating insights. Based on that, 
advances in diversity-oriented organic synthesis coupled with rapidly developing 
methodology and techniques of biological science should enable the chemical biology 
approach to be practical to explore all facets of biology with small-molecule modulators. 
In general, the chemical biology approach by using small molecules has become a 
promising tool to cure lethal diseases of human beings in recent years.    
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2 Background 
 
2.1  Vesicular Transport in Eukaryotic Cells 
 
One of the significant features distinguishing eukaryotic and prokaryotic cells is that the 
eukaryotic cells contain phospholipid membrane enclosed organelles such as 
mitochondria, endoplasmic reticulum (ER) and Golgi apparatus. Each of these organelles 
functions distinctively and occupies an irreplaceable position in eukaryotic cells. For 
example, the Golgi apparatus is responsible for processing and sorting of proteins 
received from the ER before being transported to their eventual destinations, and ER’s 
function is to facilitate protein folding and transport of synthesized proteins. The defect 
of any one of these organelles will cause the cell to function ineffectively or even cell 
death.1  
 
For a cell to execute its functions properly, each of its numerous substances must be 
localized at the correct cellular compartments and plasma membrane. Unlike prokaryotic 
cells which do not contain membrane-bound compartments, the existence of a membrane 
surrounding the eukaryotic organelles has restricted the free movement of large 
molecules such as proteins, lipids, hormone and other essential substances from one 
compartment to another. With the exception of water, oxygen and some other small and 
non-polar molecules which are able to diffuse across phospholipids membranes, most of 
the larger polar molecules like proteins, ions and glucose pass through the membrane via 
different pathways. Molecules such as ions and glucose can be transported across 
membrane by the assistance of ion channel proteins and glucose symporter.2 For the 
super-sized molecules like proteins, passing through the membrane by channel proteins is 
not possible.  The mechanism by which proteins and other large molecules are 
transported to different compartments is called vesicular transport.  
 
Vesicular transport3 plays a central role in the interaction of cells with their environment 
and the coordination of each organelle. Besides being the route by which proteins and 
peptides are released into the surrounding milieu, it is also the process by which 
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receptors, ion channels, ion pumps and other important receptor proteins are presented at 
the surface of the plasma membrane and different compartments. Therefore, the 
selectivity of such transport is critical in maintaining the functional organization of the 
cell and contact with its surroundings. Hormone receptor proteins, for example, must be 
delivered to the plasma membrane if the cell is to recognize hormones. As for the 
corrected folding of nascent proteins which require post-translational modification, these 
must be transported from ER to Golgi apparatus for further phosphorylation, 
glycosylation or lipidation. In vesicular transport, proteins are surrounded and transported 
within vesicles made up of at least one phospholipids bilayer, so the specificity of 
transport is based on the selective packaging of intended cargo into vesicles and the 
regulating proteins localized outside the vesicles that recognize and fuse only with the 
appropriate target membrane. 
 
Protein trafficking (Figure 1) is highly regulated by various proteins at different steps. In 
general, this trafficking pathway can be divided into four steps: vesicle budding from a 
parent compartment, vesicle movement in the cytosol, vesicular tethering/docking with 
target membrane, and vesicle fusion to target membrane. In each step, different proteins 
are involved in regulating and coordinating the process. The absence or defect of anyone 
of the regulating proteins will have serious consequence to this process, or even render 
the termination of the whole transport event. 
 
 
Figure 1. Schematic illustration of protein trafficking pathway.4 
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2.2 The Roles of Rab Proteins in Protein Trafficking  
 
Of the many proteins which participate in regulating this biologically important process, 
Rab proteins have clearly emerged to be the proteins which occupy the critical position in 
protein trafficking, due to their importance and influence in all steps of trafficking.5 
Furthermore, from the genomic perspective, Rab proteins have also appeared to be 
conserved throughout eukaryotic cell evolution and play a critical role in shaping the 
current vesicular trafficking pathways.6   
 
Rab proteins belong to the largest family of the Ras superfamily of small GTPases. More 
than 60 Rab proteins have been described in mammalian cells, each with a specific 
subcellular localization, trafficking pathways, and many with specific patterns of tissue 
distribution (Table 1).7  
 
Table 1. The human Rab GTPase family: nomenclature, localization and function.4 
 
Rab Rab localization Possible function 
Rab 1 
 
Rab 2 
 
Rab 3a 
 
Rab 5a 
 
Rab 6a 
 
Rab 27 
ER-Golgi Intermediate compartment, 
cis-Golgi 
 
ER-Golgi Intermediate compartment, 
cis-Golgi 
 
SV, secretory granules, PM 
 
 
 EE, CCV, PM, SV 
 
 
ER, Golgi, TGN 
 
 
Lysosome-like organelles: 
melanosomes, cytolytic granules 
ER-Golgi, intra-Golgi transport 
 
Golgi-ER retrograde transport 
 
Regulated neurotransmitter release 
 
PM-EE transport, EE-EE fusion 
 
Retrograde Golgi-ER, intra-Golgi 
traffic, Golgi-ER vesicles 
 
Lytic granule release, melanosome 
transport 
 
Abbreviations: EE, early endosomes; CCV, clathrin-coated vesicles; PM, plasma membrane; 
TGN, trans-Golgi network; SV, synaptic vesicles    
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Rab proteins act predominantly as positive regulators, where their depletion leads to 
blocked or reduced transport in vivo or in vitro. Different kinds of Rab proteins regulate 
the transport of proteins from different compartments. For example, Rab 1 and Rab 2 
play a role in ER to Golgi transit, whereas, Rab 3 is associated with secretory vesicles 
and has a role in regulated secretion of hormones and neurotransmitters.8 The 
characteristic functions of Rab proteins in the trafficking pathway have rendered Rab 
proteins to be essential at all levels and steps of vesicular transport.  
 
2.2.1  Rab proteins assisted vesicle formation 
 
The proteins that are found to be involved in vesicle formation belong to vesicle-coated 
protein complexes, namely, Clathrin-, COPI-, COPII-coated protein complex and their 
subunit proteins.9 However, recent in vivo and in vitro studies have shown that Rab also 
plays a crucial role in this process. One revealing finding on the mechanism by which 
Rab may be involved is that the Rab 11 effector, Rabphilin-11 together with a vesicle 
coat component Sec 13 of the coat complex COPII is responsible for triggering vesicle 
formation from ER to Golgi.10 Furthermore, Rab 11, Rabphilin-11 and Sec 13 may also 
function together in the formation of trans-Golgi network vesicles (Figure 2).11  
 
Proteins
Donor
Rab GTPase
Rabphilin 11
Sec 13
Vesicle Formation
Vesicle
 
 
Figure 2. Rab proteins assisted vesicle formation.   
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2.2.2  Rab proteins mediated vesicle motility 
 
In protein transport, both microtubules and actin cytoskeleton serve as rails for the 
movement of vesicles and organelles, using kinesin and myoxin based motors, 
respectively.12 The suggestion that Rab proteins are involved in vesicle motility along 
microtubules is supported by several evidences. First, the discovery of a Golgi-associated 
Rab protein, Rab 6, binding to a member of the kinesin family subsequently termed 
Rabkinesin-6 appears to play a role in cytokinesis, a process involving membrane 
transport events (Figure 3).13 Another Rab 6 effector candidate, GAPCenA, provides an 
additional connection between Rabs and microtubules. This putative effector is 
associated with the centrosome and is involved in microtubule nucleation, suggesting a 
possible role for Rab 6 in Golgi dynamics.14  
 
Microtubule
Proteins
Rab GTPase
Rabkinesin  
 
Figure 3. Rab proteins mediated vesicle motility.  
 
2.2.3  Rab proteins regulate vesicle docking 
 
To ensure that membrane traffic proceeds in an orderly manner, transport vesicles must 
be highly selective in recognizing the correct target membrane with which to fuse. This 
crucial recognition step and docking of vesicles to the target compartment is an 
established role for Rabs. A number of Rab effectors are implicated in such a function. 
One current proposed vesicle docking model suggests that Rab recruit proteins containing 
coiled-coil domains to form the sites for vesicle docking and extended rod structures to 
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bridge the two proximal membranes which can facilitate the membrane fusion process 
(Figure 4). 15 
Rab GTPase
Effector
Acceptor
Tethering Factor
 
 
Figure 4. Vesicle docking regulated by Rabs. 
 
One example supporting this model is the Rabaptin 5 complex, which interacts 
preferentially with endosome-associated Rab 5.16 Rabaptin 5 has two distinct Rab binding 
sites that could, in principle, dock two separate endosomes together. Rab 5 also interacts 
with EEA 1, an early endosome-associated protein that contains long stretches that form 
the coiled coil domain. EEA 1 can bring endosomes together and acts as an upstream 
regulator of fusion proteins.  
 
2.2.4  Rab proteins regulate vesicle fusion  
 
The final step of vesicular transport is assigned to a family of conserved membrane 
proteins termed SNAREs (soluble N-ethylmaleimide-sensitive-factor attachment protein 
receptor). Specific combinations of SNAREs that reside on vesicles (v-SNAREs) and 
SNAREs that associate with target membrane (t-SNAREs) form complexes that can drive 
membrane fusion.17 The participation of Rabs in this step was thought to be upstream to 
the SNARE complex formation. Recent information about the interaction of Rab 
effectors with other proteins pointed out that Rabs have a direct role in SNARE complex 
formation, and give new clues regarding their mode of interaction.18  
 
A plausible model for Rab function in vesicle fusion, through the interaction with a Sec-
1-like protein, suggests that Rabs recruits an effector, which interacts with a Sec 1-like 
protein (Figure 5). Sec 1 is the prototypic t-SNARE protector. This protein binds directly 
and tightly to the t-SNARE on the presynaptic plasma membrane, syntaxin-1A. Binding 
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of Sec 1 to syntaxin-1A blocks v-SNARE and t-SNARE interaction and therefore 
prevents the fusion of the vesicle with the target membrane. The interaction of the 
effector with the Sec 1 protein induces the exposure of the t-SNARE to its 
complementary set and allows it to form a complex with the v-SNARE, an event that 
results in membrane fusion.19  
 
Rab GTPase
Effector
Sec 1
v-SNARE
t-SNARE
Membrane FusionAcceptor
 
 
Figure 5. Rab proteins regulate vesicle fusion.  
 
2.3.1  Upstream regulation of Rab proteins 
 
Like their counterparts in the Ras GTPases superfamily, the cycling between the GTP- 
and GDP-bound forms is an essential feature of the mode of operation for Rab proteins.  
This is regulated by three factors: (i) a guanine nucleotide exchange factor (GEF) that 
stimulates the release of GDP and favoring the formation of a Rab-GTP complex, (ii) a 
GTPase activating protein (GAP) which catalyzes the hydrolysis of γ-phosphate from 
GTP to GDP, and (iii) a guanine nucleotide dissociation inhibitor (GDI) that inhibits the 
release of GDP.5, 20  
 
When Rab proteins are delivered to their respective compartment, they are in the inactive 
GDP-bound state. Once Rabs are bound to a vesicle surface, they can be activated by the 
replacement of GDP with GTP catalyzed by GEF. Rab bound to GTP are in the active 
conformation and can now interact with or recruit Rab effectors on target membranes to 
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facilitate various vesicular processes like vesicle movement, tethering/docking and 
fusion. After the Rabs have accomplished their task of aiding membrane fusion, the Rab 
GTPase is hydrolyzed to the GDP-bound form with the assistance of GAP. The Rabs can 
then be recycled back to their membrane of origin. The participation of GEF and GAP is 
necessary, since most GTPase have slow intrinsic rates of GTP hydrolysis and nucleotide 
exchange, and thus require accessory factors that stimulate these reactions. GDI is 
necessary for the recycling pathway. This enzyme inhibits the exchange of GDP to GTP 
to prolong the inactive state, and delivers the Rab to its initial membrane. GDI binding 
also helps to emulsify lipid-modified Rab, thus promoting the introduction of Rab into 
the membrane and subsequent dissociation from the membrane surface (Figure 6).21   
 
 
 
Figure 6. Rab prenylation, delivery to membranes and the GTPase cycle. 22 
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2.4.1 Post-translational modification of Rab proteins 
 
The influence and the importance of Rab proteins for the vesicular trafficking pathway 
can only be realized if the proteins are post-translationally modified. In this modification, 
two 20 carbon geranylgeranyl groups (with the exception of a few members of the over 
60 mammalian Rab with only one geranylgeranyl group) are attached to a cysteine at or 
near the carboxyl terminus of the protein via a thioether. The amino acid sequences of 
Rab proteins are most dissimilar near their C-terminal tails. Experiments indicate that the 
tail determines the intracellular location of each family member, presumably by enabling 
the protein to bind to complementary proteins on the surface of the appropriate 
organelle.23 This transformation is essential to initiate the role of Rab and to move the 
proteins from the cytosol to different membrane compartments according to the type of 
Rab.   
 
The post-translational modification of Rabs is carried out by Rab 
geranylgeranyltranferase (Rab GGTase).24 In contrast to other members of the Ras family 
which require only the farnesyltransferase (FTase) or geranylgeranyltransferase I 
(GGTase I) to catalyze the transformation, the decoration of the Rab C-terminus requires 
not only Rab GGTase and geranylgeranyl pyrophosphate (GGPP), but also another 
enzyme called REP (Rab Escort Protein).21, 25 The need for the REP as an additional 
factor in posttranslational lipidation is unique to the Rab family, since other prenylating 
enzymes only recognize a specific C-terminal sequence motif (CAAX) of the modified 
proteins (mainly Ras GTPase). 
 
2.5.1  The Rab pathway as a target for disease therapy 
 
It is clear that due to the importance of Rab proteins in the vesicular trafficking pathway, 
the dysfunction of Rab proteins and its related proteins lead to serious diseases.  To date, 
several diseases have been found to be linked to the Rab transport pathway.  
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One example implicated in human genetic disease is Rab 27a. Griscelli syndrome (GS) is 
a rare autosomal recessive disorder characterized by pigment dilution of the hair (silvery 
hair), owing to the accumulation of pigment in melanocytes.26, 27 In the absence of Rab 
27a, melanosomes undertake bi-directional transport along microtubules, but are unable 
to bind to actin in the cell periphery, resulting in their net accumulation in the perinuclear 
region. 
 
In addition to GS caused by Rab 27a, loss-of-function mutations in REP 1, one of two 
REP isoforms, leads to choroideremia (CHM).28 CHM is an X-linked form of retinal 
degeneration of slow onset and progression, with affected males suffering blindness by 
middle age. Pathology results from degeneration of retinal pigment epithelium (RPE) and 
the two adjacent cell layers, the choroid and the retinal photoreceptor cells. CHM cells 
retain the ability of processing Rabs because of the presence of REP 2, which could 
explain the limited nature of the CHM phenotype. However, REP 2 compensation is not 
absolute as CHM lymphoblast cell lines exhibit an excess of unprenylated Rab 27a when 
compared with the wild type. Loss of REP 1 in CHM does not result in complete loss of 
Rab 27a function in all tissues.29  
 
The phenotype of the naturally-occurring mouse mutant, gunmetal (gm), is caused by a 
mutation in the Rggta (Rab GGTase α-subunit) gene, and is considered a model for 
Hermansky–Pudlak syndrome (HPS). HPS is a rare autosomal recessive, genetically 
heterogeneous disorder characterized by partial albinism, tendency for bleeding, and 
lysosomal accumulation of ceroid lipofuscin. This phenotype reflects defects in lysosome 
and lysosome-like organelles such as melanosomes and platelet-dense granules. Gm mice 
contain a splice-site mutation in the Rggta gene that results in a lowering of Rab GGTase 
activity to approximately 20% of the wild type.30 It is likely that the gm phenotype results 
from partial defects in prenylation and function of multiple Rabs, as in CHM. 
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2.6.1 Rab GGTase as an apoptotic target 
 
More recently, studies have shown that inhibition of Rab GGTase induces the onset of 
p53-independent proapoptotic activity and validated for the first time that this enzyme is 
a promising therapeutically relevant target for cancer therapy.31  
 
Using a chemical genetic approach, some previously validated farnesyltranferase 
inhibitors (FTIs) have been identified to trigger p53-independent apoptosis in C. elegans, 
which was mimicked by knockdown of endosomal trafficking Rab proteins, the HOPS 
complex and notably the enzyme Rab GGTase.32 These FTIs were found to inhibit 
mammalian Rab GGTase with potencies that correlated with their proapoptotic activity. 
Knockdown of Rab GGTase by siRNA induced apoptosis in mammalian cancer cell 
lines, and both Rab GGTase α and β subunits were overexpressed in several tumour 
tissues. These results indicated Rab GGTase, and by extension endosomal vesicular 
trafficking pathways, as a therapeutically relevant target for moduclation of apopotosis.  
 
The findings of this works have two implications for identifiying novel targets for cancer 
therapy. The first major implication for cancer therapy is the identification of a novel 
p53-independent pathway for inducing apoptosis in cancer cells. Strong evidence has 
been provided that inhibition of Rab GGTase, which results in blocking the 
posttranslational modification of Rab proteins, leads to programmed cell death, 
suggesting that interfering with endosomal vesicular trafficking pathways is a novel 
approach to cancer chemotherapy. Although the Rab GTPases could be considered as 
targets for developing novel proapoptotic anticancer drugs, Rab GGTase is clearly a 
better target for structure-based rational drug design, since its structure and biochemistry 
have been studied.33 Furthermore, because of active site similarities with FTase and 
GGTase I,34 one can build on the extensive experience with the design of FTase and 
GGTase I inhibitor to design selective Rab GGTase inhibitors.35  
 
The other major implication of the findings is that certain FTIs can potently inhibit Rab 
GGTase, suggesting that these compounds have targets other than FTase that contribute 
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to their antitumor activity, particularly their proapoptotic activity. This is important since 
it demonstrates for the first time that, though FTIs were designed and identified to inhibit 
selectively FTase, they can recognize other targets; in this case, a related 
prenyltransferase family member, Rab GGTase. Furthermore, at present, it is not known 
why some tumor cells are sensitive, whereas others are not. The discovery that certain 
FTIs can potently inhibit Rab GGTase opens a new avenue to address this important 
question. It would, therefore, be very important to determine whether there is a 
correlation between the levels of expression of Rab GGTase α and β subunits and/or 
inhibition of Rab GGTase and clinical activities/toxicities seen in clinical trials.  
 
2.7.1 Regulation of Rab GGTase activity to study endosomal vesicular trafficking 
and cancer 
 
One of many possible ways to study the functions and mechanisms of vesicular transport 
diseases is to reduce or knockdown the activity of Rabs and its related proteins. By 
inhibiting Rabs activity, the outcome on the phenotype and transport pathways in the 
corresponding cell can be observed easily. This knockdown approach can be done in two 
ways either by chemical biology or genetic methods.36 The chemical biology approach 
normally involves the use of small molecules to inhibit a particular function or activity of 
a protein, and thus the concomitant consequences of the inhibition can be observed. The 
genetic approach mainly involves the use of gene mutation to produce a mutated protein 
or knockout the proteins completely from the cell.   
 
There are several advantages in using the chemical biology approach to study the 
function of Rab in trafficking pathways over the classical genetic means. The effect of 
small molecules towards the protein functions is reversible, as the effect can be removed 
metabolically or by washing. In addition temporal control of the experiment is possible as 
the small molecules can be added at any time during the experiment. Furthermore, the 
effect of small molecules against the target proteins is always very fast. 
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By employing the chemical biology approach, a variety of upstream regulating proteins 
can be used to study the mechanism of vesicular trafficking pathways and disease. 
However, a potential target for Rabs regulations must fulfill several criteria. First, the 
underlying proteins must be specific, interacting only with Rab GTPase. Second, by 
inhibiting the corresponding proteins, the functions of other proteins should not be 
affected. Third, the protein involved should preferentially function in a catalytic manner 
towards Rabs. Among the many upstream regulators of Rabs, such as Rab GGTase, REP, 
GDI, GAP and GEF, Rab GGTase appears to be the best candidate for this chemical 
biology study.      
 
Inhibiting the post-translational modification activity of Rab GGTase will only affect 
Rab. As mentioned before, inhibiting the activity of Rab GGTase will hamper the 
lipidation of the C-terminus of Rabs which means that the Rab proteins will not be able to 
associate with vesicle membrane. GAP and GEF are not suitable in the studies due to 
their general interaction with other members of Ras GTPase super family. Inhibiting the 
GAP and GEF can cause general knockdown of activity of many proteins and renders 
many proteins within the Ras family to be inactive.  
 
The usage of small molecules to inhibit Rab GGTase should give some insight into Rabs 
localization in various membrane compartments and the biological response of to non-
lipidated Rab in protein trafficking. Furthermore, the development of inhibitors against 
Rab GGTase allows the study of some diseases known to be related to the protein, such 
as Hermansky–Pudlak syndrome, Paget’s disease and cancer.   
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3 Aim of the Dissertation  
 
While now, there are only very few publications reporting the chemical biology 
approach, where small molecules altering the activities of Rab GGTase are used to study 
the functions and effects of Rabs in protein trafficking.37 Compared to various effective 
and specific inhibitors discovered for FTase and GGTase I, the identification of potent 
inhibitors for Rab GGTase has lagged behind and proceeded very slowly. This is despite 
the relative importance of Rab GGTase, which is linked with some skeletal diseases, such 
as excessive osteoclast-mediated bone resorption which can cause tumor-induced 
osteolysis and post-menopausal osteoporosis. Furthermore, recent studies have shown 
that inhibition of Rab GGTase induces the onset of p53-independent proapoptotic activity 
and validated for the first time that this enzyme is a promising therapeutically relevant 
target for cancer therapy. 
 
In order to study how the inhibition of Rab GGTase influence the activity of Rab proteins 
in detail and its relationship with diseases, chemical biology means will be used to study 
the influence of different inhibitors towards Rab GGTase and finally to Rabs. So far, only 
two compounds that affect Rab GGTase activity have previously been described, and 
neither shows a high degree of potency or specificity for Rab GGTase.38  
 
The aim of this thesis is to develop a compound library, which contains potential 
inhibiting effects against Rab GGTase over FTase and GGTase I. Recent findings31 have 
raised the concerns over the high-potency dual inhibition of Rab GGTase and FTase. The 
findings showed that dual inhibition of FTase and Rab GGTase by multiple compounds 
with diverse structures, indicating that it is not unusual for a compound to interact with 
both proteins. The common but not universal potential crossreactivity of antiproliferative 
and proapoptotic effect of some FTIs with Rab GGTase has prompted us to re-assess the 
previously validated FTase inhibitor, Pepticinnamin E (Figure 7), as a lead structure for 
this thesis.39  
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Pepticinnamin E is a natural occurring bisubstrate inhibitor of FTase. It has been shown 
to act as FTase inhibitor with IC50 = 42 µM. It consists of three amino aicds as central 
core, an ester functionalized C-terminus and a α-β unsaturated phenyl capped N-
terminus.40  
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Figure 7. Structure of Pepticinnamin E. 
 
In this project, derivatives of Pepticinnamin E should be prepared through solid phase 
peptide synthesis strategy (SPPS). The synthesized peptide-based inhibitors should be 
screened against Rab GGTase using a continuous fluorometric assay.  Kinetic studies of a 
selected potent inhibitor should be probed to determine the mode of inhibition, such as 
competitive inhibition or non-competitive inhibition. In addition, a selected set of 
inhibitors should be subjected to in vivo study and selectivity screening against FTase and 
GGTase I.  
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4  Results and Discussion 
  
 
4.1.1  Fluorescence assay of Rab GGTase  
 
 
Enzymatic studies and the search for potent, specific inhibitors of Rab prenylation led us 
to consider alternatives to the existing radioactivity-based and HPLC assays for Rab 
GGTase activity, which are discontinuous, laborious, and poorly amenable to 
miniaturization and parallelization.41 Continuous fluorescence assays are much better 
suited for high-throughout screening and characterization of potential inhibitors. Efficient 
continuous fluorescence assays for FTase and GGTase I that utilize the fluorescence 
changes of a dansylated pentapeptide containing the CAAX motif following prenylation 
have been reported previously.42 These are presumed to take advantage of the increase in 
hydrophobicity of the acceptor peptide following incorporation of an isoprenoid moiety 
in the vicinity of an environmentally sensitive dye like dansyl. However, this concept of 
intramolecular fluorescence enhancement cannot be directly applied to Rab GGTase, 
which recognizes the Rab:REP complex instead of a short peptide. Although a modified 
set-up for a fluorescence assay with semisynthetic Rab 7 protein substrates that have a 
fluorescence label at the C terminus has been reported,43 it gave a fluorescent change of 
less than a factor of 2. This is probably due to the fact that the hydrophobic 
geranylgeranyl groups are buried in REP to increase the solubility of prenylated Rab 
proteins. In addition, construction of fluorescent protein sensors requires labor-intensive 
screening for fluorophores and labeling positions.  
 
In this project, it is very helpful that a rapid, sensitive and homogeneous assay is 
available to screen large amounts of inhibitors in a very short time towards the activity of 
Rab GGTase enzyme. Hence, a recently reported continuous fluorometric assay for Rab 
GGTase by Wu et. al.44 is used in our studies to determine the inhibitors activities 
towards Rab GGTase. In this assay, a fluorophore is incorporated into the soluble 
isoprenoid donor that will undergo strong changes of fluorescence during the prenylation 
reaction. Towards this end, a fluorescent analogue of geranylgeranyl pyrophosphate, 
{3,7,11-trimethyl-12-(7-nitrobenzo[1,2,5]oxadiazo-4-ylamino)dodeca-2,6,10-trien-1} 
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pyrophosphate (NBD-FPP) 1, which has been demonstrated to be a lipid donor for Rab 
GGTase and GGTase I, was prepared.45 This phosphoisoprenoid was used to develop the 
solution-based Rab prenylation assay (Scheme 1).  
 
 
 
 
Scheme 1. Schematic illustration of fluorescent prenylation sensor. 
 
The purpose of incorporating a NBD fluorescent group at terminal carbon of farnesyl 
pyrophosphate is that the fluorescent intensity of NBD group in water is very low, but it 
has very high fluorescent intensity in hydrophobic environment. By using this property of 
the NBD group, the inhibition of Rab GGTase can be determined by calculating the 
increment of fluorescence intensity. The rate of fluorescence intensity increment will be 
very low, if an inhibitor gives an inhibition at low concentration. The idea of attaching a 
NBD fluorophore group at the farnesyl pyrophosphate rather than a native substrate 
geranylgeranyl pyrophosphate (GGPP) is to compensate for the length of one isoprene 
unit by the introduction of NBD group. The active site of Rab GGTase and hydrophobic 
pocket of REP will be too small for a NBD-GGPP if the underlying substrate is used.  
 
Upon incorporation of the NBD-farnesyl group into Rab proteins, an increase in 
fluorescence intensity over time with excitation at 479 nm and emission at 520 nm is 
observed (Figure 8). Fluorescence emission spectra taken before and after the reaction 
show a shift of the emission maximum from 547 to 525 nm as well as a 23-fold 
enhancement of fluorescence intensity at 525 nm. This dramatic increase in fluorescence 
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is a consequence of the Rab-conjugated NBD-farnesyl group's binding into the 
hydrophobic pocket on REP. In this case, REP plays the dual role of both Rab chaperone 
and conjugated fluorescent isoprenoid trapper, enhancing its fluorescence in the 
process.46 
 
 
 
Figure 8. Time-course of the fluorescence change upon prenylation of the Rab7:REP-1 complex 
catalyzed by Rab GGTase in the presence of NBD-FPP.  
 
 
4.1.2  Synthesis of the fluorescence substrate NBD-FPP 1 
 
 
Rab 7, Rep 1 and Rab GGTase proteins were obtained by protein expression strategy and 
provided by group Dr. Kirill Alexandrov. Fluorescent substrate NBD-FPP 1 was prepared 
by means of chemical synthesis. The synthesis of 1 (Figure 9) involves several functional 
group manipulations and requires eight synthetic steps starting from commercially 
available farnesyl alcohol.  
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Figure 9. Structure of NBD-FPP 1. 
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The plan for the synthesis of fluorescent substrate 1 was first designed to obtain the 
desired product in 3 steps as illustrated by retro analysis in Scheme 2.  
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Scheme 2. Retro synthetic analysis of 1. 
 
The fluorescent product 1 can be envisioned to be obtained through nucleophilic 
substitution of 2 using a pyrophosphate salt to give 1. The intermediate 2 can be 
synthesized through Mitsunobu reaction by coupling of 3 and 4. The starting material for 
this synthetic route can be derived from commercially available compound 5. The main 
advantage of this synthetic route is its short and succinct synthetic steps. However, allylic 
oxidation of 5 and subsequent Mitsunobu reaction might cause some side reactions or 
even destroy the intermediates, as the allylic chloride is a reactive compound. 
 
Allylic oxidation of 5 was performed using SeO2/t-BuOOH/salicylic acid in DCM to 
furnish 3 in 27% yield. Following oxidation of 5, 3 was subjected to Mitsunobu reaction 
employing DIAD and PPh3 reagents to introduce fluorescence substrate 4, which was 
prepared by reacting NBD-Cl with ammonia, to replace the alcohol. Unfortunately, no 
desired product 2 was obtained in this reaction. In addition, no starting material 3 was 
recovered from the reaction as observed by the TLC. Several attempts to vary the 
reaction conditions by changing the addition sequence were futile. The failure to obtain 2 
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might be due to the formation of undesired ylide side product which is a very common 
reaction between reactive allylic chloride and PPh3 (Scheme 3).47 Compound 3 can react 
with PPh3 and DIAD at the same time with its two functional groups, OH and Cl. In this 
case, the stoichiometric PPh3 was consumed by forming a side product ylide with allylic 
chloride moiety and thus renders the Mitsunobu reaction impossible to proceed with the 
allylic alcohol functional group.      
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Scheme 3. Attempted synthesis of compound 2. 
 
After disappointing efforts to synthesize 1 in a shorter route, a previously reported 
synthetic protocol was adapted to prepare the fluorescent target 1.48 Before functional 
group manipulation at the terminal carbon of farnesyl alcohol 6, compound 6 was 
protected with THP in order to avoid any side reaction in the next few steps of synthesis. 
Protection of 6 with THP and catalytic amount of PPTS gave compound 7 in quantitative 
yield without the need for the further purification. Functionalization at the terminal 
carbon of 7 was carried out using the allylic oxidation reaction employing SeO2/t-
BuOOH/salicylic acid to give 8 in 29% yield. This step must be carefully monitored by 
TLC, as prolonged reaction time can increase the formation of side products from over 
oxidation of starting material to obtain more than one allylic alcohol at other allylic 
positions. The low yield of this step is generally attributed to this reason (Scheme 4).  
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Scheme 4. Synthesis of allylic alcohol 8. 
 
Compound 8 was converted to 9 by employing Mitsunobu reaction using PPh3, 
phthalimide, and DIAD as reagents to give product 9 in 66% yield. 9 was then treated 
with hydrazine in ethanol overnight at room temperature to furnish 10 in 55% yield. The 
resultant white suspension formed when hydrazine reacts with the phthalimide group was 
easily separated by filtration. Incorporation of the NBD group on allylic amine 10 was 
achieved using 25mM NaHCO3  and NBD chloride in CH3CN at room temperature to 
give 11 in 60 % yield. Deprotection of the THP group on 11 using PPTS at 60 oC resulted 
in 83% yield of 12 (Scheme 5).  
 
OTHP
OTHPPPh3, DIAD
66%
OTHP
HO
98
ethanol,r.t.
55%
N
O
O
phthalimide
NH2-NH2
THF, r.t.
NBD-Cl, r.t.
CH3CN/25mM NaHCO3
60%10
OTHP
PPTS
ethanol, 60 oC
83%
OH
H
N
11 12
H2N
H
N
NBD NBD
 
 
Scheme 5. Synthesis of fluorophore incorporated allylic alcohol 12. 
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Chlorination of 12 was performed using DMS and NCS as a chlorinating agent at DCM 
to give compound 13 without any purification. Compared to its precursors which are 
stable at room temperature and can be kept for very long time, 13 is acid sensitive due to 
its farnesyl chain and the very reactive allylic chloride. After simple workup, NBD 
attached allylic chloride 13 was treated subsequently with (Bu4N)3HP2O7 in CH3CN at 
room temperature overnight. The resulting tetrabutylammonium NBD-FPP 14 was 
converted to the ammonium salt by passing 13 through a cation ion-exchange resin to 
give the target product NBD-FPP 1 in 16 % yield over two steps (Scheme 6). The NBD-
FPP 1 is both acid and base labile and can only be stored between pH 7-10.       
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Scheme 6. Synthesis of fluorophore incorporated farnesyl pyrophosphate 1. 
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4.2  Synthesis of Rab GGTase Inhibitors 
 
4.2.1  Synthetic plan 
 
For the generation of compound libraries, it is particularly useful to apply solid phase 
synthesis strategies. The solid support can be easily separated and sorted into different 
portions to react with different building blocks or starting materials to afford highly 
diverse derivatives. In this dissertation, the synthesis of Rab GGTase inhibitors was 
carried out on solid supports. The synthesis of the Rab GGTase inhibitors was conducted 
together with Dr. Ester Rozas Guiu.  
 
A straightforward modification strategy of the lead structure Pepticinnamin E was 
envisioned by dividing the structure into three regions, N-terminus, C-terminus and a 
three amino acids central core. The compounds library of Pepticinnamin E can be 
synthesized by means of the building block strategy. This strategy is the best method to 
construct a highly diverse library, as every position of the derivatives can be modified 
easily and freely by introducing different substrates which are compatible to the reaction 
condition.  
 
The diversity of three amino acids central core can be introduced by adding different 
amino acids during the course of the synthesis. The central core amino acid residues of 
the lead structure are basically derivatives of tyrosine and phenylalanine. In order to 
cover broad range of derivatives, aliphatic residues and other natural amino acids were 
also considered and introduced during the synthesis.  
 
Two different approaches were considered for the modifications of the N-terminus. The 
first approach introduced greater variety of aromatic functionalities which shows good 
binding properties with the zinc ion in Rab GGTase active site. The second approach was 
based on the introduction of aliphatic residues such as long aliphatic chains which are 
similar to the lipid substrate of Rab proteins with the aim of promoting competition with 
the substrate. Moreover, to study the influence of the C-terminus, this position was 
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further modified by introducing a wide spectrum of diverse amide, acid, and ester 
functionalities (Scheme 7).   
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Scheme 7. Modifications of Pepticinnamin E. 
 
4.2.2  Choice of linkers  
 
Since the first disclosure of solid phase synthesis by R. B. Merrifield,49 a great number of 
linkers50 (more than 200) have been developed over the past decades in order to allow 
many multi-step organic syntheses to be performed and the use of a broad range of 
reagents, allowing cleavages in a very selective manner. Most of the linkers used in the 
synthesis are either acid or base labile which means that the product attached to the solid 
support can be released under acid or base condition. There is another class of linkers 
which is inert to acid and base condition, but can be cleaved off by various nucleophiles 
after activation of the linker. This type of linker is called safety catch linker.     
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Safety catch linker not only represents a novel class of temporary protecting group to the 
target molecule, but also presents itself as a superior set of linker in diversity-oriented 
synthesis. Safety catch linker strategies in which a stable linkage is activated for cleavage 
by a discrete chemical modification have proven to be particular useful in the synthesis of 
compound libraries. These linkers are often compatible with a broad range of reactions, 
yet target compounds can be released from solid support under mild conditions after the 
activating step. In addition, the activation step can potentially provide a reactive linkage 
functionality for cleavage with diverse nucleophiles. Therefore, an additional element of 
diversity can be added to the structure of the target compounds in the cleavage step.51    
 
In order to introduce large diversity on the C-terminus of Rab GGTase inhibitors, the 
hydrazine linker was used in the synthesis of compounds library and attached to the C-
terminus of the peptides. The hydrazine linker has been used in the synthesis of several 
base and acid labile lipopeptides. The linker is stable to Fmoc and Boc deprotection 
conditions.52 
 
The hydrazine linker 15 is suitable for the synthesis of Rab GGTase inhibitors as it 
presents great versatility and allows the creation of a wide variety of functional groups 
ranging from esters, amides, and acids at the C-terminus. The product can be released 
from the solid support via activation of the linker and subsequent nucleophilic addition. 
The activation of hydrazine linker 15 can be effected by very mild oxidation condition 
employing NBS/pyridine or Cu(OAc)2.53 The activated intermediate 16 can be subjected 
to different nucleophiles like amines, alcohols or water to release the product from the 
solid support (Scheme 8).     
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Scheme 8. Oxidative cleavage of hydrazine linker to obtain amide, carboxylic acid, and ester 
derivatives.     
 
The preparation of Rab GGTase inhibitors library was carried out using the Fmoc-
protecting strategy. The hydrazine linker is highly compatible to the Fmoc-deprotection 
conditions. Furthermore, the deprotection of the Fmoc group can be achieved in very 
short time to afford total deprotection.   
 
4.2.3  Synthesis of the hydrazine linker 21 and loading to the resin 
 
The linker was prepared by protection of 4-hydrazine benzoic acid 20 with the Fmoc 
group. The protection was carried out in water and dioxane using Fmoc-Cl and Na2CO3 
overnight to give Fmoc-protected hydrazine linker 21 in ≈ 50% yield (Scheme 9). Amino 
methylated polystyrene resin 22 was chosen as a solid support for the loading of the 
linker 21. The reason to use this resin was that the formation of amide bond between 
linker and solid support can be sustained in the subsequent elongation, deprotection and 
cleavage condition.  
 
 
________________________________________________________________________ 
116 
H
N
OH
O
H2N
Fmoc-Cl, Na2CO3
H2O/Dioxane
0oC to r.t., overnight
50 to 60%
H
N
OH
O
N
H
O
O
H2N
 DIC/HOBT
DMF/CH2Cl2
H
N
H
N
O
N
H
O
O
20 21
22
23  
 
Scheme 9. Synthesis of Fmoc-protected hydrazine linker 21 and loading to the resin 22. 
 
Two coupling conditions using different coupling reagents were surveyed to find out the 
best loading conditions. The loading of the first substances to the resin is very critical, as 
low loading and side product formation can render a low yield to the subsequent coupling 
reaction and difficult purification of the desired product. Table 2 outlines the loading 
condition using HOBT/HBTU/DIPEA and DIC/HOBT respectively. In general, the 
coupling of the linker to the resin using either method gave similar results. DIC/HOBT 
was chosen as the standard coupling method for loading of the linker to the resin due to 
the lower cost and since the method does not involve the addition of DIPEA base which 
can cause partial deprotection of Fmoc group and racemization of amino acids. The 
loading of the linker to the resin was achieved using DIC/HOBT in DCM and DMF 
overnight to obtain 90 to 100% loading yield. The loading of the linker to the resin was 
determined by measuring UV absorption intensity at wavelength 301 nm of deprotected 
Fmoc group.54        
 
Table 2. Comparison of two coupling methods. 
 
Entry Coupling condition Loading yield 
1 HOBT/HBTU/DIPEA 85-100% 
2 DIC/HOBT 90-100% 
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4.2.4  Incorporation of amino acids and the N-terminal substrates 
 
The Fmoc group of the hydrazine resin 23 was deprotected using 20% piperidine in DMF 
to give 24 prior to the introduction of amino acids. A DIC and HOBT coupling cocktail 
dissolved in DMF was the standard coupling condition for the incorporation of all amino 
acids and N-terminal substrates. After deprotection, Fmoc-protected phenylalanine was 
introduced to the resin using the standard coupling cocktail for 2 hours at room 
temperature. The reaction was monitored by the Kaiser test until it was completed. 
Typically this peptide coupling reaction can be completed within one hour; however, an 
additional hour was added to ensure that all the free amine on the resin has been reacted. 
Following that, the resin was washed with DCM and DMF to get rid of the excess amino 
acid and coupling reagents. The resin 25 was then subjected to another round of Fmoc 
deprotection using the standard deprotection cocktail to give resin 26. The 
coupling/washing/deprotection process was repeated until three Fmoc-protected amino 
acids and the N-terminal carboxylic acid substrates were introduced (Scheme 10). This 
solid phase peptide strategy was applied to prepare all the peptides used for the screening 
of Rab GGTase inhibitors. By using this strategy, numerous diverse Pepticinnamin E 
derivatives were obtained in a very short time. 
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Scheme 10. General scheme for the synthesis of peptides.  
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In this compound library, 16 different substrates were introduced at N-terminal position 
of the peptides. Figure 10 shows all the carboxylic acids in this peptide library. The N-
terminus of the peptides contain great variety of aromatic substrates from compounds N-i 
to N-xii, in which compound N-vii and N-xi were the byproducts from compound N-ii 
and N-xi respectively, after release from the resin using NBS/pyridine condition. The N-
terminus of the peptides also includeed zinc ion bindng functionality, such as compound 
N-x, N-viiii and N-xiiii. Various long aliphatic chains residues were also integrated in 
this library, such as compound N-viii, N-xv and N-xvi.   
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Figure 10. 16 different substrates were placed in N-terminus of peptide sequences in the 
compound library.   
 
Various amino acids were placed in different positions of the peptide seqeuences to 
expand the diversity of the library. L-phenylalanine, L-tyrosine, L-serine, L-leucine, L-
glutamine, L-glutamic acid, L-arginine and L-histidine were introduced at the second 
position of the peptide sequences. At the 3rd position of the peptide sequences, glycine, L-
phenylalanine, L-leucine, L-serine, L-alanine, L-histidine, D-valine, L-isoleucine, L-
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lysine and L-tyrosine were incorporated in the sequence. L-leucine, L-serine, L-alanine, 
L-phenylalanine, L-threonine, D-alanine, L-lysine, L-isoleucine, glycine, L-tyrosine and 
L-histidine were placed at the 4th position of the peptide sequence.      
 
4.2.5  Oxidative cleavage by NBS 
 
After completion of the peptide synthesis, the product must be released from the resin. 
Two oxidative cleavage methods were used to release the peptides from the solid support. 
The first oxidative release condition was the treatment of resin bound peptide with 
NBS/pyridine.  The NBS/pyridine oxidative cleavage is a two step reaction involving 
oxidation of the hydrazine linker 28 utilizing NBS/pyridine and nucleophilic 
displacement of reactive acyldiazine 29 to give the desire product. The driving force of 
this reaction is the generation of nitrogen gas and aryl resin 30 after nucleophilic addition 
(Scheme 11).  
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Scheme 11. Mechanism of oxidative cleavage by NBS. 
 
Peptide bound resin 27 was treated with 2 equivalents of NBS and pyridine in DCM for 5 
minutes. The resultant yellow solution was filtered and the resin was washed with DCM. 
The release of peptide was achieved by treating methanol and DIPEA in DCM to the 
acyldiazine for 2 hours to furnish product 38 in 18% yield (Scheme 12) after purification. 
Besides methanol, substrates such as water, ammonia, aniline, benzyl amine and etc. can 
also be applied as nucleophiles. Some nucleophiles such as water which are not able to 
dissolve in DCM were dissolved in dioxane.  The addition of base is only applicable to 
oxygen nucleophiles, nitrogen nucleophiles do not require the introduction of additional 
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amine base. Extending the reaction time did not improve the yield of the product. Around 
250 peptides were prepared by using this oxidative cleavage method. Deprotection of all 
the protecting groups was carried out with deprotection cocktail TFA/TES/H2O (50/1/1) 
in one hour.    
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Scheme 12. Release of product 38 from hydrazine linker using NBS with MeOH as nucleophile. 
 
 
Figure 11 displays the LC_MS trace of crude product 38. The peak at 9.59 minutes 
corresponds to product 38 with the molecular mass of 570 and 592 (plus a proton 
[569+H] and sodium atom [569+ Na] respectively).   
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Figure 11. LC_MS trace of crude product 38 
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Table 3 shows some of the peptides obtained using the NBS/pyridine oxidative cleavage 
strategy.  
 
Table 3. Various peptides prepared using NBS oxidative condition  
 
Entry Nr. R5 R4 R3 R2 R1 
Yield 
% 
1 39 
O
 
L-Leu L-Phe L-Phe OH 3 
2 40 
O
 
L-Pro Gly L-Phe HN
F
F  
28 
3 41 
O
F  
L-Ala Gly L-Tyr OH 7 
4 42 
O
 
D-Ala L-Phe L-Gln O OH  3 
5 43 
O
 
D-Ala L-Phe L-Gln NH 5 
6 44 
O
 
L-Ala L-Phe L-Gln O Cl  1 
7 45 
O
F  
L-Ile L-Ala L-Gln
HN Cl
F  1 
8 46 
O
F  
L-Tyr Gly- L-Tyr HN  10 
9 47 
O
F  
L-Tyr Gly- L-Tyr N O  7 
10 48 
O
O
9  
L-Tyr L-Tyr L-Tyr O NH2  4 
11 49 
O
 
L-Ile D-Val L-Gln HN N
S
 6 
12 50 
O
F  
L-Ser Gly L-Ser O 9  6 
 
 
In general, amine nucleophiles gave higher yield than alcohol nucleophiles. This 
difference of yield can be attributed to the better nucleophilicity of the nitrogen atom than 
the oxygen atom. Figure 12 shows the nucleophiles used in the NBS/pyridine cleavage 
condition. More than 30 different alcohol and amine nucleophiles were used to perform 
the nucleophiliic displacement reaction to release the peptides from the solid support. The 
amine nucleophiles consist of aromatic and aliphatic amines. The alcohol nucleophiles 
consist of only aliphatic alcohol.      
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Figure 12. Nucleophiles used in the NBS/pyridine nucleophilic release condition.  
 
Although 250 peptides have been synthesized using this cleavage method, the yield from 
this cleavage condition is not satisfactory. Some of the peptides released from the solid 
support using the NBS/pyridine method gave less than 2% yield. In addition to this 
problem, the NBS/pyridine cleavage method also introduced side reactions to the peptide 
if double bonds were presented in the peptide sequence. For example, peptide 31 which 
consists of a double bond at the N-terminal substrate was brominated to give side product 
33 during oxidative cleavage (Scheme 13). Figure 13 and 14 shows the crude LC_MS 
traces of 32 and 33, respectively. Figure 13 shows the small peak at 11.02 corresponding 
to 32 with the molecular mass of 865 plus a sodium atom [865+Na]; whereas Figure 14 
shows the higher peak at 11.34 belonging to the side product 33, the mass spectrum 
shows a typical dibromo pattern with 1:2:1 isotope distribution and molecular mass of 
1048 [1023+Na].  
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Scheme 13. Side product 33 from NBS/pyridine cleavage condition of compound 31. 
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Figure 13. LC_MS trace of crude compound 32. 
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Figure 14. LC_MS trace of crude material 33. 
 
In order to overcome this problem, an alternative cleavage method was considered to 
boost the yield and reduce the side reaction. 
 
4.2.6  Oxidative cleavage by Cu(OAc)2  
 
The oxidative cleavage reaction performed by Cu(OAc)2 is a one step reaction involving 
the addition of Cu(OAc)2 to oxidize the hydrazine linker and in situ nucleophilic addition 
to release the peptide from the solid support. In contrast to the NBS/pyridine approach, 
only catalytic amount of Cu(OAc)2 is required for the oxidative process. The Cu(II) 
specie can be regenerated by the oxidation of Cu(I) in the solution by O2. Peptide 36 is 
one of the 130 peptides released from the resin employing Cu(OAc)2. The resin 34 was 
treated with 0.5 equivalent of Cu(OAc)2 and 1 mL of methanol in 2 mL DCM with 10 
equivalents of pyridine for two hours to give peptide 35. In this cleavage condition, 
utilization of DIPEA and Et3N as base did not give any desired product. If the 
nucleophiles are amines, the addition of pyridine is not necessary. The excess amine, 
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pyridine and Cu(OAc)2 in the reaction mixture can be washed away by extraction with 
1M HCl. Deprotection of all the protecting groups was carried out with deprotection 
cocktail TFA/TES/H2O (50/1/1) in one hour to give product 51 in 25% yield after 
purification (Scheme 14). The oxidative release of peptides from resin using Cu(OAc)2 
condition gave very clean LC_MS trace with only desired product and deprotected 
protecting group. Figure 15 shows the crude LC_MS trace of peptide 51. The peak at 
7.57 minutes corresponds to 51 with the molecular mass of 648 plus a proton [647+H]+.   
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Scheme 14. Oxidative release and cleavage of protecting groups of compound 51 with 
TFA/TES/H2O. 
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Figure 15. LC_MS trace of crude material 51. 
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Table 4 shows some of the peptides released from the solid support using the Cu(OAc)2 
method. In general, fewer side products were observed by using the Cu(OAc)2 oxidative 
condition.  
 
Table 4. Various peptides prepared using Cu(OAc)2 oxidative condition 
 
Entry Nr. R5 R4 R3 R2 R1 
Yield 
% 
1 52 
O
9  L-Tyr L-His L-Tyr NH 2 
2 53 
O
9  L-Tyr L-His L-Tyr HN OH
OH
 20 
3 54 
O
9  L-Tyr L-His L-Tyr 
HN
NH2  22 
4 55 
O
9  L-Tyr L-His L-Tyr 
O
NH2  7 
5 56 
O
O
9
L-His L-His L-His OH 20 
6 57 
O
O
9
L-His L-His L-His OMe 11 
7 58 
O
O
9
L-His L-His L-His NH 7 
8 59 
O
9  L-His L-His L-Tyr 
N N
 12 
9 60 
O
9  L-His L-His L-Tyr HN N
N
 15 
10 61 
O
9  L-Tyr L-His L-Tyr 
HN
NH2
 
20 
11 62 O
O
 
L-His Gly L-Tyr HN SN  2 
12 63 
O
9  L-His L-His L-Ser HN OH
OH
 26 
13 64 O
O
 
L-His β-Ala L-Tyr OMe 4 
14 65 O
O
 
L-His β-Ala L-Tyr NH 1 
15 66 O
O
 
L-His β-Ala L-Tyr HN N N  6 
16 67 
O
9  L-His L-Phe L-Tyr 
HN
OH  13 
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Figure 16 shows 12 different nucleophiles used in the Cu(OAc)2 cleavage condition to 
release the peptides from the solid support. 10 equivalents of nucleophiles (relative to the 
resin) were used in the reaction except water, methanol and ammonia which 1 mL of 
solution was added to the reaction condition.     
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Figure 16. Nucleophiles used in the Cu(OAc)2 peptides release condition.  
 
4.2.7 Comparison of the NBS and the Cu(OAc)2 oxidative cleavage condition  
 
The efficiency of the oxidative nculeophilic release of peptides from solid support 
employing NBS and Cu(OAc)2 was studied by comparison the yield of the two cleavage 
conditions. Table 5 compares the yield of the peptides released from the NBS and 
Cu(OAc)2 conditions respectively after HPLC purification.  
 
Table 5. Comparison of the efficient oxidative release of peptides by the NBS and Cu(OAc)2 
conditions. 
 
Entry Nr. Peptides NBS 
(Yield) % 
Cu(OAc)2 
(Yield) % 
1 39 
 
3 5 
N
H
O H
N
N
H
OH
O
O
O
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2 81 
 
7 18 
3 141  3 15 
4 187 
 
6 16 
5 260  2 5 
6 280  2 16 
7 346 
 
2 12 
 
In general, Cu(OAc)2 oxidative cleavage condition gave higher yield after HPLC 
purification. When amine substrates were used as nuclephiles in the two oxidative 
cleavage conditions, the difference of the yield is more pronounce than the alcohol 
nucleophiles. For example, the yield for peptides at entries 1 and 5 is similar, either the 
peptides were released from the solid support by NBS or Cu(OAc)2 methods. The yield 
for Cu(OAc)2 oxidative cleavage condition is around 10 % higher than NBS condition if 
amine substrates were used as nucleophiles. The reasons of the lower yield for NBS 
condition are probably due to the production of mono- and dibrominated sideproduct for 
the olefinic substrates and generation of acyldiazine radical from NBS.   
 
4.2.8 Summary and Discussion of the peptide library synthesis 
 
382 peptides were produced in total by both NBS and Cu(OAc)2 oxidative release 
condition. Among these 382 compounds, 250 peptide inhibitors were generated by NBS 
oxidative release approach. 16 different carboxylic derivatives were introduced at the N-
terminus of the peptides in which both zinc ion binding and long lipid chain residues 
were included at the N-terminus. 12 natural and 4 non-natural amino acids were 
incorporated at various positions of the peptides. More than 30 different amine and 
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alcohol nucleophiles were applied to the C-terminus of the peptides. The yield of the 
peptides generated by two oxidative released condition ranges from as low as 1% to 30 % 
with purity of most peptides greater than 95% after purification. All the peptides prepared 
using NBS and Cu(OAc)2 cleavage conditions are listed in appendix. 
 
The successful synthesis of 382 Rab GGTase peptide inhibitors has demonstrated that the 
hydrazine linker is an excellent linker for the preparation of compounds library, 
especially peptides library. The linker is acid and base stable but labile to mild oxidation 
method. By using this synthesis strategy, large number of peptide inhibitors can be 
assembled in a very short time. In this project, the diversity of the peptide library was 
achieved through the addition of different nucleophiles at C-terminus of peptides by 
oxidative nucleophilic reaction and building block strategy.  
 
The LC_MS trace of the crude peptides after oxidative release from solid support showed 
relatively clean spectra which make the purification of the crude material easier. If the 
olefinic functionality containing peptides were treated with NBS, the major side reaction 
was the addition of mono- or dibromo to the olefin. This side reaction can be avoided by 
releasing the peptides from the resin using the Cu(OAc)2 conditions. 
 
The use of Cu(OAc)2 cleavage condition for the synthesis of peptide library has several 
advantages over NBS condition. The yield for the Cu(OAc)2 cleavage condition is 
normally higher than the NBS condition. There is fewer side products observed in the 
crude LC-MS trace for Cu(OAc)2 condition. Unlike NBS condition, the oxidative 
cleavage reaction performed by Cu(OAc)2 is a one step reaction involving in situ 
nucleophilic addition to release the peptide from the solid support. This property makes 
the Cu(OAc)2 oxidative condition easier to handle than the NBS condition, as one 
reaction step of addition of NBS and washing avoided. Furthermore, the Cu(OAc)2 
oxidative condition exists the opportunity to be optimized and performed in a automatic 
peptide synthesizer which can render the synthesis of peptide library more efficient and 
time saving.  
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4.3  Biochemical Investigation of Rab GGTase Inhibitors 
 
4.3.1 In vitro screening of the peptide library 
 
382 peptides were subjected to in vitro screening to identify the potential inhibitors of 
Rab GGTase. The screening of inhibitors was performed in 96 well plates using a 
continuous fluorometric assay for Rab GGTase developed by Wu et. al.44 The in vitro 
screening was first carried out with 50 µM concentration of inhibitors and in the presence 
of 0.01 % detergent Triton X-100. IC50 values were determined subsequently for 
compounds showing >50% inhibition at 50 µM. The screening was performed in 
duplicate. Around 160 compounds were screened at 100 µM.   
 
The screening protocol is briefly described here. 50 µL of 0.4 µM Rab GGTase and 4 µM 
NBD-FPP 1 was added to the well followed by 0.5 µL of inhibitor in 10 mM DMSO 
solution. The solution was mixed well and incubated at 37°C for two minutes. 50 µL of 4 
µM Rab-7:REP-1 cocktail solution was added to the same well. The measurement was 
started immediately. Instead of 0.5 µL inhibitor, the positive control of the assay was 
carried out with the addition 0.5 µL DMSO.  
 
During the screening of the inhibitors using this assay, fluorescent bleaching of NBD-
FPP 1 in the measurement was observed in every case. The fluorescent bleaching of 
NBD-FPP 1 is depending upon the type and concentration of inhibitors. To take into 
account the fluorescent bleaching effect during the measurement, two negative controls 
were included in the screening. In one negative control, the same concentration and 
volume of inhibitors was introduced to 50 µL of 0.4 µM Rab GGTase and 4 µM NBD-
FPP 1 cocktail solution and 50 µL of buffer solution. The other negative control involved 
the addition of DMSO to buffer solution and Rab GGTase and NBD-FPP 1 cocktail 
solution.  
 
18 compounds were identified in the screening to inhibit the biological activity of Rab 
GGTase to less than 50% at 50 µM concentration (for the inhibition activity of all the 
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compounds, see appendix). The compounds were selected to determine their IC50 against 
Rab GGTase. Table 6 shows IC50 values and structure of the inhibitors.  
 
Table 6. Structure of peptide inhibitors and their IC50 values 
Entry Nr. R5 R4 R3 R2 R1 
IC50 
(µM) 
1 38 
O
 
L-Leu L-Phe L-Phe OMe 61.9 ± 9.9
2 71 
O
 
L-Leu L-Phe L-Phe 
HN
 71.5 ± 11 
3 72 
O
 
L-Ala L-Phe L-Gln HN N
H  37.4 ± 5.4
4 73 
O
 
L-Phe L-Phe L-Tyr OH 42.6 ± 6.4
5 74 
O
 
L-Phe L-Phe L-Tyr 
HN
 68.7 ± 12 
6 75 
O
O
9
L-His L-His L-His HN NH2  13.3 ± 22 
7 76 
O
O
9
L-His L-His L-His HN N
N
 
20.5 ± 1.7
8 69 
O
O
9
L-His L-Tyr L-Phe HN NH2  14.0 ± 4.0
9 59 
O
9  L-His L-His L-Tyr 
N N
 4.8 ± 0.6 
10 48 
O
O
9
L-Tyr L-Tyr L-Tyr O NH2  28.2 ± 3.1
11 77 
O
O
9
L-Tyr L-Tyr L-Tyr HN NH2  8.8 ± 0.5 
12 78 
O
O
9
L-His L-His L-His N N  24.7 ± 1.7
13 79 
O
O
9
L-His L-Tyr L-Phe 
HN
 20.5 ± 4.1
14 80 
O
9  L-Tyr L-His L-Tyr 
N N
 2.4 ± 0.5 
15 81 
O
9  L-His L-Phe L-Tyr 
N N
 0.96 ± 0.1
16 82 
O
9  H2N OH
O
NH L-His L-His 
HN N
 27.8 ± 1.8
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17 83 
O
9  H2N OH
O
NH L-His L-His N N  31.7 ± 2.3
18 84 
O
9  L-His L-His L-Ser 
HN
NH2
 
35.3 ± 4.2
19  EGR 1120 O
O
N
 
L-His Gly L-His(Trt) OH 21 
 
 
The IC50 values of the inhibitors were measured using five different concentrations, 100 
µM, 50 µM, 25 µM, 12.5 µM and 6.25 µM respectively. For compounds 59, 80, and 81, 
the IC50 values were measured using seven different concentrations, 10 µM, 5 µM, 2.5 
µM, 1.25 µM, 0.625 µM, 0.3125 µM and 0.1562 µM respectively.  
 
Three peptides, 38 (61.9 µM), 71 (71.5 µM) and 74 (68.7 µM), exhibited IC50 value of 
more than 50 µM. The high IC50 value of these three compounds did not coordinate well 
with the screening results which showing these three compounds have exhibited the 
remaining Rab GGTase < 50%. This might be due to the precipitation of the inhibitors at 
higher concentration which cause partial scattering of fluorescent, therefore giving high 
IC50 value.  
 
Seven peptides, 72 (37.4 µM), 73 (42.6 µM), 48 (28.2 µM), 78 (24.7 µM), 82 (27.8 µM), 
83 (31.7 µM) and 84 (35.3 µM) gave IC50 value in between 20 µM and 50 µM. These 
seven peptides showed moderate inhibition activity against Rab GGTase. Another four 
compounds which have shown IC50 value in between 10 µM to 20 µM are 75 (13.3 µM), 
76 (20.5 µM), 69 (14.0 µM), 79 (20.5 µM) respectively.  
   
Three peptides were identified to have IC50 value of less than 10 µM. They are 59 (4.8 
µM), 80 (2.4 µM), and 81 (0.96 µM).  Especially 81, it has IC50 value of nanomolar 
concentration. These three peptides are the most potent inhibitors identified so far. Figure 
17 shows 4 nonlinear fitting curves from the selected inhibitors.  
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A      B 
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Figure 17. Nonlinear fitting curve of compounds A) 76, B) 59, C) 80 and D) 81 showing the IC50 
values and their slope factors.  
 
Most of the nonlinear fitting curves of the inhibitors have the slope factors between 0.7 to 
2 in which clearly indicated that the compounds are not likely to be false positive 
inhibitors. The IC50 values of the active peptides against Rab GGTase were re-evaluated 
again using the robot-assisted screening and the results showed very close match to the 
activity and IC50 value measured manually.   
 
4.3.2 Structure activity relationship (SAR) of inhibitors 
 
Compound 81 is the most potent in vitro Rab GGTase inhibitors identified so far in this 
peptide library. The characteristic features of 81 are its long lipid chain at the N-terminus, 
R5 position, and N-Methyl 2-ethyl pyridine moiety at its C-terminus, R1 position. The 
other two potent inhibitors, 59 and 80 have similar features as 81 with the differences of 
 
________________________________________________________________________ 
134 
type and sequence of amino acids in the peptide central core.  Table 7 compares 12 
peptides in the compound library consisting of N-Methyl 2-ethyl pyridine moiety at R1 
position, with various substitutes at R5 and different amino acids at R2, R3 and R4 
position.  
 
Table 7. Structure activity relationship (SAR) analysis of peptides constitute fix moiety at R1 
position and variable building block at R2, R3 R4 and R5 
Entry Nr. R5 R4 R3 R2 R1 
IC50 
(µM) 
1 59 
O
9  L-His L-His L-Tyr 
N N
 4.8 ± 0.6 
2 78 
O
O
9
L-His L-His L-His N N  24.7 ± 1.7
3 80 
O
9  L-Tyr L-His L-Tyr 
N N
 2.4 ± 0.5 
4 81 
O
9  L-His L-Phe L-Tyr 
N N
 0.96 ± 0.1
5 83 
O
9  H2N OH
O
NH L-His L-His N N  31.7 ± 2.3
6 85 
O
O
9
L-Tyr L-Tyr L-Tyr N N  100 %
a 
7 86 
O
O
9
L-His L-Tyr L-Phe N N  100 %
a 
8 87 
O
9  L-Tyr L-His L-His 
N N
 34%
a 
10 68 
O
9  L-His L-His L-Ser 
N N
 66%
a 
11 88 O
O
 
L-His Gly L-Tyr N N  85%
a 
12 89 O
O
 
L-His β-Ala L-Tyr N N  86%
a 
 
a: Entries 6 to 12 show the remaining Rab GGTase activity in percentage. IC50 was not measured.  
 
Placing the long lipid chain at R5 position increases significantly the inhibition activity of 
peptides against Rab GGTase. This rationale is supported by the fact that all the peptides 
in entries 1 to 5 of Table 7 have one lipid chain at its N-terminus. The peptides without 
the lipid chain substituent at the R5 position, entries 11 to 12, show little inhibition of Rab 
GGTase activity. Different lipid chain groups also contribute to distinctive IC50 value. 
 
________________________________________________________________________ 
135 
For example, entry 2 of Table 7 consists of a 4-undecyloxybenzoic group at R5 position 
gives higher IC50 value to the undecyl lipid chain. The reason for peptides containing 
long alkyl groups presenting better inhibition activity and IC50 value might be due to the 
insertion of the lipid chain into the Rab GGTase active site which consists of a long and 
large tunnel for the binding to native substrate GGPP.  
 
The type and sequence of amino acids are also the important factors contributing to the 
biological activity of the peptides. For example, entries 1, 3, 4, 5, 8 and 10 of Table 7 
have the same functional group at the R1 and R5 position, yet the bioactivity of these 6 
substrates to Rab GGTase are very different. Though entries 1 and 10 in Table 7 differ 
only at R2 position with entry 1 consists of a L-tyrosine and entry 10 has a L-serine, the 
difference of the bioactivity is significant. Entry 1 which is 59 has IC50 of about 5 µM, 
entry 10 which is 68 does not inhibit Rab GGTase very much with remaining Rab 
GGTase of 66% at 100 µM. Another example comes from entries 2 and 6. By changing 
all the amino acids from L-histidine (peptide 78) to L-tyrosine (peptide 85), the inhibition 
activity against Rab GGTase decreases from 24.7 µM to no inhibition, even at 50 µM.  
 
It is also noteworthy to compare the influence of various substituents at the R1 position of 
the C-terminus to understand the structure activity relationship of the peptides against 
Rab GGTase. Table 8 shows the peptides consists of the same moieties at R5, R4, R3 and 
R2 position, but variable at R1 position.   
 
Table 8. Comparison the effect of various substituents at R1 position towards the understanding 
of structure activity relationship.   
Entry Nr. R5 R4 R3 R2 R1b 
%c Rab 
GGTase 
Activity  
1 81 
O
9  L-His L-Phe L-Tyr 
N N
 
0.96 ± 
0.1a 
2 90 
O
9  L-His L-Phe L-Tyr HN OH
OH
 46%  
3 91 
O
9  L-His L-Phe L-Tyr N
OMe  41% 
4 92 
O
9  L-His L-Phe L-Tyr HN OH
OH
 100% 
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5 93 
O
9  L-His L-Phe L-Tyr NH 100% 
6 51 
O
9  L-His L-Phe L-Tyr OMe 100% 
7 94 
O
9  L-His L-Phe L-Tyr 
O
NH2  60% 
8 95 
O
9  L-His L-Phe L-Tyr 
HN
NH2
 
76% 
9 96 
O
9  L-His L-Phe L-Tyr OH 37% 
10 98 
O
9  L-His L-Phe L-Tyr NH-OH 58% 
11 97 
O
9  L-His L-Phe L-Tyr 
HN
O  78% 
 
a: IC50 value; b: Entries 2 and 4 are diastereoisomer with the variable stereochemistry at the C-
terminal secondary alcohol. c: The screening was performed at 50 µM. 
 
Table 8 contains a series of peptides with different substitution at R1 position. The 
inhibition activity of entry 1, compound 81, against Rab GGTase is the most potent in 
this series of peptides with IC50 value of 0.96 µM. Entries 4, 5 and 6 show no inhibition 
for Rab GGTase. Entries 2, 3, 7, 9 and 10 give similar inhibition activity for Rab 
GGTase.  Inhibition activity of entries 8 and 11 for Rab GGTase is comparable.  
 
From the different bioactivity results presented in Table 8, chemical moieties at the R1 
position play a decisive role in shaping the potency of inhibitors. In general, chemical 
moieties containing potential zinc ion binding functional group provide better inhibition 
activity. This argument is supported by good inhibition results shown in entries 1, 2, 3, 7, 
9 and 10, and vice versa from the counter examples shown by entries 2, 3 and 4. Entry 10 
has a hydroxamic group at the R1 position which is believed to be able to coordinate to 
the zinc ion in the active site of Rab GGTase. The bioactiviy of the peptide for the 
enzyme decreases by 20%, if the hydroxamic group was protected with tert butyl group 
(entry 11). This finding further verifies that a potential zinc ion coordinating residue 
gives positive enhancement for the inhibition activity of peptides. Different 
diastereoisomers also affect inhibition activity. Entries 2 and 4 show the difference of 
inhibition activity by 50%. These two peptides have identical sequence and chemical 
moiety at R1 position, except the stereochemistry conformation at secondary alcohol (The 
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relative and absolute stereochemistry of entries 2 and 4 were not determined). This result 
indicated that having the right conformation of the chemical moiety at R1 position can 
facilitate better coordination of ligand to the zinc ion with which increase the bioactivity.    
 
In summary of the in vitro screening results from Table 6, 7, 8 and activity data in the 
appendix, a few conclusions from structure activity relationship analysis can be drawn: 
 
(1) A change of chemical moiety profoundly influences the inhibition activity of 
peptides, especially the chemical moieties position at R1 and R5. 
 
(2) Substrates containing long lipid chain at the N-terminus confer better 
inhibition activity against Rab GGTase. It is preferable and essential to have 
this long aliphatic chain to gain good bioactivity. This is believed that the 
long lipid chain fit nicely to the binding pocket of Rab GGTase which 
encloses a deep, large and hydrophobic active site for GGPP. The insertion of 
long lipid chain to the binding pocket gives hydrophobic interaction between 
the lipid chain and the binding site. This conclusion is confirmed by many of 
low IC50 inhibitors having lipid containing peptides at R5 position. 
Incorporation of an extra aryl ring is not beneficial to the increase of 
bioactivity against Rab GGTase as the entire moiety may become too long to 
fit into the Rab GGTase pocket.    
 
(3) In vitro screening results from a series of peptides in Table 6 and 8 show that 
chemical moiety at R1 position which is able to chelate or bind to metal give 
better inhibitor bioactivity. Out of the 382 peptides screened, N-Methyl 2-
ethyl pyridine substrate at R1 position is the most promising candidate for the 
further development of more potent inhibitor.    
 
(4) The type and sequence of amino acids play very significant role in 
determining the bioactivity of peptides. Most of the potent peptides identified 
contain at least one histidine, and the best amino acids in peptides identified 
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so far containing L-histidine at 4th position, L-phenylalanine at 3rd position 
and L-tyrosine at 2nd position of the peptide sequence. Incorporation of L-
histidine at 2nd position of the peptide increases the IC50 value.   
 
(5) Majority of the peptides containing amino acids such as L-alanine, L-leucine 
and L-serine in this chemical library show no activity against Rab GGTase. 
Therefore, it is reasonable to conclude that by placing a zinc ion chelating 
amino acids such as L-histidine can improve the interaction of peptides with 
the enzyme. This argument can be supported that most of the peptides 
showing low IC50 in the screening have at least one L-histidine in the peptide 
central core.  
 
Figure 18 shows the summary of the structure activity relationships (SAR) for the peptide 
library. The SAR outlines some essential amino acids and chemical moieties at the 
peptide in order to give potent inhibition activity towards Rab GGTase.   
 
R5 NH
H
N
O
R4
O
N
H
O
R3
O
R3
R1 +: Zinc ion binding residues+: Long lipid chain- : Aryl ring
+: Histidine, Tyrosine
- : Aliphatic amino acids
+: Tyrosine 
- : Histidine
+: Histidine, Phenylalanine, Tyrosine
- : Aliphatic amino acids  
 
Figure 18. Structure activity relationship (SAR) of peptide library. + : Positive effect, - : 
Negative effect. 
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4.3.3 In vivo study of peptide inhibitors 
 
Six selected in vitro potent peptide inhibitors, 77, 75, 76, 80, 59, and 81 were subjected to 
in vivo study to identify active peptide inhibitors towards Rab GGTase in COS-7 cell. 
The principles of the in vivo testing are briefly described in the following paragraphs.    
 
Approximately 24 hours after beginning of transfection, the cells were rinsed with fresh 
medium and inhibitors were added to the medium in various concentration. After another 
24 hours of incubation with inhibitors, COS-7 cell lysates were collected and assayed for 
the presence of unprenylated Rab. An in vitro assay was carried out to assess the amount 
of unprenylated Rab in the lysate and to measure the in vivo inhibition of Rab 
prenylation.  
 
The assay contains 4 µM Biotin-GPP, 3µM Rab GGTase and 2 µM REP-1. These 
reagents are made up into a stock solution at room temperature. Lysate was then added 
and incubated at room temperature for 30 minutes. The reaction was stopped by the 
addition of 5 µL of sample buffer. Samples are boiled for 2 minutes and subsequently 
resolved by SDS-PAGE, Western Blot and probed with strepavidin-horse radish peroxide 
(Strepavidin-HRS). If the protein, Rab GGTase, is inhibited inside the cell, the in vitro 
prenylation assay will show a positive result which should have a prenylated YFP-Rab7 
blot band. If a compound tested does not inhibit the protein, then the YFP-Rab7 will be 
prenylated inside the COS-7 cell, as such no YFP-Rab7 band should be observed. The in 
vivo experiment was conducted by Dr. Christine Delon from Department of Physical 
Biochemistry, Max-Planck Institute, Dortmund. 
 
Figure 19 shows the results of the in vivo testing. The peptides were screened at three 
different concentrations, 100 µM, 50 µM and 10 µM respectively. The blot bands where 
the peptides showed in vivo activity toward Rab GGTase correspond to the biotin 
prenylated YFP-Rab7 protein with strepavadin. Compactin which inhibits the synthesis 
of isoprenyl lipid was added as a positive control. Negative control was done with only 
DMSO.  
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All the six compounds tested were not cytotoxic to the COS-7 cells. Three peptide 
inhibitors, 59, 80 and 81, were identified to be in vivo active against Rab GGTase in 
COS-7 cell. These three peptide inhibitors all exhibited inhibition of Rab GGTase at 100 
µM. 59 and 80 also showed in vivo activity against Rab GGTase at 50 µM, although the 
band color is not as intense as those shown at 100 µM. The three peptide inhibitors did 
not exhibit any inhibition at 10 µM as shown from Figure 19.  
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Figure 19. Western Blot of the in vivo assay. Cells over-expressing YFP-Rab7 were treated with 
20 µM compactin, which inhibits the synthesis of isoprenyl lipid, as a positive control and with 
1/1000v/v DMSO as a negative control. The inhibitors were screened at three different 
concentrations, 100 µM, 50 µM and 10 µM. Cell lysates were prenylated in vitro with Biotin 
labeled geranylgeranyl analogs, resolved by SDS-PAGE, Western blotted and analyzed with 
HRP-Streptavidin. The bands correspond to YFP-Rab7. 
 
The estimated IC50 values of the three in vivo active compounds were calculated by 
integration of the band intensity. By fitting the data to the quadratic equation using Grafit, 
the estimated IC50 values of 59, 80 and 81 are 47 µM, 60 µM and 52 µM respectively.  
 
4.3.4 Selectivity studies of inhibitors towards Rab GGTase, FTase and GGTase I 
 
Three selected compounds, 59, 80 and 81, were subjected to SDS-PAGE end-point gel 
assays for their selective inhibitory activity studies towards two other prenyltransferase, 
FTase and GGTase I. The IC50 values of the three selected compounds towards Rab 
GGTase were also determined using gel assay to give supplementary data for the 96-well 
plate format assay and also to have standard comparison with FTase and GGTase I.   
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The assay was performed using the same principle as in 96-well plate format. In an 
eppendorf tube, protein substrate GST-Rho A and GST-K Ras, and prenyltransferases 
GGTase I and FTase were incubated with inhibitors in buffer and 5% DMSO at 37°C for 
2 minutes respectively. Fluorescent substrates NBD-FPP and NBD-GPP of GGTase I and 
FTase respectively were added to the mixture to initiate the prenylation reaction. The 
reaction mixture was incubated at 37°C for 10 minutes and quenched by addition of 
excess SDS-PAGE buffer. The reaction mixture was then subjected to SDS-PAGE to 
determine the fluorescent intensity of bands corresponding to the NBD-isoprenylated 
GTPase in the gel. The fluorescent intensity was determined by the integration of the 
corresponding bands. IC50 of the peptide inhibitors towards Rab GGTase were 
determined in the same manner as FTase and GGTase I.  
 
Table 9 shows the IC50 values of three inhibitors towards FTase, GGTase I and Rab 
GGTase determined by SDS-PAGE assay. The selectivity data of a previously identified 
inhibitor, EGR 1120, towards these three prenyltransferase was included for comparison. 
The IC50 value determined using gel assay were highly comparable to the value 
established by 96-well plate format. In general, the IC50 value determined using SDS-
PAGE gel assay was about 2 times higher than the results derived from 96-well plate 
assay. The consistent difference of plate format and gel assay for three structurally 
similar inhibitors indicates that the assay used for the screening of Rab GGTase inhibitors 
is indeed very reliable.  
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Table 9. Comparison of IC50 values of inhibitors towards FTase, GGTase I and Rab  
GGTase using 96-well plate format continuous fluorescence assay and SDS-PAGE assay 
Rab GGTase  
Inhibitors 
Plate assay Gel assay 
FTase 
(Gel assay) 
GGTase I 
(Gel assay) 
81 0.97 ± 0.1 2.7 ± 0.2 29a >100 
80 2.4 ± 0.7 4.4 ± 0.4 42b >100 
59 4.9 ± 0.6 10 ± 0.9         36 61 
EGR 1120 21 14 14 5.2 
  
a: The inhibitor showed about 50% inhibition at the range of 6-100 µM concentration; b: The 
inhibitor showed about 50% inhibition at the range of 25-100 µM concentration 
 
As shown in Table 9, 81 and 80 exhibit very high inhibitory selectivity towards Rab 
GGTase over GGTase I. The IC50 of both inhibitors towards GGTase I are above 100 µM 
concentration which makes 81 and 80 at least 50 and 20 times (compared with gel assay) 
more specific towards Rab GGTase over GGTase I respectively. Compound 59 is not so 
selective, as it exhibits IC50 value towards Rab GGTase at 10 µM and GGTase I at 61 
µM.  
 
The three peptides exhibit similar IC50 value towards FTase. The IC50 of 81 and 80 
towards FTase gave 50% inhibition of the enzyme at the range of 6-100 µM for 81 and 
25-100 µM for 80. The reasons of this inhibition pattern still remain unknown. Third 
peptide 59 shows good nonlinear regression curve and give IC50 of FTase at 36 µM. Due 
to the structural similarity of the three peptides used for selectivity measurement, one can 
assume that 80 and 81 will also exhibit IC50 value between 30 µM to 40 µM to FTase.  
 
The three peptides were also compared with the previously identified potent peptide 
inhibitor EGR 1120 of Rab GGTase. At the concentration of 50 µM, EGR 1120 does not 
show high selectivity for all three enzymes. Both 81 and 80 showed excellent inhibition 
of Rab GGTase activity at 50 µM where enzyme activity drops to 20% and below. FTase 
was also inhibited to around 50 % activity. However, the inhibition ability of 80 and 81 
towards GGTase I is very weak, as the enzyme still exhibited around 85 % activity at 50 
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µM (Figure 20). On the other hand, 59 shows strong inhibition at 50 µM towards all three 
enzymes. The selectivity experiments were performed by Yaowen Wu. 
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Figure 20. Initial reaction velocity of four inhibitors EGR 1120, 81, 80 and 59 at 50 µM.  
 
In summary, the three inhibitors, 59, 80, and 81, show generally high inhibition 
specificity towards Rab GGTase. The peptides do not inhibit FTase and GGTase I at low 
micro molar concentration. The high specificity of these three peptides promised 
potential usage as selective molecular sensor to study biological pathway involving Rab 
proteins over Ras and Rho proteins in cell and molecular biology.   
 
4.3.5 Kinetic analysis of compound 81 towards Rab GGTase inhibition  
 
The most potent in vitro compound 81 in this peptide library was subjected to kinetic 
studies in order to determine the possible mode of inhibition. The experiment was 
conducted with NBD-FPP 1 at different concentration together with a constant 
concentration of Rab-7:REP-1 at 1.2 µM and Rab GGTase at 0.08 µM respectively. The 
concentration of inhibitor 81 used in this experiment was 4 µM and 8 µM respectively.  
The profile of Lineweaver-Burk plot suggested that 81 is a non-competitive inhibitor with 
respect to NBD-FPP, as it has the intercept point at X-axis (Figure 21).  
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Figure 21.  Lineweaver-Burk plot against NBD-FPP with constant concentration of Rab7:REP-1 
of 1.2 µM and 0.08 µM Rab GGTase. The concentrations of inhibitor 81 were as indicated in the 
plot.  
 
A titration experiment was performed to determine the Kd value of inhibitor 81 with Rab 
GGTase and also to confirm the mode of inhibition (non-competitive inhibitor of Rab 
GGTase) as obtained from Lineweaver-Burk plot. Figure 22 shows the raw data for a 
titration of NBD-FPP:Rab GGTase with 81 and finally with GGPP.   
 
 
 
Figure 22. Titration curve of NBD-FPP:Rab GGTase with 81 and finally with GGPP.  
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The initial level of the fluorescence signal in Figure 22 represents the fluorescence of free 
NBD-FPP (400 nM). In the first step, Rab GGTase was added to a final concentration of 
550 nM. Subsequently, 81 was titrated into the cuvette in 1 µM units each addition. 
Finally, GGPP was added to a final concentration of 4 µM. 
 
As shown in Figure 22, the fluorescence signal decreased dramatically after the addition 
of Rab GGTase to NBD-FPP, suggesting binding of NBD-FPP 1 to Rab GGTase. With 
an increasing concentration of 81 in the solution, there was a dose-dependent increase in 
fluorescence, consistent with dissociation of the NBD-FPP from Rab GGTase. This 
displacement of NBD-FPP 1 reached saturation after 5 µM of inhibitor was added. At this 
point an excess of GGPP was added to the reaction, the fluorescence increased to the 
level of free NBD-FPP, indicating that the NBD-FPP 1 was then fully displaced. 
 
This initial displacement of NBD-FPP 1 suggests that binding of 81 to Rab GGTase 
might occur at a site close to the lipid substrate binding site and has influenced the lipid 
substrate binding with Rab GGTase at the beginning of titration. The saturation of 
fluorescent signal after addition of 5 µM inhibitor further verified that 81 is indeed a non-
competitive inhibitor to Rab GGTase.  This finding is also consistent with that from the 
enzyme kinetics experiment using Lineweaver-Burk plot, indicating 81 is mostly non-
competitive to the lipid substrate of Rab GGTase, hence, NBD-FPP 1.  
 
Fitting of the data from titration experiment (Figure 22) by numerical simulation to a 
non-competitive model led to a Kd value of 645 nM for the interaction of 81 with Rab 
GGTase (Figure 23). Titrations were fitted using the quadratic equation in the program 
Grafit 5 (Erithacus Software). The fits were performed using a model file that allows 
simulation and fitting to a set of numerical equations. 
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Figure 23. The raw data from Figure 22 were fitted by numerical simulation to a non-competitive 
model to give a Kd value of 645 nM for compound 81 with Rab GGTase.  
 
A further titration experiment was conducted to elucidate the binding of 81 to Rab 
GGTase. An independent co-titration experiment was performed in which Rab GGTase 
was titrated into 200 nM NBD-FPP 1 in the absence of 81 (open circle), in the presence 
of 2 µM (filled triangle) and 5 µM 81 (filled square) respectively (Figure 24).  
 
 
 
Figure 24. Titration of 200 nM solution of NBD-FPP with Rab GGTase in the absence of 81 
(open circle and white line) and in the presence of 2 µM (filled triangle and blue line) and 5 µM 
81 (filled square and red line). The data were fitted with a quadratic equation to give apparent Kd 
values. The fluorescence of NBD was excited at 479 nm, and the data collected at 547 nm. 
Kdapp=223nM 
Kdapp=204nM 
Kd      =157nM 
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A similar inhibition trend was observed when the titration in the presence of 81 was 
compared with the free titration (in the absence of an inhibitor). When the data was fitted 
to a quadratic equation, an apparent Kd value of 157 nM was obtained for NBD-FPP 1 
with Rab GGTase in the absence of the inhibitor, and apparent Kd value of 204 nM and 
223 nM in the presence of 2 µM and 5 µM of 81 respectively. The similar apparent Kd 
value in the absence and presence of the inhibitor indicate that the inhibitor does not 
weaken the affinity of NBD-FPP 1 binding to Rab GGTase and it is independent of 
inhibitor’s concentration. This data provides further evidence that 81 is a non-competitive 
inhibitor towards Rab GGTase.   
 
Fitting the data obtained above by numerical simulation (Figure 24) to a non-competitive 
model led to a genuine Kd value of 486 nM for the interaction of 81 with Rab GGTase 
(Figure 25). This result correlates very closely with the affinity of 81 to Rab GGTase 
obtained from Figure 22 (Kd = 645 nM). 
 
 
 
Figure 25. Numerical simulation of 81 to a non-competitive model to give a Kd value of 486 nM 
to Rab GGTase.  
 
The data shown from the Lineweaver-Burk plot and two different titration experiments 
indicate that 81 should be a non-competitive inhibitor of Rab GGTase. The two different 
titration methods gave similar Kd values and complement each other by providing valid 
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kinetic data of 81 to Rab GGTase. From the titration results obtained from Figure 22, the 
binding site of 81 might be very close to prenyl binding site of Rab GGTase due to the 
initial displacement of NBD-FPP 1 from the enzyme. Further details on the inhibitor 
binding site in Rab GGTase can only be disclosed with more biochemistry experiments 
and X-ray crystallography. The kinetic experiments were performed by Yaowen Wu  
 
4.3.6 Summary and discussions of biochemical investigation of Rab GGTase 
inhibitors 
  
Out of the 382 peptides screened, 18 peptides were found to be active against Rab 
GGTase. The IC50 of these peptide inhibitors were determined and one of them, 81, gave 
an IC50 value as low as 0.96 µM. Structure activity relationship analysis of the peptide 
library revealed that peptides containing long lipid chains at its N-terminus and moieties 
with metal chelating ability at C-terminus were found to be the most active substrates to 
inhibit Rab GGTase. Furthermore, incorporation of L-histidine amino acid together with 
the long lipid chain and zinc ion chelating residues improves the IC50 value. This is 
probably due to the potential binding of L-histidine to the zinc ion in the Rab GGTase 
pocket.     
 
Three compounds, 59, 80 and 81, were found to have in vivo activity against Rab 
GGTase. Selectivity screening of these three peptides against FTase, GGTase I and Rab 
GGTase using gel assay showed that the peptides selectively inhibit Rab GGTase, but 
gave no inhibition against GGTase I and only moderate activity against FTase. The 
kinetic analysis of 81 by titration and Lineweaver-Burk plot confirmed that the inhibitor 
is a non-competitive inhibitor of Rab GGTase with respect to the fluophore lipid 
substrate 1.    
 
From the bioactivity resultes presented in Table 7, 8, 9 and in appendix, the initial 
approach of incorporation a long lipid chain residues in the peptides works very well. The 
large hydrophocity of long lipid chain can impart the driving force to the peptides to 
diffuse the inhibitors to the hydrophobic pocket of Rab GGTase. In contrast to Rab 
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GGTase, FTase and GGTase I which known as the CAAX prenylases, both recognize the 
tetrapeptide motif CAAX at the C-terminus of their substrates and catalyze the transfer of 
FPP and GGPP to the cysteine residues. The different catalytic nature of three 
prenyltranferases has helped to explain the high inhibition specificity of three peptides 
59, 80 and 81 towards Rab GGTase over FTase and GGTase I. 59, 80 and 81 do not 
contain any simple aliphatic amino acids and cysteine, therefore the low bioactivity of 
these three peptides towards FTase and GGTase I could be understood.  
 
Several potent peptide inhibitors for Rab GGTase have been successfully optimized and 
synthesized starting from a previously validated FTase peptides library.55 The synthetic 
modification of the FTase inhibitors based on the incorporation of long lipid chain moiety 
and potential zinc ion binding residues have diluted the effect of cross-activity for FTIs 
with Rab GGTase. This results demonstrat that cross-activity of FTIs with Rab GGTase 
and GGTase I can be modulated by rationale design of inhibitors.   
 
5 Conclusions and Outlook  
 
In conclusion, the synthesis of Pepticinnamine E derivatives using safety catch linker and 
building block strategy has successfully generated 382 peptides with different chemical 
functionalities at N-terminus and C-terminus with the incorporation of various amino 
acids at the peptides central core. The bioactivity screen of these peptides has revealed 
several potent and selective inhibitors against Rab GGTase over FTase and GGTase I. 
The identification of three in vivo active peptides 59, 80 and 81 in this peptides library 
has increased the value of the work.   
 
The future work for this project will be the modification of N-terminus and C-terminus 
moieties together with the amino acids sequence of the derivatives, based on the 
identified potent in vitro peptide inhibitors, 59, 80 and 81 to increase the bioactivity of 
the peptides and at the same time improve the inhibition selectivity of Rab GGTase over 
FTase and GGTase I. The binding site of the inhibitors should also be characterized to 
facilitate the search for more potent and selective inhibitors.   
 
________________________________________________________________________ 
150 
6 Appendix 
 
 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
1 38 N
H
O H
N
N
H
OMe
O
O
O
 
18 (> 95) 5 (62 µM) 
2 39 N
H
O H
N
N
H
OH
O
O
O
 
3 (> 95) 39 a 
3 40 O
N
H
NO
O
N
H O
H
N
F
F
 
28 (> 85) 24 a 
4 41 
N
H
H
N
N
H
H
N
O
O
O
O
F
OH
F
F  
23 (> 90) -6 a 
5 42 N
H
O H
N
N
H
O
O
O
H2N O
O
OH
 
3 (> 95) 4 a 
6 43 N
H
O H
N
N
H
NH2
O
O
H2N O
O
 
5 (> 95) 113 a 
7 44 N
H
O H
N
N
H
O
O
O
H2N O
O
Cl
 
1 (> 95) 95 a 
8 45 
N
H
O H
N
N
H
H
N
O
O
OH2N
O
F
Cl
F  
1 (> 95) 64 a 
9 46 
N
H
H
N
N
H
H
N
O
F
O
O
OH OH
O  
10 (> 95) 123 b 
10 47 
N
H
H
N
N
H
N
O
F
OH
O
O
OH
O
O
 
7 (> 95) 94 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
11 48 
O
N
H
O H
N
N
H
O
O
OH
OH
O
O
OH
NH2
 
4 (> 95) 26 (28 µM) b 
12 49 N
H
O H
N
N
H
H
N
O
O
H
N O
H
O N
S
 
6 (> 95) 60 a 
13 50 N
H
H
N
N
H
O
HO
O
O
HO
O
F
O
 
6 (> 95) 86 b 
14 51 N
H
H
N
N
H
OMe
O N
NH
O
O
OH
O
 
25 (> 95) 100 b 
15 52 N
H
H
N
N
H
NH2
O
O
NH
N
O
OH
O
OH
 
2 (> 95) 92 b 
16 53 N
H
H
N
N
H
H
N
O
O
NH
N
O
OH
O
OH
OH
OH
 
20 (> 95) 106 b 
17 54 
N
H
H
N
N
H
H
N
O
O
NH
N
O
OH
O
OH
NH2
 
22 (> 95) 68 b 
18 55 
N
H
H
N
N
H
O
O
O
NH
N
O
OH
O
OH
NH2
 
7 (> 95) 60 b 
19 56 
O
N
H
O H
N
N
H
OH
O
O
O
NH
N
N
NH
N
NH
 
20 (> 95) 45 b 
20 57 
O
N
H
O H
N
N
H
OMe
O
O
O
NH
N
N
NH
N
NH
 
11 (> 95) 86 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
21 58 
O
N
H
O H
N
N
H
NH2
O
O
O
NH
N
N
NH
N
NH
 
7 (> 95) 98 b 
22 59 N
H
H
N
N
H
N
O
NH
N
O
NH
N
O
OH
O
N
 
12 (> 95) 2 (5 µM) b 
23 60 N
H
H
N
N
H
H
N
O
NH
N
O
NH
N
O
OH
O
N
N
 
15 (> 95) 92 b 
24 61 N
H
H
N
N
H
H
N
O
OH
O
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N
O
OH
O
NH2
 
20 (> 85) 77 b 
25 62 
O N
H
H
N
N
H
H
N
O N
NH
O
O
OH
O
S
N  
2 (> 95) 87 b 
26 63 NH
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
OH
OH
 
26 (> 95) 75 b 
27 64 O N
H
H
N
O N
NH
O
H
N
O
OMe
O
OH  
4 (> 95) 88 b 
28 65 O N
H
H
N
O N
NH
O
H
N
O
NH2
O
OH  
1 (> 95) 89 b 
29 66 O N
H
H
N
O N
NH
O
H
N
O
N
H
O
OH
N
N
 
6 (> 95) 88 b 
30 67 N
H
H
N
N
H
O
O
O
O
H
N
OH
OH
N
H
N
 
13 (> 95) 58 b 
 
 
 
 
 
________________________________________________________________________ 
153 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
31 68 NH
H
N
N
H
O
O
O
OH
O
N
N
H
N
NHN
N
 
6 (> 95) 66 b 
32 69 
O
N
H
O H
N
N
H
H
N
NH
N
O
OH
O
O
NH2
 
6 (> 95) -40 (14 µM) b 
33 70 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
H
N N N
 
20 (> 95) 34 b 
34 71 N
H
O H
N
N
H
H
N
O
O
O
 
18 (> 95) 13 (71 µM) 
35 72 N
H
O H
N
N
H
H
N
O
O
H2N O
O
N
H
 
2 (> 95) -14 ( 37 µM) 
36 73 N
H
H
N
N
H
O
O
O
OH
O
OH
 
12 (> 95) 11 ( 42 µM) 
37 74 N
H
H
N
N
H
O
O
O
OH
O
H
N
 
2 (> 95) 20 (68 µM) 
38 75 
O
N
H
O H
N
N
H
H
N
O
O
O
NH
N
N
NH
N
NH
NH2
 
20 (> 95) -43 (13 µM) b 
39 76 
O
N
H
O H
N
N
H
H
N
O
O
O
NH
N
N
NH
N
NH
N N
 
21 (> 95) 4 (20 µM) b 
40 77 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
NH2
 
18 (> 95) 17 (8 µM) b 
 
 
 
________________________________________________________________________ 
154 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
41 78 
O
N
H
O H
N
N
H
N
O
O
O
NH
N
N
NH
N
NH
N
 
25 (> 95) -35 (24 µM) b 
42 79 
O
N
H
O H
N
N
H
H
N
NH
N
O
OH
O
O
 
1 (> 85) 30 (20 µM) b 
43 80 N
H
H
N
N
H
N
O
O
NH
N
O
OH
O
OH
N
 
12 (> 85) 18 (2 µM) b 
44 81 N
H
H
N
N
H
N
O N
NH
O
O
OH
O
N
 
18 (> 95) 23 (1 µM) b 
45 82 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
H
N N
 
9 (> 95) 17 (28 µM) b 
46 83 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
N N
 
14 (> 95) 36 (31 µM) b 
47 84 NH
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
NH2
 
23 (> 85) 33 (35 µM) b 
48 85 
O
N
H
O H
N
N
H
N
O
OH
OH
O
O
OH
N
 
2 (> 95) 104 b 
49 86 
O
N
H
O H
N
N
H
N
NH
N
O
OH
O
O
N
 
2 (> 95) 104 b 
50 87 N
H
H
N
N
H
N
O
OH
O
NH
N
O
NH
N
O
N
 
10 (> 95) 34 b 
 
 
________________________________________________________________________ 
155 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
51 88 
O N
H
H
N
N
H
N
O N
NH
O
O
OH
O
N
 
2 (> 95) 85 b 
52 89 O N
H
H
N
O N
NH
O
H
N
O
N
O
OH
N
 
1 (> 95) 86 b 
53 90 N
H
H
N
N
H
H
N
O N
NH
O
O
OH
O
OH
OH
 
3 (> 95) 47 b 
54 91 N
H
H
N
N
H
N
O N
NH
O
O
OH
O
OMe
 
1 (> 95) 41 b 
55 92 N
H
H
N
N
H
H
N
O N
NH
O
O
OH
O
OH
OH
 
35 (> 95) 100 b 
56 93 N
H
H
N
N
H
NH2
O N
NH
O
O
OH
O
 
13 (> 95) 100 b 
57 94 N
H
H
N
N
H
O
O N
NH
O
O
OH
O
NH2
 
12 (> 95) 60 b 
58 95 N
H
H
N
N
H
H
N
O
O
O
OH
O
NH2
NHN
 
5 (> 95) 76 b 
59 96 N
H
H
N
N
H
OH
O N
NH
O
O
OH
O
 
22 (> 95) 37 b 
60 97 N
H
H
N
N
H
O
O
O
O
H
N
O
OH
N
H
N
 
5 (> 95) 78 b 
 
 
 
 
________________________________________________________________________ 
156 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
61 98 
N
O
H
N
O
N
H
O
O
OH
 
45 (> 95) 42a 
62 99 
N
O
H
N
O
N
H
O
O
H
N
 
22 (> 95) 35a 
63 100 
N
O
H
N
O
N
H
O
O
H
N
 
42 (> 95) 45a 
64 101 
N
O
H
N
O
N
H
O
O
OMe
 
32 (> 95) 102 a 
65 102 N
H
O H
N
N
H
H
N
O
O
O
F
F
 
18 (> 95) 82 a 
66 103 O
N
H
NO
O
N
H O
O
 
19 (> 95) 43 a 
67 104 N
H
O H
N
N
H
H
N
O
O
O
 
31 (> 95) 72 a 
68 105 O
N
H
NO
O
N
H O
H
N
F
F
 
31 (> 95) 49 a 
69 106 N
H
O H
N
N
H
H
N
O
O
O
Cl
NO2
 
17 (> 80) 90 a 
70 107 N
H
O H
N
N
H
H
N
O
O
O
 
20 (> 90) 112 a 
71 108 N
H
O H
N
N
H
O
O
O
O
 
5 (> 95) 62 a 
 
 
 
 
________________________________________________________________________ 
157 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
72 109 N
H
O H
N
N
H
O
O
O
O
Br  
6 (> 90) 40 a 
73 110 O
N
H
NO
O
N
H O
H
N
 
34 (> 95) 106 a 
74 111 O
N
H
NO
O
N
H O
O
 
16 (> 95) 95 a 
75 112 O
N
H
NO
O
N
H O
OH
 
7 (> 95) 49 a 
76 113 O
N
H
NO
O
N
H O
OMe
 
16 (> 95) 75 a 
77 114 O
N
H
NO
O
N
H O
O
 
6 (> 80) 86 a 
78 115 
N
H
H
N
N
H
OH
O
O
O
O
F
OH
 
7 (> 95) 44 a 
79 116 N
H
H
N
N
H
H
N
O
O
O
OH
O
F
OH
 
8 (> 95) 51 a 
80 117 
N
H
H
N
N
H
H
N
O
O
O
O
F
OH
 
8 (> 95) 41 a 
81 118 N
H
H
N
N
H
O
O
O
O
OH
O
F
OH
 
3 (> 95) -9 a 
82 119 
N
H
H
N
N
H
OMe
O
O
O
O
F
OH
 
10 (> 80) 66 a 
83 120 N
H
H
N
N
H
OH
O
O
O
OH
O
F
OH
 
6 (> 95) 89 a 
 
 
 
________________________________________________________________________ 
158 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
84 121 O
N
H
NO
O
N
H O
H
N
 
20 (> 95) 130 a 
85 122 N
H
H
N
N
H
H
N
O
O
O
OH
O
F
OH
 
17 (> 90) 92 a 
86 123 N
H
O H
N
N
H
OMe
O
O
O
O
 
29 (> 95) 97 a 
87 124 N
H
O H
N
N
H
O
O
O
O
O
Cl
 
16 (> 95) 117 a 
88 125 N
H
O H
N
N
H
O
O
O
O
O
Cl
 
14 (> 95) 77 a 
89 126 N
H
O H
N
N
H
OH
O
O
O
O
 
16 (> 95) 66 a 
90 127 N
H
O H
N
N
H
OH
O
O
O
O
 
8 (> 95) 50 a 
91 128 N
H
O H
N
N
H
NH2
O
O
O
O
 
30 (> 95) 76 a 
92 129 N
H
O H
N
N
H
OMe
O
OH
O
O
 
29 (> 95) 91 a 
93 130 
N
H
O H
N
N
H
OH
O
OH
O
O  
10 (> 95) 81 a 
94 131 
N
H
O H
N
N
H
OMe
O
OH
O
O  
25 (> 95) 63 a 
 
 
 
________________________________________________________________________ 
159 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
95 132 N
H
O H
N
N
H
O
O
OH
O
O
Cl
 
10 (> 95) 8 a 
96 133 
N
H
O H
N
N
H
NH2
O
OH
O
O  
20 (> 90) 93 a 
97 134 N
H
O H
N
N
H
NH2
O
OH
O
O
 
20 (> 95) 97 a 
98 135 N
H
O H
N
N
H
O
O
O
O
O
 
6 (> 95) 90 a 
99 136 N
H
O H
N
N
H
NH2
O
O
O
O
 
26 (> 95) 93 a 
100 137 N
H
O H
N
N
H
O
O
O
O
O
 
30 (> 95) 92 a 
101 138 
F
N
H
O H
N
N
H
H
N
O
OH
O
O
N
H
 
1 (> 90) 74 a 
102 139 
F
N
H
O H
N
N
H
NH2
O
OH
O
O  
3 (> 90) 63 a 
103 140 
F
N
H
O H
N
N
H
OMe
O
OH
O
O  
3 (> 95) 83 a 
104 141 
F
N
H
O H
N
N
H
H
N
O
OH
O
O S
N
 
3 (> 95) 93 a 
105 142 
F
N
H
O H
N
N
H
NH2
O
O
O
O
 
8 (> 95) 138 a 
 
 
 
 
________________________________________________________________________ 
160 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
106 143 
F
N
H
O H
N
N
H
OMe
O
O
O
O
 
7 (> 95) 98 a 
107 144 
F
N
H
O H
N
N
H
N
O
O
O
O
OMe
 
3 (> 95) 80 a 
108 145 
F
N
H
O H
N
N
H
H
N
O
O
O
O S
N
 
5 (> 95) 70 a 
109 146 
N
H
O H
N
N
H
O
O
OH
O
O
Cl
 
7 (> 95) 52 a 
110 147 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O
OH
 
5 (> 90) 93 a 
111 148 N
H
O H
N
N
H
O
OH
O
O
H2N O
O
 
1 (> 90) 52 a 
112 149 
F
N
H
O H
N
N
H
OH
O
OH
O
O  
3 (> 95) 80 a 
113 150 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O
 
1 (> 95) 52 a 
114 151 
F
N
H
O H
N
N
H
N
O
OH
O
O
OMe
 
5 (> 95) 13 a 
115 152 N
H
O H
N
N
H
N
OH
O
O
H2N O
O
OMe
 
1 (> 95) 66 a 
116 153 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O S
N
 
2 (> 95) 66 a 
 
 
________________________________________________________________________ 
161 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
117 154 N
H
O H
N
N
H
OMe
OH
O
O
H2N O
O
 
2 (> 95) 77 a 
118 155 N
H
O H
N
N
H
NH2
OH
O
O
H2N O
O
 
1 (> 85) 65 a 
119 156 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O S
N
Br
Br
 
3 (> 95) 40 a 
120 157 N
H
O H
N
N
H
O
OH
O
O
H2N O
O
Cl
Br
Br
 
1 (> 90) 7 a 
121 158 N
H
O H
N
N
H
O
OH
O
O
H2N O
O
OH
Br
Br
 
4 (> 95) 60 a 
122 159 N
H
O H
N
N
H
O
OH
O
O
H2N O
O
 
2 (> 95) 64 a 
123 160 
F
N
H
O H
N
N
H
OH
O
O
O
O
 
3 (> 90) 52 a 
124 161 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O
Cl
F
 
2 (> 90) 50 a 
125 162 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O
N Br
 
2 (> 95) 53 a 
126 163 N
H
O H
N
N
H
OH
OH
O
O
H2N O
O
 
2 (> 95) 59 a 
 
 
 
________________________________________________________________________ 
162 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
127 164 N
H
O H
N
N
H
O
OH
O
O
H2N O
O
Cl
 
1 (> 95) 66 a 
128 165 N
H
O H
N
N
H
OEt
O
O
H2N O
O
 
4 (> 95) 88 a 
129 166 N
H
O H
N
N
H
O
O
O
H2N O
O
 
2 (> 95) 49 a 
130 167 N
H
O H
N
N
H
N
O
O
H2N O
O
OMe
 
6 (> 95) 69 a 
131 168 N
H
O H
N
N
H
H
N
O
O
H2N O
O N
S
 
4 (> 95) 99 a 
132 169 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O
N Br
Br
Br
 
2 (> 95) 59 a 
133 170 N
H
O H
N
N
H
N
OH
O
O
H2N O
O
OMeBr
Br
 
8 (> 95) 75 a 
134 171 N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O
Cl
F
Br
Br
 
1 (> 95) 16 a 
135 172 N
H
O H
N
N
H
O
O
O
H2N O
O
 
1 (> 95) 108 a 
136 173 N
H
O H
N
N
H
H
N
O
O
H2N O
O
 
2 (> 95) -68 a 
 
 
 
 
________________________________________________________________________ 
163 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
137 174 N
H
O H
N
N
H
OH
O
O
H2N O
O
 
6 (> 95) 62 a 
138 175 O
N
H
NO
O
N
H O
H
N
 
12 (> 95) 142 a 
139 176 N
H
O H
N
N
H
H
N
O
O
H2N O
O
Cl
F
 
1 (> 95) 63 a 
140 177 
N
H
H
N
N
H
H
N
O
F
O
O
OH
O  
9 (> 85) 17 a 
141 178 N
H
O H
N
N
H
H
N
O
O
H2N O
O
OH
 
1 (> 95) 70 a 
142 179 N
H
O H
N
N
H
H
N
O
O
H2N O
O
N Br
 
1 (> 95) 71 a 
143 180 N
H
O H
N
N
HO
OH
O
H2N O
O
OMe
 
2 (> 85) 38 a 
144 181 N
H
O H
N
N
HO
OH
O
H2N O
O
OH
 
6 (> 95) 45 a 
145 182 N
H
O H
N
N
HO
OH
O
H2N O
O
N
OMe
 
7 (> 95) 71 a 
146 183 N
H
O H
N
N
HO
OH
O
H2N O
O
NH2
 
8 (> 80) 77 a 
 
 
 
 
________________________________________________________________________ 
164 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
147 184 N
H
O H
N
N
HO
OH
O
H2N O
O
H
N
NH2
 
3 (> 85) 38 a 
148 185 N
H
O H
N
N
H
O
O
OH
O
H2N O
O
OH
 
4 (> 95) 47 a 
149 186 N
H
O H
N
N
HO
O
N
O
O NH2
 
25 (> 95) 81 a 
150 187 N
H
O H
N
N
HO
OH
O
H2N O
O
H
N
N
S
 
6 (> 95) 80 a 
151 188 N
H
O H
N
N
H
O
O
OH
O
H2N O
O
 
4 (> 95) 92 a 
152 189 N
H
O H
N
N
H
H
N
O
OH
O
H2N O
O
Cl
F
 
5 (> 95) -61 a 
153 190 N
H
O H
N
N
HO
OH
O
H2N O
O
H
N
N
H
 
1 (> 85) 65 a 
154 191 
N
O
H
N
O
N
H
O
O
OMe
 
5 (> 95) 99 a 
155 192 N
H
O H
N
N
H
H
N
O
OH
O
H2N O
O
N Br
 
6 (> 70) 45 a 
156 193 
N
H
O H
N
N
H
OH
O
O
OH2N
O
F  
1 (> 95) 66 a 
 
 
 
 
 
________________________________________________________________________ 
165 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
157 194 
N
H
O H
N
NH2
O
N
H
N
NH
O
HO
O
OMe
 
10 (> 85) 88 a 
158 195 
N
H
H
N
N
H
H
N
O
NH2
O
N
NH
O
OH
O
F
 
25 (> 85) 93 a 
159 196 
N
H
O H
N
NH2
O
N
H
N
NH
O
HO
OH
O
 
6 (> 95) 80 a 
160 197 
N
H
H
N
N
H
H
N
O
NH2
O
N
NH
O
OH
O
F
F
 
4 (> 90) 78 a 
161 198 
N
H
O H
N
NH2
O
N
H
N
NH
O
HO
H
N
O
F
F
 
1 (> 95) 89 a 
162 199 
N
H
O H
N
N
H
H
N
O
O
OH2N
O
F
N
S
 
1 (> 95) 40 a 
163 200 
N
H
O H
N
NH2
O
N
H
N
NH
O
HO
O
H
N
 
3 (> 95) 94 a 
164 201 
N
H
O H
N
N
H
N
O
O
OH2N
O
F
OMe
 
1 (> 95) 54 a 
165 202 
N
H
O H
N
N
H
OMe
O
O
OH2N
O
F  
1 (> 95) 58 a 
166 203 
N
H
O H
N
N
H
O
O
O
OH2N
O
F
OH
 
1 (> 85) 81 a 
 
 
 
 
________________________________________________________________________ 
166 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
167 204 
N
H
O H
N
N
H
H
N
O
O
OH2N
O
F
N Br
 
1 (> 90) 95 a 
168 205 
N
H
O H
N
N
H
H
N
O
O
OH2N
O
F
N
H
 
1 (> 80) 93 a 
169 206 N
H
O H
N
N
H
OH
O
O
H
N O
H
O
 
3 (> 95) 89 a 
170 207 
N
H
O H
N
N
H
O
O
O
OH2N
O
F
Cl
 
1 (> 70) -81 a 
171 208 N
H
O H
N
N
H
OMe
O
O
H
N O
H
O
 
2 (> 80) 83 a 
172 209 N
H
O H
N
N
H
NH2
O
O
H
N O
H
O
 
5 (> 90) 102 a 
173 210 N
H
O H
N
N
H
H
N
O
O
H
N O
H
O
N Br
 
1 (> 80) 89 a 
174 211 N
H
O H
N
N
H
O
O
O
H
N O
H
O
OH
 
3 (> 95) 96 a 
175 212 N
H
O H
N
N
H
N
O
O
H
N O
H
O
OMe
 
5 (> 95) 105 a 
176 213 N
H
O H
N
N
H
H
N
O
O
H
N O
H
O
N
H
OMe
O
 
2 (> 95) 101 a 
 
 
 
 
________________________________________________________________________ 
167 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
177 214 N
H
O H
N
N
H
N
O
O
H
N O
H
O
O
 
7 (> 90) 98 a 
178 215 N
H
O H
N
N
H
O
O
O
H
N O
H
O S
N
 
1 (> 95) 52 a 
179 216 N
H
O H
N
N
H
N
O
O
H
N O
H
O
 
3 (> 95) 87 a 
180 217 N
H
O H
N
N
H
O
O
O
H
N O
H
O
Cl
 
2 (> 80) 101 a 
181 218 N
H
O H
N
N
H
H
N
O
O
H
N O
H
O
NH2
 
1 (> 70) 85 a 
182 219 
N
H
O H
N
N
H
H
N
O
O
O
Cl
F
NH
O
NH2  
6 (> 80) 81 a 
183 220 N
H
N
N
H
O
O2N
HN O
O
O
OHO
OMe
O
 
3 (> 95) 112 a 
184 221 
N
N
H
H
N
N
H
NH2
O
O
O
NH
NHH2N
O
 
5 (> 75) 94 a 
185 222 N
H
N
N
H
O
O2N
HN O
O
O
OHO
H
N
O
NH2
 
7 (> 95) 111 a 
 
 
 
 
________________________________________________________________________ 
168 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
186 223 N
H
N
N
H
O
O2N
HN O
O
O
OHO
OH
O
 
6 (> 95) 128 a 
187 224 N
H
N
N
H
O
O2N
HN O
O
O
OHO
H
N
O
N
H
OMe
O
 
5 (> 95) 107 a 
188 225 
N
H
O H
N
N
H
OMe
O
O
ONH
O
NH2  
8 (> 95) 118 a 
189 226 
N
H
O H
N
N
H
OH
O
O
ONH
O
NH2  
34 (> 95) 120 a 
190 227 
N
H
O H
N
N
H
OH
O
O
ONH
O
NH2  
30 (> 95) 116 a 
191 228 
N
N
H
O H
N
N
H
OMe
O
O
NH
NHH2N
O
 
4 (> 95) 110 a 
192 229 NH
O
N
H
H
N
N
H
NH2
O
O
NH2
O
O
 
5 (> 85) 99 a 
193 230 N
H
N
N
H
O
O2N
HN O
O
O
OHO
H
N
O
NH2
 
1 (> 95) 80 a 
194 231 N
H
N
N
H
O
O2N
HN O
O
O
OHO
NH2
O
 
3 (> 95) 97 a 
 
 
 
 
________________________________________________________________________ 
169 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
195 232 
N
N
H
O H
N
N
H
OH
O
O
NH
NHH2N
O
 
8 (> 95) 127 a 
196 233 N
H
N
N
H
O
O2N
HN O
O
O
OHO
H
N
O
Cl
F
 
10 (> 95) 87 a 
197 234 N
H
N
N
H
O
O2N
HN O
O
O
OHO
H
N
O
 
7 (> 95) 114 a 
198 235 N
H
N
N
H
O
O2N
HN O
O
O
OHO
O
O
 
1 (> 80) -22 a 
199 236 N
H
H
N
N
H
O
O
HO
O
O
O NH2
O
 
3 (> 95) 110 a 
200 237 N
H
H
N
N
H
O
HO
O
O
O NH2
O
H
N
NH2
 
12 (> 70) 93 a 
201 238 N
H
H
N
N
H
H
N
O
HO
O
O
O NH2
O
 
4 (> 85) 80 a 
202 239 N
H
H
N
N
H
O
HO
O
O
O NH2
O
OMe
 
9 (> 95) 112 a 
203 240 N
H
H
N
N
H
H
N
O
HO
O
O
O NH2
O
 
15 (> 95) 98 a 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
204 241 N
H
H
N
N
H
O
HO
O
O
O NH2
O
H
N
F
 
14 (> 95) 116 a 
205 242 N
H
H
N
N
H
O
HO
O
O
O NH2
O
OH
 
4 (> 95) 121 a 
206 243 N
H
H
N
N
H
H
N
O
HO
O
O
O NH2
O
 
10 (> 95) 104 a 
207 244 N
H
H
N
N
H
H
N
O
HO
O
O
O NH2
O
F
F
 
10 (> 95) 105 a 
208 245 N
H
H
N
N
H
O
HO
O
O
O NH2
O
NH2
 
15 (> 95) 127 a 
209 246 N
H
H
N
N
H
H
N
O
HO
O
O
O NH2
O
OMe
 
8 (> 95) 93 a 
210 247 N
H
H
N
N
H
O
HO
O
O
O NH2
O
H
N
NO2
 
8 (> 95) 121 b 
211 248 N
H
H
N
N
H
O
O
O
O NH2
O
NH2
 
3 (> 85) 95 b 
212 249 N
H
H
N
N
H
O
O
O
O NH2
O
OH
 
3 (> 95) 79 b 
213 250 N
H
H
N
N
H
O
O
O
O NH2
O
OMe
 
6 (> 95) 82 b 
 
 
 
 
________________________________________________________________________ 
171 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
214 251 N
H
H
N
N
H
O
O
O
O NH2
O
H
N
 
6 (> 95) 75 b 
215 252 N
H
H
N
N
H
O
O
O
O NH2
O
H
N
 
7 (> 95) 102 b 
216 253 N
H
H
N
N
H
O
O
O
O NH2
O
H
N
NH2
 
6 (> 85) 84 b 
217 254 N
H
H
N
N
H
O
O
O
O NH2
O
H
N
 
8 (> 95) 94 b 
218 255 HN N
H
H
N
N
H
O
N
NH
O
O
O NH2
OH
OBr
OH
 
1 (> 95) 82 b 
219 256 N
H
H
N
N
H
O
O
O
O NH2
O
N
O
 
2 (> 95) 91 b 
220 257 N
H
H
N
N
H
O
O
O
O NH2
O
H
N
F
F
 
11 (> 95) 99 b 
221 258 N
H
H
N
N
H
O
O
O
O NH2
O
H
N
N
H
 
1 (> 95) 80 b 
222 259 N
H
H
N
N
H
OH
O
OH
O
O
OH
O  
4 (> 95) 91 b 
223 260 N
H
H
N
N
H
OMe
O
OH
O
O
OH
O  
2 (> 95) 87 b 
224 261 N
H
H
N
N
H
H
N
O
OH
O
O
OH
O
NH2
 
6 (> 80) 81 b 
225 262 N
H
H
N
N
H
H
N
O
OH
O
O
OH
O  
7 (> 95) 92 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
226 263 N
H
H
N
N
H
H
N
O
OH
O
O
OH
O  
6 (> 95) 81 b 
227 264 NH
H
N
N
H
OH
O
HO
O
O
HO
O
 
3 (> 95) 91 b 
228 265 NH
H
N
N
H
H
N
O
HO
O
O
HO
O
F
F
 
17 (> 95) 118 b 
229 266 
O
N
H
O H
N
N
H
NH2
O
OH
OH
O
O
OH
 
9 (> 95) 124 b 
230 267 NH
H
N
N
H
H
N
O
HO
O
O
HO
O
Cl
F
 
11 (> 95) 125 b 
231 268 NH
H
N
N
H
H
N
O
HO
O
O
HO
O
 
8 (> 95) 88 b 
232 269 NH
H
N
N
H
H
N
O
HO
O
O
HO
O
 
15 (> 95) 107 b 
233 270 NH
H
N
N
H
H
N
O
HO
O
O
HO
O
 
3 (> 95) 107 b 
234 271 NH
H
N
N
H
O
HO
O
O
HO
O
N
 
1 (> 95) 78 b 
235 272 NH
H
N
N
H
O
HO
O
O
HO
O
O
 
1 (> 95) 91 b 
236 273 NH
H
N
N
H
O
HO
O
O
HO
O
H
N
N
O  
6 (> 95) 100 b 
237 274 NH
H
N
N
H
O
HO
O
O
HO
O
N
O
 
4 (> 95) 100 b 
238 275 NH
H
N
N
H
O
HO
O
O
HO
O
F
OH
 
2 (> 95) 96 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
239 276 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
F
F
 
10 (> 95) 120 b 
240 277 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
 
13 (> 95) 99 b 
241 278 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
Br
F
F
Br
 
5 (> 95) 119 b 
242 279 NH
H
N
N
H
O
HO
O
O
HO
O
F
OH
Br
Br
 
1 (> 95) 96 b 
243 280 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
 
2 (> 95) 112 b 
244 281 
N
H
H
N
N
H
O
O
O
O
F
H
N
F
F
Br
Br
OH
 
3 (> 95) 86 b 
245 282 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
F
Cl
 
8 (> 95) 110 b 
246 283 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
Br
Br
 
3 (> 80) 115 b 
247 284 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
 
4 (> 95) 116 b 
248 285 NH
H
N
N
H
O
HO
O
O
HO
O
F
N
O
 
3 (> 95) 100 b 
249 286 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
N
O  
5 (> 95) 96 b 
250 287 NH
H
N
N
H
O
HO
O
O
HO
O
F
H
N
Br
N
O
Br
 
3 (> 85) 63 b 
251 288 NH
H
N
N
H
O
HO
O
O
HO
O
F
O
Cl
 
4 (> 95) 84 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
252 289 NH
H
N
N
H
O
HO
O
O
HO
O
F
Br
Br
O
Cl
 
2 (> 95) 88 b 
253 290 NH
H
N
N
H
O
HO
O
O
HO
O
F
Br
Br
O
 
2 (> 95) 82 b 
254 291 NH
H
N
N
H
O
HO
O
O
HO
O
F
O
 
5 (> 95) 81 b 
255 292 NH
H
N
N
H
O
HO
O
O
HO
O
F
O
 
1 (> 95) 85 b 
256 293 
O
N
H
O H
N
N
H
O
O
OH
OH
O
O
OH
Cl
 
4 (> 95) 114 b 
257 294 N
H
H
N
N
H
N
O
OH
O
O
OH
O
O
 
2 (> 95) 103 b 
258 295 N
H
H
N
N
H
NH2
O
OH
O
O
OH
O  
2 (> 95) 91 b 
259 296 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
OH
OH
 
12 (> 95) 127 b 
260 297 
N
H
H
N
N
H
O
F
O
O
OH OH
O
OH
F
 
15 (> 95) 100 b 
261 298 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O F
F
 
20 (> 95) 103 b 
262 299 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O
F F  
22 (> 95) 57 b 
263 300 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O  
22 (> 95) 90 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
264 301 
N
H
H
N
N
H
O
O
F
OH
O
O
OH
O  
8 (> 95) 60 b 
265 302 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O  
16 (> 85) 91 b 
266 303 
N
H
H
N
N
H
OH
O
F
OH
O
O
OH
O  
17 (> 95) 81 b 
267 304 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O
F  
12 (> 95) 85 b 
268 305 
N
H
H
N
N
H
N
O
F
OH
O
O
OH
O
OMe
 
9 (> 95) 100 b 
269 306 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O  
10 (> 95) 124 b 
270 307 
N
H
H
N
N
H
OH
O
F
O
O
OH OH
O  
26 (> 95) 91 b 
271 308 
N
H
H
N
N
H
O
O
F
O
O
OH OH
O  
8 (> 90) 93 b 
272 309 
N
H
H
N
N
H
O
O
F
O
O
OH OH
O  
3 (> 95) 57 b 
273 310 
N
H
H
N
N
H
O
F
O
O
OH OH
O
H
N
 
9 (> 90) 96 b 
274 311 
N
H
H
N
N
H
O
F
O
O
OH OH
O
H
N
F
F  
11 (> 95) 85 b 
275 312 
N
H
H
N
N
H
O
F
O
O
OH OH
O
H
N
 
6 (> 95) 87 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
276 313 
N
H
H
N
N
H
O
F
O
O
OH OH
O
H
N
 
4 (> 95) 136 b 
277 314 
N
H
H
N
N
H
O
F
O
O
OH OH
O
N
OMe
 
11 (> 85) 94 b 
278 315 
N
H
H
N
N
H
O
F
O
O
OH OH
O
H
N
NH2
 
15 (> 90) 98 b 
279 316 
N
H
H
N
N
H
O
O
F
OH
O
O
OH
O
Cl
 
4 (> 95) 69 b 
280 317 
N
H
H
N
N
H
O
O
F
OH
O
O
OH
O  
19 (> 85) 99 b 
281 318 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O  
16 (> 95) 78 b 
282 319 
N
H
H
N
N
H
O
F
O
O
OH OH
O
O
Cl
 
1 (> 95) 79 b 
283 320 N
H
H
N
N
H
H
N
OF
F
OH
O
OH
O
OH
O
N N
 
3 (> 95) 89 b 
284 321 N
H
H
N
N
H
OMe
OF
F
OH
O
OH
O
OH
O
 
1 (> 95) 61b 
285 322 N
H
H
N
N
H
H
N
OF
F
OH
O
OH
O
OH
O
F
F
 
3 (> 90) 111 b 
286 323 N
H
H
N
N
H
H
N
OF
F
OH
O
OH
O
OH
O
 
1 (> 90) 114 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
287 324 N
H
H
N
N
H
H
N
OF
F
OH
O
OH
O
OH
O
 
3 (> 95) 113b 
288 325 N
H
H
N
N
H
O
OF
F
OH
O
OH
O
OH
O
Cl
 
2 (> 95) 92 b 
289 326 N
H
H
N
N
H
H
N
OF
F
OH
O
OH
O
OH
O S
N
 
3 (> 95) 99 b 
290 327 N
H
H
N
N
H
H
N
OF
F
OH
O
OH
O
OH
O
NH2
 
20 (> 95) 85 b 
291 328 N
H
H
N
N
H
O
OF
F
OH
O
OH
O
OH
O
NH2
 
1 (> 95) 97 b 
292 329 N
H
H
N
N
H
OH
OF
F
OH
O
OH
O
OH
O
 
32 (> 95) 88 b 
293 330 N
H
H
N
O
O
OH
N
H
OH
O
O
OH
OH  
7 (> 80) 65 b 
294 331 N
H
H
N
O
O
OH
N
H
OMe
O
O
OH
OH  
8 (> 80) 94 b 
295 332 N
H
H
N
O
O
OH
N
H
H
N
O
O
OH
OH
N
S
 
10 (> 85) 103 b 
296 333 N
H
H
N
O
O
OH
N
H
H
N
O
O
OH
OH
F
F
 
5 (> 95) 82 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
297 334 N
H
H
N
O
O
OH
N
H
H
N
O
O
OH
OH
N
O  
8 (> 90) 96 b 
298 335 N
H
H
N
O
O
OH
N
H
N
O
O
OH
OH
OMe
 
15 (> 95) 97 b 
299 336 N
H
H
N
O
O
OH
N
H
H
N
O
O
OH
OH  
7 (> 95) 98 b 
300 337 N
H
H
N
O
O
OH
N
H
H
N
O
O
OH
OH
NH2
 
20 (> 95) 63 b 
301 338 N
H
H
N
O
O
OH
N
H
N
O
O
OH
OH
O
 
18 (> 95) 106 b 
302 339 N
H
H
N
O
O
OH
N
H
O
O
O
OH
OH
Cl
 
8 (> 95) 104 b 
303 340 N
H
H
N
O
O
OH
N
H
H
N
O
O
OH
OH
F
F
 
7 (> 95) 64 b 
304 341 N
H
H
N
O
O
OH
N
H
H
N
O
O
OH
OH
N N
 
17 (> 95) 100 b 
305 342 N
H
H
N
O
O
OH
N
H
O
O
O
OH
OH
NH2
 
7 (> 95) 76 b 
306 343 
N
H
H
N
N
H
O
F
O
O
OH OH
O
N
O
 
5 (> 95) 95 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
307 344 
O
N
H
O H
N
N
H
OH
O
OH
OH
O
O
OH
 
22 (> 95) 65 b 
308 345 
O
N
H
O H
N
N
H
OMe
O
OH
OH
O
O
OH
 
8 (> 95) 86 b 
309 346 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
N
 
2 (> 95) 114 b 
310 347 
O
N
H
O H
N
N
H
N
O
OH
OH
O
O
OH
OMe
 
4 (> 95) 114 b 
311 348 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
 
6 (> 95) 130 b 
312 349 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
F
F
 
12 (> 95) 123 b 
313 350 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
F
F
 
12 (> 95) 138 b 
314 351 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
N N
 
15 (> 95) 114 b 
315 352 
O
N
H
O H
N
N
H
OH
O
OH
OH
O N
NH
O
 
9 (> 95) 101 b 
316 353 
O
N
H
O H
N
N
H
H
N
O
OH
OH
O
O
OH
N
S
 
19 (> 95) 113 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
317 354 N
H
H
N
N
H
OMe
O
NH
N
O
NH
N
O
OH
O
 
16 (> 95) 63 b 
318 355 
O
N
H
O H
N
N
H
H
N
O
O
O
NH
N
N
NH
N
NH
OH
OH
 
12 (> 95) 114 b 
319 356 
O
N
H
O H
N
N
H
H
N
O
O
O
NH
N
N
NH
N
NH
OH
OH
 
13 (> 95) 98 b 
320 357 
O
N
H
O H
N
N
H
OMe
NH
N
O
OH
O
O
 
10 (> 95) 86 b 
321 358 N
H
H
N
N
H
OH
O
NH
N
O
NH
N
O
OH
O
 
16 (> 95) 45 b 
322 359 
O
N
H
O H
N
N
H
O
O
O
O
NH
N
N
NH
N
NH
NH2
 
7 (> 95) 58 b 
323 360 
O
N
H
O H
N
N
H
H
N
NH
N
O
OH
O
O
N
S
 
4 (> 95) 132 b 
324 361 
O
N
H
O H
N
N
H
N
NH
N
O
OH
O
O
OMe
 
4 (> 95) 189 b 
325 362 
O
N
H
O H
N
N
H
H
N
NH
N
O
OH
O
O
N N
 
4 (> 85) 174 b 
326 363 
O
N
H
O H
N
N
H
O
NH
N
O
OH
O
O
NH2
 
1 (> 95) 43 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
327 364 
O
N
H
O H
N
N
H
NH2
NH
N
O
OH
O
O
 
3 (> 95) 93 b 
328 365 
O
N
H
O H
N
N
H
OH
NH
N
O
OH
O
O
 
8 (> 95) 80 b 
329 366 
O
N
H
O H
N
N
H
H
N
NH
N
O
OH
O
O
OH
OH
 
9 (> 90) 59 b 
330 367 
O
N
H
O H
N
N
H
N
NH
N
O
OH
O
O
O
 
5 (> 95) 100 b 
331 368 N
H
H
N
N
H
O
O
OH
O
NH
N
O
NH
N
O
NH2
 
3 (> 90) 64 b 
332 369 N
H
H
N
N
H
H
N
O
NH
N
O
NH
N
O
OH
O
OH
OH
 
17 (> 95) 104 b 
333 370 N
H
H
N
N
H
H
N
O
NH
N
O
NH
N
O
OH
O
NH2
 
13 (> 95) 70 b 
334 371 N
H
H
N
N
H
O
O
NH
N
O
NH
N
O
OH
O
NH2
 
8 (> 95) 68 b 
335 372 N
H
H
N
N
H
OH
O
O
NH
N
O
OH
O
OH
 
12 (> 95) 52 b 
336 373 N
H
H
N
N
H
OMe
O
O
NH
N
O
OH
O
OH
 
23 (> 95) 75 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
337 374 N
H
H
N
N
H
H
N
O
O
NH
N
O
OH
O
OH
N
N
 
18 (> 95) 97 b 
338 375 N
H
H
N
N
H
H
N OH
O
OH
O
NH
N
O
NH
N
O
OH
 
20 (> 95) 98 b 
339 376 N
H
H
N
N
H
H
N
O N
NH
O
O
OH
O
N
N
 
32 (> 95) 113 b 
340 377 N
H
H
N
N
H
OMe
O
OH
O
NH
N
O
NH
N
O
 
5 (> 90) 65 b 
341 378 N
H
H
N
N
H
H
N
O
OH
O
NH
N
O
NH
N
O
NH2
 
20 (> 95) 70 b 
342 379 N
H
H
N
N
H
H
N
O
OH
O
NH
N
O
NH
N
O
N N
 
16 (> 95) 65 b 
343 380 
N
H
H
N
N
H
H
N
O
O
O
O
NH2
OH
N
NH
NHN
 
3 (> 95) 41 b 
344 381 N
H
H
N
N
H
N
O
OH
O
NH
N
O
NH
N
O
OMe
 
1 (> 95) 34 b 
345 382 N
H
H
N
N
H
NH2
O
OH
O
NH
N
O
NH
N
O
 
4 (> 85) 46 b 
346 383 N
H
H
N
N
H
OH
O
OH
O
NH
N
O
NH
N
O
 
8 (> 85) 75 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
347 384 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
OMe
 
5 (> 90) 100 b 
348 385 N
H
H
N
N
H
H
N N
O
O
OH
N
NH
O N
NH
O
 
11 (> 85) 63 b 
349 386 
N
H
H
N
N
H
H
N
O
O
OH
NHN
O
N NH
O NH2
 
23 (> 85) 80 b 
350 387 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
OMe
 
1 (> 95) 87 b 
351 388 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
NH2
 
4 (> 95) 55 b 
352 389 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
H
N
NH2
 
13 (> 95) 43 b 
353 390 NH
H
N
N
H
O
O
O
OH
O
OH
N
H
N
NHN
 
18 (> 95) 95 b 
354 391 NH
H
N
N
H
O
O
O
OH
O
O
N
H
N
NHN
NH2
 
13 (> 95) 90 b 
355 392 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
H
N
NH2
 
18 (> 95) 68 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
356 393 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
O
NH2
 
5 (> 85) 63 b 
357 394 
N
H
H
N
N
H
O
O
N
NH
O N
NH
O
NH
OH
 
7 (> 95) 38 b 
358 395 NH
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
N N
 
13 (> 95) 68 b 
359 396 NH
H
N
N
H
O
O
O
OH
O
O
N
H
N
NHN
 
23 (> 85) 87 b 
360 397 NH
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
NH2
 
26 (> 95) 90 b 
361 398 NH
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
N
 
8 (> 85) 65 b 
362 399 NH
H
N
N
H
O
O
O
OH
O
NH2
N
H
N
NHN
 
3 (> 95) 75 b 
363 400 
O N
H
H
N
N
H
O
O N
NH
O
O
OH
O
NH2
 
3 (> 95) 112 b 
364 401 
O N
H
H
N
N
H
OH
O N
NH
O
O
OH
O  
4 (> 95) 91 b 
365 402 
O N
H
H
N
N
H
OMe
O N
NH
O
O
OH
O  
3 (> 95) 102 b 
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Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
366 403 
O N
H
H
N
N
H
NH2
O N
NH
O
O
OH
O  
3 (> 95) 89 b 
367 404 
O N
H
H
N
N
H
H
N
O N
NH
O
O
OH
O
OH
OH
 
4 (> 95) 87 b 
368 405 
O N
H
H
N
N
H
H
N
O N
NH
O
O
OH
N  
2 (> 95) 80 b 
369 406 
O N
H
H
N
N
H
H
N
O N
NH
O
O
OH
O
N N
 
3 (> 90) 87 b 
370 407 O N
H
H
N
O N
NH
O
H
N
O
O
O
OH
NH2
 
1 (> 95) 87 b 
371 408 O N
H
H
N
O N
NH
O
H
N
O
N
H
O
OH
OH
OH
 
5 (> 95) 93 b 
372 409 O N
H
H
N
O N
NH
O
H
N
O
N
H
O
OH
NH2
 
3 (> 95) 77 b 
373 410 O N
H
H
N
O N
NH
O
H
N
O
OH
O
OH  
2 (> 95) 72 b 
374 411 O N
H
H
N
O N
NH
O
H
N
O
N
H
O
OH
S
N
 
1 (> 95) 67 b 
375 412 
N
H
H
N
N
H
O
O
N
NH
O
O
H
N
OH
OH OH
 
10 (> 95) 70 b 
376 413 
N
H
H
N
N
H
O
O
N
NH
O
O
H
N
O
OH OH
 
5 (> 95) 80 b 
 
 
 
________________________________________________________________________ 
186 
Entries Nr. Peptides Yield (Purity) % 
Rab GGTase 
Activity  % 
(IC50) 
377 414 N
H
H
N
N
H
O
O
O
O
H
N
OH
N
H
N
N
H
N
OH
 
6 (> 95) 57 b 
378 415 N
H
H
N
N
H
O
O
O
O
H
N
O
N
H
N
N
H
N
OH
 
5 (> 95) 53 b 
379 416 
N
H
H
N
N
H
O
O
O
O
H
N
OH
N
H
N
N
H
N
NH
 
5 (> 85) 45 b 
380 417 
N
H
H
N
N
H
O
O
O
O
H
N
O
N
H
N
N
H
N
NH
 
5 (> 95) 54 b 
381 418 NH
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
OH
 
6 (> 95) 67 b 
382 419 NH
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
O
 
4 (> 95) 74 b 
 
a: The screening was performed at 100 µM without negative control  
b: The screening was performed at 50 µM with negative control 
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7 Experimental Part 
 
5.1.1 Materials and Methods 
 
Nuclear Magnetic Resonance Spectroscopy 
 
1H and 13C NMR spectra were recorded on one of the following instruments: Varian Mercury 
400, Bruker DRX 400 and Bruker DRX 500 with tetramethylsilane as the internal reference. The 
chemical shifts are provided in ppm and the coupling constants in Hz. The following 
abbreviations for multiplicities are used: s, singlet; d, doublet; dd, double doublet; dt, doublet 
triplet; t, triplet; q, quadruplet; m, multiplet; br, broad. The 1H and 13C spectra are calibrated to 
the solvent signals of CDCl3 (7.26 ppm and 77.00 ppm), DMSO (2.50 ppm, 39.43 ppm) and 
MeOH (3.31 ppm, 49.05 ppm).  
 
High Resolution Mass Spectrometry 
 
High resolution mass spectra (HR-MS, 70 eV) were measured on a Jeol SX 102A spectrometer 
by using fast atom bombardment (FAB) techniques and on Thermo Orbitrap coupled to Thermo 
Accela HPLC machine by using electron spray ionization technique (ESI) The matrix used for 
FAB was 3-nitrobenzylalcohol (3-NBA).  
 
Reversed-Phase High-Pressure Liquid Chromatography 
 
Analytical HPLC was recorded on an Agilent HPLC (1100 series machine). The standard 
gradient began at 10% acetonitrile and was raised to 90% over 15 min. After 3 min at 90% 
acetonitrile, the column was washed for 5 min with 100% acetonitrile. The column was then 
equilibrated for 3 min with 10% acetonitrile. TFA (0.1% v/v) was added to the HPLC solvents. 
Analytical HPLC-MS measurements were recorded on an Agilent HPLC (1100 series) coupled to 
a Finnigan LCQ ESI spectrometer. The column used is indicated in parenthesis. Preparative 
HPLC was run on an Agilent HPLC (1100 series) and Waters HPLC 2767 using a 125/21 
NUCLEODUR C18 and C4 Gravity, 5 µ (Macherey-Nagel column)  
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Thin-Layer Chromatography (TLC) 
 
Thin-layer chromatography (TLC) plates were obtained from Merck (Silica gel 60, F254). The 
TLCs were visualized by UV light (λ = 254 nm, 366 nm) or by staining with KMnO4 solution. 
The solvent system and Rf values are noted for the synthesized compounds. 
 
Flash Chromatography 
 
Flash column chromatography was performed using flash silica gel (Merck, Darmstadt, 40-64 
µM) with pressure ranging from 0.5 - 1.0 bar.  
 
Ultraviolet Spectroscopy 
 
UV/VIS spectra were measured with a Cary 100 Spectrometer (Varian Inc.). 
 
Optical Rotation 
 
Optical rotations were measured with a Schmidt + Haensch Polartronic HH8 polarimeter at 589 
nm. Concentrations are given in g/100 ml. 
 
Chemicals 
 
Chemicals were obtained from the following suppliers and used without further purification: 
Acros, Aldrich, Fluka, Novabiochem, Senn Chemicals. The solid support was purchased from 
Novabiochem. With the exception of DMF and NMP, all solvents were distilled prior to use 
following standard protocols. Dry DMF was purchased from Fluka.  
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5.2.2 Experimental procedures and analytical data 
 
 
HO-Far-Cl (3) 
Cl
HO  
 
 
To trans-trans-farnesy chloride 5 (0.72 g, 3 mmol) was dissolved in 6 mL CH2Cl2 at room 
temperature, t-BuOOH (1.08 g, 12 mmol, 70 % aqueous solution), SeO2 (33 mg, 0.3 mmol) and 
salycilic acid (39 mg, 0.3 mmol) were added respectively. The reaction mixture was stirred 
vigorously at room temperature for 2.5 hours. The excess t-BuOOH was co-evaporated with 
toluene. The residue was re-dissolved in Et2O and the organic phase was washed with saturated 
solution of NaHCO3, brine and dried over MgSO4. The solution was filtered and concentrated in 
vacuo. The crude product was purified by silica gel chromatography to obtain 200 mg of 3 as 
colourless oil.   
 
Yield = 27 %; Rf  = 0.4 (cyclohexane : Ethyl acetate = 4:1); 1H NMR (400 MHz, CDCl3): δ = 
5.44 (ddt, J = 7.9, 2.5, 1.2 Hz, 1H), 5.38 (ddt, J = 7.0, 2.6, 1.2 Hz, 1H), 5.10 (dt, J = 6.7, 1.1 Hz, 
1H), 4.09 (d, J = 7.9 Hz, 2H), 3.99 (s, 2H), 2.17-1.98 (m, 8H), 1.72 (s, 3H), 1.66 (s, 3H), 1.60 (s, 
3H) ppm; 13C NMR (100 MHz, CDCl3): δ = 142.6, 135.2, 134.7, 125.9, 123.7, 120.3, 68.9, 41.1, 
39.3, 39.2, 26.1, 26.0, 16.0, 16.0, 13.6 ppm. 
 
Far-OTHP (7) 
O O
 
 
To trans-trans-farnesol (4.4 g, 20 mmol) in 20 mL CH2Cl2 was added 2,3-dihydropyran (DHP) 
(2.6 g, 30 mmol) and pyridinium-para-toluenesulfonate (PPTS) (0.5 g, 2 mmol) at room 
temperature and stirred overnight. The mixture was washed with saturated solution of NaHCO3, 
brine, and dried over MgSO4. The solution was filtered and concentrated under reduced pressure 
to obtain 5.7 g (100%) of 7 as colourless oil. 
 
Yield = Quantitative; Rf = 0.7 (cyclohexane : Ethyl acetate = 4:1); 1H NMR (400 MHz, 
CDCl3): δ = 5.37 (dq, J = 7.5, 1.3 Hz, 1H), 5.16-5.04 (m, 2H), 4.63 (dd, J = 4.2, 2.8 Hz, 1H), 
4.24 (ddd, J = 11.9, 6.4, 0.7 Hz, 1H), 4.03 (ddd, J = 11.9, 7.4, 0.5 Hz, 1H), 3.90 (ddd, J = 11.3, 
7.6, 3.7 Hz, 1H), 3.55-3.47 (m, 1H), 2.18-2.01 (m, 6H), 2.01-1.93 (m, 2H), 1.90-1.78 (m, 1H), 
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1.78-1.70 (m, 1H), 1.68 (s, 6H), 1.60 (s, 6H), 1.58-1.46 (m, 4H) ppm; 13C NMR (100 MHz, 
CDCl3): δ = 140.2, 135.2, 131.2, 124.3, 123.8, 120.6, 97.7, 63.6, 62.2, 39.7, 39.6, 30.7, 26.7, 
26.3, 25.6, 25.5, 19.6, 17.6, 16.4, 16.0 ppm. 
 
HO-Far-OTHP (8) 
O O
HO
 
 
To THP protected trans-trans-farnesol 7 (5.7 g, 20 mmol) was dissolved in 40 mL CH2Cl2 at 
room temperature, t-BuOOH (7.2 g, 80 mmol, 70 % aqueous solution), SeO2 (221 mg, 2 mmol) 
and salycilic acid (276 mg, 2 mmol) were added respectively. The reaction mixture was stirred 
vigorously at room temperature for 2.5 hours. The excess t-BuOOH was co-evaporated with 
toluene. The residue was re-dissolved in Et2O and the organic phase was washed with saturated 
solution of NaHCO3, brine and dried over MgSO4. The solution was filtered and concentrated in 
vacuo. The crude product was purified by silica gel chromatography to obtain 1.7 g of 8 as 
colourless oil.   
 
Yield = 27 %; Rf = 0.2 (cyclohexane : Ethyl acetate = 4:1); 1H NMR (400 MHz, CDCl3): δ = 
5.46-5.28 (m, 2H), 5.11 (dt, J = 6.7, 6.5, 1.1 Hz, 1H), 4.62 (t, J = 4.2 Hz, 1H), 4.23 (dd, J = 11.6, 
6.6 Hz, 1H), 4.03 (dd, J = 12.5, 6.7 Hz, 1H), 3.99 (s, 2H), 3.89 (ddd, J = 10.9, 7.5, 3.2 Hz, 1H), 
3.56-3.45 (m, 1H), 2.17-1.97 (m, 8H), 1.91-1.77 (m, 1H), 1.68 (s, 3H), 1.66 (s, 3H), 1.60 (s, 3H), 
1.59-1.48 (m, 4H) ppm. 
 
Phthalimide-Far-OTHP (9) 
O O
N
O
O  
 
To a  20 mL solution of 2 (1.7 g, 5.3 mmol), phthalimide (853 mg, 5.8 mmol) and PPh3 (1.5 g, 5.8 
mmol) in THF were added DIAD (1.17 g, 5.8 mmol) dropwise for 0.5 hour at room temperature 
and the reaction mixture was stirred overnight. The mixture was evaporated to dryness and Et2O 
was added to precipitate Ph3PO. The white suspension was filtered and the filtrate was 
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concentrated in vacuo. The crude product was purified by silica gel chromatography to obtain 1.6 
g of 9 as colourless oil. 
Yield = 66 %; Rf = 0.3 (cyclohexane : Ethyl acetate = 6:1); 1H NMR (400 MHz, CDCl3): δ = 
7.85 (dd, J = 5.4, 3.0 Hz, 2H), 7.71 (dd, J = 5.4, 3.0 Hz, 2H), 5.40-5.27 (m, 2H), 5.10-5.03 (m, 
1H), 4.62 (dd, J = 4.3, 2.8 Hz, 1H), 4.22 (dd, J = 12.4, 5.8 Hz, 1H), 4.19 (s, 2H), 4.02 (dd, J = 
11.7, 7.2 Hz, 1H), 3.89 (ddd, J = 11.2, 7.4, 3.5 Hz, 1H), 3.59-3.43 (m, 1H), 2.25-1.91 (m, 8H), 
1.90-1.78 (m, 1H), 1.77-1.68 (m, 1H), 1.66 (s, 3H), 1.64 (s, 3H), 1.56 (s, 3H), 1.56-1.51 (m, 4H) 
ppm; 13C NMR (100 MHz, CDCl3): δ =168.2, 140.1, 134.7, 133.8, 132.1, 129.1, 127.4, 124.2, 
123.2, 120.6, 97.7, 63.6, 62.2, 44.9, 39.5, 39.1, 30.7, 26.9, 26.4, 25.5, 19.6, 15.9, 14.6 ppm; 
HRMS (FAB, m-NBA) m/z calc. for C28H37NO4 451.2723, found 452.2786 [M+H]+. 
 
NH2-Far-OTHP (10) 
O O
H2N
 
 
To a 40 mL ethanol solution of 9 (1.6 g, 3.5 mmol) was added hydrazine and the reaction mixture 
was stirred at room temperature overnight. The solution was evaporated to dryness. 100 mL 
CH2Cl2 was added and the white solid was filtered. The filtrate was concentrated in vacuo and 
purified by silica gel chromatography to obtain 600 mg of 10 as colourless oil.  
 
Yield = 53 %; Rf = 0.25 (Ethyl acetate : Et3N = 99:1); 1H NMR (400 MHz, CDCl3): δ = 5.36 
(ddq J = 8.7, 5.0, 1.2, 1.2, 1.2 Hz, 1H), 5.32-5.24 (m, 1H), 5.11 (dt, J = 6.8, 6.6, 1.1 Hz, 1H), 
4.62 (dd, J = 4.2, 2.8 Hz, 1H), 4.23 (ddd, J = 11.7, 6.3, 0.6 Hz, 1H), 4.03 (dd, J = 11.9, 7.4 Hz, 
1H), 3.89 (ddd, J = 11.1, 7.6, 3.5 Hz), 3.55-3.46 (m, 1H), 3.18 (s, 2H), 2.22-1.95 (m, 8H), 1.93-
1.70 (m, 2H), 1.68 (s, 3H), 1.64 (s, 3H), 1.60 (s, 3H), 1.58-1.47 (m, 4H) ppm; 13C NMR (100 
MHz, CDCl3): δ =140.1, 139.8, 134.9, 124.4, 124.0, 120.6, 97.8, 63.6, 62.2, 49.7, 39.6, 39.4, 
30.7, 26.3, 26.2, 25.5, 19.6, 16.4, 16.0, 14.5 ppm; HRMS (FAB, m-NBA) m/z calc. for 
C20H35NO2 321.2668, found 322.2756 [M+H]+. 
 
NBD-Far-OTHP (11) 
O O
N
H
O2N
N
O
N
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To a solution of 10 (600 mg, 1.8 mmol) in 30 mL acetonitrile/25mM NaHCO3 (1:1) was added 
NBD-Cl (335 mg, 1.8 mmol) at room temperature. The reaction mixture was stirred for one hour, 
another equivalent of NBD-Cl (335 mg, 1.8 mmol) was added and the mixture was stirred 
overnight. The mixture was poured into 200 mL CH2Cl2 and extracted twice with brine. The 
organic solution was dried over MgSO4 and concentrated in vacuo. The crude product was 
purified by silica gel chromatography to obtain 543 mg of 11 as red brown oil. 
 
Yield = 60 %; Rf = 0.1 (CH2Cl2); 1H NMR (400 MHz, CDCl3): δ = 8.47 (d, J = 9.1 Hz, 1H), 6.19 
(d, J = 8.6 Hz, 1H), 5.53-5.45 (m, 1H), 5.38-5.30 (m, 1H, ), 5.14-5.06 (m, 1H), 4.62 (dd, J = 4.2, 
2.8 Hz, 1H), 4.24 (ddd, J = 11.9, 6.2, 0.7 Hz, 1H), 4.09-4.02 (m, 1H), 4.02-3.99 (m, 2H), 3.94-
3.85 (m, 1H), 3.59-3.44 (m, 1H), 2.45-1.92 (m, 8H), 1.92-1.78 (m, 2H), 1.73 (s, 3H), 1.67 (d, J = 
0.6 Hz, 3H), 1.60 (d, J = 0.8 Hz, 3H), 1.58-1.47 (m, 4H) ppm; 13C NMR (100 MHz, 
CDCl3): δ =143.8, 140.8, 139.8, 136.2, 134.3, 132.9, 129.3, 128.8, 128.5, 124.6, 120.7, 99.1, 
97.9, 63.7, 62.4, 51.5, 39.5, 39.0, 30.7, 26.2, 26.2, 25.4, 19.6, 16.4, 15.9, 14.7 ppm. 
 
NBD-Far-OH (12) 
OH
N
H
O2N
N
O
N
 
 
To a solution of 11 (543mg, 1.1 mmol) in 20 mL ethanol was added pyridinium-para-
toluenesulfonate (PPTS) (562 mg, 2.24 mmol). The reaction mixture was stirred at 60°C for 2 
hours and poured into 200 mL Et2O. The mixture was washed twice with brine and dried over 
MgSO4. The organic solution was filtered and evaporated to dryness. The crude product was 
purified by silica gel chromatography to obtain 370 mg of 12 as red brown oil. 
 
Yield = 83 %; Rf = 0.3 (cyclohexane : Ethyl acetate = 2:1); 1H NMR (400 MHz, CDCl3): δ = 
8.46 (d, J = 8.6 Hz, 1H), 6.72 (t, J = 4.9, 4.9 Hz, 1H), 6.16 (d, J = 8.6 Hz, 1H), 5.45 (dt, J = 7.1, 
7.1, 1.0 Hz, 1H), 5.37 (dt, J = 7.0, 7.0, 1.3 Hz, 1H), 5.08 (dt, J = 6.8, 6.6, 1.0 Hz, 1H), 4.17 (d, J 
= 6.8 Hz, 2H), 4.00 (d, J = 5.5 Hz, 2H), 2.28-2.05 (m, 6H), 2.03-1.96 (m, 2H), 1.73 (s, 3H), 1.66 
(s, 3H), 1.59 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ =144.2, 144.0, 139.2, 136.3, 134.3, 
128.8, 128.5, 124.5, 124.2, 123.4, 123.1, 99.1, 59.4, 51.3, 39.3, 38.9, 26.0, 26.0, 16.2, 15.9, 14.7 
ppm; HRMS (FAB, m-NBA) m/z calc. for C21H28N4O4 400.2111, found 400.2126 [M]+. 
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NBD-Far-Cl (13) 
Cl
N
H
O2N
N
O
N
 
 
To NCS (40 mg, 0.30 mmol) in dry CH2Cl2 under argon atmosphere was added Dimethylsulfide 
(DMS) (42 mg, 0.67 mmol) dropwise at -30°C. The mixture was stirred for 5 minutes at 0°C and 
cooled again to -30°C. A solution of the alcohol 12 (120 mg, 0.30 mmol) in 1 mL dry CH2Cl2 was 
added and the mixture was stirred for 2 hours at 0°C. The mixture was poured into CH2Cl2 and the 
organic phase was washed twice with brine, dried with MgSO4 and concentrated in vacuo. The 
crude product 13 was used for the next step without further purification. 
 
Yield: quantitative; Rf = 0.4 (cyclohexane : ethyl acetate = 3:1); 1H NMR (500 MHz, CDCl3): δ = 
1.55 (br, 3H,), 1.67 (d, J = 1.0, 3H), 1.70 (br, 3H), 1.96-2.16 (m, 8H), 4.03 (d, J = 7.8 Hz, 2H), 
4.05 (d, J = 8.0 Hz, 2H), 5.04 (qt, J = 6.4, 1.0 Hz, 1H), 5.38 (qt, J = 8.0, 1.2 Hz, 1H) 5.47 (qt, J = 
6.6, 0.9 Hz, 1H), 6.18 (d, J = 8.7 Hz, 1H), 6.78 (d, J = 5.8), 8.41 (d, J = 8.7 Hz) ppm. 
 
NBD-Far-OPP (1) 
H
N
O
NO
N
O2N
P
O
O
O
P
O
O
O (NH4)3
 
 
A solution of the compound 13 (125 mg, 0.3 mmol) was added to a solution of (Bu4N)3HP2O7 
(540 mg, 0.6 mmol) in dry CH3CN (2 mL). The mixture was stirred for 4 hours at room 
temperature and the solvent was evaporated. The residue was dissolved in ammonium 
bicarbonate buffer (25 mM)/isorporpanol (39:1, 4 mL). The resulting solution was passed through 
a 1 x 8 cm Dowex 50X8 ion exchange column (NH4+ form), and lyophilization of the eluent 
yielded an orange solid. The sample was purified with a C18-Sep-Pak® catridge and a linear 
gradient elution starting from ammonium bicarbonate buffer (25 mM) to CH3CN to yield pure 
pyrophosphate 1 as an orange solid (10 mg, 16 % from alcohol 12). 
 
Yield = 16 % (2 steps, from alcohol 12); 1H NMR (200 MHz, D2O): δ = 1.52 (s, 6H,) 1.94 (t, J = 
7.3 Hz), 2.04 (dt, J = 7.3 Hz, J = 7.0 Hz, 2H), 3.90 (s, 2H), 4.29 (t, J = 6.9 Hz, 2H), 5.26 (t, J = 
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6.9 Hz, 1H), 5.32 (t, J = 7.0 Hz, 1H) 6.13 (d, J = 8.7 Hz, 1H), 8.25 (d, J = 8.7 Hz) ppm; 31P NMR 
(162 MHz, D2O ): δ = -9.20 (dd, J = 22.2, 2.8 Hz, 1P), -9.72 (dd, J = 21.0, 2.0 Hz, 1P) ppm. 
 
General procedure (GP 1) for the synthesis of hydrazine linker 21 
O N
H
H
N
O
OH
O  
 
To hydrazinebenzoic acid (4 g, 26 mmol) in dioxane (30 mL) was added Na2CO3 (5.3 g, 50 
mmol) in H2O (90 mL). The clear solution was cooled at ice-bath and Fmoc chloride (7.3 g, 28 
mol) in dioxane (30 mL) was added slowly. The reaction mixture was stirred at 0°C for 0.5 hour 
and room temperature overnight. The reaction mixture was extracted three times with diethyl 
ether and the organic phase was discarded. The remained aqueous/dioxane phase was acidific 
with 1M HCl till pH 1. Ethyl acetate was added and the aqueous phase was extracted three times 
with ethyl acetate. The collected organic phase was washed with brine, dried over MgSO4, 
filtered and concentrated in vacuo. The crude product was dissolved in minimum methanol 
followd by addition of ethyl acetate until cloudly. The solution was let to stand overnight until the 
formation of precipitate. The solid was filtered and collected to give 50 % yield of colourless 
solid.     
 
Yield = 50 %; Rf = 0.4 (CH2Cl2 : Methanol = 9:1); 1H NMR (500 MHz, CDCl3): δ = 7.82 (d, J = 
7.7 Hz, 2H), 7.69 (d, J = 7.2 Hz, 2H), 7.42 (t, J = 7.1 Hz, 2H), 7.33 (t, J = 7.0 Hz, 1H), 6.66 (d, J 
= 8.2 Hz, 2H), 4.54 (d, J = 5.8 Hz, 2H), 4.25 (t, J = 5.8 Hz, 1H) ppm. 
 
Determination of Fmoc-loading. Resin (1-2 mg) was weighed into a volumetric flask and filled 
with 3 mL 20% piperidine in DMF. After 20 minutes of gentile agitation, 1 mL was transferred to 
a quartz UV cuvette and diltuted to 3 mL with DMF. The absorbance was measured against 
reference at λ = 301 nm. The loading CL is determined according to Beer’s Law, A = εcd, where ε 
= 7800 at 301 nm.  
 
CL = M
VCv ×
 = 
M7800
10009A
×
××
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where CV is the volume concentration, A is the absorbance, d is the path length of the UV cuvette, 
V is the total volume, M is the mass of the resin. 
 
Determination of Theoretical Loading. The theoretical loading of the resin was determined 
according to the following formula: 
 
Loadingnew (mol/g) = )g/mol(loading1
)g/mol(loading
old
old
×∆+  
 
Where loadingold is the previous loading and ∆ is the mass difference of the added compound to 
the resin. 
 
General procedure (GP 2) for the synthesis of the peptide libraries 
 
Coupling using DIC/HOBT activation. The Fmoc-amino acid to be coupled (3 equivalents 
relative to resin loading) was dissolved in dry DMF, followed by addition of HOBt (3 
equivalents) and DIC (3 equivalents). The mixture was stirred for 1 minute and added to the 
hydrazine resin at room temperature. The mixture was shaken at room temperature for 2 hours. 
The resin was filtered, washed three times with DMF, three times with CH2Cl2, and three times 
with DMF.  
 
Removal of Fmoc protecting group. The resin (200 mg, average loading 0.66 mmol/g) was 
washed 3 times with 3 mL 20% piperidine/DMF (5 minutes each time) to remove the Fmoc group 
from the amino acid. Subsequently, the resin was washed again three times with DMF, three 
times with CH2Cl2, three times with DMF (each time 2 to 5 mL). 
 
General procedure (GP 3) for the release of peptides using NBS/pyridine/nucleophile  
 
To 250 mg peptidyl hydrazine resin (initial loading 0.66 mmol/g) was added NBS (58 mg, 0.33 
mmol) and pyridine (26 mg, 0.33 mmol) in CH2Cl2 (2 mL). The reaction mixture was shaken for 
5 minutes at room temperature. The resin was filtered and washed four times with CH2Cl2. 
Nucleophiles (10 equivalents, 1.65 mmol) in 2 mL CH2Cl2 was added to the NBS/pyridine 
pretreated resin and shaken for 2 hours. The resin was filtered and washed four times with 
CH2Cl2. The filtrate was washed with 1M HCl (5 mL) and brine. The organic layer was 
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evaporated to dryness. The crude product was treated with deprotection cocktail TFA/TES/H2O 
(50/1/1, 5 mL) for 1 hour to cleave the protecting group. The reaction mixture was concentrated 
in vacuo and purified by preparative HPLC. The deprotection cocktail was used in every case, 
unless otherwise stated. 
 
Remarks: For small hydrophilic nucleophiles such as H2O and NH3, 1 mL of the substrates was 
mixed with 2 mL of dioxane. For alcohol nucleohpiles and amine nucleophiles containing HCl 
salt, additional 10 equivalents of DIPEA were added. Dioxane can be used as a solvent if the 
nuclephile cannot dissolve in CH2Cl2. 
 
General procedure (GP 4) for the release of peptides using Cu(OAc)2/pyridine/nucleophiles  
 
To 250 mg peptidyl hydrazine resin (initial loading 0.66 mmol/g) in CH2Cl2 (2 mL) was added 
Cu(OAc)2 (15 mg, 0.8 mmol), pyridine (130 mg, 1.65 mmol) and nucleophiles (10 equivalents, 
1.65 mmol). The reaction mixture was shaken for 2 hours at room temperature under oxygen. The 
resin was filtered and washed four times with CH2Cl2. The filtrate was washed with 1M HCl (5 
mL), brine. The organic layer was evaporated to dryness. The crude product was treated with 
deprotection cocktail TFA/TES/H2O (50/1/1, 5 mL) for 1 hour to cleave the protecting group. The 
reaction mixture was concentrated in vacuo and purified by preparative HPLC. The deprotection 
cocktail was used in every case, unless otherwise stated. 
   
Remarks: For small hydrophilic nucleophiles such as H2O and NH3, 1 mL of the substrates was 
mixed with 2 mL of dioxane. Dioxane can be used as a solvent if the nuclephile cannot dissolve 
in CH2Cl2. Pyridine was not added for amine nucleophiles. 
 
General procedure (GP 5) for the synthesis of C-terminal hydroxyl amide peptides 
 
To 250 mg peptidyl hydrazine resin (initial loading 0.66 mmol/g) in dioxane (2 mL) was added 
Cu(OAc)2 (15 mg, 0.8 mmol), pyridine (130 mg, 1.65 mmol) and H2O (1 mL). The reaction 
mixture was shaken for 2 hours at room temperature under oxygen. The resin was filtered and 
washed with four times with CH2Cl2. The filtrate was washed with 1M HCl (5 mL), brine, and 
concentrated in vacuo. The resulting crude material was reacted with NH2-O-tBu.HCl (20 mg, 
0.165 mmol), EDC.HCl (47 mg, 0.247 mmol), HOBT (38 mg, 0.247 mmol) and Et3N (25 mg, 
0.247 mmol) overnight at room temperature. The reaction mixture was washed two times with 0.5 
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M H2SO4 (5 mL each), brine, and concentrated in vacuo. The protection group of crude material 
was cleaved off using 5 mL TFA/CH2Cl2 (50/50) for 48 hours. The reaction mixture was 
concentrated in vacuo and purified by preparative HPLC. 
 
Analytical data of compound 38 
N
H
O H
N
N
H
OMe
O
O
O
 
 
Peptide 38 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
18 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 570.0 [M+H]+, 592.2 [M+Na]+; Rt = 
9.79 min; 1H NMR (400 MHz, CDCl3): δ = 7.63 (d, J = 15.6 Hz, 1H), 7.51-7.48 (m, 2H), 7.37-
7.36 (m, 3H), 7.23-7.14 (m, 8H), 7.00 (dd, J = 7.64, 1.76 Hz, 2H), 6.38 (d, J = 15.6 Hz, 1H), 
4.80-4.75 (m, 1H), 4.71-4.67 (m, 1H), 4.61-4.56 (m, 1H), 3.66 (s, 1H), 3.09-2.98 (m, 4H), 1.64-
1.59 (m, 2H), 1.54-1.50 (m, 1H), 0.92 (d, J = 4.4 Hz, 1H), 0.90 (d, J = 4.6 Hz, 1H) ppm; 13C 
NMR (100 MHz, CDCl3): δ = 172.2, 171.5, 170.4, 166.2, 142.2, 136.4, 135.8, 134.8, 130.1, 
129.5, 129.3, 129.0, 128.8, 128.7, 128.1, 127.3, 127.1, 120.0, 54.6, 53.5, 52.4, 52.0, 41.1, 38.2, 
38.1, 25.0, 23.0, 22.3 ppm. 
 
Analytical data of compound 39 
N
H
O H
N
N
H
OH
O
O
O
 
 
Peptide 39 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 556.5 [M+H]+, 578.7 [M+Na]+; Rt = 8.87 
min. 
 
Analytical data of compound 40 
O
N
H
NO
O
N
H O
H
N
F
F
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Peptide 40 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
28 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 575.0 [M+H]+, 597.2 [M+Na]+; Rt = 
8.58 min; 1H NMR (400 MHz, CDCl3): δ = 7.65 (d, J = 15.3 Hz, 1H), 7.47-7.45 (m, 2H), 7.35-
7.34 (m, 3H), 7.21-7.14 (m, 1H), 7.12-7.03 (m, 5H), 6.82-6.78 (m, 2H), 6.70 (d, J = 15.4 Hz, 
1H), 4.60 (dd, J = 15.1, 7.3 Hz, 1H), 4.46 (s, 2H), 4.37 (dd, J = 16.3, 8.0 Hz, 1H), 3.70- 3.61 (m, 
2H), 3.13-3.10(m, 1H), 3.06-2.99 (m, 1H), 2.15-2.08 (m, 2H), 2.06-1.98 (m, 2H) ppm; 13C NMR 
(100 MHz, CDCl3): δ = 172.7, 170.7, 169.3, 166.1, 162.7 and 162.6 (d, C-F), 160.2 and 160.2 (d, 
C-F), 143.9, 134.5, 130.1, 129.3, 129.0, 128.8, 128.3, 128.0, 126.6, 117.2, 113.4, 111.3, 111.0, 
60.8, 49.8, 47.6, 43.2, 37.8, 31.3, 28.3, 25.1 ppm. 
 
Analytical data of compound 41 
N
H
H
N
N
H
H
N
O
O
O
O
F
OH
F
F  
 
Peptide 41 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
23 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 568.9 [M+H]+; Rt = 7.84 min. 
 
Analytical data of compound 42 
N
H
O H
N
N
H
O
O
O
H2N O
O
OH
 
 
Peptide 42 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 569.1 [M+H]+, 591.3 [M+Na]+; Rt = 7.00 
min; 1H NMR (400 MHz, CD3OD): δ = 7.64-6.88 (m, 10H), 4.63 (dd, J = 9.8, 4.7 Hz, 1H), 4.42 
(dd, J = 9.4, 4.6 Hz, 1H), 4.23-4.10 (m, 3H), 3.58 (t, J = 6.31 Hz, 2H), 3.26 (dd, J = 13.7, 5.0 Hz, 
1H), 2.99-2.80 (m, 4H), 2.58-2.44 (m, 2H), 2.37-2.19 (m, 2H), 2.09-1.96 (m, 1H), 1.79-1.66 (m, 
2H), 1.65-1.55 (m, 2H), 1.06 (d, J = 7.1 Hz, 3H) ppm. 
 
Analytical data of compound 43 
N
H
O H
N
N
H
NH2
O
O
H2N O
O
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Peptide 43 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 496.2 [M+H]+, 518.3 [M+Na]+; Rt = 6.48 
min; 1H NMR (400 MHz, CD3OD): δ = 7.75-6.75 (m, 10H), 4.55 (dd, J = 10.3, 5.0 Hz, 1H), 4.32 
(dd, J = 9.6, 4.2 Hz, 1H), 4.14 (q, J = 7.0 Hz, 1H), 3.25 (dd, J = 14.0, 5.0 Hz, 1H), 2.91 (dd, J = 
14.2, 10.0 Hz, 1H), 2.88-2.82 (m, 2H), 2.48 (dd, J = 8.9, 6.7 Hz, 2H), 2.30 (t, J = 7.4 Hz, 2H), 
2.25-2.13 (m, 1H), 2.08-1.95 (m, 1H), 1.08 (d, J = 7.4 Hz, 3H); 13C NMR (100 MHz, 
CD3OD): δ = 177.9, 176.3, 176.1, 175.3, 173.6, 142.3, 138.6, 130.2, 129.5, 129.4, 129.4, 127.8, 
127.1, 56.3, 54.4, 50.9, 38.3, 37.8, 32.9, 32.6, 28.8, 17.2 ppm. 
 
Analytical data of compound 44 
N
H
O H
N
N
H
O
O
O
H2N O
O
Cl
 
 
Peptide 44 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 559.3 [M+H]+, 581.3 [M+Na]+; Rt = 7.53 
min. 
 
Analytical data of compound 45 
N
H
O H
N
N
H
H
N
O
O
OH2N
O
F
Cl
F  
 
Peptide 45 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 606.5 [M+H]+, 628.6 [M+Na]+; Rt = 8.39 
min. 
 
Analytical data of compound 46 
N
H
H
N
N
H
H
N
O
F
O
O
OH OH
O  
 
Peptide 46 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 613.0 [M+H]+, 635.2 [M+Na]+; Rt = 
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7.93 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.16 (s, 1H), 9.12 (s, 1H), 8.60 (d, J = 8.1 Hz, 
1H), 8.42 (t, J = 6.0, 6.0 Hz, 1H), 8.29 (t, J = 5.7, 5.7 Hz, 1H), 8.02 (d, J = 8.4 Hz, 1H), 7.86 (dd, 
J = 8.9, 5.5 Hz, 2H), 7.35-7.22 (m, 4H), 7.23-7.16 (m, 1H), 7.14-7.08 (m, 4H), 6.99 (d, J = 8.5 
Hz, 2H), 6.62 (d, J = 8.5 Hz, 4H), 4.57 (ddd, J = 11.5, 7.9, 3.9 Hz, 1H), 4.45 (dt, J = 8.5, 8.4, 5.7 
Hz, 1H), 4.28 (dd, J = 15.2, 6.1 Hz, 1H), 4.20 (dd, J = 15.2, 5.8 Hz, 1H), 3.80 (dd, J = 16.5, 6.1 
Hz, 1H), 3.63 (dd, J = 16.5, 5.4 Hz, 1H), 3.00 (dd, J = 13.9, 4.1 Hz, 1H), 2.95-2.82 (m, 2H), 2.72 
(dd, J = 13.6, 8.8 Hz, 1H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 171.7, 170.7, 168.3, 
165.2, 162.5, 155.6, 155.5, 138.9, 130.0, 129.9, 129.9, 128.3, 128.0, 127.6, 126.8, 126.4, 115.0, 
114.8, 114.8, 114.7, 55.4, 54.4, 41.9, 41.8, 36.9, 36.0 ppm; 19F NMR (188 MHz, DMSO-
D6): δ = -109.5 ppm; [ ] =α 20D  - 8.0° (C = 0.6, DMSO). 
 
Analytical data of compound 47 
N
H
H
N
N
H
N
O
F
OH
O
O
OH
O
O
 
 
Peptide 47 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 621.1 [M+H]+, 643.3 [M+Na]+; Rt = 7.40 
min; 1H NMR (400 MHz, DMF-D7): δ = 9.54 (br s, 1H), 8.39 (t, J = 5.7, 5.7 Hz, 1H, CO-NH), 
8.30 (d, J = 7.5 Hz, 1H), 8.20 (s, 1H), 7.42-7.32 (m, 2H), 7.27-7.18 (m, 6H), 7.00-6.83 (m, 4H), 
5.12 (dt, J = 14.4, 7.2, 7.2 Hz, 1H), 4.70 (ddd, J = 9.2, 7.6, 4.9 Hz, 1H), 4.08 (dd, J = 16.7, 6.1 
Hz, 1H), 3.92 (dd, J = 16.7, 5.5 Hz, 1H), 3.68-3.52 (m, 6H), 3.53-3.41 (m, 1H), 3.40-3.32 (m, 
1H), 3.22 (dd, J = 13.9, 4.9 Hz, 1H), 3.15-3.09 (m, 1H), 3.05-2.95 (m, 4H), 2.72-2.58 (m, 2H) 
ppm; 13C NMR (100 MHz, DMF-D7): δ = 172.4, 172.4, 170.0, 168.8, 157.1, 156.8, 130.9, 130.6, 
130.5, 130.4, 128.7, 128.0, 115.5, 115.4, 115.3, 115.1, 66.6, 66.6, 55.7, 50.5, 47.2, 42.7, 42.5, 
37.9, 37.6, 37.0, 35.6 ppm. 
 
Analytical data of compound 48 
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Peptide 48 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
4 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 825.3 [M+H]+, 847.4 [M+Na]+; Rt = 8.55 
min. 
 
Analytical data of compound 49 
N
H
O H
N
N
H
H
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Peptide 49 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 621.3 [M+H]+, 643.3 [M+Na]+; Rt = 8.49 
min. 
 
Analytical data of compound 50 
N
H
H
N
N
H
O
HO
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O
HO
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Peptide 50 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 552.0 [M+H]+, 574.3 [M+Na]+; Rt = 
10.23 min. 
 
Analytical data of compound 51 
N
H
H
N
N
H
OMe
O N
NH
O
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Peptide 51 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
25 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 648.3 [M+H]+, 670.4 [M+Na]+; Rt = 7.55 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (s, 1H), 8.50 (d, J = 7.4 Hz, 1H), 7.99 (d, J = 8.3 
Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.26-7.14 (m, 8H), 6.97 (d, J = 8.4 Hz, 2H), 6.64 (d, J = 8.4 
Hz, 2H), 4.59-4.47 (m, 2H), 4.39 (q, J = 7.4 7.2 Hz, 1H), 3.55 (s, 3H), 2.98 (dd, J = 10.4, 3.9 Hz, 
1H), 2.93 (dd, J = 11.7, 6.8 Hz, 1H), 2.85 (dd, J = 11.0, 7.3 Hz, 2H), 2.78 (dd, J = 13.6, 4.1 Hz, 
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2H), 2.01 (t, J = 7.4 Hz, 1H), 1.36 ( p, J = 7.4 Hz, 2H), 1.28-1.16 (m, 14H), 1.14-1.08 (m, 2H), 
0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 5.0° (C = 2.2, DMSO). 
 
Analytical data of compound 52 
N
H
H
N
N
H
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O
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Peptide 52 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
2 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 649.3 [M+H]+, 671.4 [M+Na]+; Rt = 6.88 
min. 
 
Analytical data of compound 53 (two diastereoisomers) 
N
H
H
N
N
H
H
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OH
OH
OH
 
 
Peptide 53 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
20 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 723.3 [M+H]+, 745.4 [M+Na]+; Rt = 6.58 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.18 (br s, 1H), 9.14 (br s, 1H), 8.93 (s, 1H), 8.23 (d, J 
= 8.0 Hz, 1H), 8.07 (dd, J = 10.2, 5.3 Hz, 1H), 8.00 (d, J = 7.5 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 
7.30 (s, 1H), 7.02 (d, J = 8.39 Hz, 4H), 6.64 (d, J = 8.1 Hz, 2H), 6.62 (d, J = 8.3 Hz, 1H), 4.57 
(dd, J = 14.0, 7.6 Hz, 1H), 4.45-4.39 (m, 1H), 4.36 (ddd, J = 11.2, 7.8, 3.5 Hz, 1H), 3.55-3.42 
(m, 1H), 3.34-3.10 (m, 3H), 3.11-2.91 (m, 3H), 2.91-2.77 (m, 2H), 2.72 (dd, J = 13.9, 8.3 Hz, 
1H), 2.60 (dd, J = 13.9, 10.5 Hz, 1H), 2.01 (t, J = 7.2, 7.2 Hz, 1H), 1.52-1.31 (m, 2H), 1.31-1.01 
(m, 14H), 0.85 (t, J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 172.4, 171.7, 
171.3, 171.2, 169.3, 155.7, 155.6, 133.5, 129.9, 129.8, 129.0, 127.8, 127.2, 127.2, 116.8, 114.7, 
114.6, 70.1, 70.1, 63.4, 63.4, 54.3, 54.2, 51.2, 42.1, 41.9, 36.8, 36.7, 36.7, 36.1, 35.0, 31.2, 28.8, 
28.8, 28.6, 28.5, 28.3, 26.9, 25.1, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for 
C38H54N6O8 722.4003, found 723.4063 [M+H]+; [ ] =α 20D  + 13.1° (C = 1.6, DMSO). 
 
Analytical data of compound 54 
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Peptide 54 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
22 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 720.4 [M+H]+, 742.4 [M+Na]+; Rt = 5.95 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.21 (br s, 1H), 8.95 (d, J = 0.9 Hz, 1H), 8.27 (d, J = 
8.1 Hz, 1H), 8.06 (t, J = 5.6, 5.6 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.97 (d, J = 4.3 Hz, 1H), 7.78 
(br s, 3H), 7.29 (s, 1H), 7.04-6.97 (m, 4H), 6.75-6.52 (m, 4H), 4.56 (dt, J = 8.0, 8.0, 5.8 Hz, 1H), 
4.45-4.23 (m, 2H), 3.49 (s, 4H), 3.16-3.02 (m, 2H), 3.02-2.90 (m, 2H), 2.88-2.67 (m, 5H), 2.60 
(dd, J = 14.1, 10.4 Hz, 1H), 2.01 (t, J = 7.0, 7.0 Hz, 2H), 1.52-1.30 (m, 6H), 1.30-1.01 (m, 14H), 
0.85 (t, J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 172.4, 171.8, 170.7, 
169.3, 155.8, 155.6, 133.5, 129.9, 129.8, 129.1, 127.8, 127.2, 116.7, 114.8, 114.6, 54.4, 54.3, 
51.3, 38.4, 37.8, 36.9, 36.0, 35.0, 31.2, 28.8, 28.8, 28.6, 28.5, 28.4, 26.8, 25.7, 25.1, 24.3, 21.9, 
13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for C39H57N7O6 719.4370, found 719.4377 [M]+; 
[ ] =α 20D  + 7.0° (C = 1.8, DMSO). 
 
Analytical data of compound 55 
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Peptide 55 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
7 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 693.3 [M+H]+, 715.4 [M+Na]+; Rt = 6.11 
min; [ ] =α 20D  + 7.0° (C = 0.5, DMSO). 
 
Analytical data of compound 56 
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Peptide 56 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
20 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 704.3 [M+H]+, 726.4 [M+Na]+; Rt = 7.81 
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min; 1H NMR (400 MHz, DMSO-D6): δ = 8.75 (s, 1H), 8.73 (s, 1H), 8.70 (s, 1H), 8.54 (d, J = 
5.3 Hz, 1H), 8.52 (d, J = 5.8 Hz, 1H), 8.26 (d, J = 7.5 Hz, 1H), 7.78 (d, J = 8.7 Hz, 2H), 7.30 (s, 
1H), 7.26 (s, 2H), 6.97 (d, J = 8.8 Hz, 2H), 4.79-4.60 (m, 1H), 4.60-4.42 (m, 2H), 4.01 (t, J = 6.5, 
6.5 Hz, 2H), 3.39-2.83 (m, 6H), 1.83-1.57 (m, 2H), 1.47-1.35 (m, 2H), 1.35-1.18 (m, 16H), 0.85 
(t, J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 171.7, 170.4, 169.7, 166.0, 
161.2, 158.3, 158.0, 133.8, 133.8, 130.5, 129.9, 129.7, 129.2, 125.4, 116.7, 116.6, 113.8, 67.6, 
52.8, 51.8, 51.6, 31.1, 28.8, 28.6, 28.5, 28.4, 25.3, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z 
calc. for C36H49N9O6 703.3806, found 704.3914 [M+H]+; [ ] =α 20D  - 11.4° (C = 1.6, DMSO). 
 
Analytical data of compound 57 
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Peptide 57 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
3 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 718.3 [M+H]+, 740.4 [M+Na]+; Rt = 7.66 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (s, 3H), 8.61 (d, J = 7.7 Hz, 1H), 8.53 (d, J = 7.7 
Hz, 1H), 8.36 (d, J = 7.9 Hz, 1H), 7.76 (d, J = 8.8 Hz, 2H), 7.35 (s, 1H), 7.28 (d, J = 3.2 Hz, 2H), 
6.96 (d, J = 8.9 Hz, 2H), 4.69-4.63 (m, 1H), 4.61-4.50 (m, 2H), 3.99 (t, J = 6.5 Hz, 2H), 3.18-
2.95 (m, 6H), 3.60 (s, 3H), 1.73-1.65 (m, 2H), 1.44-1.33 (m, 2H), 1.34-1.18 (m, 16H), 0.83 (t, J = 
6.8 Hz, 3H) ppm; [ ] =α 20D  - 15.8° (C = 0.8, DMSO). 
 
Analytical data of compound 58 
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Peptide 58 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
7 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 703.4 [M+H]+, 725.5 [M+Na]+; Rt = 7.72 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.85 (s, 1H), 8.80 (s, 1H), 8.53 (d, J = 7.3 Hz, 1H), 
8.30 (d, J = 7.2 Hz, 1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.52 (s, 1H), 7.31-7.25 (m, 4H), 6.97 (d, J = 
8.9 Hz, 2H), 4.69-4.62 (m, 1H), 4.55-4.49 (m, 1H), 4.45 (dd, J = 13.5, 7.6 Hz, 1H), 3.99 (t, J = 
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6.5 Hz, 2H), 3.16-3.04 (m, 3H), 3.03-2.91 (m, 3H), 1.74-1.66 (m, 2H), 1.44-1.34 (m, 2H), 1.34-
1.21 (m, 16H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 5.3° (C = 0.3, DMSO). 
 
Analytical data of compound 59 
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Peptide 59 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
12 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 742.3 [M+H]+, 764.4 [M+Na]+; Rt = 5.41 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.96 (s, 1H), 8.94 (s, 1H), 8.20-8.10 (m, 2H), 7.36-
7.21 (m, 5H), 7.01-6.96 (m, 2H), 6.67-6.60 (m, 2H), 4.73-4.66 (m, 1H), 4.60-4.50 (m, 2H), 3.76-
3.67 (m, 1H), 3.49 (t, J = 7.5 Hz, 1H), 3.10-2.95 (m, 3H), 2.90-2.81 (m, 2H), 2.75 (s, 3H), 2.70-
2.64 (m, 1H), 2.06-2.01 (m, 2H), 1.45-1.33 (m, 2H), 1.29-1.14 (m, 14H), 1.14-1.09 (m, 2H), 0.83 
(t, J = 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 172.5, 170.0, 169.1, 166.2, 162.1, 
155.9, 133.6, 130.0, 130.0, 128.8, 127.4, 126.8, 123.1, 122.3, 121.7, 116.7, 116.6, 116.6, 114.8, 
51.4, 50.7, 49.7, 40.3, 34.9, 31.1, 28.8, 28.8, 28.6, 28.6, 28.5, 28.4, 24.9, 21.9, 13.8 ppm; HRMS 
(ESI) m/z calc. for C40H55N9O5 741.4326, found 742.4404 [M+H]+; [ ] =α 20D  - 0.8° (C = 0.9, 
DMSO). 
 
Analytical data of compound 60 
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Peptide 60 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
15 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 731.5 [M+H]+, 753.4 [M+Na]+; Rt = 5.11 
min; 1H NMR (400 MHz, DMSO-D6): δ =  8.95 (s, 1H), 8.91 (t, J = 1.3 Hz, 2H), 8.20 (d, J = 7.8 
Hz, 1H), 8.16 (d, J = 8.6 Hz, 1H), 8.14 (d, J = 7.7 Hz, 2H), 7.67 (s, 1H), 7.64 (s, 1H), 7.25 (d, J 
= 3.5 Hz, 2H), 6.99 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.4 Hz, 2H), 4.59-4.48 (m, 2H), 4.31 (q, J = 
7.3 Hz, 1H), 4.01 (t, J = 7.1 Hz, 2H), 3.11-3.01 (m, 3H), 3.01-2.89 (m, 3H), 2.89-2.83 (m, 1H), 
2.81 (d, J = 6.3 Hz, 1H), 2.74 (dd, J = 13.7, 7.8 Hz, 1H), 2.04 (t, J = 7.5 Hz, 2H), 1.88-1.80 (m, 
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2H), 1.41-1.33 (m, 2H), 1.30-1.13 (m, 14H), 1.14-1.07 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; 
[ ] =α 20D  - 3.9° (C = 1.3, DMSO). 
 
Analytical data of compound 61 
N
H
H
N
N
H
H
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OH
O
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Peptide 61 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
20 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 740.3 [M+H]+, 762.5 [M+Na]+; Rt = 7.19 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.28 (s, 1H), 8.94 (s, 1H), 8.94 (s, 1H), 8.32 (d, J = 
8.0 Hz, 1H), 8.15 (d, J = 6.9 Hz, 1H), 7.97 (t, J = 7.4 Hz, 1H), 7.60 (dd, J = 6.0, 3.1 Hz, 1H), 
7.32 (s, 1H), 7.29 (dd, J = 6.1, 3.0 Hz, 1H), 7.06 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 
6.98-6.88 (m, 2H), 6.66 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 6.5 Hz, 2H), 4.61 (dd, J = 14.6, 8.0 Hz, 
1H), 4.55 (dd, J = 14.5, 7.4 Hz, 1H), 4.39-4.32 (m, 1H), 3.13-3.04 (m, 2H), 3.00-2.91 (m, 2H), 
2.90-2.78 (m, 2H), 2.00 (t, J = 7.3 Hz, 2H), 1.39-1.31 (m, 2H), 1.28-1.13 (m, 14H), 1.12-1.04 (m, 
2H), 0.86-0.81 (m, 3H) ppm; [ ] =α 20D  + 20.0° (C = 1.7, DMSO). 
 
Analytical data of compound 62 
O N
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Peptide 62 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 592.1 [M+H]+, 614.1 [M+Na]+; Rt = 5.81 
min. 
 
Analytical data of compound 63 
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Peptide 63 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
26 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 621.3 [M+H]+, 643.4 [M+Na]+; Rt = 5.52 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.90 (s, 1H), 8.90 (s, 1H), 8.19 (s, 1H), 8.17 (s, 1H), 
8.15 (s, 1H), 7.96 (dd, J = 9.2, 5.6 Hz, 1H), 7.32 (s, 1H), 7.28 (s, 1H), 4.61 (dd, J = 13.2, 7.4 Hz, 
1H), 4.54 (dt, J = 8.4 5.4 Hz, 1H), 4.25 (dq, J = 5.6, 2.6 Hz, 1H), 3.58 (dq, J = 11.2, 5.5 Hz, 2H), 
3.52-3.45 (m, 1H), 3.28 (dd, J = 5.3, 2.5 Hz, 2H), 3.26-3.18 (m, 1H), 3.10 (dd, J = 15.1, 5.5 Hz, 
1H), 3.07-2.98 (m, 2H), 2.88 (dd, J = 15.2, 8.9 Hz, 1H), 2.05 (t, J = 7.4 Hz, 2H), 1.38 ( p, J = 7.4 
Hz, 2H), 1.27-1.15 (m, 14H), 1.14-1.08 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 3.8° (C 
= 2.6, DMSO). 
 
Analytical data of compound 64 
O N
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Peptide 64 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 538.2 [M+H]+, 560.2 [M+Na]+; Rt = 5.62 
min. 
 
Analytical data of compound 65 
O N
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Peptide 65 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 523.2 [M+H]+, 545.2 [M+Na]+; Rt = 5.04 
min. 
 
Analytical data of compound 66 
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Peptide 66 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 631.2 [M+H]+, 653.3 [M+Na]+; Rt = 4.37 
min. 
 
Analytical data of compound 67 
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Peptide 67 was synthesized and released from solid support according to GP 2 and GP 5. Yield = 
13 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 649.4 [M+H]+, 671.3 [M+Na]+; Rt = 9.87 
min; 1H NMR (400 MHz, DMSO-D6): δ = 10.58 (s, 1H), 8.86 (s, 1H), 8.27 (d, J = 8.0 Hz, 1H), 
7.99 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.19 (d, J = 6.2 Hz, 2H), 7.15 (d, J = 7.0 Hz, 
2H), 6.98 (d, J = 8.4 Hz, 2H), 6.62 (d, J = 8.3 Hz, 2H), 4.55 (dt, J = 8.5, 8.3 Hz, 1H), 4.49 (dt, J 
= 8.6 4.5 Hz, 1H), 4.29 (q, J = 7.7 Hz, 1H), 3.00-2.91 (m, 2H), 2.85-2.72 (m, 3H), 2.68 (dd, J = 
13.9, 7.5 Hz, 1H), 2.01 (t, J = 7.5 Hz, 1H), 1.40-1.31 (m, 1H), 1.30-1.15 (m, 14H), 1.14-1.08 (m, 
2H), 0.83 (t, J = 6.7Hz, 3H) ppm; [ ] =α 20D  - 14.1° (C = 1.1, DMSO). 
 
Analytical data of compound 68 
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Peptide 68 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
6 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 666.3 [M+H]+, 688.4 [M+Na]+; Rt = 5.25 
min. 
 
Analytical data of compound 69 
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Peptide 69 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
6 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 810.5 [M+H]+, 832.5 [M+Na]+; Rt = 7.70 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.13 (d, J = 5.5 Hz, 1H), 8.65 (tt, J = 7.8 1.3 Hz, 1H), 
8.36 (d, J = 8.0 Hz, 1H), 8.26 (d, J = 8.1 Hz, 1H), 8.17 (d, J = 6.8 Hz, 1H), 8.15 (d, J = 6.8 Hz, 
1H), 7.92 (t, J = 5.7 Hz, 1H), 7.81 (s, 1H), 7.57 (d, J = 8.9 Hz, 2H), 7.26-7.12 (m, 7H), 6.93 (d, J 
= 9.0 Hz, 2H), 6.83 (d, J = 8.5 Hz, 2H), 6.41 (d, J = 8.4 Hz, 2H), 4.77 (dt, J = 9.0, 5.7 Hz, 1H), 
4.47-4.35 (m, 2H), 4.00 (t, J = 6.5 Hz, 2H), 3.15-3.05 (m, 2H), 3.25-3.20 (m, 2H), 3.02-2.88 (m, 
4H), 2.84-2.68 (m, 4H), 1.71 (p, J = 6.8 Hz, 2H), 1.48-1.31 (m, 4H), 1.32-1.22 (m, 16H), 0.83 (t, 
J = 6.6 Hz, 3H) ppm; [ ] =α 20D  + 5.5° (C = 0.4, DMSO). 
 
Analytical data of compound 70 
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Peptide 70 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
20 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 756.4 [M+H]+, 778.4 [M+Na]+; Rt = 5.26 
min. 
 
Analytical data of compound 71 
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Peptide 71 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
18 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 637.2 [M+H]+, 659.4 [M+Na]+; Rt = 
10.40 min; 13C NMR (100 MHz, CDCl3): δ =172.5, 170.9, 169.8, 166.1, 141.5, 141.5, 139.6, 
136.9, 136.4, 135.0, 132.6, 129.9, 129.6, 129.5, 129.0, 128.5, 128.0, 126.8, 54.4, 54.4, 52.0, 48.4, 
42.3, 39.2, 39.2, 32.9, 32.7, 30.8, 25.7, 25.1, 23.1, 22.7 ppm. 
 
Analytical data of compound 72 
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Peptide 72 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
Purity > 95% (LC_MS); 2 %; LC-MS (C18, ESI_MS) 587.3 [M+H]+, 609.4 [M+Na]+; Rt = 7.41 
min. 
 
Analytical data of compound 73 
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Peptide 73 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
12 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 606.0 [M+H]+, 628.2 [M+Na]+; Rt = 
8.41 min; 1H NMR (400 MHz, CD3OD): δ =  7.58-7.49 (m, 2H), 7.46 (d, J = 15.7 Hz, 1H, Ph-
CH=), 7.42-7.35 (m, 3H), 7.26-7.08 (m, 10H), 7.03 (d, J = 8.6 Hz, 2H), 6.70 (d, J = 8.6 Hz, 2H), 
6.55 (d, J = 15.7 Hz, 1H), 4.71 (dd, J = 9.4, 5.3 Hz, 1H), 4.64 (dd, J = 8.7, 5.3 Hz, 1H), 4.57 (dd, 
J = 7.9, 5.5 Hz, 3H), 3.17-3.02 (m, 3H), 2.97-2.78 (m, 3H) ppm; 13C NMR (100 MHz, 
CD3OD): δ = 174.4, 173.2, 172.9, 168.3, 142.4, 138.5, 138.2, 136.2, 131.4, 130.9, 130.4, 130.2, 
130.0, 129.4, 129.4, 128.9, 128.9, 127.7, 127.6, 121.3, 116.3, 116.3, 56.0, 55.7, 55.4, 38.9, 38.6, 
37.7 ppm. 
 
Analytical data of compound 74 
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Peptide 74 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 687.1 [M+H]+, 709.4 [M+Na]+; Rt = 
12.11 min. 
 
Analytical data of compound 75 
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Peptide 75 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
20 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 774.4 [M+H]+, 796.4 [M+Na]+; Rt = 5.43 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.91 (d, J = 0.8 Hz, 1H), 8.89 (s, 1H), 8.85 (s, 1H), 
8.56 (d, J = 7.6 Hz, 1H), 8.35 (d, J = 7.7 Hz, 2H), 8.12 (t, J = 5.6, 5.6 Hz, 1H), 7.82 (br s, 3H), 
7.75 (d, J = 8.8 Hz, 2H), 7.31 (s, 1H), 7.29 (s, 2H), 6.95 (d, J = 8.9 Hz, 2H), 4.71-4.62 (m, 1H), 
4.54 (dd, J = 13.3, 7.8 Hz, 1H), 4.48 (dd, J = 13.8, 7.9 Hz, 1H), 3.99 (t, J = 6.5, 6.5 Hz, 2H), 
3.24-3.05 (m, 5H), 3.05-2.90 (m, 3H), 2.85-2.68 (m, 2H), 1.75-1.63 (m, 2H), 1.57-1.43 (m, 2H), 
1.43-1.34 (m, 4H), 1.34-1.16 (m, 16H), 0.83 (t, J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, 
DMSO-D6): δ = 170.5, 169.7, 169.5, 166.2, 161.2, 158.6, 158.3, 133.7, 133.7, 129.9, 129.4, 
129.2, 125.4, 116.7, 116.6, 116.5, 113.7, 67.6, 52.5, 51.9, 51.9, 38.3, 38.0, 31.1, 28.8, 28.6, 28.5, 
28.4, 26.9, 26.9, 26.5, 26.5, 26.1, 25.7, 25.3, 24.3, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z 
calc. for C40H59N11O5 773.4701, found 774.4810 [M+H]+; [ ] =α 20D  - 12.3° (C = 1.8, DMSO). 
  
Analytical data of compound 76 
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Peptide 76 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
21 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 811.5 [M+H]+, 833.5 [M+Na]+; Rt = 5.45 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.98 (s, 1H), 8.90 (d, J = 0.8 Hz, 1H), 8.89 (d, J = 0.8 
Hz, 1H), 8.84 (s, 1H), 8.58 (d, J = 7.8 Hz, 1H), 8.42 (d, J = 7.5 Hz, 1H), 8.39 (d, J = 7.6 Hz, 1H), 
8.21 (t, J = 5.6 Hz, 1H), 7.75 (d, J = 8.8 Hz, 2H), 7.70 (t, J = 1.4 Hz, 1H), 7.63 (t, J = 1.3 Hz, 
1H), 7.32 (s, 1H), 7.29 (s, 2H), 6.95 (d, J = 8.9 Hz, 2H), 4.70-4.63 (m, 1H), 4.54 (dt, J = 7.9, 4.9 
Hz, 1H), 4.46 (dd, J = 13.9, 7.7 Hz, 1H), 4.12 (t, J = 6.8, Hz, 2H), 3.99 (t, J = 6.5 Hz, 2H), 3.20-
2.94 (m, 6H), 1.95-1.86 (m, 2H), 1.69 (p, J = 6.6 Hz, 2H), 1.43-1.34 (m, 2H), 1.34-1.21 (m, 
16H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 17.1° (C = 1.9, DMSO). 
 
Analytical data of compound 77 
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Peptide 77 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
18 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 852.4 [M+H]+, 874.6 [M+Na]+; Rt = 8.39 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.11 (s, 2H), 8.32 (d, J = 8.1 Hz, 1H), 7.98 (d, J = 8.2 
Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H) 7.77-7.72 (m, 3H), 7.05 (d, J = 8.5 Hz, 2H), 7.02-6.92 (m, 6H), 
6.64 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.5 Hz, 2H), 6.54 (d, J = 8.50 Hz, 2H), 4.58-4.46 (m, 1H), 
4.40 (dt, J = 8.4, 8.3, 5.0 Hz, 1H), 4.34 (dd, J = 14.2, 8.1 Hz, 1H), 4.00 (t, J = 6.5, 6.5 Hz, 2H), 
3.15-2.92 (m, 2H), 2.89-2.79 (m, 4H), 2.79-2.62 (m, 4H), 1.82-1.63 (m, 2H), 1.51-1.35 (m, 4H), 
1.33-1.20 (m, 18H), 0.84 (t, J = 7.0, 7.0 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-
D6): δ = 171.4, 170.5, 170.4, 165.8, 160.9, 155.6, 155.6, 155.5, 130.0, 129.9, 129.1, 128.3, 127.4, 
127.4, 125.9, 114.7, 114.7, 113.7, 67.5, 55.0, 54.2, 54.1, 38.4, 37.7, 36.9, 36.5, 36.5, 35.7, 35.7, 
31.1, 28.8, 28.6, 28.5, 28.4, 25.7, 25.3, 24.2, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for 
C49H65N5O8 851.4833, found 852.4888 [M+H]+; [ ] =α 20D  - 28.3° (C = 1.3, DMSO). 
 
Analytical data of compound 78 
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Peptide 78 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
25 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 822.4 [M+H]+, 844.4 [M+Na]+; Rt = 5.71 
min. 
 
Analytical data of compound 79 
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Peptide 79 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
1 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 821.3 [M+H]+; Rt = 8.68 min. 
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Analytical data of compound 80 
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Peptide 80 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
12 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 768.3 [M+H]+, 790.4 [M+Na]+; Rt = 6.41 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.22 (s, 1H), 9.12 (s, 1H), 8.96 (d, J = 1.0 Hz, 1H), 
8.48 (dd, J = 14.0, 5.0 Hz, 1H), 8.21 (d, J = 6.77 Hz, 2H), 7.95 (d, J = 8.02 Hz, 1H), 7.78-7.66 
(m, 1H), 7.35-7.19 (m, 3H), 7.00 (d, J = 8.6 Hz, 2H), 6.98 (d, J = 8.2 Hz, 2H), 6.66-6.58 (m, 4H), 
4.71 (q, J = 7.3 Hz, 1H), 4.57 (dd, J = 13.8, 7.1 Hz, 1H), 4.35 (ddd, J = 10.7, 8.3, 3.9 Hz, 1H), 
3.70 (ddd, J = 12.5, 8.5, 6.1 Hz, 2H), 3.49 (t, J = 8.0 Hz, 2H), 3.06-2.99 (m, 1H), 2.94 (dd, J = 
15.1, 7.6 Hz, 1H), 2.88-2.79 (m, 2H), 2.71-2.65 (m, 1H), 2.59 (dd, J = 13.9, 10.5 Hz, 1H), 1.99 (t, 
J = 7.4 Hz, 2H), 1.38-1.30 (m, 2H), 1.27-1.04 (m, 14H), 0.83 (t, J = 6.8 Hz, 3H) ppm; 13C NMR 
(100 MHz, DMSO-D6): δ = 173.2, 172.4, 171.4, 169.8, 156.7, 156.4, 143.3, 134.3, 130.8, 130.8, 
130.8, 130.6, 129.6, 128.6, 119.4, 117.6, 115.6, 115.4, 55.0, 53.0, 51.8, 41.1, 36.9, 35.8, 35.6, 
31.9, 29.6, 29.5, 29.4, 29.3, 29.1, 25.9, 22.7, 14.6 ppm; HRMS (ESI) m/z calc. for C43H57N7O6 
767.4370, found 768.4455 [M+H]+; [ ] =α 20D  + 12.7° (C = 0.8, DMSO). 
 
Analytical data of compound 81 
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Peptide 81 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
18 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 752.3 [M+H]+, 774.4 [M+Na]+; Rt = 6.62 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.92 (dd, J = 2.8, 1.3 Hz, 1H), 8.49 (dd, J = 16.9, 5.5 
Hz, 1H), 8.44-8.40 (m, 1H), 8.01 (dd, J = 8.3, 2.0 Hz, 1H), 7.83 (d, J = 7.9 Hz, 1H), 7.78 (d, J = 
7.8 Hz, 1H), 7.33-7.10 (m, 10H), 6.98 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 6.63 (d, J = 
8.5 Hz, 1H), 6.63 (d, J = 8.5 Hz, 1H), 4.73 (q, J = 7.4 Hz, 1H), 4.59-4.54 (m, 1H), 4.54-4.49 (m, 
1H), 3.68 (ddd, J = 12.7, 8.4, 6.5 Hz, 2H), 3.46-3.39 (m, 2H), 3.01-2.91 (m, 2H), 2.87-2.75 (m, 
3H), 2.74-2.71 (m, 3H), 2.64 (dd, J = 13.4, 6.7 Hz, 1H), 2.02 (t, J = 7.4 Hz, 2H), 1.40-1.32 (m, 
2H), 1.29-1.08 (m, 14H), 0.83 (t, J = 6.7 Hz, 3H); 13C NMR (100 MHz, DMSO-D6): δ = 172.2, 
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172.2, 170.4, 170.4, 170.0, 169.6, 169.6, 155.8, 137.8, 137.1, 136.9, 133.5, 130.0, 129.4, 129.3, 
129.1, 129.1, 127.8, 127.7, 127.0, 126.1, 126.1, 123.7, 123.3, 121.9, 121.7, 117.3, 116.6, 114.8, 
53.3, 53.3, 53.2, 51.0, 51.0, 51.0, 47.3, 37.3, 36.6, 36.6, 35.9, 34.9, 34.8, 33.3, 31.1, 28.8, 28.7, 
28.6, 28.6, 28.5, 28.4, 26.7, 26.7, 26.7, 26.7, 24.9, 21.9, 13.8 ppm; HRMS (ESI) m/z calc. for 
C43H57N7O5 751.4421, found 752.4504 [M+H]+; [ ] =α 20D  - 5.9° (C = 1.6, DMSO). 
 
Analytical data of compound 82 
N
H
H
N
N
H
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O
N
NH
O N
NH
O
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H
N N
 
 
Peptide 82 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
9 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 725.4 [M+H]+, 747.5 [M+Na]+; Rt = 6.01 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.95 (d, J = 1.4 Hz, 1H), 8.94 (d, J = 1.2 Hz, 1H), 
8.39 (d, J = 7.5 Hz, 1H), 8.31 (d, J = 6.7 Hz, 1H), 8.15 (d, J = 7.2 Hz, 1H), 7.39-7.35 (m, 2H), 
7.31 (d, J = 6.9 Hz, 2H), 7.12 (d, J = 7.3 Hz, 2H), 7.04 (d, J = 7.0 Hz, 2H), 6.97 (d, J = 7.0 Hz, 
2H), 6.68-6.57 (m, 3H), 4.60-4.49 (m, 2H), 4.32-4.24 (m, 1H), 3.23-3.04 (m, 4H), 3.03-2.93 (m, 
2H), 2.20-2.05 (m, 2H), 2.04-1.87 (m, 1H), 1.74-1.59 (m, 1H), 1.55-1.42 (m, 2H), 1.28-1.17 (m, 
16H), 0.84-0.79 (m, 3H) ppm; [ ] =α 20D  - 3.2° (C = 0.7, DMSO). 
 
Analytical data of compound 83 
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Peptide 83 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
14 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 767.4 [M+H]+, 789.4 [M+Na]+; Rt = 5.57 
min. 
 
Analytical data of compound 84 
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Peptide 84 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
23 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 638.3 [M+H]+, 660.3 [M+Na]+; Rt = 5.83 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.32 (s, 1H), 8.94-8.93 (m, 2H), 8.93 (s, 2H), 8.27 (d, 
J = 7.84 Hz, 1H), 8.20 (d, J = 6.9 Hz, 1H), 8.16 (d, J = 7.9 Hz, 1H), 7.63 (dd, J = 6.0, 3.1 Hz, 
1H), 7.35 (d, J = 3.3 Hz, 2H), 7.32-7.29 (m, 3H), 7.07 (dd, J = 7.8, 1.4 Hz, 1H), 6.92 (dt, J = 8.0, 
1.5 Hz, 1H), 6.71 (dd, J = 8.0, 1.3 Hz, 1H), 6.53 (dt, J = 7.6, 1.4 Hz, 1H), 4.72-4.62 (m, 1H), 
4.59-4.52 (m, 1H), 4.44 (q, J = 5.7, 5.6 Hz, 1H), 3.88 (dd, J = 5.2, 2.7 Hz, 1H), 3.74 (dd, J = 
10.8, 5.6 Hz, 1H), 3.66 (dd, J = 10.8, 5.6 Hz, 1H), 3.18 (dd, J = 15.7, 5.7 Hz, 1H), 3.13-2.98 (m, 
2H), 2.89 (dd, J = 15.3, 9.4 Hz, 1H), 2.05 (t, J = 7.4 Hz, 2H), 1.42-1.34 (m, 1H), 1.29-1.14 (m, 
14H), 1.14-1.09 (m, 2H), 0.89-0.78 (m, 3H) ppm. 
 
Analytical data of compound 85 
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Peptide 85 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
2 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 900.3 [M+H]+, 922.5 [M+Na]+; Rt = 8.88 
min. 
 
Analytical data of compound 86 
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Peptide 86 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
2 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 858.3 [M+H]+, 880.5 [M+Na]+; Rt = 7.45 
min. 
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Analytical data of compound 87 
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Peptide 87 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
10 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 742.4 [M+H]+, 764.4 [M+Na]+; Rt = 5.67 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.96 (d, J = 1.3 Hz, 1H), 8.95 (d, J = 1.3 Hz, 1H), 
8.55 (d, J = 4.0 Hz, 1H), 8.28 (d, J = 7.8 Hz, 2H), 7.93 (d, J = 7.7 Hz, 1H), 7.52-7.16 (m, 5H), 
6.98 (d, J = 8.6 Hz, 2H), 6.60 (d, J = 8.5 Hz, 2H), 5.14-4.76 (m, 1H), 4.56-4.47 (m, 1H), 4.38-
4.26 (m, 1H), 3.80-3.63 (m, 4H), 3.53-3.43 (m, 1H), 3.12-2.93 (m, 6H), 2.92 (s, 3H), 2.84-2.73 
(m, 3H), 2.55 (dd, J = 13.7, 11.0 Hz, 1H), 1.99 (dt, J = 7.4, 7.4, 2.9 Hz, 2H), 1.51-1.28 (m, 2H), 
1.28-1.01 (m, 14H), 0.83 (t, J = 6.9, 6.9 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-
D6): δ = 172.5, 171.8, 170.6, 169.4, 158.2, 157.9, 155.6, 142.2, 133.6, 133.6, 129.8, 129.0, 128.7, 
127.7, 124.2, 124.1, 117.1, 116.7, 114.6, 54.2, 53.5, 51.4, 51.3, 35.0, 34.9, 31.1, 28.8, 28.7, 28.6, 
28.5, 28.4, 26.7, 26.5, 26.3, 26.2, 25.0, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for 
C40H55N9O5 741.4326, found 741.4352 [M]+; found 742.4373 [M+H]+; [ ] =α 20D  - 7.6° (C = 0.6, 
DMSO). 
 
Analytical data of compound 88 
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Peptide 88 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 628.2 [M+H]+, 650.2 [M+Na]+; Rt = 4.72 
min. 
 
Analytical data of compound 89 
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Peptide 89 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 642.2 [M+H]+, 664.3 [M+Na]+; Rt = 4.75 
min. 
 
Analytical data of compound 90 
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Peptide 90 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
3 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 707.4 [M+H]+, 729.4 [M+Na]+; Rt = 6.32 
min. 
 
Analytical data of compound 91 
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Peptide 91 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
1 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 677.3 [M+H]+, 699.4 [M+Na]+; Rt = 7.40 
min. 
 
Analytical data of compound 92 
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Peptide 92 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
35 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 707.4 [M+H]+, 729.4 [M+Na]+; Rt = 6.89 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (s, 1H), 8.17 (dd, J = 8.2, 2.3 Hz, 1H), 7.99 (d, J 
= 8.3 Hz, 1H), 7.88 (dd, J = 7.8, 2.2 Hz, 1H), 7.82 (dt, J = 5.8, 2.8 Hz, 1H), 7.22-7.12 (m, 6H), 
6.99 (dd, J = 8.4, 1.4 Hz, 2H), 6.61 (d, J = 8.4 Hz, 2H), 4.55 (dt, J = 8.7, 5.5 Hz, 1H), 4.50-4.44 
(m, 1H), 4.44-4.37 (m, 1H), 3.43 (td, J = 15.9, 5.2 Hz, 1H), 3.28-3.22 (m, 2H), 3.21-3.13 (m, 
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1H), 3.03-2.91 (m, 3H), 2.88-2.68 (m, 3H), 2.01 (t, J = 7.4, Hz, 2H), 1.36 (p, J = 7.5 Hz, 2H), 
1.29-1.16 (m, 16H), 1.13-1.07 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 4.9° (C = 3.7, 
DMSO). 
 
Analytical data of compound 93 
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Peptide 93 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
13 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 633.3 [M+H]+, 655.4 [M+Na]+; Rt = 7.12 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (s, 1H), 8.11 (d, J = 8.1 Hz, 1H), 8.01 (d, J = 8.3 
Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.26 (br s, 1H), 7.24-7.13 (m, 5H), 7.04 (br s, 1H), 7.01 (d, J = 
8.5 Hz, 2H), 6.63 (d, J = 8.52 Hz, 2H), 4.56 (dt, J = 8.5, 8.5, 5.5 Hz, 1H), 4.48 (dt, J = 8.4, 8.4, 
4.6 Hz, 1H), 4.36 (dt, J = 8.2, 8.2, 5.5 Hz, 1H), 3.04-2.92 (m, 2H), 2.93-2.77 (m, 3H), 2.72 (dd, J 
= 14.1, 8.5 Hz, 1H), 2.03 (t, J = 7.4, 7.4 Hz, 2H), 1.50-1.31 (m, 2H), 1.31-1.07 (m, 14H), 0.85 (t, 
J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 172.5, 172.2, 170.3, 169.9, 
155.6, 137.3, 133.6, 129.9, 129.5, 129.0, 127.8, 127.6, 126.1, 116.6, 114.7, 54.0, 53.8, 51.1, 37.2, 
36.7, 34.9, 31.1, 28.9, 28.8, 28.6, 28.5, 28.4, 26.8, 24.9, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) 
m/z calc. for C35H48N6O5 632.3686, found 633.3773 [M+H]+; [ ] =α 20D  - 7.5° (C = 1.2, DMSO). 
 
Analytical data of compound 94 
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Peptide 94 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
12 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 676.4 [M+H]+, 677.4 [M+Na]+; Rt = 6.31 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (s, 1H), 8.45 (d, J = 7.6 Hz, 1H), 8.01 (d, J = 8.3 
Hz, 1H), 7.95 (d, J = 8.1 Hz, 1H), 7.25-7.14 (m, 6H), 6.99 (d, J = 8.5 Hz, 2H), 6.65 (d, J = 8.5 
Hz, 2H), 4.57-4.48 (m, 2H), 4.22 (td, J = 11.3, 5.5 Hz, 1H), 4.18-4.11 (m, 1H), 3.05 (dd, J = 8.1, 
5.4 Hz, 2H), 3.00 (dd, J = 9.7, 4.7 Hz, 1H), 2.98-2.91 (m, 2H), 2.85 (dd, J = 14.4, 8.5 Hz, 1H), 
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2.81-2.72 (m, 2H), 2.01 (t, J = 7.5 Hz, 2H), 1.40-1.31 (m, 2H), 1.28-1.16 (m, 14H), 1.13-1.08 (m, 
2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 4.5° (C = 0.9, DMSO). 
 
Analytical data of compound 95 
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Peptide 95 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
5 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 724.3 [M+H]+, 746.4 [M+Na]+; Rt = 7.49 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.15 (s, 1H), 8.90 (d, J = 1.3 Hz, 1H), 8.35 (d, J = 7.4 
Hz, 1H), 8.01 (d, J = 8.3 Hz, 1H), 7.93 (d, J = 7.9 Hz, 1H), 7.23-7.17 (m, 6H), 7.16-7.12 (m, 
1H), 7.06 (d, J = 8.5 Hz, 2H), 6.98 (dd, J = 7.8, 1.4 Hz, 1H), 6.69 (dd, J = 8.0, 1.3 Hz, 1H), 6.66 
(d, J = 8.5 Hz, 2H), 4.61-4.52 (m, 3H), 3.05-2.91 (m, 3H), 2.88-2.77 (m, 3H), 2.02 (t, J = 7.4 Hz, 
2H), 1.41-1.32 (m, 2H), 1.26-1.16 (m, 14H), 1.14-1.08 (m, 2H), 0.83 (t, J = 6.8Hz, 3H) ppm; 
[ ] =α 20D  + 2.1° (C = 2.3, DMSO). 
 
Analytical data of compound 96 
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Peptide 96 was synthesized and released from solid support according to GP 2 and GP 4. Yield = 
22 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 634.3 [M+H]+, 656.3 [M+Na]+; Rt = 7.29 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.76 (s, 1H), 8.36 (d, J = 7.7 Hz, 1H), 7.96 (d, J = 8.3 
Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.22-7.14 (m, 6H), 7.00 (d, J = 8.5 Hz, 2H), 6.64 (d, J = 8.5 
Hz, 2H), 4.58-4.49 (m, 2H), 4.36 (dt, J = 7.9, 5.7 Hz, 1H), 3.00 (dd, J = 14.0, 4.2 Hz, 1H), 2.95 
(dd, J = 8.9, 5.8 Hz, 1H), 2.91 (dd, J = 7.4, 5.9 Hz, 1H), 2.82 (dd, J = 8.6, 5.6 Hz, 1H), 2.80-2.73 
(m, 2H), 2.01 (t, J = 7.4 Hz, 2H), 1.40-1.32 (m, 2H), 1.28-1.17 (m, 14H), 1.14-1.08 (m, 2H), 0.83 
(t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 0.4° (C = 1.7, DMSO). 
 
Analytical data of compound 97 
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Peptide 97 was synthesized and released from solid support according to GP 2 and GP 5. Yield = 
5 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 705.4 [M+H]+, 727.4 [M+Na]+; Rt = 7.67 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.85 (s, 1H), 8.35 (d, J = 8.1 Hz, 1H), 7.97 (d, J = 8.4 
Hz, 1H), 7.82 (d, J = 8.0 Hz, 1H), 7.22-7.14 (m, 5H), 7.00 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.5 
Hz, 2H), 4.56 (dd, J = 8.8, 5.2 Hz, 1H), 4.50 (dd, J = 7.9, 4.4 Hz, 1H), 4.36 (q, J = 7.5 Hz, 1H), 
3.00-2.91 (m, 2H), 2.83-2.68 (m, 4H), 2.01 (t, J = 7.5 Hz, 2H), 1.40-1.32 (m, 2H), 1.29-1.15 (m, 
14H), 1.13-1.07 (m, 2H), 1.05-1.03 (m, 9H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 8.4° (C = 
0.5, DMSO). 
 
Analytical data of compound 98 
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Peptide 98 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
45 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 450.5 [M+H]+, 472.4 [M+Na]+; Rt = 
7.15 min; 1H NMR (400 MHz, CD3OD): δ = 7.61 (d, J = 15.5 Hz, 1H), 7.58-7.55 (m, 2H), 7.38-
7.36 (m, 3H), 7.21 (d, J = 4.46 Hz, 5H), 6.97 (d, J = 15.5 Hz, 1H), 4.68 (dd, J = 8.6, 5.2 Hz, 1H), 
4.49 (dd, J = 8.3, 5.2 Hz, 1H), 3.96 (d, J = 17.0 Hz, 1H), 3.90-3.80 (m, 2H), 3.75 (d, J = 17.0 Hz, 
1H), 3.24 (dd, J = 14.0, 5.2 Hz, 1H), 3.11 (dd, J = 14.0, 8.7 Hz, 1H), 2.26-2.20 (m, 1H), 2.19-
2.09 (m, 1H), 2.06-1.99 (m, 2H) ppm. 
 
Analytical data of compound 99 
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Peptide 99 was synthesized and released from solid support according to GP 2 and GP 3. Yield = 
22 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 531.7 [M+H]+, 553.5 [M+Na]+; Rt = 
8.52 min; 1H NMR (400 MHz, CD3OD): δ = 7.67 (d, J = 15.5 Hz, 1H), 7.60-7.57 (m, 2H), 7.40-
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7.36 (m, 3H), 7.23-7.19(m, 5H), 7.01 (d, J = 15.5 Hz, 1H), 4.56 (dd, J = 9.1, 5.9 Hz, 1H), 4.46 
(dd, J = 8.2, 5.3 Hz, 1H), 3.93-3.82 (m, 2H), 3.78 (d, J = 3.7 Hz, 2H), 3.64-3.58 (m, 1H), 3.24 
(dd, J = 13.8, 5.8 Hz, 1H), 3.05 (dd, J = 13.8, 9.2 Hz, 1H), 2.32-2.27 (m, 1H), 2.16 -1.98 (m, 
3H), 1.82-1.68 (m, 5H), 1.36-1.12 (m, 5H) ppm; 13C NMR (100 MHz, CD3OD): δ = 175.8, 
172.3, 171.5, 167.7, 144.4, 138.7, 136.2, 132.2, 130.2, 130.0, 129.4, 129.2, 127.7, 119.3, 62.8, 
56.5, 50.1, 49.3, 43.9, 39.0, 33.6, 33.5, 30.5, 26.6, 26.1, 26.1, 26.1 ppm. 
 
Analytical data of compound 100 
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Peptide 100 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 42 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 519.7 [M+H]+, 541.5 [M+Na]+; Rt = 
8.55 min; 1H NMR (400 MHz, CD3OD): δ = 7.66 (d, J = 15.5 Hz, 1H), 7.60-7.56 (m, 2H), 7.39-
7.37 (m, 3H), 7.24-7.12 (m, 5H), 7.00 (d, J = 15.5 Hz, 1H), 4.57 (dd, J = 9.3, 5.6 Hz, 1H), 4.45 
(dd, J = 8.3, 5.3 Hz, 1H), 3.94-3.84 (m, 2H), 3.82 (d, J = 16.9 Hz, 1H), 3.75 (d, J = 16.9 Hz, 1H), 
3.26 (dd, J = 13.9, 5.7 Hz, 1H), 3.20 (dt, J = 7.1, 7.1, 2.4 Hz, 2H), 3.06 (dd, J = 13.9, 9.3 Hz, 
1H) 2.30-2.25 (m, 1H), 2.18-2.10(m, 1H), 2.08-1.99 (m, 2H), 1.61-1.50 (m, 1H), 1.36 (m, 2H), 
0.89 (d, J = 1.4 Hz, 3H), 0.88 (d, J = 1.4 Hz, 3H) ppm; 13C NMR (100 MHz, 
CD3OD): δ = 175.8, 173.2, 171.6, 167.7, 144.4, 138.8, 136.2, 131.2, 130.2, 130.0, 129.4, 129.2, 
127.7, 119.3, 62.8, 56.6, 43.9, 39.1, 38.8, 38.8, 30.5, 26.7, 26.1, 22.8, 22.8 ppm. 
 
Analytical data of compound 101 
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Peptide 101 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 32 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 464.3 [M+H]+, 464.4 [M+Na]+; Rt = 
7.82 min; 1H NMR (400 MHz, CD3OD): δ = 7.61 (d, J = 15.5 Hz, 1H), 7.56-7.54 (m, 2H), 7.38-
7.34 (m, 3H), 7.21-714 (m, 5H), 6.97 (d, J = 15.5 Hz, 1H), 4.68 (dd, J = 8.3, 6.0 Hz, 1H), 4.48 
(dd, J = 8.3, 5.3 Hz, 1H), 3.94 (d, J = 17.0 Hz, 1H), 3.88-3.81 (m, 2H), 3.76 (d, J = 17.0 Hz, 1H), 
3.68 (s, 3H), 3.20 (dd, J = 13.9, 6.0 Hz, 1H), 3.10 (dd, J = 13.8, 8.4 Hz, 1H), 2.26-2.22 (m, 1H), 
2.17-2.13 (m, 1H), 2.05-2.01 (m, 2H) ppm; 13C NMR (100 MHz, CD3OD): δ = 175.3, 173.3, 
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171.6, 167.5, 144.3, 138.2, 136.2, 131.1, 130.2, 129.9, 129.4, 129.2, 127.8, 119.3, 62.3, 55.4, 
52.7, 43.5, 43.1, 38.4, 30.5, 26.0 ppm. 
 
Analytical data of compound 102 
N
H
O H
N
N
H
H
N
O
O
O
F
F
 
 
Peptide 102 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 18 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 667.7 [M+H]+, 689.7 [M+Na]+; Rt = 
9.81 min. 
 
Analytical data of compound 103 
O
N
H
NO
O
N
H O
O
 
 
Peptide 103 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 19 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 502.4 [M+H]+, 524.5 [M+Na]+; Rt = 
8.47 min; 1H NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 15.4 Hz, 1H), 7.51-7.48 (m, 3H), 7.37-
7.36 (m, 3H), 7.23-7.28 (m, 2H), 7.13-7.12 (m, 2H), 6.71 (d, J = 15.4 Hz, 1H), 4.86 (dd, J = 6.5, 
6.1 Hz, 1H), 4.66 (q, J = 2.4 Hz, 1H), 4.63 (q, J = 2.4 Hz, 1H), 4.61-4.58 (m, 1H), 4.14 (dd, J = 
16.8, 7.1 Hz, 1H), 3.79-3.73 (m, 2H), 3.66 (dd, J = 16.6, 8.2 Hz, 1H), 3.20 (dd, J = 13.9, 5.9 Hz, 
1H), 3.10 (dd, J = 13.9, 6.5 Hz, 1H), 2.36-2.31 (m, 1H), 2.17-2.10 (m, 1H), 2.04-1.96 (m, 2H), 
1.84 (t, J = 2.4 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ = 172.0, 170.7, 169.0, 166.3, 
143.8, 135.8, 134.7, 130.0, 129.4, 128.8, 128.4, 128.0, 126.9, 117.4, 83.7, 72.6, 60.5, 53.5, 53.3, 
47.5, 43.1, 37.5, 27.8, 25.0, 3.6 ppm. 
 
Analytical data of compound 104 
N
H
O H
N
N
H
H
N
O
O
O
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Peptide 104 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 31 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 637.6 [M+H]+, 659.7 [M+Na]+; Rt = 
10.20 min; 13C NMR (100 MHz, CDCl3): δ =172.4, 170.9, 169.9, 165.9, 141.2, 136.4, 136.1, 
134.8, 129.7, 129.4, 129.3, 128.8, 128.4, 128.3, 128.2, 127.8, 126.7, 126.6, 54.2, 54.0, 51.7, 48.3, 
39.3, 39.1, 32.6, 32.4, 25.4, 24.9, 22.8, 22.5 ppm. 
 
Analytical data of compound 105 
O
N
H
NO
O
N
H O
H
N
F
F
 
 
Peptide 105 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 31 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 631.7 [M+H]+, 653.7 [M+Na]+; Rt = 
9.33 min; 1H NMR (400 MHz, CDCl3): δ = 7.74 (d, J = 15.4 Hz, 1H), 7.54-7.52 (m, 2H), 7.40-
7.39 (m, 2H), 7.28-7.12 (m, 5H), 6.90-6.82 (m, 3H), 6.73 (d, J = 15.4 Hz, 1H), 4.70 (dd, J = 
14.6, 7.7 Hz, 1H), 4.55 (dd, J = 14.3, 5.4 Hz, 1H), 4.46-4.39 (m, 2H), 4.20-4.11 (m, 3H), 3.75-
3.71 (m, 1H), 3.68-3.64 (m, 1H), 3.21 (dd, J = 14.1, 5.9 Hz, 1H), 3.13 (dd, J = 14.1, 7.5 Hz, 1H), 
2.05-1.97 (m, 3H), 1.89-1.83 (m, 1H), 1.53-1.44 (m, 2H), 1.37-1.32 (m, 1H), 0.84 (d, J = 6.24 
Hz, 3H), 0.77 (d, J = 6.03 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ = 172.1, 171.7, 170.7, 
166.7, 162.9 and 162.8 (d, C-F), 160.4 and 160.3 (d. C-F), 144.3, 136.8, 134.4, 130.3, 129.2, 
129.1, 128.9, 128.4, 128.0, 126.6, 117.0, 111.3, 111.0, 60.3, 53.8, 53.3, 47.6, 39.8, 37.3, 31.4, 
27.3, 24.9, 22.8, 21.4 ppm. 
 
Analytical data of compound 106 
N
H
O H
N
N
H
H
N
O
O
O
Cl
NO2
 
 
Peptide 106 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 17 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 711.3 [M+H]+, 732.7 [M+Na]+; Rt = 
10.43 min. 
 
Analytical data of compound 107 
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N
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Peptide 107 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 20 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 625.7[M+H]+, 647.6 [M+Na]+; Rt = 
10.15 min; 1H NMR (400 MHz, CDCl3): δ = 7.59 (d, J = 15.7 Hz, 1H), 7.51-7.49 (m, 1H), 7.33-
7.26 (m, 4H), 7.21-7.10 (m, 6H), 7.08-7.01 (m, 1H), 6.99-6.96 (m, 3H), 6.81 (d, J = 15.8 Hz, 
1H), 5.24-5.17 (m, 2H), 5.09-5.03 (m, 1H), 3.29-3.25 (m, 2H), 3.08-2.93 (m, 2H), 1.73-1.67 (m, 
2H), 1.47-1.39 (m, 1H), 1.29-1.23 (m, 2H), 0.93 (d, J = 5.91 Hz, 5H), 0.83-0.81 (m, 8H) ppm; 
13C NMR (100 MHz, CDCl3): δ = 172.2, 170.9, 170.6, 165.8, 140.8, 136.7, 136.1, 135.0, 129.5, 
129.4, 129.3, 128.7, 128.3, 128.3, 128.2, 127.8, 126.5, 121.5, 54.1, 53.8, 51.7, 42.5, 39.3, 39.0, 
38.0, 37.8, 25.6, 25.0, 22.9, 22.8, 22.5, 22.4 ppm. 
 
Analytical data of compound 108 
N
H
O H
N
N
H
O
O
O
O
 
 
Peptide 108 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 608.5 [M+H]+, 630.6 [M+Na]+; Rt = 
9.99 min; 1H NMR (400 MHz, CDCl3): δ = 7.61 (d, J = 15.6 Hz, 1H), 7.55-7.47 (m, 2H), 7.40-
7.37 (m, 3H), 7.24-7.14 (m, 8H), 7.04-7.00 (m, 2H), 6.34 (d, J = 15.6 Hz, 1H), 4.80 (dd, J = 
13.40, 5.92 Hz, 1H), 4.68-4.63 (m, 2H), 4.62-4.06 (m, 1H), 4.57-4.49 (m, 1H), 3.13-3.08 (m, 2H), 
3.05-3.00 (m, 2H), 1.87 (t, J = 2.4, 2.4 Hz, 3H), 1.64-1.58 (m, 2H), 0.91 (d, J = 3.8 Hz, 1H), 0.90 
(d, J = 3.8 Hz, 1H) ppm; 13C NMR (100 MHz, CDCl3): δ = 171.9, 170.2, 170.1, 165.9, 142.0, 
136.3, 135.4, 134.5, 129.9, 129.3, 129.3, 128.8, 128.6, 128.5, 127.8, 127.1, 126.9, 119.7, 83.9, 
72.5, 54.4, 53.6, 53.1, 51.7, 40.7, 37.9, 37.6, 24.7, 22.8, 22.0, 3.6 ppm. 
 
Analytical data of compound 109 
N
H
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Peptide 109 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 758.3 [M+H]+, 782.4 [M+Na]+; Rt = 
10.77 min; 1H NMR (400 MHz, CDCl3): δ = 7.57 (d, J = 15.3 Hz, 1H), 7.29-6.88 (m, 24H), 6.26 
(d, J = 15.4 Hz), 5.11 (s, 2H), 4.76-4.74 (m, 1H), 4.684.66 (m, 1H), 4.51-4.45 (m, 1H), 3.08-2.83 
(m, 6H) ppm. 
 
Analytical data of compound 110 
O
N
H
NO
O
N
H O
H
N
 
 
Peptide 110 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 34 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 575.7 [M+H]+, 597.7 [M+Na]+; Rt = 
9.57 min; 1H NMR (400 MHz, CDCl3): δ = 7.78 (d, J = 15.5 Hz, 1H), 7.60-7.50 (m, 2H), 7.44-
7.37 (m, 3H), 7.25-7.13 (m, 5H), 6.76 (d, J = 15.4 Hz, 1H), 4.68 (dt, J = 8.5, 8.5, 5.7 Hz, 1H), 
4.53 (dd, J = 7.8, 3.8 Hz, 1H), 4.20-4.10 (m, 1H), 3.86-3.76 (m, 1H), 3.76-3.67 (m, 1H), 3.38-
3.17 (m, 6H), 3.12 (dd, J = 14.09, 8.50 Hz, 1H), 2.29-2.14 (m, 1H), 2.14-1.99 (m, 3H), 1.65-1.42 
(m, 3H), 1.42-1.28 (m, 3H), 0.89 (d, J = 1.78 Hz, 3H), 0.87 (d, J = 1.81 Hz, 3H), 0.85 (d, J = 
6.37 Hz, 3H), 0.78 (d, J = 6.23 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ = 172.2, 171.6, 
170.9, 166.8, 144.5, 137.2, 134.4, 130.4, 129.1, 128.9, 128.4, 128.1, 126.6, 116.9, 60.7, 54.0, 
53.3, 47.6, 39.8, 38.0, 37.8, 37.3, 27.7, 25.6, 25.0, 24.9, 22.9, 22.4, 22.3, 21.4 ppm. 
 
Analytical data of compound 111 
O
N
H
NO
O
N
H O
O
 
 
Peptide 111 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 558.7 [M+H]+, 580.6 [M+Na]+; Rt = 
9.33 min; 1H NMR (400 MHz, CDCl3): δ = 7.74 (d, J = 15.5 Hz, 1H), 7.59-7.47 (m, 2H), 7.42-
7.36 (m, 3H), 7.31-7.27 (m, 2H), 7.26-7.15 (m, 3H), 6.74 (d, J = 15.4 Hz, 1H), 4.88 (dt, J = 7.8, 
6.0, 6.0 Hz, 1H), 4.70 (q, J = 2.5, 2.4, 2.4 Hz, 1H), 4.69-4.64 (m, 2H), 4.30 (ddd, J = 9.1, 7.5, 5.5 
Hz, 1H), 3.76-3.72 (m, 1H), 3.69-3.60 (m, 1H), 3.21 (dd, J = 13.9, 5.8 Hz, 1H), 3.11 (dd, J = 
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13.9, 6.7 Hz, 1H), 2.43-2.35 (m, 1H), 2.21-1.98 (m, 2H), 1.87 (t, J = 2.4, 2.4 Hz, 3H), 1.70-1.62 
(m, 1H), 1.60-1.42 (m, 2H), 0.86 (d, J = 6.4 Hz, 3H), 0.82 (d, J = 6.4 Hz, 3H) ppm; 13C NMR 
(100 MHz, CDCl3): δ = 171.6, 171.4, 170.7, 166.4, 143.6, 135.8, 134.7, 130.0, 129.4, 128.8, 
128.4, 128.0, 126.9, 117.5, 83.7, 72.6, 59.9, 53.6, 52.9, 52.1, 47.4, 40.0, 37.6, 27.0, 25.0, 24.8, 
22.8, 21.7, 3.6 ppm. 
 
Analytical data of compound 112 
O
N
H
NO
O
N
H O
OH
 
 
Peptide 112 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 506.6 [M+H]+, 528.7 [M+Na]+; Rt = 
8.07 min; 1H NMR (400 MHz, CDCl3): δ = 7.74 (d, J = 15.5 Hz, 1H), 7.58-7.48 (m, 2H), 7.42-
7.34 (m, 3H), 7.25-7.15 (m, 5H), 6.73 (d, J = 15.5 Hz, 1H), 4.79 (dd, J = 13.7, 6.2 Hz, 1H), 4.64-
4.61 (m, 1H), 4.41-4.23 (m, 1H), 3.70-3.60 (m, 2H), 3.23 (dd, J = 13.8, 5.1 Hz, 1H), 3.06 (dd, J 
= 13.9, 7.2 Hz, 1H), 2.40-2.21 (m, 1H), 2.21-2.03 (m, 2H), 1.61-1.40 (m,4H), 0.85 (d, J = 6.14 
Hz, 3H), 0.81 (d, J = 6.30 Hz, 3H) ppm. 
 
Analytical data of compound 113 
O
N
H
NO
O
N
H O
OMe
 
 
Peptide 113 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 520.8 [M+H]+, 542.6 [M+Na]+; Rt = 
8.80 min; 1H NMR (400 MHz, CDCl3): δ = 7.74 (d, J = 15.4 Hz, 1H), 7.60-7.50 (m, 2H), 7.44-
7.37 (m, 3H), 7.31-7.26 (m, 2H), 7.24-7.11 (m, 3H), 6.74 (d, J = 15.4 Hz, 1H), 4.84 (dd, J = 
13.7, 6.6 Hz, 1H), 4.67 (dd, J = 8.1, 2.1 Hz, 1H), 4.30 (ddd, J = 9.1, 7.5, 5.3 Hz, 1H), 3.79-3.72 
(m, 1H), 3.71 (s, 3H), 3.69-3.59 (m, 1H), 3.18 (dd, J = 13.95, 5.79 Hz, 1H), 3.08 (dd, J = 13.89, 
6.71 Hz, 1H), 2.46-2.30 (m, 1H), 2.21-1.80 (m, 4H), 1.74-1.61 (m, 1H), 1.60-1.40 (m, 1H), 0.86 
(d, J = 6.43 Hz, 3H), 0.82 (d, J = 6.42 Hz, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ = 171.8, 
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171.5, 171.4, 166.4, 143.6, 136.0, 134.7, 130.1, 129.2, 128.8, 128.4, 128.0, 126.9, 117.5, 59.9, 
53.4, 52.2, 52.1, 47.4, 39.9, 37.8, 27.0, 25.0, 24.8, 22.8, 21.7 ppm. 
 
Analytical data of compound 114 
O
N
H
NO
O
N
H O
O
 
 
Peptide 114 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 602.7 [M+H]+, 624.7 [M+Na]+; Rt = 
11.48 min; 1H NMR (400 MHz, CDCl3): δ = 7.70 (d, J = 15.4 Hz, 1H), 7.53-7.45 (m, 2H), 7.41-
7.32 (m, 3H), 7.25-7.16 (m, 3H), 7.13-7.07 (m, 2H), 6.71 (d, J = 15.4 Hz, 1H), 5.81 (ddt, J = 
16.9, 10.2, 6.7, 6.7 Hz, 1H), 4.99 (ddt, J = 17.0, 2.1, 1.5, 1.5 Hz, 1H), 4.93 (ddt, J = 10.2, 2.28, 
1.2, 1.2 Hz, 1H), 4.80 (dd, J = 6.5, 6.3 Hz, 1H), 4.61 (dd, J = 7.7, 3.5 Hz, 1H), 4.14 (dd, J = 16.9, 
7.8 Hz, 1H, Gly-α-H), 4.02 (dt, J = 6.7, 6.7, 2.8 Hz, 2H), 3.81-3.73 (m, 1H), 3.77 (dd, J = 16.8, 
5.2 Hz, 1H), 3.70-3.60 (m, 1H), 3.15 (dd, J = 13.8, 6.0 Hz, 1H), 3.09 (dd, J = 13.8, 6.4 Hz, 1H), 
2.09-1.93 (m, 2H), 1.60-1.45 (m, 2H), 1.44-1.33 (m, 2H), 1.33-1.18 (m, 14H) ppm; 13C NMR 
(100 MHz, CDCl3): δ = 171.9, 171.5, 168.8, 166.3, 143.6, 139.1, 136.0, 134.8, 130.0, 129.3, 
128.8, 128.4, 128.0, 126.8, 117.5, 114.1, 65.5, 60.5, 53.4, 47.5, 43.2, 37.8, 33.7, 29.4, 29.1, 29.0, 
28.9, 28.4, 27.7, 25.7, 25.7, 25.1 ppm. 
 
Analytical data of compound 115 
N
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Peptide 115 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 458.1 [M+H]+, 480.2 [M+Na]+; Rt = 
6.38 min. 
 
Analytical data of compound 116 
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Peptide 116 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 479.3 [M+H]+, 501.4 [M+Na]+; Rt = 
6.50 min 
 
Analytical data of compound 117 
N
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Peptide 117 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 527.5 [M+H]+, 549.5 [M+Na]+; Rt = 
7.47 min. 
 
Analytical data of compound 118 
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Peptide 118 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 550.1 [M+H]+, 572.2 [M+Na]+; Rt = 
9.61 min. 
 
Analytical data of compound 119 
N
H
H
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Peptide 119 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 472.2 [M+H]+, 494.4 [M+Na]+; Rt = 
6.83 min. 
 
Analytical data of compound 120 
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Peptide 120 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 397.9 [M+H]+; Rt = 5.43 min. 
 
Analytical data of compound 121 
O
N
H
NO
O
N
H O
H
N
 
 
Peptide 121 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 20 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 575.7 [M+H]+, 597.7 [M+Na]+; Rt = 
9.57 min. 
 
Analytical data of compound 122 
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Peptide 122 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 17 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 467.3 [M+H]+, 489.4 [M+Na]+; Rt = 
6.53 min. 
 
Analytical data of compound 123 
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Peptide 123 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 29 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 616.3 [M+H]+, 638.4 [M+Na]+; Rt = 
10.64 min.  
 
Analytical data of compound 124 
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Peptide 124 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 664.2 [M+H]+, 686.4 [M+Na]+; Rt = 
10.95 min. 
 
Analytical data of compound 125 
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Peptide 125 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 14 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 638.4 [M+Na]+; Rt = 10.32 min. 
 
Analytical data of compound 126 
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Peptide 126 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 554.1 [M+H]+, 576.3 [M+Na]+; Rt = 
9.09 min. 
 
Analytical data of compound 127 
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Peptide 127 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 602.0 [M+H]+, 624.3 [M+Na]+; Rt = 
9.79 min. 
 
Analytical data of compound 128 
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Peptide 128 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 30 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 553.4 [M+H]+, 575.4 [M+Na]+; Rt = 
8.79 min. 
 
Analytical data of compound 129 
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Peptide 129 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 29 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 560.2 [M+H]+, 582.2 [M+Na]+; Rt = 
9.12 min. 
 
Analytical data of compound 130 
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Peptide 130 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 498.1 [M+H]+, 520.2 [M+Na]+; Rt = 
7.74 min. 
 
Analytical data of compound 131 
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Peptide 131 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 25 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 512.2 [M+H]+, 534.3 [M+Na]+; Rt = 
8.37 min; 1H NMR (400 MHz, CD3OD): δ = 7.30-7.06 (m, 10H), 4.64 (dd, J = 9.3, 5.2 Hz, 1H), 
4.49 (dd, J = 8.7, 6.1 Hz, 1H), 4.43 (t, J = 5.4, 5.4 Hz, 1H), 3.77 (d, J = 5.4 Hz, 2H), 3.71 (s, 
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3H), 3.14 (dd, J = 13.9, 5.2 Hz, 1H), 2.87 (dd, J = 14.0, 9.3 Hz, 1H), 2.78 (dt, J = 7.4, 7.4, 1.7 
Hz, 2H), 2.45 (dt, J = 7.6, 7.6, 1.9, 2H), 1.82-1.52 (m, 3H), 0.96 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 
6.3 Hz, 3H) ppm; 13C NMR (100 MHz, CD3OD): δ = 175.3, 174.5, 173.7, 172.1, 142.1, 138.4, 
130.3, 129.5, 129.4, 129.3, 127.7, 127.1, 63.1, 56.6, 56.1, 52.7, 52.3, 41.5, 38.6, 32.7, 25.9, 23.3, 
21.9 ppm. 
 
Analytical data of compound 132 
N
H
O H
N
N
H
O
O
OH
O
O
Cl
 
 
Peptide 132 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 608.3 [M+H]+, 630.3 [M+Na]+; Rt = 
9.52 min; 1H NMR (400 MHz, CD3OD): δ = 7.85-7.77 (m, 2H), 7.73-7.62 (m, 4H), 7.50-7.42 (m, 
2H), 7.41-7.14 (m, 6H), 4.89 (dd, J = 9.5, 5.2 Hz, 1H), 4.58-4.46 (m, 2H), 4.44-4.29 (m, 2H), 
3.84 (d, J = 5.6 Hz, 2H), 3.76 (t, J = 5.5, 5.5 Hz, 2H), 3.10 (dd, J = 13.9, 9.4 Hz, 2H), 1.82-1.57 
(m, 3H), 0.96 (d, J = 6.4 Hz, 3H), 0.93 (d, J = 6.3 Hz, 3H) ppm; 13C NMR (100 MHz, 
CD3OD): δ = 173.9, 173.6, 172.2, 170.1, 145.9, 141.2, 138.6, 133.8, 130.4, 130.0, 129.5, 129.1, 
129.1, 128.1, 128.0, 127.8, 66.1, 63.1, 56.8, 56.7, 52.4, 42.6, 41.5, 38.5, 25.9, 23.2, 22.0 ppm. 
 
Analytical data of compound 133 
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Peptide 133 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 20 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 497.1 [M+H]+, 519.2 [M+Na]+; Rt = 
7.37 min. 
 
Analytical data of compound 134 
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Peptide 134 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 20 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 545.1 [M+H]+, 567.2 [M+Na]+; Rt = 
8.17 min. 
 
Analytical data of compound 135 
N
H
O H
N
N
H
O
O
O
O
O
 
 
Peptide 135 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 706.4 [M+H]+, 728.5 [M+Na]+; Rt = 
13.23 min. 
 
Analytical data of compound 136 
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Peptide 136 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 26 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 601.2 [M+H]+, 623.3 [M+Na]+; Rt = 
9.56 min. 
 
Analytical data of compound 137 
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Peptide 137 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 30 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 568.5 [M+H]+, 590.4 [M+Na]+; Rt = 
9.93 min. 
 
Analytical data of compound 138 
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Peptide 138 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 604.1 [M+H]+, 626.3 [M+Na]+; Rt = 
8.59 min. 
 
Analytical data of compound 139 
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Peptide 139 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 513.1 [M+H]+, 535.2 [M+Na]+; Rt = 
7.55 min; 1H NMR (400 MHz, CD3OD): δ = 7.60-7.53 (m, 2H), 7.47 (d, J = 15.8 Hz, 1H, Ph-
CH=), 7.31-7.25 (m, 5H), 7.15-7.08 (m, 2H), 6.58 (d, J = 15.9 Hz, 1H), 4.72 (dd, J = 9.0, 5.5 Hz, 
1H), 4.45-4.31 (m, 2H), 3.85 (dd, J = 10.7, 5.3 Hz, 1H), 3.72 (dd, J = 10.7, 6.3 Hz, 1H), 3.21 (dd, 
J = 14.0, 5.4 Hz, 1H), 2.99 (dd, J = 14.0, 9.0 Hz, 1H), 1.88-1.53 (m, 3H), 0.95 (d, J = 6.2 Hz, 
3H), 0.91 (d, J = 6.2 Hz, 3H) ppm; 13C NMR (100 MHz, CD3OD): δ = 177.7, 173.9, 172.4, 
168.6, 141.3, 138.3, 131.0, 130.9, 130.3, 129.5, 127.9, 121.1, 117.0, 116.7, 62.9, 56.8, 53.1, 41.5, 
38.6, 25.9, 23.7, 21.6 ppm. 
 
Analytical data of compound 140 
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Peptide 140 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 528.1 [M+H]+, 550.2 [M+Na]+; Rt = 
8.46 min; 1H NMR (400 MHz, CD3OD): δ = 7.64-7.51 (m, 2H), 7.46 (d, J = 15.8 Hz, 1H), 7.30-
7.16 (m, 5H), 7.15-7.07 (m, 2H), 6.57 (d, J = 15.8 Hz, 1H), 4.76 (dd, J = 9.1, 5.3 Hz, 1H), 4.54-
4.37 (m, 2H), 3.79 (d, J = 5.5 Hz, 2H), 3.70 (s, 3H), 3.23 (dd, J = 14.0, 5.3 Hz, 1H), 2.98 (dd, J = 
14.0, 9.1 Hz, 1H), 1.76-1.51 (m, 3H), 0.94 (d, J = 6.4 Hz, 3H), 0.91 (d, J = 6.3 Hz, 3H) ppm; 13C 
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NMR (100 MHz, CD3OD): δ = 174.5, 173.7, 172.2, 168.5, 141.2, 138.4, 131.0, 130.9, 130.3, 
129.5, 127.8, 121.1, 116.9, 116.7, 63.0, 56.8, 56.7, 56.5, 52.7, 41.6, 38.7, 25.9, 23.3, 21.9 ppm. 
 
Analytical data of compound 141 
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Peptide 141 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 596.2 [M+H]+, 618.2 [M+Na]+; Rt = 
8.55 min; 1H NMR (400 MHz, CD3OD): δ = 7.63-7.51 (m, 1H), 7.47 (d, J = 15.8 Hz, 1H), 7.44 
(d, J = 3.63 Hz, 1H), 7.29-7.15 (m, 6H), 7.15-7.06 (m, 2H), 6.57 (d, J = 15.7 Hz, 1H), 4.80-4.73 
(m, 1H), 4.70-4.63 (m, 1H), 4.46 (t, J = 5.8, 5.8 Hz, 1H), 3.87 (dd, J = 10.6, 5.6 Hz, 1H), 3.77 
(dd, J = 10.7, 6.1 Hz, 1H), 3.23 (dd, J = 14.0, 5.3 Hz, 1H), 2.99 (dd, J = 14.0, 9.1 Hz, 1H), 1.92-
1.55 (m, 3H), 0.99-0.92 (m, 6H) ppm; 13C NMR (100 MHz, CD3OD): δ = 173.9, 172.6, 172.5, 
168.5, 166.3, 159.9, 141.2, 138.3, 138.3, 131.0, 130.9, 130.3, 129.5, 127.8, 116.9, 116.7, 114.9, 
62.9, 56.6, 56.5, 53.3, 41.5, 38.7, 25.9, 23.5, 21.8 ppm. 
 
Analytical data of compound 142 
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Peptide 142 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 569.3 [M+H]+, 591.3 [M+Na]+; Rt = 
8.85 min. 
 
Analytical data of compound 143 
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Peptide 143 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 584.3 [M+H]+, 606.3 [M+Na]+; Rt = 
9.93 min. 
 
Analytical data of compound 144 
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Peptide 144 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 613.1 [M+H]+, 635.3 [M+Na]+; Rt = 
9.71 min. 
 
Analytical data of compound 145 
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Peptide 145 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 652.3 [M+H]+, 674.3 [M+Na]+; Rt = 
9.99 min. 
 
Analytical data of compound 146 
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Peptide 146 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 560.4 [M+H]+, 582.3 [M+Na]+; Rt = 
8.84 min. 
 
Analytical data of compound 147 
 
________________________________________________________________________ 
237 
N
H
O H
N
N
H
H
N
OH
O
O
H2N O
O
OH
 
 
Peptide 147 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 568.7 [M+H]+, 593.4 [M+Na]+; Rt = 
5.37 min. 
 
Analytical data of compound 148 
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Peptide 148 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 581.2 [M+H]+, 603.2 [M+Na]+; Rt = 
7.69 min. 
 
Analytical data of compound 149 
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Peptide 149 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3%; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 514.2 [M+H]+, 536.2 [M+Na]+; Rt = 
7.91 min; 1H NMR (400 MHz, CD3OD): δ = 7.60-7.53 (m, 2H), 7.46 (d, J = 16.0 Hz, 1H), 7.32-
7.17 (m, 6H), 7.15-7.07 (m, 1H), 6.57 (d, J = 15.8 Hz, 1H), 4.80-4.70 (m, 1H), 4.51-4.39 (m, 
2H), 3.79 (d, J = 5.1 Hz, 2H), 3.27-3.18 (m, 1H), 2.98 (dd, J = 13.9, 9.2 Hz, 1H), 1.89-1.48 (m, 
3H), 0.95 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 6.4 Hz, 3H) ppm. 
 
Analytical data of compound 150 
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Peptide 150 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 606.3 [M+H]+, 628.3 [M+Na]+; Rt = 
7.50 min. 
 
Analytical data of compound 151 
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Peptide 151 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 556.9 [M+H]+, 579.2 [M+Na]+; Rt = 
8.48 min; 1H NMR (400 MHz, CD3OD): δ = 7.60-7.52 (m, 2H), 7.46 (d, J = 15.8 Hz, 1H), 7.33-
7.15 (m, 6H), 7.15-7.07 (m, 1H), 6.56 (d, J = 15.8 Hz, 1H), 4.99-4.90 (m, 1H), 4.79 (dd, J = 9.4, 
5.2 Hz, 1H), 4.45 (t, J = 5.4, 5.4 Hz, 1H), 3.81 (s, 3H), 3.78 (t, J = 5.4, 5.4 Hz, 2H), 3.24 (dd, J = 
14.1, 5.1 Hz, 1H), 3.19 (s, 3H), 2.97 (dd, J = 14.1, 9.2 Hz, 1H2), 1.84-1.39 (m, 3H), 0.94 (d, J = 
6.6 Hz, 3H), 0.94 (d, J = 6.5 Hz, 3H) ppm; 13C NMR (100 MHz, CD3OD): δ = 173.7, 172.1, 
170.7, 168.4, 141.1, 138.5, 131.0, 130.9, 130.3, 129.5, 127.8, 121.2, 116.9, 116.7, 63.2, 62.0, 
56.6, 56.3, 49.7, 41.5, 38.8, 26.0, 23.7, 21.8 ppm. 
 
Analytical data of compound 152 
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Peptide 152 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 568.0 [M+H]+, 690.2 [M+Na]+; Rt = 
6.76 min. 
 
Analytical data of compound 153 
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Peptide 153 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 607.2 [M+H]+, 629.2 [M+Na]+; Rt = 
7.13 min. 
 
Analytical data of compound 154 
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Peptide 154 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 539.1 [M+H]+, 561.2 [M+Na]+; Rt = 
6.93 min. 
 
Analytical data of compound 155 
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Peptide 155 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 524.1 [M+H]+, 546.2 [M+Na]+; Rt = 
6.39 min. 
 
Analytical data of compound 156 
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Peptide 156 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 767.0 [M+H]+, 788.9 [M+Na]+; Rt = 
7.75 min. 
 
Analytical data of compound 157 
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Peptide 157 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 747.0 [M+H]+, 769.0 [M+Na]+; Rt = 
8.07 min. 
 
Analytical data of compound 158 
N
H
O H
N
N
H
O
OH
O
O
H2N O
O
OH
Br
Br
 
 
Peptide 158 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 757.1 [M+H]+, 779.0 [M+Na]+; Rt = 
7.38 min. 
 
Analytical data of compound 159 
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Peptide 159 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 593.4 [M+H]+, 615.3 [M+Na]+; Rt = 
7.89 min. 
 
Analytical data of compound 160 
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Peptide 160 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 570.0 [M+H]+, 592.3 [M+Na]+; Rt = 
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9.11 min; 1H NMR (400 MHz, CD3OD): δ = 7.58-7.53 (m, 2H), 7.48 (d, J = 15.7 Hz, 1H), 7.33-
7.16 (m, 6H), 7.15-7.08 (m, 1H), 6.57 (d, J = 15.7 Hz, 1H), 4.80-4.76 (m, 1H), 4.52-4.41 (m, 
2H), 3.71 (dd, J = 9.0, 4.4 Hz, 1H), 3.55 (dd, J = 8.8, 5.4 Hz, 1H), 3.28-3.23 (m, 1H), 2.98 (dd, J 
= 14.2, 9.5 Hz, 1H), 1.88-1.46 (m, 3H), 1.15 (s, 9H), 0.94 (d, J = 6.33 Hz, 3H), 0.92 (d, J = 6.27 
Hz, 3H) ppm. 
 
Analytical data of compound 161 
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Peptide 161 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 652.2 [M+H]+, 674.3 [M+Na]+; Rt = 
8.03 min. 
 
Analytical data of compound 162 
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Peptide 162 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 679.1 [M+H]+, 703.2 [M+Na]+; Rt = 
7.77 min. 
 
Analytical data of compound 163 
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Peptide 163 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 525.0 [M+H]+, 547.2 [M+Na]+; Rt = 
6.64 min. 
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Analytical data of compound 164 
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Peptide 164 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 587.3 [M+H]+, 609.3 [M+Na]+; Rt = 
7.39 min. 
 
Analytical data of compound 165 
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Peptide 165 was synthesized and released from solid support according to GP 2 and GP 3. = 4 %; 
Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 525.2 [M+H]+, 547.2 [M+Na]+; Rt = 7.34 min; 
1H NMR (400 MHz, CD3OD): δ = 7.65-6.77 (m, 10H), 4.62 (dd, J = 9.9, 4.9 Hz, 1H), 4.40 (dd, J 
= 9.5, 4.6 Hz, 1H), 4.17 (d, J = 7.1 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 3.24 (dd, J = 14.0, 4.8 Hz, 
1H), 2.92-2.81 (m, 3H), 2.54-2.42 (m, 2H), 2.34-2.28 (m, 2H), 2.27-2.16 (m, 1H), 2.06-1.92 (m, 
1H), 1.26 (t, J = 7.1 Hz, 3H), 1.06 (d, J = 7.1 Hz, 3H) ppm; 13C NMR (100 MHz, 
CD3OD): δ = 177.6, 175.2, 175.1, 173.5, 172.8, 142.3, 138.5, 130.3, 129.5, 129.4, 129.3, 127.7, 
127.2, 62.4, 55.6, 53.5, 50.7, 38.4, 38.2, 32.6, 32.5, 28.3, 17.5, 14.5 ppm. 
 
Analytical data of compound 166 
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Peptide 166 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 565.3 [M+H]+, 587.3 [M+Na]+; Rt = 
8.03 min; 1H NMR (400 MHz, CD3OD): δ = 7.58-6.91 (m, 10H), 5.90-5.69 (m, 1H), 5.19-4.92 
(m, 2H), 4.62 (dd, J = 10.5, 4.6 Hz, 1H), 4.41 (dd, J = 9.6, 4.5 Hz, 1H), 4.20-4.07 (m, 3H), 2.98-
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2.77 (m, 3H), 2.48 (d, J = 8.31 Hz, 2H), 2.36-2.26 (m, 2H), 2.28-2.17 (m, 1H), 2.17-2.08 (m, 
2H), 2.06-1.95 (m, 1H), 1.77-1.69 (m, 2H), 1.05 (d, J = 6.9 Hz, 3H) ppm. 
 
Analytical data of compound 167 
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Peptide 167 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 540.3 [M+H]+, 562.3 [M+Na]+; Rt = 
6.86 min; 1H NMR (400 MHz, CD3OD): δ = 7.65-6.74 (m, 10H), 4.61 (dd, J = 9.8, 5.0 Hz, 1H), 
4.20 (q, J = 7.3 Hz, 1H), 3.80 (s, 3H), 3.27-3.11 (m, 4H), 2.95-2.81 (m, 3H), 2.52-2.44 (m, 2H), 
2.34-2.27 (m, 2H), 2.15-2.05 (m, 1H), 1.97-1.85 (m, 1H), 1.07 (d, J = 7.2 Hz, 3H) ppm; 13C 
NMR (100 MHz, CD3OD): δ = 177.7, 177.1, 177.1, 175.1, 173.3, 142.3, 138.5, 130.4, 129.5, 
129.4, 129.4, 127.7, 127.2, 60.8, 55.6, 50.6, 50.5, 38.5, 38.2, 32.7, 32.6, 28.4, 24.2, 17.7 ppm. 
 
Analytical data of compound 168 
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Peptide 168 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 579.2 [M+H]+, 601.2 [M+Na]+; Rt = 
7.25 min; 1H NMR (400 MHz, CD3OD): δ =  7.44 (d, J = 3.6 Hz, 1H), 7.30-7.09 (m, 11H), 4.72-
4.50 (m, 2H), 4.19 (q, J = 7.2 Hz, 1H), 3.25 (dd, J = 14.0, 5.0 Hz, 1H), 2.92 (dd, J = 14.1, 9.8 
Hz, 1H), 2.87-2.78 (m, 2H), 2.52-2.44 (m, 2H), 2.35 (t, J = 7.37 Hz, 2H), 2.29-2.17 (m, 1H), 
2.14-2.03 (m, 1H), 1.10 (d, J = 7.1 Hz, 3H) ppm; 13C NMR (100 MHz, CD3OD): δ = 177.6, 
175.7, 175.3, 173.7, 171.2, 160.3, 142.2, 138.4, 138.3, 137.7, 130.3, 129.4, 129.4, 129.3, 127.8, 
127.1, 56.0, 54.3, 50.9, 38.3, 38.0, 32.6, 32.5, 24.2, 17.4 ppm. 
 
Analytical data of compound 169 
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Peptide 169 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 840.9 [M+H]+, 860.9 [M+Na]+; Rt = 
8.44 min. 
 
Analytical data of compound 170 
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Peptide 170 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 727.8 [M+H]+, 750.0 [M+Na]+; Rt = 
7.49 min. 
 
Analytical data of compound 171 
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Peptide 171 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 812.0 [M+H]+, 834.0 [M+Na]+; Rt = 
8.65 min. 
 
Analytical data of compound 172 
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Peptide 172 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 553.2 [M+H]+, 575.2 [M+Na]+; Rt = 
7.89 min. 
 
Analytical data of compound 173 
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Peptide 173 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 578.3 [M+H]+, 600.4 [M+Na]+; Rt = 
7.69 min. 
 
Analytical data of compound 174 
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Peptide 174 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 497.1 [M+H]+, 519.2 [M+Na]+; Rt = 
6.75 min; 1H NMR (400 MHz, CD3OD): δ = 7.37-7.00 (m, 10H), 4.62 (dd, J = 10.0, 4.7 Hz, 1H), 
4.41 (dd, J = 9.4, 4.3 Hz, 1H), 4.17 (q, J = 7.2 Hz, 1H), 3.24 (dd, J = 14.0, 4.7 Hz, 1H), 2.88 (dd, 
J = 14.0, 8.8 Hz, 1H), 2.88-2.82 (m, 2H), 2.47 (dd, J = 8.6, 6.7 Hz, 2H), 2.31 (t, J = 7.35 Hz, 
2H), 2.29-2.18 (m, 1H), 2.07-1.92 (m, 1H), 1.05 (d, J = 7.2 Hz, 3H) ppm; 13C NMR (100 MHz, 
CD3OD): δ = 177.8, 175.2, 175.1, 174.4, 173.5, 142.3, 138.5, 130.4, 129.4, 129.4, 129.4, 127.7, 
127.1, 55.6, 53.3, 50.7, 38.4, 38.2, 32.6, 28.5, 24.2, 17.6 ppm. 
 
Analytical data of compound 175 
O
N
H
NO
O
N
H O
H
N
 
 
 
________________________________________________________________________ 
246 
Peptide 175 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 12 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 587.8 [M+H]+, 609.7 [M+Na]+; Rt = 
9.65 min. 
 
Analytical data of compound 176 
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Peptide 176 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 624.3 [M+H]+, 646.2 [M+Na]+; Rt = 
8.28 min; 1H NMR (400 MHz, CD3OD): δ = 7.94 (dd, J = 6.8, 2.7 Hz, 1H), 7.61-7.51 (m, 1H), 
7.32-7.02 (m, 11H), 4.55 (dd, J = 10.0, 4.6 Hz, 1H), 4.46 (dd, J = 9.8, 4.4 Hz, 1H), 4.17 (q, J = 
7.1 Hz, 1H), 3.30-3.19 (m, 1H), 2.96 (dd, J = 14.2, 9.9 Hz, 1H), 2.86-2.71 (m, 2H), 2.50-2.22 (m, 
5H), 2.20-2.08 (m, 1H), 1.14 (d, J = 7.1 Hz, 3H) ppm; 13C NMR (100 MHz, CD3OD): δ = 177.7, 
176.6, 175.3, 173.8, 171.0, 144.2, 142.2, 138.5, 130.2, 129.5, 129.4, 129.2, 127.9, 127.1, 123.2, 
121.4, 121.3, 117.6, 117.4, 56.8, 55.1, 51.0, 38.1, 35.4, 32.8, 32.4, 28.5, 17.1 ppm. 
 
Analytical data of compound 177 
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Peptide 177 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 9 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 539.2 [M+H]+, 561.3 [M+Na]+; Rt = 
7.65 min. 
 
Analytical data of compound 178 
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Peptide 178 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 540.5 [M+H]+; Rt = 5.42 min. 
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Analytical data of compound 179 
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Peptide 179 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 651.3 [M+H]+, 673.2 [M+Na]+; Rt = 
7.96 min. 
 
Analytical data of compound 180 
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Peptide 180 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 513.2 [M+H]+, 535.2 [M+Na]+; Rt = 
6.78 min. 
 
Analytical data of compound 181 
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Peptide 181 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 499.0 [M+H]+, 521.2 [M+Na]+; Rt = 
6.55 min; 1H NMR (400 MHz, CD3OD): δ =  7.98 (d, J = 8.2 Hz, 2H), 7.76 (d, J = 8.2 Hz, 2H), 
7.68 (d, J = 7.4 Hz, 2H), 7.47 (t, J = 7.5, 7.5 Hz, 2H), 7.39 (t, J = 7.2, 7.2 Hz, 1H), 4.63 (d, J = 
4.2 Hz, 1H), 4.50-4.36 (m, 2H), 4.36-4.27 (m, 1H), 2.46-2.28 (m, 2H), 2.28-2.19 (m, 1H), 2.01-
1.87 (m, 1H), 1.43 (d, J = 7.1 Hz, 3H), 1.29 (d, J = 6.3 Hz, 3H); 13C NMR (100 MHz, 
CD3OD): δ = 174.9, 172.6, 172.6, 169.4, 167.5, 146.0, 141.2, 133.7, 130.0, 129.1, 129.1, 128.1, 
128.1, 68.8, 60.5, 53.2, 50.6, 32.7, 28.7, 20.2, 17.6 ppm. 
 
Analytical data of compound 182 
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Peptide 182 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 542.0 [M+H]+, 564.2 [M+Na]+; Rt = 
6.65 min. 
 
Analytical data of compound 183 
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Peptide 183 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 498.1 [M+H]+, 520.2 [M+Na]+; Rt = 
6.39 min; 1H NMR (400 MHz, CD3OD): δ = 7.99 (d, J = 8.2 Hz, 2H), 7.76 (d, J = 8.2 Hz, 2H), 
7.68 (dd, J = 8.4, 1.1 Hz, 2H), 7.47 (t, J = 7.7 Hz, 2H), 7.40 (d, J = 7.5 Hz, 1H), 4.63 (d, J = 4.1 
Hz, 1H), 4.40-4.26 (m, 3H), 2.45-2.25 (m, 2H), 2.22-2.10 (m, 1H), 2.02-1.89 (m, 1H), 1.43 (d, J 
= 7.21 Hz, 3H), 1.30 (d, J = 6.39 Hz, 3H); 13C NMR (100 MHz, CD3OD): δ = 177.8, 176.3, 
175.0, 173.1, 170.1, 146.1, 141.2, 133.7, 130.0, 129.1, 129.1, 128.1, 128.1, 68.9, 60.6, 54.1, 51.2, 
32.7, 28.9, 20.3, 17.3 ppm. 
 
Analytical data of compound 184 
N
H
O H
N
N
HO
OH
O
H2N O
O
H
N
NH2
 
 
Peptide 184 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 513.2 [M+H]+, 535.3 [M+Na]+; Rt = 
6.07 min. 
 
Analytical data of compound 185 
 
________________________________________________________________________ 
249 
N
H
O H
N
N
H
O
O
OH
O
H2N O
O
OH
 
 
Peptide 185 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 571.1 [M+H]+, 593.3 [M+Na]+; Rt = 
6.63 min. 
 
Analytical data of compound 186 
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Peptide 186 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 25 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 612.1 [M+H]+, 634.3 [M+Na]+; Rt = 
8.15 min; 1H NMR (400 MHz, DMSO-D6): Major isomer δ = 8.65 (dd, J = 8.4, 3.6 Hz, 1H), 8.22 
(d, J = 8.8 Hz, 1H), 7.90 (d, J = 5.4 Hz, 1H), 7.88 (d, J = 5.4 Hz, 1H), 7.78-7.69 (m, 5H), 7.49 (t, 
J = 7.5 Hz, 2H), 7.43-7.37 (m, 3H), 7.25 (t, J = 7.52 Hz, 2H), 4.89-4.81 (m, 1H), 4.28-4.23 (m, 
1H), 4.21-4.16 (m, 1H), 3.11 (dd, J = 13.6, 4.7 Hz, 1H), 3.01 (dd, J = 13.5, 10.7 Hz, 1H), 2.05-
1.79 (m, 4H), 1.79-1.68 (m, 1H), 1.21 (d, J = 6.8 Hz, 3H), 0.82 (d, J = 6.4 Hz, 3H), 0.80 (d, J = 
6.5 Hz, 3H) ppm; HRMS (ESI) m/z calc. for C35H41N5O5 611.3108, found 612.3179 [M+H]+. 
 
Analytical data of compound 187 
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Peptide 187 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 581.1 [M+H]+, 603.1 [M+Na]+; Rt = 
7.09 min. 
 
Analytical data of compound 188 
 
________________________________________________________________________ 
250 
N
H
O H
N
N
H
O
O
OH
O
H2N O
O
 
 
Peptide 188 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 567.2 [M+H]+, 589.2 [M+Na]+; Rt = 
7.68 min. 
 
Analytical data of compound 189 
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Peptide 189 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 626.2 [M+H]+, 648.2 [M+Na]+; Rt = 
7.99 min. 
 
Analytical data of compound 190 
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Peptide 190 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 589.2 [M+H]+, 611.2 [M+Na]+; Rt = 
7.18 min. 
 
Analytical data of compound 192 
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Peptide 192 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 70% (LC_MS); LC-MS (C18, ESI_MS) 653.0 [M+H]+, 675.1 [M+Na]+; Rt = 
7.67 min. 
 
Analytical data of compound 193 
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Peptide 193 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 479.3 [M+H]+, 501.4 [M+Na]+; Rt = 
6.79 min. 
 
Analytical data of compound 194 
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Peptide 194 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 517.8 [M+H]+, 540.1 [M+Na]+; Rt = 
1.32 min. 
 
Analytical data of compound 195 
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Peptide 195 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 25 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 610.4 [M+H]+; Rt = 4.52 min. 
 
Analytical data of compound 196 
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Peptide 196 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 503.3 [M+H]+; Rt = 2.23 min. 
 
Analytical data of compound 197 
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Peptide 197 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 614.3 [M+H]+, 636.4 [M+Na]+; Rt = 
4.07 min. 
 
Analytical data of compound 198 
N
H
O H
N
NH2
O
N
H
N
NH
O
HO
H
N
O
F
F
 
 
Peptide 198 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 614.3 [M+H]+, 636.3 [M+Na]+; Rt = 
4.46 min. 
 
Analytical data of compound 199 
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Peptide 199 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 561.5 [M+H]+, 583.4 [M+Na]+; Rt = 
7.27 min. 
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Peptide 200 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 584.6 [M+H]+, 606.7 [M+Na]+; Rt = 
4.18 min. 
 
Analytical data of compound 201 
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Peptide 201 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 522.3 [M+H]+, 544.4 [M+Na]+; Rt = 
6.87 min. 
 
Analytical data of compound 202 
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Peptide 202 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 493.4 [M+H]+, 515.4 [M+Na]+; Rt = 
7.03 min. 
 
Analytical data of compound 203 
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Peptide 203 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 551.4 [M+H]+, 573.4 [M+Na]+; Rt = 
6.85 min. 
 
Analytical data of compound 204 
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Peptide 204 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 633.3 [M+H]+, 657.2 [M+Na]+; Rt = 
7.92 min. 
 
Analytical data of compound 205 
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Peptide 205 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 569.2 [M+H]+, 591.4 [M+Na]+; Rt = 
7.45 min. 
 
Analytical data of compound 206 
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Peptide 206 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 539.4 [M+H]+, 561.4 [M+Na]+; Rt = 
7.35 min. 
 
Analytical data of compound 207 
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Peptide 207 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 70% (LC_MS); LC-MS (C18, ESI_MS) 541.4 [M+H]+, 563.5 [M+Na]+; Rt = 
7.46 min. 
 
Analytical data of compound 208 
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Peptide 208 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 553.4 [M+H]+, 575.4 [M+Na]+; Rt = 
8.37 min. 
 
Analytical data of compound 209 
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Peptide 209 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 538.3 [M+H]+, 560.3 [M+Na]+; Rt = 
9.70 min. 
 
Analytical data of compound 210 
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Peptide 210 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 693.5 [M+H]+, 715.4 [M+Na]+; Rt = 
11.91 min. 
 
Analytical data of compound 211 
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Peptide 211 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 611.5 [M+H]+, 633.4 [M+Na]+; Rt = 
10.37 min. 
 
Analytical data of compound 212 
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Peptide 212 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 582.3 [M+H]+, 604.4 [M+Na]+; Rt = 
10.44 min. 
 
Analytical data of compound 213 
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Peptide 213 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 611.4 [M+H]+, 633.4 [M+Na]+; Rt = 
7.87 min. 
 
Analytical data of compound 214 
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Peptide 214 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 608.3 [M+H]+, 630.4 [M+Na]+; Rt = 
7.96 min. 
 
Analytical data of compound 215 
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Peptide 215 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 664.4 [M+H]+, 686.4 [M+Na]+; Rt = 
10.71 min. 
 
Analytical data of compound 216 
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Peptide 216 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 606.5 [M+H]+, 628.5 [M+Na]+; Rt = 
11.03 min. 
 
Analytical data of compound 217 
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Peptide 217 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 601.6 [M+H]+, 623.5 [M+Na]+; Rt = 
11.55 min. 
 
Analytical data of compound 218 
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Peptide 218 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 70% (LC_MS); LC-MS (C18, ESI_MS) 553.4 [M+H]+, 575.5 [M+Na]+; Rt = 
9.30 min. 
 
Analytical data of compound 219 
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Peptide 219 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 623.5 [M+H]+, 645.3 [M+Na]+; Rt = 
6.30 min. 
 
Analytical data of compound 220 
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Peptide 220 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 564.2 [M+H]+, 586.3 [M+Na]+; Rt = 
6.64 min. 
 
Analytical data of compound 221 
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Peptide 221 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 75% (LC_MS); LC-MS (C18, ESI_MS) 539.3 [M+H]+, 561.3 [M+Na]+; Rt = 
4.90 min. 
 
Analytical data of compound 222 
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Peptide 222 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 564.4 [M+H]+, 586.4 [M+Na]+; Rt = 
5.65 min. 
 
Analytical data of compound 223 
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Peptide 223 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 550.2 [M+H]+, 572.3 [M+Na]+; Rt = 
6.27 min. 
 
Analytical data of compound 224 
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Peptide 224 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 622.0 [M+H]+, 644.2 [M+Na]+; Rt = 
6.09 min. 
 
Analytical data of compound 225 
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Peptide 225 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 510.4 [M+H]+, 532.4 [M+Na]+; Rt = 
5.47 min. 
 
Analytical data of compound 226 
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Peptide 226 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 34 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 496.4 [M+H]+, 518.4 [M+Na]+; Rt = 
5.15 min. 
 
Analytical data of compound 227 
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Peptide 227 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 30 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 496.4 [M+H]+, 518.4 [M+Na]+; Rt = 
5.15 min. 
 
Analytical data of compound 228 
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Peptide 228 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 554.4 [M+H]+; Rt = 5.76 min. 
 
Analytical data of compound 229 
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Peptide 229 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 495.4 [M+H]+, 517.4 [M+Na]+; Rt = 
4.54 min. 
 
Analytical data of compound 230 
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Peptide 230 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 592.2 [M+H]+; Rt = 7.14 min. 
 
Analytical data of compound 231 
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Peptide 231 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 549.0 [M+H]+, 571.3 [M+Na]+; Rt = 
5.86 min. 
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Analytical data of compound 232 
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Peptide 232 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 540.4 [M+H]+; Rt = 5.08 min. 
 
Analytical data of compound 233 
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Peptide 233 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 677.0 [M+H]+, 699.2 [M+Na]+; Rt = 
7.88 min. 
 
Analytical data of compound 234 
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Peptide 234 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 631.2 [M+H]+, 653.3 [M+Na]+; Rt = 
7.30 min. 
 
Analytical data of compound 235 
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Peptide 235 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 702.4 [M+H]+, 724.4 [M+Na]+; Rt = 
10.05 min. 
  
Analytical data of compound 236 
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Peptide 236 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 665.5 [M+H]+, 687.5 [M+Na]+; Rt = 
10.10 min. 
 
Analytical data of compound 237 
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Peptide 237 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 12 %; Purity > 70% (LC_MS);  LC-MS (C18, ESI_MS) 527.2 [M+H]+, 549.3 [M+Na]+; Rt = 
6.16 min. 
 
Analytical data of compound 238 
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Peptide 238 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 594.3 [M+H]+, 616.3 [M+Na]+; Rt = 
7.56 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.01 (d, J = 7.7 Hz, 1H), 7.96 (d, J = 8.2 Hz, 
1H), 7.93 (d, J = 7.4 Hz, 1H), 7.61 (d, J = 7.8 Hz, 1H), 7.29-7.13 (m, 10H), 6.74 (s, 1H), 5.02 (t, 
J = 5.60 Hz, 1H), 4.48 (dt, J = 8.6, 4.69 Hz, 1H), 4.28 (q, J = 6.3 Hz, 1H), 4.17 (dt, J =  8.3, 5.7 
Hz, 1H), 3.48 (t, J = 5.30 Hz, 2H), 3.06 (dd, J = 14.0, 4.4 Hz, 1H), 2.84 (dd, J = 13.9, 8.9 Hz, 
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1H), 2.80-2.74 (m, 2H), 2.45-2.39 (m, 2H), 2.09-1.98 (m, 2H), 1.92-1.78 (m, 1H), 1.79-1.60 (m, 
5H), 1.59-1.48 (m, 1H), 1.34-1.04 (m, 5H) ppm; HRMS (ESI) m/z calc. for C32H43N5O6 
593.3213, found 594.3286 [M+H]+. 
 
Analytical data of compound 239 
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Peptide 239 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 9 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 527.2 [M+H]+, 549.3 [M+Na]+; Rt = 
6.93 min. 
 
Analytical data of compound 240 
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Peptide 240 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 15 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 588.3 [M+H]+, 610.3 [M+Na]+; Rt = 
7.59 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.87 (s, 1H), 8.19 (d, J = 7.7 Hz, 1H), 8.02 (d, J 
= 7.8 Hz, 1H), 7.96 (d, J = 7.6 Hz, 1H), 7.62 (dd, J = 8.6, 1.1 Hz, 2H), 7.35-7.12 (m, 15H), 7.09-
7.04 (m, 1H), 6.79 (s, 1H), 5.01 (t, J = 5.4 Hz, 1H), 4.54 (dt, J = 8.6, 4.3 Hz, 1H), 4.36 (dt, J = 
8.0, 5.6 Hz, 1H), 4.30 (q, J = 6.1 Hz, 1H), 3.50 (t, J = 5.6 Hz, 2H), 3.10 (dd, J = 14.0, 4.4 Hz, 
1H), 2.86 (dd, J = 13.9, 9.0 Hz, 1H), 2.80-2.75 (m, 2H), 2.47-2.38 (m, 2H), 2.18-2.10 (m, 2H), 
2.03-1.92 (m, 1H), 1.91-1.79 (m, 1H) ppm; HRMS (ESI) m/z calc. for C32H37N5O6 587.2744, 
found 588.2814 [M+H]+. 
 
Analytical data of compound 241 
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Peptide 241 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 14 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 606.2 [M+H]+, 628.3 [M+Na]+; Rt = 
7.69 min; 1H NMR (400 MHz, CD3OD): δ = 9.93 (s, 1H), 8.20 (d, J = 7.6 Hz, 1H), 8.02 (d, J = 
8.0 Hz, 1H), 7.97 (s, 1H), 7.95 (s, 2H), 7.64 (dd, J = 9.1, 5.0 Hz, 2H), 7.34-7.07 (m, 12H), 6.79 
(s, 1H), 5.01 (t, J = 5.5 Hz, 1H), 4.53 (dt, J = 8.4, 8.2, 4.5 Hz, 1H), 4.40-4.21 (m, 2H), 3.50 (t, J 
= 5.8 Hz, 2H), 3.09 (dd, J = 13.8, 4.4 Hz, 1H), 2.88-2.82 (m, 1H), 2.77 (t, J = 8.0 Hz, 2H), 2.46-
2.38 (m, 2H), 2.23-2.05 (m, 2H), 2.04-1.91 (m, 1H), 1.91-1.78 (m, 1H) ppm; 13C NMR (100 
MHz, CD3OD): δ = 173.3, 171.6, 170.6, 170.2, 169.7, 141.1, 137.4, 129.1, 128.1, 128.0, 127.8, 
126.1, 125.7, 121.0, 120.9, 115.2, 115.0, 61.5, 54.9, 53.8, 53.1, 36.5, 35.6, 31.2, 30.8, 27.5 ppm; 
19F NMR (188 MHz, CD3OD): δ = -119.4, -119.5, -119.5, -119.5, -119.5, -119.6, -119.6 ppm; 
HRMS (FAB, m-NBA) m/z calc. for C32H36FN5O6 605.2650, found 606.2750 [M+H]+. 
 
Analytical data of compound 242 
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Peptide 242 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 513.3 [M+H]+, 535.2 [M+Na]+; Rt = 
6.61 min. 
 
Analytical data of compound 243 
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Peptide 243 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 602.3 [M+H]+, 624.4 [M+Na]+; Rt = 
7.52 min; 1H NMR (400 MHz, DMSO-D6); δ = 8.22 (t, J = 6.0 Hz, 1H), 8.07 (d, J = 7.9 Hz, 1H), 
8.01 (d, J = 7.9 Hz, 1H), 7.90 (d, J = 7.6 Hz, 1H), 7.34-7.09 (m, 15H), 6.74 (s, 1H), 4.98 (t, J = 
5.4 Hz, 1H), 4.50 (dt, J = 8.6, 4.6 Hz, 1H), 4.32-4.18 (m, 4H), 3.45 (t, J = 5.9 Hz, 2H), 3.06 (dd, 
J = 14.1, 4.5 Hz, 1H), 2.82 (dd, J = 14.0, 9.1 Hz, 1H), 2.78-2.72 (m, 2H), 2.40 (dt, J = 7.5, 1.7 
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Hz, 2H), 2.10-2.04 (m, 2H), 1.97-1.85 (m, 1H), 1.80-1.69 (m, 1H) ppm; HRMS (ESI) m/z calc. 
for C33H39N5O6 601.2900, found 602.2973 [M+H]+. 
 
Analytical data of compound 244 
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Peptide 244 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 624.4 [M+H]+, 646.5 [M+Na]+; Rt = 
7.69 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.71 (s, 1H), 8.25 (d, J = 7.7 Hz, 1H), 7.98 (d, J 
= 8.0 Hz, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.79 (dt, J = 9.0, 6.3 Hz, 1H), 7.37-7.13 (m, 13H), 7.08 
(t, J =  8.8 Hz, 1H), 6.80 (s, 1H), 4.96 (t, J = 5.45 Hz, 1H), 4.55 (dt, J = 8.6, 4.7 Hz, 1H), 4.47 
(td, J = 8.1, 5.6 Hz, 1H), 4.29 (q, J =  6.1 Hz, 1H), 3.48 (t, J = 5.7 Hz, 2H), 3.09 (dd, J = 13.8, 
4.3 Hz, 1H), 2.84 (dd, J = 13.9, 9.0 Hz, 1H), 2.80-2.75 (m, 2H), 2.42 (dt, J =7.3, 1.5 Hz, 2H), 
2.16 (td, J = 9.4, 6.3 Hz, 2H), 2.05-1.91 (m, 1H), 1.91-1.78 (m, 1H) ppm; HRMS (ESI) m/z calc. 
for C32H35F2N5O6 623.2555, found 624.2628 [M+H]+. 
 
Analytical data of compound 245 
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Peptide 245 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 15 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 512.2 [M+H]+, 534.2 [M+Na]+; Rt = 
6.40 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.07 (d, J = 7.7 Hz, 1H), 7.95 (d, J = 2.9 Hz, 
1H), 7.93 (d, J = 2.4 Hz, 1H), 7.33-7.12 (m, 10H), 7.09 (d, J = 7.0 Hz, 2H), 6.75 (s, 1H), 4.48 
(dt, J = 9.3, 4.8 Hz, 1H), 4.29 (q, J = 6.32 Hz, 1H), 4.14 (dt, J = 8.6, 5.2 Hz, 1H), 3.48 (dd, J = 
5.9, 3.4 Hz, 2H), 3.08 (dd, J = 13.9, 4.4 Hz, 1H), 2.85 (dd, J = 14.0, 9.3 Hz, 1H), 2.80-2.74 (m, 
2H), 2.42 (dt, J = 7.4, 1.8 Hz, 2H), 2.07 (t, J = 8.14 Hz, 2H), 1.96-1.85 (m, 1H), 1.79-1.65 (m, 
1H) ppm; HRMS (ESI) m/z calc. for C26H33N5O6 511.2431, found 512.2503 [M+H]+. 
 
Analytical data of compound 246 
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Peptide 246 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 618.3 [M+H]+, 640.3 [M+Na]+; Rt = 
7.52 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.72 (s, 1H), 8.16 (d, J = 7.7 Hz, 1H), 8.02 (d, J 
= 7.8 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.52 (d, J = 9.1 Hz, 2H), 7.30-7.11 (m, 10H), 6.89 (d, J 
= 9.1 Hz, 2H), 6.78 (s, 1H), 5.01 (t, J = 5.0 Hz, 1H), 4.53 (dt, J =  8.8, 4.26 Hz, 1H), 4.37-4.25 
(m, 2H), 3.72 (s, 3H), 3.50 (t, J = 5.6 Hz, 2H), 3.09 (dd, J = 14.0, 4.4 Hz, 1H), 2.88-2.83 (m, 
1H), 2.78 (t, J = 7.5 Hz, 2H), 2.43 (dd, J = 8.8, 5.9 Hz, 2H), 2.16-2.09 (m, 2H), 2.02-1.91 (m, 
1H), 1.89-1.77 (m, 1H) ppm; HRMS (ESI) m/z calc. for C33H39N5O7 617.2849, found 618.2922 
[M+H]+. 
 
Analytical data of compound 247 
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Peptide 247 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 633.0 [M+H]+, 655.2 [M+Na]+; Rt = 
7.72 min; 1H NMR (400 MHz, DMF-D7): δ = 10.39 (s, 1H), 8.32 (d, J = 6.9 Hz, 2H), 8.25 (d, J 
= 9.2 Hz, 2H), 8.08 (d, J = 7.0 Hz, 1H), 8.02 (d, J = 9.3 Hz, 2H), 7.45 (s, 1H), 7.36-7.09 (m, 
10H), 6.88 (s, 1H), 5.31 (t, J = 5.4, 5.4 Hz, 1H), 4.61 (dt, J = 9.0, 9.0, 4.4 Hz, 1H), 4.52-4.39 (m, 
2H), 3.75 (dt, J = 11.2, 5.7, 5.7 Hz, 1H), 3.65 (dt, J = 10.8, 5.5, 5.5 Hz, 1H), 3.23 (dd, J = 14.0, 
4.2 Hz, 1H), 3.01 (dd, J = 14.0, 9.2 Hz, 1H), 2.83 (t, J = 8.2 Hz, 2H), 2.54 (dd, J = 8.6, 6.5 Hz, 
2H), 2.32 (t, J = 7.5, 7.5 Hz, 2H), 2.18 (dt, J = 13.1, 7.2, 7.2 Hz, 1H), 2.01 (dt, J = 16.3, 7.4, 7.4 
Hz, 1H) ppm; 13C NMR (100 MHz, DMF-D7): δ = 174.4, 172.9, 171.9, 171.8, 171.8, 145.7, 
143.3, 142.0, 138.3, 129.7, 128.7, 128.7, 128.6, 126.8, 126.3, 125.2, 119.7, 62.7, 56.2, 55.6, 54.7, 
37.6, 37.2, 32.0, 31.7, 27.9 ppm; [ ] =α 20D  - 6.2° (C = 0.4, DMSO). 
 
Analytical data of compound 248 
 
________________________________________________________________________ 
268 
N
H
H
N
N
H
O
O
O
O NH2
O
NH2
 
 
Peptide 248 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 482.0 [M+H]+, 504.1 [M+Na]+; Rt = 
6.45 min; 1H NMR (400 MHz, DMF-D7): δ = 8.42-8.35 (m, 2H), 8.23 (d, J = 7.9 Hz, 1H), 7.57 
(s, 1H), 7.52-7.29 (m, 10H), 7.24 (s, 1H), 6.96 (s, 1H), 4.74 (dt, J = 9.2, 9.1, 4.5 Hz, 1H), 4.47 
(dt, J = 8.6, 8.5, 4.7 Hz, 1H), 4.02 (dd, J = 16.3, 5.5 Hz, 1H), 3.90 (dd, J = 16.3, 5.7 Hz, 1H), 
3.35 (dd, J = 13.9, 4.5 Hz, 1H), 3.01 (t, J = 8.4, 8.4 Hz, 2H), 2.69 (t, J = 8.4, 8.4 Hz, 2H), 2.41 (t, 
J = 7.6, 7.6 Hz, 2H), 2.27 (dt, J = 13.2, 7.7, 7.7 Hz, 1H), 2.07 (dt, J = 16.3, 7.4, 7.4 Hz, 1H) 
ppm; 13C NMR (100 MHz, DMF-D7): δ = 174.7, 173.9, 173.1, 171.5, 170.4, 142.1, 138.6, 129.7, 
128.7, 128.7, 128.6, 126.7, 126.3, 55.4, 53.4, 43.2, 37.5, 37.4, 32.1, 31.6, 28.4 ppm. 
 
Analytical data of compound 249 
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Peptide 249 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 483.0 [M+H]+, 505.1 [M+Na]+; Rt = 
6.76 min 
 
Analytical data of compound 250 
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Peptide 250 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 497.1 [M+H]+, 519.2 [M+Na]+; Rt = 
6.90 min; 1H NMR (400 MHz, DMF-D7): δ = 8.57 (d, J = 7.4 Hz, 1H), 8.28 (t, J = 5.5, 5.5 Hz, 
1H), 8.19 (d, J = 8.4 Hz, 1H), 7.57 (s, 1H), 7.50-7.26 (m, 10H), 6.99 (s, 1H), 4.83 (dt, J = 8.7, 
8.7, 4.6 Hz, 1H), 4.53 (dt, J = 8.9, 8.9, 5.1 Hz, 1H), 4.00 (dd, J = 16.5, 5.7 Hz, 1H), 3.91 (dd, J = 
16.5, 5.6 Hz, 1H), 3.83 (s, 3H), 3.34 (dd, J = 13.8, 4.5 Hz, 1H), 3.11-3.07 (m, 1H), 3.01 (t, J = 
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8.1, 8.1 Hz, 2H), 2.69 (t, J = 8.3, 8.3 Hz, 2H), 2.45 (t, J = 7.2, 7.2 Hz, 2H), 2.26 (dt, J = 13.1, 
12.8, 7.7 Hz, 1H), 2.08 (dt, J = 14.2, 7.7, 7.7 Hz, 1H) ppm; 13C NMR (100 MHz, DMF-
D7): δ = 174.2, 172.7, 171.8, 169.6, 142.1, 138.4, 129.8, 128.7, 128.7, 128.5, 126.7, 126.3, 54.6, 
52.6, 51.9, 43.0, 37.9, 37.6, 31.6, 31.6, 27.4 ppm. 
 
Analytical data of compound 251 
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Peptide 251 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 564.2 [M+H]+, 586.4 [M+Na]+; Rt = 
7.57 min; 1H NMR (400 MHz, DMF-D7): δ = 8.36 (d, J = 5.4 Hz, 1H), 8.32 (d, J = 7.4 Hz, 1H), 
8.22 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 7.9 Hz, 1H), 7.58 (s, 1H), 7.51-7.32 (m, 10H), 6.95 (s, 1H), 
4.75 (ddd, J = 9.1, 7.8, 4.5 Hz, 1H), 4.47 (dt, J = 8.3, 8.3, 4.9 Hz, 1H), 4.06 (dd, J = 16.4, 5.7 Hz, 
1H), 3.93 (dd, J = 16.2, 5.6 Hz, 1H), 3.85-3.71 (m, 1H), 3.36 (dd, J = 13.9, 4.4 Hz, 1H), 3.12 (dd, 
J =13.9, 7.8 Hz, 1H), 3.04 (t, J = 8.3, 8.3 Hz, 2H), 2.71 (t, J = 8.3, 8.3 Hz, 2H), 2.41 (t, J = 7.6, 
7.6 Hz, 2H), 2.29-2.18 (m, 1H), 2.16-2.02 (m, 1H), 2.01-1.90 (m, 2H), 1.90-1.81 (m, 2H), 1.77-
1.66 (m, 1H), 1.58-1.22 (m, 5H) ppm; 13C NMR (100 MHz, DMF-D7): δ = 174.7, 173.0, 171.3, 
170.6, 170.4, 142.0, 138.5, 129.7, 128.7, 128.7, 128.6, 126.7, 126.3, 55.4, 53.5, 48.4, 43.2, 37.6, 
37.4, 32.9, 32.9, 32.1, 31.6, 28.6, 25.9, 25.2, 25.2 ppm. 
 
Analytical data of compound 252 
N
H
H
N
N
H
O
O
O
O NH2
O
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Peptide 252 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 572.2 [M+H]+, 594.4 [M+Na]+; Rt = 
7.46 min; 1H NMR (400 MHz, DMF-D7): δ = 8.37-8.30 (m, 3H), 8.27 (t, J = 6.0, 6.0 Hz, 1H), 
7.55 (br s, 1H), 7.51-7.32 (m, 15H), 6.95 (br s, 1H), 4.79 (ddd, J = 9.0, 7.6, 4.7 Hz, 1H), 4.58 (dd, 
J = 8.6, 4.3 Hz, 1H), 4.55 (d, J = 5.9 Hz, 2H), 4.03 (dd, J = 16.4, 5.6 Hz, 1H), 3.93 (dd, J = 16.4, 
5.7 Hz, 1H), 3.36 (dd, J = 13.9, 4.7 Hz, 1H), 3.13 (dd, J = 14.0, 9.0 Hz, 1H), 3.05 (t, J = 7.5, 7.5 
Hz, 2H), 2.71-2.65 (m, 2H), 2.43 (t, J = 8.9, 8.9 Hz, 2H), 2.32 (ddt, J = 8.6, 8.6, 5.1, 3.5 Hz, 1H), 
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2.21-2.03 (m, 1H) ppm; 13C NMR (100 MHz, DMF-D7): δ = 174.6, 173.0, 171.8, 171.6, 170.3, 
142.0, 140.1, 138.5, 129.7, 128.7, 128.7, 128.7, 128.6, 127.6, 127.1, 126.7, 126.3, 55.3, 53.7, 
43.1, 42.8, 37.5, 37.5, 32.1, 31.6, 28.4 ppm. 
 
Analytical data of compound 253 
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Peptide 253 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 497.0 [M+H]+, 519.1 [M+Na]+; Rt = 
6.24 min. 
 
Analytical data of compound 254 
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Peptide 254 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 558.2 [M+H]+, 580.4 [M+Na]+; Rt = 
7.57 min; 1H NMR (400 MHz, DMF-D7): δ = 9.80 (s, 1H), 8.54-8.36 (m, 3H), 7.97 (d, J = 1.2 
Hz, 1H), 7.95 (d, J = 1.1 Hz, 1H), 7.61 (br s, 1H), 7.54-7.20 (m, 15H), 7.00 (br s, 1H), 4.78 (ddd, 
J = 9.2, 7.3, 4.4 Hz, 1H), 4.65 (ddd, J = 8.9, 7.9, 4.8 Hz, 1H), 4.09 (dd, J = 16.2, 5.4 Hz, 1H), 
3.95 (dd, J = 16.2, 5.7 Hz, 1H), 3.40 (dd, J = 14.0, 4.3 Hz, 1H), 3.16 (dd, J = 14.0, 9.3 Hz, 1H), 
3.03-2.96 (m, 2H), 2.76-2.57 (m, 2H), 2.50 (t, J = 7.3, 7.3 Hz, 1H), 2.39 (ddt, J = 13.6, 13.6, 7.5, 
5.9 Hz, 1H), 2.31-2.12 (m, 1H) ppm; 13C NMR (100 MHz, DMF-D7): δ =174.5, 173.2, 171.6, 
170.9, 170.7, 142.0, 139.7, 138.4, 129.7, 129.0, 128.7, 128.6, 128.6, 126.8, 126.3, 123.8, 119.8, 
55.7, 54.4, 43.3, 37.5, 37.4, 32.1, 31.5, 28.1 ppm. 
 
Analytical data of compound 255 
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Peptide 255 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 788.3 [M+H]+, 810.4 [M+Na]+; Rt = 
8.19 min. 
 
Analytical data of compound 256 
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H
H
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Peptide 256 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 552.1 [M+H]+, 574.3 [M+Na]+; Rt = 
6.83 min. 
 
Analytical data of compound 257 
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Peptide 257 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 11 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 594.0 [M+H]+, 616.3 [M+Na]+; Rt = 
7.65 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.69 (s, 1H), 8.35 (d, J = 7.6 Hz, 1H), 8.10-8.04 
(m, 2H), 7.79 (dt, J =  9.0, 6.2 Hz, 1H), 7.36-7.12 (m, 15H), 4.57 (dt, J = 8.7, 4.2 Hz, 1H), 4.47 
(td, J = 8.1, 5.4 Hz, 1H), 3.73 (dd, J = 16.4, 5.8 Hz, 1H), 3.57 (dd, J = 16.5, 5.6 Hz, 1H), 3.05 
(dd, J = 13.6, 4.4 Hz, 1H), 2.84-2.73 (m, 3H), 2.44-2.34 (m, 2H), 2.18 (td, J = 8.6 5.9 Hz, 2H), 
2.07-1.94 (m, 1H), 1.93-1.83 (m, 1H) ppm; [ ] =α 20D  + 6.0° (C = 0.4, DMSO). 
 
Analytical data of compound 258 
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Peptide 258 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 573.1 [M+H]+, 595.3 [M+Na]+; Rt = 
7.50 min. 
 
Analytical data of compound 259 
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Peptide 259 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 382.0 [M+H]+, 404.2 [M+Na]+; Rt = 
5.56 min. 
 
Analytical data of compound 260 
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Peptide 260 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 396.0 [M+H]+; Rt = 5.79 min. 
 
Analytical data of compound 261 
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Peptide 261 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 396.0 [M+H]+, 418.2 [M+Na]+; Rt = 
4.90 min. 
 
Analytical data of compound 262 
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Peptide 262 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 471.1 [M+H]+, 493.2 [M+Na]+; Rt = 
6.57 min. 
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Analytical data of compound 263 
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Peptide 263 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 457.0 [M+H]+; Rt = 6.63 min. 
 
Analytical data of compound 264 
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Peptide 264 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 472.0 [M+H]+, 494.2 [M+Na]+; Rt = 
6.63 min. 
 
Analytical data of compound 265 
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Peptide 265 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 17 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 583.0 [M+H]+, 605.3 [M+Na]+; Rt = 
7.81 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.65 (s, 1H), 8.19 (d, J = 7.6 Hz, 1H), 7.99 (d, J 
= 8.0 Hz, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.82 (dt, J = 9.0 6.2 Hz, 1H), 7.35-7.12 (m, 14H), 7.11-
7.04 (m, 1H), 5.07 (t, J = 5.5 Hz, 1H), 4.91 (t, J = 5.5 Hz, 1H), 4.60 (dd, J = 8.5, 4.1 Hz, 1H), 
4.55 (dd, J = 13.5, 5.8 Hz, 1H), 4.28 (q, J = 6.0 Hz, 1H), 3.68 (dt, J = 5.6 1.9 Hz, 2H), 3.47 (t, J 
= 5.8 Hz, 2H), 3.10 (dd, J = 13.9, 4.2 Hz, 1H), 2.84 (dd, J = 13.8, 9.1 Hz, 1H), 2.78 (t, J = 7.9 
Hz, 2H), 2.43 (dt, J = 7.6 2.1 Hz, 2H) ppm; [ ] =α 20D  - 9.7° (C = 0.7, DMSO). 
 
Analytical data of compound 266 
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Peptide 266 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 9 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 781.1 [M+H]+, 803.5 [M+Na]+; Rt = 9.77 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.11 (s, 1H), 9.07 (s, 1H), 9.07 (s, 1H), 8.28 (d, J = 
8.2 Hz, 1H), 7.95 (d, J = 7.7 Hz, 1H), 7.87 (d, J = 8.3 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.03 (d, 
J = 8.5 Hz, 2H), 6.99-6.91 (m, 6H), 6.61 (d, J = 8.5 Hz, 2H), 6.57 (d, J = 8.4 Hz, 2H), 6.52 (d, J 
= 8.4 Hz, 2H), 4.54-4.47 (m, 1H), 4.40-4.29 (m, 2H), 3.98 (t, J = 6.5 Hz, 2H), 2.92-2.77 (m, 4H), 
2.76-2.61 (m, 2H), 1.73-1.65 (m, 2H), 1.44-1.34 (m, 2H), 1.35-1.18 (m, 16H), 0.83 (t, J = 6.8 Hz, 
3H) ppm; [ ] =α 20D  - 42.9° (C = 0.4, DMSO). 
 
Analytical data of compound 267 
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Peptide 267 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 11 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 599.0 [M+H]+, 621.2 [M+Na]+; Rt = 
8.31 min; 1H NMR (400 MHz, DMSO-D6): δ = 10.09 (s, 1H), 8.15 (d, J = 7.5 Hz, 1H), 8.02 (d, J 
= 7.8 Hz, 1H), 7.98-7.94 (m, 2H), 7.53 (ddd, J = 9.0, 4.3, 2.6 Hz, 1H), 7.37 (t, J = 9.0, Hz, 1H), 
7.28-7.12 (m, 12H), 5.07 (t, J = 5.5Hz, 1H), 4.94 (t, J = 5.5 Hz, 1H), 4.56 (dt, J = 8.9, 4.4 Hz, 
1H), 4.40 (q, J = 6.0 Hz, 1H), 4.28 (q, J = 6.2 Hz, 1H), 3.66 (t, J = 6.2, Hz, 2H), 3.48 (t, J = 5.9 
Hz, 2H), 3.09 (dd, J = 14.0, 4.3 Hz, 1H), 2.85 (dd, J = 14.0, 9.0 Hz, 1H), 2.78 (t, J = 7.9 Hz, 2H), 
2.43 (dt, J = 7.5 1.4 Hz, 2H) ppm; [ ] =α 20D  - 12.1° (C = 0.6, DMSO). 
 
Analytical data of compound 268 
N
H
H
N
N
H
H
N
O
HO
O
O
HO
O
 
 
Peptide 268 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 547.0 [M+H]+, 569.3 [M+Na]+; Rt = 
7.73 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.81 (s, 1H), 8.10 (d, J = 7.7 Hz, 1H), 8.01 (d, J 
= 7.8 Hz, 1H), 7.94 (d, J = 7.5 Hz, 1H), 7.63 (d, J = 1.1 Hz, 1H), 7.61 (d, J = 1.0 Hz, 1H), 7.32-
7.11 (m, 14H), 7.06-7.01 (m, 1H), 5.01 (t, J = 5.5 Hz, 1H), 4.94 (t, J = 5.5 Hz, 1H), 4.55 (dt, J = 
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9.1 4.4 Hz, 1H), 4.43 (q, J = 5.9 Hz, 1H), 4.27 (q, J = 6.2 Hz, 1H), 3.65 (t, J = 5.7 Hz, 2H), 3.47 
(t, J = 6.0 Hz, 2H), 3.08 (dd, J = 13.9, 4.2 Hz, 1H), 2.84 (dd, J = 13.8, 9.0 Hz, 1H), 2.78 (t, J = 
7.9 Hz, 2H), 2.41 (dt, J = 7.6 1.5 Hz, 2H) ppm; [ ] =α 20D  - 15.0° (C = 0.4, DMSO). 
 
Analytical data of compound 269 
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Peptide 269 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 15 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 561.1 [M+H]+, 583.3 [M+Na]+; Rt = 
7.62 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.22 (t, J = 5.9, 5.9 Hz, 1H), 8.04 (s, 1H), 8.02 
(s, 1H), 7.92 (d, J = 7.6 Hz, 1H), 7.39-7.10 (m, 15H), 4.94 (br s, 1H), 4.56 (dt, J = 8.6, 8.4, 4.6 
Hz, 1H), 4.39-4.22 (m, 4H), 3.61 (d, J = 5.6 Hz, 2H), 3.46 (d, J = 5.5 Hz, 2H), 3.32 (d, J = 1.3 
Hz, 2H), 3.08 (dd, J = 14.0, 4.7 Hz, 1H), 2.84 (dd, J = 14.0, 9.1 Hz, 1H), 2.77 (t, J = 7.9, 7.9 Hz, 
1H), 2.42 (dt, J = 7.7, 7.7, 2.3 Hz, 1H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 171.5, 170.6, 
170.1, 169.6, 141.1, 139.0, 137.5, 129.1, 128.1, 128.0, 128.0, 127.8, 126.8, 126.5, 126.0, 125.7, 
61.5, 61.5, 55.2, 54.9, 53.8, 41.9, 36.9, 36.6, 30.8 ppm; HRMS (FAB, m-NBA) m/z calc. for 
C31H36N4O6 560.2635, found 561.2694 [M+H]+; [ ] =α 20D  + 1.6° (C = 0.8, DMSO). 
 
Analytical data of compound 270 
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Peptide 270 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 553.2 [M+H]+, 575.3 [M+Na]+; Rt = 
7.67 min. 
 
Analytical data of compound 271 
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Peptide 271 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 539.2 [M+H]+, 561.4 [M+Na]+; Rt = 
7.22 min. 
 
Analytical data of compound 272 
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Peptide 272 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 624.1 [M+H]+, 646.4 [M+Na]+; Rt = 
10.54 min. 
 
Analytical data of compound 273 
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Peptide 273 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 632.1 [M+H]+, 654.3 [M+Na]+; Rt = 
7.13 min. 
 
Analytical data of compound 274 
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Peptide 274 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 541.1 [M+H]+, 563.3 [M+Na]+; Rt = 
6.80 min. 
 
Analytical data of compound 275 
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Peptide 275 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 488.0 [M+H]+, 510.2 [M+Na]+; Rt = 
6.95 min. 
 
Analytical data of compound 276 
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Peptide 276 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 599.0 [M+H]+, 621.2 [M+Na]+; Rt = 
7.99 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.64 (s, 1H), 8.19 (d, J = 7.8 Hz, 1H), 8.11 (d, J 
= 7.7 Hz, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.81 (dt, J = 9.1, 6.3 Hz, 1H), 7.62 (d, J = 5.5 Hz, 1H), 
7.59 (d, J = 5.4 Hz, 1H), 7.40 (d, J = 15.7 Hz, 1H), 7.33-7.02 (m, 11H), 6.75 (d, J = 15.8 Hz, 
1H), 5.05 (t, J = 5.5 Hz, 1H), 4.97 (t, J = 5.5 Hz, 1H), 4.60 (dt, J = 8.7, 4.2 Hz, 1H), 4.53 (dd, J 
= 13.3, 5.9 Hz, 1H), 4.40 (q, J = 6.0, 5.9 Hz, 1H), 3.66 (t, J = 6.3 Hz, 2H), 3.54 (t, J = 5.8 Hz, 
2H), 3.09 (dd, J = 13.9, 4.5 Hz, 1H), 2.83 (dd, J = 14.1, 9.1 Hz, 1H) ppm; [ ] =α 20D  + 1.4° (C = 
0.5, DMSO). 
 
Analytical data of compound 277 
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Peptide 277 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 13 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 577.1 [M+H]+, 599.3 [M+Na]+; Rt = 
7.81 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.21 (t, J = 6.1 Hz, 1H), 8.13 (d, J = 4.2 Hz, 1H), 
8.11 (d, J = 4.6 Hz, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.61 (d, J = 5.5 Hz, 1H), 7.59 (d, J = 5.5 Hz, 
1H), 7.39 (d, J = 15.8 Hz, 1H), 7.32-7.09 (m, 14H), 6.74 (d, J = 15.8 Hz, 1H), 4.56 (dt, J = 8.5 
4.3 Hz, 1H), 4.39 (q, J = 6.0 Hz, 1H), 4.31-4.27 (m, 4H), 3.60 (d, J = 5.6 Hz, 2H), 3.54 (d, J = 
7.0 Hz, 2H), 3.07 (dd, J = 13.9, 4.4 Hz, 1H), 2.82 (dd, J = 14.1, 9.3 Hz, 1H) ppm; [ ] =α 20D  + 7.4° 
(C = 0.7, DMSO). 
 
Analytical data of compound 278 
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Peptide 278 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 758.7 [M+H]+, 780.9 [M+Na]+; Rt = 
8.63 min. 
 
Analytical data of compound 279 
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Peptide 279 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 647.8 [M+H]+, 669.8 [M+Na]+; Rt = 
7.68 min. 
 
Analytical data of compound 280 
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Peptide 280 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 569.1 [M+H]+, 591.3 [M+Na]+; Rt = 
7.89 min. 
 
Analytical data of compound 281 
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Peptide 281 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 728.8 [M+H]+, 750.9 [M+Na]+; Rt = 
8.35 min. 
 
Analytical data of compound 282 
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Peptide 282 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 615.0 [M+H]+, 637.2 [M+Na]+; Rt = 
8.41 min. 
 
Analytical data of compound 283 
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Peptide 283 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 722.8 [M+H]+, 744.9 [M+Na]+; Rt = 
8.55 min. 
 
Analytical data of compound 284 
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Peptide 284 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 563.0 [M+H]+, 585.1 [M+Na]+; Rt = 
7.91 min. 
 
Analytical data of compound 285 
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Peptide 285 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 557.0 [M+H]+, 579.2 [M+Na]+; Rt = 
6.95 min. 
 
Analytical data of compound 286 
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Peptide 286 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 648.0 [M+H]+, 670.1 [M+Na]+; Rt = 
7.31 min. 
 
Analytical data of compound 287 
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Peptide 287 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 808.0 [M+H]+, 830.0 [M+Na]+; Rt = 
8.00 min. 
 
Analytical data of compound 288 
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Peptide 288 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 550.0 [M+H]+; Rt = 7.74 min. 
 
Analytical data of compound 289 
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Peptide 289 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 709.8 [M+H]+, 731.8 [M+Na]+; Rt = 
8.42 min. 
 
Analytical data of compound 290 
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Peptide 290 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 661.8 [M+H]+, 683.8 [M+Na]+; Rt = 
7.98 min. 
 
Analytical data of compound 291 
N
H
H
N
N
H
O
HO
O
O
HO
O
F
O
 
 
Peptide 291 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 502.0 [M+H]+, 524.2 [M+Na]+; Rt = 
7.25 min. 
 
Analytical data of compound 292 
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Peptide 292 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 640.1 [M+H]+, 662.3 [M+Na]+; Rt = 
10.56 min. 
 
Analytical data of compound 293 
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Peptide 293 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 844.3 [M+H]+, 866.4 [M+Na]+; Rt = 
10.31 min. 
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Analytical data of compound 294 
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Peptide 294 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 451.1 [M+H]+, 473.2 [M+Na]+; Rt = 
5.55 min. 
 
Analytical data of compound 295 
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Peptide 295 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 381.0 [M+H]+; Rt = 5.52 min. 
 
Analytical data of compound 296 
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Peptide 296 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 12 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 855.3 [M+H]+, 877.5 [M+Na]+; Rt = 
9.52 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.13 (s, 1H), 9.08 (s, 1H), 9.08 (s, 1H), 8.28 (d, J 
= 8.3 Hz, 1H), 8.01 (d, J = 7.5 Hz, 1H), 7.91 (d, J = 8.3 Hz, 1H), 7.78 (t, J = 5.7 Hz, 1H), 7.73 
(d, J = 8.8 Hz, 2H), 7.06 (d, J = 8.5 Hz, 2H), 7.02-6.94 (m, 6H), 6.63 (d, J = 8.3 Hz, 2H), 6.59 
(d, J = 8.5 Hz, 2H), 6.53 (d, J = 8.4 Hz, 2H), 4.67 (d, J = 4.8 Hz, 1H), 4.57-4.50 (m, 1H), 4.46 
(dd, J = 12.0, 5.9 Hz, 1H), 4.43-4.37 (m, 2H), 4.00 (t, J = 6.5 Hz, 2H), 3.44 (qd, J = 9.8, 4.9 Hz, 
1H), 3.25 (td, J = 11.3, 5.6 Hz, 2H), 3.21-3.13 (m, 1H), 3.01-2.94 (m, 1H), 2.92-2.78 (m, 4H), 
2.75-2.63 (m, 2H), 1.71 ( p, J = 6.8 Hz, 2H), 1.47-1.36 (m, 2H), 1.35-1.23 (m, 16H), 0.83 (t, J = 
6.8 Hz, 3H) ppm; [ ] =α 20D  - 38.8° (C = 0.7, DMSO). 
 
Analytical data of compound 297 
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Peptide 297 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 15 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 541.9 [M+H]+, 564.1 [M+Na]+; Rt = 
7.28 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.18 (s, 1H), 9.15 (s, 1H), 8.33 (d, J = 5.5 Hz, 
1H), 8.31-8.28 (m, 1H), 8.27 (d, J = 3.2 Hz, 1H), 8.05 (d, J = 8.0 Hz, 1H), 7.61 (dt, J = 8.5, 6.7 
Hz, 1H), 7.35-7.28 (m, 1H), 7.15 (dt, J = 8.6 2.5 Hz, 1H), 7.07 (d, J = 8.4 Hz, 2H), 7.00 (d, J = 
8.4 Hz, 2H), 6.64 (d, J = 8.5 Hz, 2H), 6.64 (d, J = 8.5 Hz, 2H), 4.61 (dt, J = 9.5 4.4 Hz, 1H), 4.36 
(dt, J = 8.5 5.4 Hz, 1H), 3.79 (dd, J = 16.7, 5.7 Hz, 1H), 3.68 (dd, J = 16.6, 5.6 Hz, 1H), 2.99 
(dd, J = 13.9, 4.1 Hz, 1H), 2.93 (dd, J = 14.0, 5.3 Hz, 1H), 2.84-2.73 (m, 2H) ppm; HRMS (ESI) 
m/z calc. for C27H25F2N3O7 541.5001, found 542.1733 [M+H]+; [ ] =α 20D  + 8.5° ( C = 0.9, 
DMSO). 
 
Analytical data of compound 298 
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Peptide 298 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 20 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 677.1 [M+H]+, 699.3 [M+Na]+; Rt = 
8.45 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.16 (br d, J = 14.8 Hz, 1H), 8.43 (t, J = 5.9, 5.9 
Hz, 1H), 8.17 (t, J = 5.7, 5.7 Hz, 1H), 8.07 (d, J = 8.1 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.33-
6.84 (m, 9H), 6.64 (d, J = 0.9 Hz, 2H), 6.62 (d, J = 0.9 Hz, 2H), 4.53-4.34 (m, 2H), 4.28 (dd, J = 
15.3, 5.9 Hz, 1H), 4.19 (dd, J = 15.1, 5.2 Hz, 1H), 3.78 (dd, J = 16.6, 6.0 Hz, 1H), 3.59 (dd, J = 
16.5, 5.4 Hz, 1H), 2.89 (s, 3H), 2.90-2.84 (m, 2H), 2.73 (d, J = 0.6 Hz, 3H), 2.72-2.60 (m, 4H), 
2.33 (dt, J = 7.6, 7.4, 2.2 Hz, 2H) ppm; 13C NMR (100 MHz, DMSO-D6): δ =171.7, 171.2, 
170.9, 168.3, 162.4, 162.2, 162.1, 161.6, 160.9, 160.8, 159.9, 159.8, 159.2, 158.4, 158.3, 155.7, 
155.6, 137.2, 137.2, 130.2, 130.2, 130.1, 130.1, 129.9, 129.9, 129.7, 129.6, 127.9, 127.5, 122.0, 
122.0, 121.9, 121.8, 114.8, 114.8, 114.7, 114.6, 111.0, 111.0, 110.8, 110.8, 103.6, 103.3, 103.0, 
54.4, 54.3, 41.8, 36.8, 36.6, 36.5, 35.6, 35.3, 35.2, 30.6, 29.8 ppm; 19F NMR (188 MHz, DMSO-
D6): δ = -112.745, -112.783, -112.825, -112.867, -112.910, -115.048, -115.089, -115.139, -
115.183, -117.862, -117.893, -117.909, -117.939, -117.969, -117.985, -118.016; HRMS (FAB, 
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m-NBA) m/z calc. for C36H35F3N4O6 676.2509, found 677.2606 [M+H]+; [ ] =α 20D  + 2.6° (C = 1.6, 
DMSO). 
 
Analytical data of compound 299 
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Peptide 299 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 22 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 663.0 [M+H]+, 685.2 [M+Na]+; Rt = 
8.48 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.80 (s, 1H), 9.15 (s, 1H), 9.12 (s, 1H), 8.15 (t, J 
= 5.7, 5.7 Hz, 1H), 8.10 (d, J = 8.0 Hz, 1H), 8.04 (d, J = 8.1 Hz, 1H), 7.66 (dt, J = 8.9, 8.9, 6.2 
Hz, 1H), 7.28 (ddd, J = 10.9, 9.0, 2.9 Hz, 1H), 7.16-6.85 (m, 9H), 6.63 (d, J = 8.5 Hz, 2H), 6.61 
(d, J = 8.5 Hz, 2H), 4.67 (dt, J = 8.8, 8.7, 5.7 Hz, 1H), 4.39 (ddd, J = 10.0, 8.2, 4.5 Hz, 1H), 3.77 
(dd, J = 16.7, 5.9 Hz, 1H), 3.59 (dd, J = 16.7, 5.5 Hz, 1H), 2.94 (dd, J = 13.7, 5.1 Hz, 1H), 2.89-
2.83 (m, 1H), 2.78 (dd, J = 13.7, 9.0 Hz, 1H), 2.66 (t, J = 7.7, 7.7 Hz, 2H), 2.60 (dd, J = 13.8, 9.9 
Hz, 1H), 2.31 (dt, J = 7.6, 7.3, 1.44 Hz, 2H) ppm; 13C NMR (100 MHz, DMSO-D6): δ =171.6, 
171.2, 170.3, 168.5, 161.6, 159.2, 155.7, 155.6, 137.2, 137.2, 130.0, 129.9, 129.7, 129.6, 127.9, 
127.2, 126.0, 125.9, 125.9, 114.8, 114.7, 114.6, 54.5, 54.2, 41.7, 36.9, 36.6, 36.5, 35.6 ppm; 19F 
NMR (188 MHz, DMSO-D6): δ = -114.7, -114.7, -114.7, -114.7, -114.8, -114.8, -117.8, -117.9, -
117.9, -117.9, -117.9, -118.0, -119.0, -119.1, -119.1, -119.1 ppm; HRMS (FAB, m-NBA) m/z 
calc. for C35H33F3N4O6 662.2352, found 663.2459 [M+H]+; [ ] =α 20D  + 11.0° (C = 1.4, DMSO). 
 
Analytical data of compound 300 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O  
 
Peptide 300 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 22 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 641.1 [M+H]+, 663.3 [M+Na]+; Rt = 
8.25 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.17 (s, 1H), 9.15 (s, 1H), 8.42 (t, J = 6.0, 6.0 
Hz, 1H), 8.16 (t, J = 5.7, 5.7 Hz, 1H), 8.07 (d, J = 8.0 Hz, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.95 (s, 
1H), 7.31-6.92 (m, 13H), 6.64 (d, J = 3.2 Hz, 2H), 6.62 (d, J = 3.2 Hz, 2H), 4.49-4.42 (m, 1H), 
4.40 (ddd, J = 9.8, 8.0, 4.40 Hz, 1H), 4.29 (dd, J = 15.2, 5.9 Hz, 1H), 4.21 (dd, J = 15.3, 5.7 Hz, 
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1H), 3.78 (dd, J = 16.5, 6.0 Hz, 1H), 3.59 (dd, J = 16.6, 5.4 Hz, 1H), 2.94-2.84 (m, 2H), 2.72-
2.64 (m, 3H), 2.64-2.58 (m, 1H), 2.33 (dt, J = 7.6, 7.3, 1.6 Hz, 2H2) ppm; 13C NMR (100 MHz, 
DMSO-D6): δ = 171.6, 171.2, 170.7, 168.3, 159.2, 155.7, 155.6, 138.9, 137.2, 137.2, 129.9, 
129.9, 129.7, 129.6, 128.0, 126.8, 126.5, 114.8, 114.7, 114.6, 54.4, 54.3, 41.8, 36.9, 36.6, 36.5, 
35.6 ppm; 19F NMR (188 MHz, DMSO-D6): δ = -117.8, -117.8, -117.8, -117.9, -117.9, -117.9, -
118.0 ppm; HRMS (FAB, m-NBA) m/z calc. for C36H37FN4O6 640.2697, found 641.2761 
[M+H]+; [ ] =α 20D  + 5.8° (C = 1.4, DMSO). 
 
Analytical data of compound 301 
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Peptide 301 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 608.1 [M+H]+, 630.2 [M+Na]+; Rt = 
8.78 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.20 (s, 1H), 9.14 (s, 1H), 8.19 (d, J = 5.6 Hz, 
1H), 8.16 (d, J = 7.4 Hz, 1H), 8.06 (d, J = 7.9 Hz, 1H), 7.12 (d, J = 5.8 Hz, 1H), 7.10 (d, J = 5.6 
Hz, 1H), 7.03 (d, J = 9.0 Hz, 2H), 7.01-6.96 (m, 6H), 6.65 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 
Hz, 2H), 4.43-4.34 (m, 2H), 3.97 (t, J = 6.4 Hz, 2H), 3.76 (dd, J = 16.5, 6.0 Hz, 1H), 3.63 (dd, J 
= 16.7, 5.3 Hz, 1H), 2.90-2.82 (m, 3H), 2.72-2.64 (m, 3H), 2.37-2.30 (m, 2H), 1.51-1.38 (m, 2H), 
1.28-1.18 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H) ppm; [ ] =α 20D  + 14.0° (C = 0.1, DMSO). 
 
Analytical data of compound 302 
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Peptide 302 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 16 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 633.1 [M+H]+, 655.3 [M+Na]+; Rt = 
8.34 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.14 (s, 1H), 9.12 (s, 1H), 8.17 (t, J = 5.7 Hz, 
1H), 8.06 (d, J = 8.1 Hz, 1H), 7.89 (d, J = 8.3 Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.12 (d, J = 5.6 
Hz, 1H), 7.10 (d, J = 5.6 Hz, 1H), 7.04 (d, J = 8.9 Hz, 2H), 7.00 (d, J = 6.7 Hz, 2H), 6.97 (d, J = 
6.9 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 4.44-4.32 (m, 2H), 3.73 (dd, J = 
16.6, 5.9 Hz, 1H), 3.56 (dd, J = 16.5, 5.5 Hz, 1H), 3.52-3.42 (m, 1H), 2.88 (dd, J = 13.8, 4.2 Hz, 
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1H), 2.81 (dd, J = 13.7, 5.7 Hz, 1H), 2.72-2.66 (m, 3H), 2.63 (dd, J = 9.9, 3.8 Hz, 1H), 2.37-2.31 
(m, 2H) ppm; [ ] =α 20D  + 7.0° (C = 0.9, DMSO) 
 
Analytical data of compound 303 
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Peptide 303 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 7%; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 552.0 [M+H]+, 574.2 [M+Na]+; Rt = 
7.36 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.17 (t, J = 5.8 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 
7.99 (d, J = 7.9 Hz, 1H), 7.12 (d, J = 5.6 Hz, 1H), 7.10 (d, J = 5.6 Hz, 1H), 7.06-6.96 (m, 7H), 
6.67-6.60 (m, 5H), 4.40 (ddd, J = 9.9, 8.1, 4.4 Hz, 1H), 4.34 (dt, J = 8.3, 5.3 Hz, 1H), 3.76 (dd, J 
= 16.7, 6.0 Hz, 1H), 3.61 (dd, J = 16.7, 5.5 Hz, 1H), 2.93 (dd, J = 14.0, 5.2 Hz, 1H), 2.87 (dd, J 
= 14.1, 4.4 Hz, 1H), 2.78 (dd, J = 13.8, 8.5 Hz, 1H), 2.72-2.64 (m, 3H), 2.60 (dd, J = 14.1, 4.3 
Hz, 1H), 2.56-2.54 (m, 1H), 2.33 (dt, J = 7.6, 2.0 Hz, 2H) ppm; [ ] =α 20D  + 20.8° (C = 0.8, 
DMSO). 
 
Analytical data of compound 304 
N
H
H
N
N
H
H
N
O
F
OH
O
O
OH
O
F  
 
Peptide 304 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 12 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 645.1 [M+H]+, 667.2 [M+Na]+; Rt = 
8.49 min; 1H NMR (400 MHz, DMSO-D6): δ = 10.00 (s, 1H), 9.16 (s, 1H), 9.14 (s, 1H), 8.20 (t, J 
= 5.7 Hz, 1H), 8.14 (d, J = 7.8 Hz, 1H), 8.07 (d, J = 8.1 Hz, 1H), 7.60 (d, J = 5.0 Hz, 1H), 7.57 
(d, J = 5.0 Hz, 1H), 7.15-7.08 (m, 6H), 7.06-6.97 (m, 6H), 6.64 (d, J = 4.6 Hz, 2H), 6.62 (d, J = 
4.6 Hz, 2H), 4.54 (dt, J = 8.2 5.8 Hz, 1H), 4.40 (dt, J = 9.8 4.5 Hz, 1H), 3.78 (dd, J = 16.6, 5.9 
Hz, 1H), 3.61 (dd, J = 16.5, 5.7 Hz, 1H), 2.94 (dd, J = 13.8, 5.6 Hz, 1H), 2.88 (dd, J = 14.0, 4.4 
Hz, 1H), 2.78 (dd, J = 14.1, 8.6 Hz, 1H), 2.74-2.58 (m, 3H), 2.38-2.28 (m, 2H) ppm; [ ] =α 20D  + 
26.8° (C = 0.6, DMSO). 
 
 
________________________________________________________________________ 
287 
Analytical data of compound 305 
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Peptide 305 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 9 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 595.0 [M+H]+, 617.3 [M+Na]+; Rt = 
7.68 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.18 (s, 1H), 9.13 (s, 1H), 8.13 (t, J = 5.9 Hz, 
1H), 8.04 (d, J = 8.2 Hz, 1H), 7.12 (d, J = 5.7 Hz, 1H), 7.10 (d, J = 5.6 Hz, 1H), 7.03 (d, J = 9.0 
Hz, 2H), 7.01-6.96 (m, 4H), 6.65 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 4.88 (s, 1H), 4.40 
(ddd, J = 10.3, 8.3, 4.7 Hz, 1H), 3.76 (dd, J = 16.6, 5.9 Hz, 1H), 3.65 (s, 3H), 3.59 (dd, J = 17.0, 
5.5 Hz, 1H), 3.07 (s, 3H), 2.87 (dd, J = 13.8, 4.4 Hz, 1H), 2.81 (dd, J = 13.7, 5.4 Hz, 1H), 2.72-
2.62 (m, 3H), 2.61 (dd, J = 14.3, 10.0 Hz, 1H), 2.32 (dd, J = 8.1, 5.8 Hz, 2H) ppm; [ ] =α 20D  + 
15.7° (C = 0.4, DMSO). 
 
Analytical data of compound 306 
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Peptide 306 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 705.2 [M+H]+, 727.4 [M+Na]+; Rt = 
10.52 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.14 (s, 1H), 9.12 (s, 1H), 8.16 (t, J = 5.6 Hz, 
1H), 8.07 (d, J = 7.9 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.81 (t, J = 5.6 Hz, 1H), 7.12 (d, J = 5.7 
Hz, 1H), 7.10 (d, J = 5.6 Hz, 1H), 7.03 (d, J = 8.9 Hz, 2H), 6.99 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 
8.4 Hz, 2H), 6.62 (d, J = 8.4 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 4.42-4.30 (m, 2H), 3.75 (dd, J = 
16.6, 6.0 Hz, 1H), 3.55 (dd, J = 16.5, 5.4 Hz, 1H), 3.03 (dd, J = 13.0, 6.1 Hz, 1H), 2.95 (dd, J = 
12.7, 5.8 Hz, 1H), 2.86 (dt, J = 13.6 4.99 Hz, 2H), 2.74-2.64 (m, 2H), 2.62 (dd, J = 11.2, 7.3 Hz, 
1H), 2.38-2.30 (m, 2H), 1.39-1.27 (m, 2H), 1.30-1.14 (m, 18H), 0.85 (t, J = 6.8 Hz, 3H) ppm; 
[ ] =α 20D  + 8.0° (C = 0.4, DMSO). 
 
Analytical data of compound 307 
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Peptide 307 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 26 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 524.0 [M+H]+, 546.2 [M+Na]+; Rt = 
7.31 min; 1H NMR (400 MHz, DMF-D7): δ = 8.84 (d, J = 7.8 Hz, 1H), 8.53 (t, J = 5.7, 5.7 Hz, 
1H), 7.86-7.67 (m, 4H), 7.42 (t, J = 8.8, 8.8 Hz, 2H), 7.35 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 
Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 6.89 (d, J = 8.4 Hz, 2H), 4.91 (ddd, J = 10.3, 7.9, 4.5 Hz, 1H), 
4.73 (dt, J = 8.1, 8.1, 5.2 Hz, 1H), 4.13 (dd, J = 16.8, 6.0 Hz, 1H), 3.96 (dd, J = 16.7, 5.4 Hz, 
1H), 3.39 (dd, J = 13.9, 4.4 Hz, 1H), 3.27-3.14 (m, 2H), 3.14-3.07 (m, 1H) ppm; 13C NMR (100 
MHz, DMF-D7): δ = 173.3, 172.3, 169.3, 166.3, 157.0, 156.8, 131.3, 131.3, 130.6, 130.6, 130.6, 
130.5, 129.1, 128.2, 115.5, 115.5, 115.4, 115.3, 56.6, 54.6, 42.7, 37.0, 36.8 ppm; HRMS (ESI) 
m/z calc. for C27H26FN3O7 523.1755, found 524.1824 [M+H]+. 
 
Analytical data of compound 308 
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Peptide 308 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 538.0 [M+H]+, 560.2 [M+Na]+; Rt = 
7.71 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.19 (s, 1H), 9.10 (s, 1H), 8.58 (d, J = 8.0 Hz, 
1H), 8.29 (t, J = 4.9 Hz, 1H), 8.16 (d, J = 7.6 Hz, 1H), 7.86 (d, J = 5.5 Hz, 1H), 7.83 (d, J = 5.5 
Hz, 1H), 7.25 (t, J = 8.8 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 8.4 Hz, 2H), 6.61 (t, J = 
8.2 Hz, 4H), 4.59-4.52 (m, 1H), 4.38 (dt, J = 8.2, 6.1 Hz, 1H), 3.76 (dd, J = 16.8, 6.0 Hz, 1H), 
3.65 (dd, J = 16.8, 5.5 Hz, 1H), 3.30 (s, 3H), 2.98 (dd, J = 13.9, 3.9 Hz, 1H), 2.91-2.83 (m, 2H), 
2.78 (dd, J = 13.6, 8.4 Hz, 1H) ppm; HRMS (FAB, m-NBA) m/z calc. for C28H28FN3O7 
537.1911, found 538.1965 [M+H]+; [ ] =α 20D  - 5.1° (C = 0.6, DMSO). 
 
Analytical data of compound 309 
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Peptide 309 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 580.0 [M+H]+, 602.2 [M+Na]+; Rt = 
8.45 min; HRMS (FAB, m-NBA) m/z calc. for C31H34FN3O7 579.2381, found 580.2479 [M+H]+. 
 
Analytical data of compound 310 
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Peptide 310 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 9 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 599.1 [M+H]+, 621.2 [M+Na]+; Rt = 
8.09 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.94 (s, 1H), 9.15 (s, 1H), 9.11 (s, 1H), 8.60 (d, J 
= 8.1 Hz, 1H), 8.33 (t, J = 5.7, 5.7 Hz, 1H), 8.13 (d, J = 8.1 Hz, 1H), 7.86 (dd, J = 8.9, 5.5 Hz, 
2H), 7.57 (dd, J = 8.6, 1.1 Hz, 2H), 7.32-7.21 (m, 4H), 7.11 (d, J = 8.5 Hz, 2H), 7.07-7.00 (m, 
3H), 6.62 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 4.69-4.41 (m, 2H), 3.80 (dd, J = 16.2, 5.6 
Hz, 1H), 3.66 (dd, J = 16.7, 5.7 Hz, 1H), 3.01 (dd, J = 13.9, 3.9 Hz, 1H), 2.95 (dd, J = 13.7, 5.4 
Hz, 1H), 2.87 (dd, J = 13.8, 10.7 Hz, 1H), 2.78 (dd, J = 13.8, 8.8 Hz, 1H) ppm; 13C NMR (100 
MHz, DMSO-D6): δ = 171.8, 169.8, 168.4, 165.2, 155.7, 155.5, 138.5, 130.0, 129.9, 129.9, 129.8, 
128.5, 128.3, 127.3, 123.3, 119.3, 115.0, 114.8, 114.8, 114.7, 55.4, 55.0, 41.9, 36.9, 36.0 ppm; 
HRMS (FAB, m-NBA) m/z calc. for C33H31FN4O6 598.2228, found 598.2203 [M]+; 599.2280 
[M+H]+; [ ] =α 20D  + 14.8° (C = 0.5, DMSO). 
 
Analytical data of compound 311 
N
H
H
N
N
H
O
F
O
O
OH OH
O
H
N
F
F  
 
Peptide 311 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 11 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 635.0 [M+H]+, 657.2 [M+Na]+; Rt = 
8.23 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.81 (s, 1H), 9.15 (s, 1H), 9.11 (s, 1H), 8.58 (d, J 
= 8.1 Hz, 1H), 8.30 (t, J = 5.7 Hz, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.87 (d, J = 5.5 Hz, 1H), 7.85 
(d, J = 5.5 Hz, 1H), 7.66 (dt, J = 9.0, 6.2 Hz, 1H), 7.33-7.22 (m, 3H), 7.11 (d, J = 8.5 Hz, 2H), 
7.05 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 8.5 Hz, 2H), 4.69 (dt, J = 8.4 5.1 
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Hz, 1H), 4.58 (ddd, J = 10.8, 8.3, 4.1 Hz, 1H), 3.80 (dd, J = 16.4, 5.6 Hz, 1H), 3.66 (dd, J = 16.7, 
5.4 Hz, 1H), 3.06-2.91 (m, 2H), 2.86 (dd, J = 13.7, 10.88 Hz, 1H), 2.78 (dd, J = 13.8, 9.1 Hz, 
1H) ppm; [ ] =α 20D  + 10.1° (C = 0.6, DMSO). 
 
Analytical data of compound 312 
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Peptide 312 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 605.1 [M+H]+, 627.3 [M+Na]+; Rt = 
8.13 min. 
 
Analytical data of compound 313 
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Peptide 313 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 747.2 [M+H]+; Rt = 12.35 min. 
 
Analytical data of compound 314 
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Peptide 314 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 11 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 567.0 [M+H]+, 589.2 [M+Na]+; Rt = 
7.48 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.16 (s, 1H), 9.09 (s, 1H), 8.56 (d, J = 8.2 Hz, 
1H), 8.25 (t, J = 5.8 Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H), 7.85 (d, J = 8.9 Hz, 2H), 7.84 (d, J = 8.8 
Hz, 2H), 7.25 (t, J = 8.8 Hz, 2H), 7.09 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.4 Hz, 2H), 6.61 (d, J = 
8.5 Hz, 2H), 6.60 (d, J = 8.7 Hz, 2H), 4.88 (s, 1H), 4.56 (ddd, J = 11.0, 8.3, 3.9 Hz, 1H), 3.76 
(dd, J = 17.2, 6.3 Hz, 1H), 3.64 (s, 3H), 3.63 (dd, J = 16.7, 5.6 Hz, 1H), 3.30 (s, 3H), 2.97 (dd, J 
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= 13.6, 3.8 Hz, 1H), 2.84 (dd, J = 11.4, 9.0 Hz, 1H), 2.79 (dd, J = 14.2, 4.9 Hz, 1H), 2.64 (dd, J 
= 13.8, 8.7 Hz, 1H) ppm; [ ] =α 20D  + 0.6° (C = 0.9, DMSO). 
 
Analytical data of compound 315 
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Peptide 315 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 15 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 594.3 [M+H]+, 616.3 [M+Na]+; Rt = 
5.65 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.17 (s, 1H), 9.14 (s, 1H), 8.61 (d, J = 8.1 Hz, 
1H), 8.31 (t, J = 5.6, 5.6 Hz, 1H), 8.05-7.90 (m, 2H), 7.90-7.83 (m, 2H), 7.66 (br s, 2H), 7.38-
7.21 (m, 2H), 7.11 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 6.62 (d, 
J = 8.5 Hz, 2H), 4.56 (ddd, J = 12.0, 8.0, 4.0 Hz, 1H), 4.35 (dt, J = 8.9, 8.7, 5.06 Hz, 1H), 3.80 
(dd, J = 16.5, 6.0 Hz, 1H), 3.58 (dd, J = 16.6, 5.2 Hz, 1H), 3.14-2.93 (m, 3H), 2.93-2.81 (m, 2H), 
2.75 (s, 2H), 2.67 (dd, J = 13.6, 9.0 Hz, 1H), 1.62-1.30 (m, 4H) ppm; 13C NMR (100 MHz, 
DMSO-D6): δ = 171.8, 170.7, 168.2, 165.3, 162.5, 155.6, 155.5, 130.0, 129.9, 129.8, 129.8, 
128.2, 127.7, 115.0, 114.8, 114.7, 55.4, 54.4, 41.9, 38.4, 37.7, 37.0, 36.0, 25.8, 24.3 ppm; HRMS 
(FAB, m-NBA) m/z calc. for C31H36FN5O6 593.2650, found 594.2720 [M]+; [ ] =α 20D  - 2.8° (C = 
0.9, DMSO). 
 
Analytical data of compound 316 
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Peptide 316 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 614.0 [M+H]+; Rt = 8.40 min; 1H NMR 
(400 MHz, DMF-D7): δ = 8.37 (t, J = 5.7, 5.7 Hz, 1H), 8.32 (dd, J = 7.4, 5.4 Hz, 2H), 7.48-7.31 
(m, 2H), 7.29-7.17 (m, 6H), 7.02-6.85 (m, 4H), 4.75 (dt, J = 7.8, 7.8, 6.1 Hz, 1H), 4.71-4.66 (m, 
1H), 4.51 (ddd, J = 5.6, 4.2, 3.1 Hz, 2H), 4.09 (dd, J = 16.8, 6.0 Hz, 1H), 4.01-3.90 (m, 3H), 
3.30-3.15 (m, 3H), 3.02-2.95 (m, 3H), 2.65 (dd, J = 8.6, 6.5 Hz, 2H) ppm; 13C NMR (100 MHz, 
DMF-D7): δ = 172.5, 172.4, 172.4, 171.8, 169.6, 157.1, 156.8, 130.6, 130.6, 130.4, 130.4, 128.7, 
127.7, 115.6, 115.4, 115.3, 65.0, 55.7, 54.8, 49.7, 42.5, 37.6, 37.0, 36.8, 36.8 ppm. 
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Analytical data of compound 317 
N
H
H
N
N
H
O
O
F
OH
O
O
OH
O  
 
Peptide 317 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 19 %; Purity > 85% (LC_MS); LC-MS (C18, ESI_MS) 566.0 [M+H]+; Rt = 7.88 min; 1H 
NMR (400 MHz, DMF-D7): δ = 8.24 (t, J = 5.8, 5.8 Hz, 1H), 8.19 (d, J = 7.8 Hz, 1H), 8.14 (d, J 
= 7.6 Hz, 1H), 7.30-7.13 (m, 6H), 6.83-6.66 (m, 4H), 4.77-4.37 (m, 2H), 4.23-3.70 (m, 2H), 3.64 
(s, 3H), 3.05 (dd, J = 13.9, 4.8 Hz, 1H), 3.01-2.93 (m, 2H), 2.85-2.76 (m, 3H), 2.48 (dd, J = 8.7, 
6.7 Hz, 2H) ppm; 13C NMR (100 MHz, DMF-D7): δ = 172.5, 172.4, 172.3, 169.4, 156.9, 156.6, 
130.4, 130.4, 130.3, 130.2, 128.5, 127.6, 115.4, 115.2, 115.2, 115.0, 55.6, 54.6, 51.8, 42.4, 37.4, 
36.8, 36.7, 36.7 ppm; [ ] =α 20D  + 12.4° (C = 0.9, DMSO). 
 
Analytical data of compound 318 
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Peptide 318 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 627.0 [M+H]+, 649.2 [M+Na]+; Rt = 
8.36 min; 1H NMR (400 MHz, DMF-D7): δ = 10.01 (s, 1H), 9.53 (s, 1H), 9.52 (s, 1H), 8.50 (t, J 
= 5.5, 5.5 Hz, 1H), 8.40 (d, J = 7.1 Hz, 1H), 8.22 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 7.8 Hz, 2H), 
7.56-7.41 (m, 2H), 7.38-7.17 (m, 9H), 6.91 (d, J = 8.3 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 4.85 (dt, 
J = 8.5, 8.5, 5.4 Hz, 1H), 4.68 (ddd, J = 9.3, 7.3, 4.9 Hz, 1H), 4.08 (dd, J = 16.6, 5.9 Hz, 1H), 
3.92 (dd, J = 16.6, 5.3 Hz, 1H), 3.31 (dd, J = 13.9, 5.2 Hz, 1H), 3.24 (dd, J = 14.0, 4.9 Hz, 1H), 
3.13 (dd, J = 13.8, 8.6 Hz, 1H), 3.04-2.96 (m, 3H), 2.67 (dd, J = 8.47, 6.58 Hz, 2H) ppm; 13C 
NMR (100 MHz, DMF-D7): δ = 172.9, 172.8, 170.6, 169.4, 156.9, 156.8, 139.7, 130.6, 130.6, 
130.4, 130.3, 129.0, 128.6, 128.5, 123.8, 120.0, 115.5, 115.4, 115.3, 115.1, 56.3, 56.0, 43.1, 37.6, 
37.4, 36.9, 36.8 ppm; [ ] =α 20D  +27.0° (C = 0.8, DMSO). 
 
Analytical data of compound 319 
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Peptide 319 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 586.0 [M+H]+, 608.2 [M+Na]+; Rt = 
8.13 min. 
 
Analytical data of compound 320 
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Peptide 320 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 755.3 [M+H]+, 778.4 [M+Na]+; Rt = 
5.90 min. 
 
Analytical data of compound 321 
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Peptide 321 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 662.0 [M+H]+, 684.2 [M+Na]+; Rt = 
7.84 min. 
 
Analytical data of compound 322 
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Peptide 322 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 758.9 [M+H]+, 781.2 [M+Na]+; Rt = 
8.39 min. 
 
Analytical data of compound 323 
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Peptide 323 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 729.1 [M+H]+; Rt = 8.20 min. 
 
Analytical data of compound 324 
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Peptide 324 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 737.0 [M+H]+, 759.4 [M+Na]+; Rt = 
8.14 min. 
 
Analytical data of compound 325 
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Peptide 325 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 710.0 [M+H]+, 732.3 [M+Na]+; Rt = 
8.17 min. 
 
Analytical data of compound 326 
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Peptide 326 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 730.1 [M+H]+, 752.2 [M+Na]+; Rt = 
7.81 min. 
 
Analytical data of compound 327 
N
H
H
N
N
H
H
N
OF
F
OH
O
OH
O
OH
O
NH2
 
 
Peptide 327 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 20 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 718.3 [M+H]+; Rt = 5.87 min. 
 
Analytical data of compound 328 
N
H
H
N
N
H
O
OF
F
OH
O
OH
O
OH
O
NH2
 
 
Peptide 328 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 691.2 [M+H]+, 713.3 [M+Na]+; Rt = 
5.92 min. 
 
Analytical data of compound 329 
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Peptide 329 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 32 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 648.0 [M+H]+, 670.2 [M+Na]+; Rt = 
7.42 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.15 (s, 2H), 8.20 (d, J = 7.7 Hz, 1H), 8.17 (dd, J 
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= 8.3, 3.6 Hz, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.56 (dt, J =8.5, 6.7 Hz, 1H), 7.35-7.27 (m, 1H), 
7.15 (dt, J = 8.3, 2.00 Hz, 1H), 7.07-6.98 (m, 6H), 6.66 (d, J = 8.54 Hz, 2H), 6.62 (d, J = 5.3 Hz, 
2H), 6.60 (d, J = 5.3 Hz, 2H), 4.57 (dt, J = 9.6, 4.2 Hz, 1H), 4.51 (dt, J =  8.7, 4.5 Hz, 1H), 4.38 
(dt, J = 7.8, 5.8 Hz, 1H), 2.99-2.87 (m, 3H), 2.83 (dd, J = 13.9, 7.9 Hz, 1H), 2.70 (dt, J = 14.2, 
9.5 Hz, 2H) ppm; HRMS (ESI) m/z calc. for C34H31F2N3O8 647.2079, found 648.2150 [M+H]+. 
 
Analytical data of compound 330 
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Peptide 330 synthesized and released from solid support according to GP 2 and GP 3. Yield = 7 
%; Purity > 80% (LC_MS); LC-MS (C4, ESI_MS) 746.1 [M+H]+, 768.4 [M+Na]+; Rt = 9.95 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.18 (s, 1H), 9.11 (s, 2H), 8.10 (d, J = 7.3 Hz, 1H), 
7.94-7.67 (m, 2H), 7.05-6.93 (m, 6H), 6.69-6.55 (m, 6H), 4.43 (dt, J = 8.3, 4.5 Hz, 1H), 4.40-
4.30 (m, 2H), 2.98-2.76 (m, 4H), 2.76-2.64 (m, 1H), 2.64-2.52 (m, 1H), 1.97 (t, J = 8.2 Hz, 2H), 
1.42-1.30 (m, 2H), 1.29-1.13 (m, 24H), 1.13-1.03 (m, 2H), 0.85 (t, J = 6.5 Hz, 3H) ppm; HRMS 
(ESI) m/z calc. for C43H59N3O8 745.4302, found 746.4374 [M+H]+. 
 
Analytical data of compound 331 
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Peptide 331 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 80% (LC_MS); LC-MS (C4, ESI_MS) 760.2 [M+H]+, 782.5 [M+Na]+; Rt = 
10.25 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.19 (s, 1H), 9.10 (s, 1H), 9.06 (s, 1H), 8.27 (d, 
J = 7.4 Hz, 1H), 7.80 (dd, J = 8.1, 6.2 Hz, 2H), 7.04-6.86 (m, 6H), 6.63 (d, J = 8.4 Hz, 2H), 6.59 
(d, J = 8.4 Hz, 2H), 6.57 (d, J = 8.4 Hz, 2H), 4.45-4.39 (m, 1H), 4.39-4.30 (m, 2H), 3.53 (s, 3H), 
2.91-2.72 (m, 4H), 2.64 (dd, J = 14.1, 8.9 Hz, 1H), 2.52 (dd, J = 12.4, 8.7 Hz, 1H), 1.96 (t, J =  
7.4 Hz, 2H), 1.42-1.28 (m, 2H), 1.29-1.10 (m, 24H), 1.11-1.00 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) 
ppm; HRMS (ESI) m/z calc. for C44H61N3O8 759.4459, found 760.4531 [M+H]+. 
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Analytical data of compound 332 
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Peptide 332 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 828.3 [M+H]+, 850.5 [M+Na]+; Rt = 
10.43 min; 1H NMR (400 MHz, DMSO-D6): δ = 12.22 (s, 1H), 9.18 (s, 1H), 9.08 (s, 2H), 8.27 
(d, J = 7.4 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.47 (d, J = 3.5 Hz, 1H), 
7.22 (d, J = 3.5 Hz, 1H), 7.05 (d, J = 3.5 Hz, 2H), 6.95 (t, J =  8.7 Hz, 4H), 6.64 (d, J = 8.5 Hz, 
2H), 6.59 (d, J = 8.5 Hz, 2H), 6.54 (d, J = 8.5 Hz, 2H), 4.70 (dd, J = 14.1, 7.6 Hz, 1H), 4.44 (dt, 
J = 8.3, 4.7 Hz, 1H), 4.39-4.32 (m, 1H), 3.00-2.75 (m, 4H), 2.67 (dd, J = 14.1, 8.6 Hz, 1H), 2.54 
(dd, J = 12.8, 8.9 Hz, 1H), 1.97 (t, J = 7.5 Hz, 2H), 1.38-1.28 (m, 2H), 1.28-1.11 (m, 24H), 1.11-
1.01 (m, 2H), 0.85 (t, J = 6.8 Hz, 3H) ppm; HRMS (ESI) m/z calc. for C46H61N5O7S 827.4292, 
found 828.4365 [M+H]+. 
 
Analytical data of compound 333 
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Peptide 333 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 857.2 [M+H]+, 879.5 [M+Na]+; Rt = 
10.63 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.73 (s, 1H), 9.14 (s, 1H), 9.07 (s, 1H), 9.06 (s, 
1H), 8.16 (d, J = 7.9 Hz, 1H), 7.81 (dd, J = 13.4, 8.4 Hz, 2H), 7.67 (dt, J =8.8, 6.2 Hz, 1H), 7.33-
7.19 (m, 1H), 7.04 (d, J = 8.4 Hz, 4H), 6.98-6.90 (m, 5H), 6.63 (d, J = 8.5 Hz, 2H), 6.57 (d, J = 
8.5 Hz, 2H), 6.55-6.52 (m, 2H), 4.67 (q, J = 7.9, 7.7 Hz, 1H), 4.41 (dt, J = 8.1, 4.4 Hz, 1H), 4.34 
(dt, J = 9.6, 4.0 Hz, 1H), 2.98-2.73 (m, 4H), 2.65 (dd, J = 14.0, 8.6 Hz, 1H), 2.53 (dd, J = 13.4, 
9.6 Hz, 1H), 1.95 (t, J = 7.4 Hz, 2H), 1.40-1.26 (m, 2H), 1.26-1.10 (m, 24H), 1.10-1.00 (m, 2H), 
0.83 (t, J = 6.8 Hz, 3H) ppm; HRMS (ESI) m/z calc. for C49H62F2N4O7 856.4587, found 
857.4659 [M+H]+. 
 
Analytical data of compound 334 
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Peptide 334 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 90% (LC_MS); LC-MS (C4, ESI_MS) 906.2 [M+H]+, 928.5 [M+Na]+; Rt = 
10.36 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.67 (s, 1H), 9.13 (s, 1H), 9.07 (s, 1H), 9.07 (s, 
1H), 8.08 (d, J = 8.1 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.80 (d, J = 7.9 Hz, 1H), 7.38 (d, J = 9.0 
Hz, 2H), 7.01 (d, J = 8.2 Hz, 2H), 6.94 (t, J =  7.7 Hz, 4H), 6.85 (d, J = 9.0 Hz, 2H), 6.61 (d, J = 
8.4 Hz, 2H), 6.57 (d, J = 8.3 Hz, 2H), 6.54 (d, J = 8.5 Hz, 2H), 4.52 (q, J = 7.07 Hz, 1H), 4.43-
4.29 (m, 2H), 3.72-3.68 (m, 4H), 3.03-3.00 (m, 4H), 2.95-2.73 (m, 4H), 2.67 (dd, J = 14.1, 8.2 
Hz, 1H), 2.54 (dd, J = 14.3, 10.2 Hz, 1H), 1.96 (t, J =  7.15 Hz, 2H), 1.41-1.26 (m, 2H), 1.27-
1.10 (m, 24H), 1.10-0.99 (m, 2H), 0.83 (t, J =  6.65 Hz, 3H) ppm; HRMS (ESI) m/z calc. for 
C53H71N5O8 905.5303, found 905.5380 [M+H]+. 
 
Analytical data of compound 335 
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Peptide 335 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 15 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 789.2 [M+H]+, 811.4 [M+Na]+; Rt = 
10.34 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.18 (s, 1H), 9.10 (s, 1H), 9.08 (s, 1H), 7.85 (d, 
J = 8.5 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.07-6.88 (m, 6H), 6.65 (d, J = 8.5 Hz, 2H), 6.59 (d, J 
= 8.3 Hz, 4H), 4.92 (br, 1H), 4.43 (dt, J = 8.4, 4.82 Hz, 1H), 4.35 (dt, J = 10.3, 4.0 Hz, 1H), 3.59 
(s, 3H), 3.05 (s, 3H), 2.89-2.77 (m, 3H), 2.74-2.61 (m, 2H), 2.54 (dd, J = 12.2, 8.5 Hz, 1H), 1.97 
(t, J =  7.3 Hz, 2H), 1.40-1.28 (m, 2H), 1.28-1.12 (m, 24H), 1.12-1.03 (m, 2H), 0.85 (t, J = 6.8 
Hz, 3H) ppm; HRMS (ESI) m/z calc. for C45H64N4O8 788.4724, found 789.4797 [M+H]+. 
 
Analytical data of compound 336 
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Peptide 336 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 827.4 [M+H]+, 849.6 [M+Na]+; Rt = 
10.71 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.12 (s, 1H), 9.11 (s, 1H), 9.08 (s, 1H), 7.90 (d, 
J = 8.3 Hz, 1H), 7.86 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 7.9 Hz, 1H), 7.61 (d, J = 7.9 Hz, 1H), 6.97 
(d, J = 8.5 Hz, 4H), 6.93 (d, J = 8.5 Hz, 2H), 6.62 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 
6.59 (d, J = 8.5 Hz, 2H), 4.41-4.32 (m, 3H), 3.51-3.41 (m, 1H), 2.87-2.76 (m, 3H), 2.74-2.64 (m, 
2H), 2.56 (dd, J = 13.8, 10.0 Hz, 1H), 1.98 (t, J = 7.3 Hz, 2H), 1.73-1.47 (m, 4H), 1.41-1.30 (m, 
2H), 1.30-1.14 (m, 28H), 1.13-0.98 (m, 4H), 0.85 (t, J =  6.8 Hz, 3H) ppm; HRMS (ESI) m/z 
calc. for C49H70N4O7 826.5245, found 827.5315 [M+H]+. 
 
Analytical data of compound 337 
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Peptide 337 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 20 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 816.4 [M+H]+, 838.5 [M+Na]+; Rt = 
8.57 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.17 (s, 1H), 9.15 (s, 1H), 9.11 (s, 1H), 7.93 (d, J 
= 8.2 Hz, 1H), 7.88 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.75 (t, J = 5.6 Hz, 1H), 7.68 
(br, 2H), 4.40-4.30 (m, 3H), 3.09-2.93 (m, 1H), 2.88-2.79 (m, 2H), 2.79-2.72 (m, 4H), 2.72-2.62 
(m, 2H), 2.56 (dd, J = 13.8, 10.3 Hz, 1H), 1.99 (t, J = 7.3 Hz, 1H), 1.50-1.41 (m, 2H), 1.41-1.31 
(m, 4H), 1.29-1.12 (m, 24H), 1.12-1.04 (m, 2H), 0.85 (t, J = 6.7 Hz, 3H) ppm; HRMS (ESI) m/z 
calc. for C47H69N5O7 815.5197, found 816.5269 [M+H]+. 
 
Analytical data of compound 338 
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Peptide 338 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 18 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 815.2 [M+H]+, 837.5 [M+Na]+; Rt = 
10.21 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.19 (s, 1H), 9.10 (s, 1H), 9.07 (s, 1H), 8.25 (d, 
J = 7.9 Hz, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 6.99-6.91 (m, 6H), 6.64 (d, J 
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= 8.4 Hz, 2H), 6.58 (d, J = 8.4 Hz, 4H), 4.78 (dd, J = 8.1, 7.8 Hz, 1H), 4.41 (dt, J = 8.3, 5.0 Hz, 
1H), 4.37-4.31 (m, 1H), 3.46 (dd, J = 13.8, 8.0 Hz, 1H), 3.43-3.36 (m, 2H), 3.27-3.22 (m, 1H), 
3.17-3.08 (m, 1H), 3.05-2.97 (m, 1H), 2.86-2.76 (m, 3H), 2.74-2.62 (m, 2H), 2.54 (dd, J = 14.0, 
10.5 Hz, 1H), 1.96 (t, J =  7.3 Hz, 2H), 1.38-1.28 (m, 2H), 1.28-1.11 (m, 24H), 1.10-1.02 (m, 
2H), 0.83 (t, J =  6.8 Hz, 3H); HRMS (ESI) m/z calc. for C47H66N4O8 814.4881, found 815.4953 
[M+H]+. 
 
Analytical data of compound 339 
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Peptide 339 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 808.2 [M+H]+, 830.5 [M+Na]+; Rt = 
10.59 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.19 (s, 1H), 9.10 (s, 1H), 9.06 (s, 1H), 8.34 (d, 
J = 7.2 Hz, 1H), 7.80 (d, J = 8.4 Hz, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.02-6.92 (m, 6H), 6.64 (d, J 
= 8.40 Hz, 2H), 6.59 (d, J = 8.19 Hz, 2H), 6.57 (d, J = 7.62 Hz, 2H), 4.47-4.38 (m, 2H), 4.38-
4.30 (m, 1H), 4.22 (t, J = 5.2 Hz, 2H), 3.75-3.64 (m, 2H), 2.93-2.80 (m, 3H), 2.77 (dd, J = 13.8, 
4.0 Hz, 1H), 2.64 (dd, J = 14.1, 8.9 Hz, 1H), 2.52 (dd, J = 11.0, 7.3 Hz, 1H), 1.95 (t, J = 7.24 Hz, 
2H), 1.37-1.27 (m, 2H), 1.27-1.10 (m, 2H), 1.10-1.00 (m, 2H), 0.83 (t, J = 6.79 Hz, 3H) ppm; 
HRMS (ESI) m/z calc. for C45H62ClN3O8 807.4225, found 808.4298 [M+H]+. 
 
Analytical data of compound 340 
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Peptide 340 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 871.3 [M+H]+, 893.5 [M+Na]+; Rt = 
10.64 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.18 (s, 1H), 9.11 (s, 1H), 9.08 (s, 1H), 8.30 (t, J 
= 5.9 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.85 (d, J = 4.8 Hz, 1H), 7.83 (d, J = 4.3 Hz, 1H), 7.20-
7.13 (m, 1H), 6.99-6.91 (m, 9H), 6.63 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 
8.5 Hz, 2H), 4.48-4.42 (m, 1H), 4.41-4.32 (m, 2H), 4.26 (dd, J = 15.4, 6.0 Hz, 1H), 4.16 (dd, J = 
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15.7, 5.2 Hz, 1H), 2.88-2.80 (m, 2H), 2.79-2.71 (m, 1H), 2.67 (dd, J = 14.0, 8.8 Hz, 1H), 2.55 
(dd, J = 12.2, 8.6 Hz, 1H), 1.98 (t, J = 7.4 Hz, 2H), 1.39-1.27 (m, 2H), 1.28-1.13 (m, 24H), 1.13-
1.03 (m, 2H), 0.85 (t, J = 6.86 Hz, 3H) ppm; HRMS (ESI) m/z calc. for C50H64F2N4O7 870.4743, 
found 871.4818 [M+H]+. 
 
Analytical data of compound 341 
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Peptide 341 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 17 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 853.5 [M+H]+, 875.6 [M+Na]+; Rt = 
8.69 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.19 (s, 2H), 8.88 (s, 1H), 8.02 (d, J = 7.7 Hz, 
1H), 7.93-7.81 (m, 3H), 7.62 (d, J = 13.5 Hz, 2H), 7.00 (d, J = 8.4 Hz, 2H), 6.95 (d, J = 8.4 Hz, 
4H), 6.64 (d, J = 8.4 Hz, 2H), 6.60 (d, J = 8.4 Hz, 4H), 4.42-4.28 (m, 3H), 4.00 (t, J = 6.8 Hz, 
2H), 2.98 (dq, J = 14.0, 6.7 Hz, 2H), 2.89-2.79 (m, 2H), 2.79-2.62 (m, 3H), 2.57 (dd, J = 13.9, 
9.9 Hz, 1H), 1.99 (t, J = 7.21 Hz, 2H), 1.90-1.77 (m, 2H), 1.42-1.30 (m, 2H), 1.30-1.13 (m, 24H), 
1.12-1.04 (m, 2H), 0.85 (t, J = 6.8 Hz, 3H) ppm; HRMS (ESI) m/z calc. for C49H68N6O7 
852.5149, found 853.5222 [M+H]+. 
 
Analytical data of compound 342 
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Peptide 342 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 789.4 [M+H]+, 811.5 [M+Na]+; Rt = 8.71 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.24 (s, 1H), 9.16 (s, 1H), 9.11 (s, 1H), 8.23 (d, J = 
7.6 Hz, 1H), 7.88 (dd, J = 8.2, 4.4 Hz, 3H), 7.01-6.93 (m, 6H), 6.67 (d, J = 8.4 Hz, 2H), 6.62 (d, 
J = 8.4 Hz, 2H), 6.59 (d, J = 8.4 Hz, 2H), 4.50 (q, J = 7.8, 7.6 Hz, 1H), 4.45-4.38 (m, 1H), 4.38-
4.31 (m, 1H), 4.23 (td, J = 11.2, 5.4 Hz, 1H), 4.16-4.10 (m, 1H), 3.05 (dd, J = 10.0, 4.9 Hz, 2H), 
2.99 (dd, J = 14.2, 5.6 Hz, 1H), 2.85 (dd, J = 14.5, 6.5 Hz, 2H), 2.78 (dd, J = 13.9, 4.1 Hz, 1H), 
2.66 (dd, J = 13.9, 9.1 Hz, 1H), 2.55 (dd, J = 13.6, 9.4 Hz, 1H), 1.99 (t, J = 7.0 Hz, 2H), 1.39-
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1.30 (m, 2H), 1.29-1.13 (m, 24H), 1.12-1.04 (m, 2H), 0.85 (t, J = 6.86 Hz, 3H) ppm; HRMS 
(ESI) m/z calc. for C45H64N4O8 788.4724, found 789.4796 [M+H]+. 
 
Analytical data of compound 343 
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Peptide 343 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 593.0 [M+H]+, 615.3 [M+Na]+; Rt = 
7.83 min. 
 
Analytical data of compound 344 
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Peptide 344 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 22 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 782.1 [M+H]+, 804.4 [M+Na]+; Rt = 
9.87 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.10 (d, J = 1.8 Hz, 1H), 9.09 (s, 1H), 8.31 (d, J 
= 8.2 Hz, 1H), 7.85 (d, J = 8.1 Hz, 1H), 7.74 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 8.8 Hz, 1H), 7.05 
(d, J = 8.5 Hz, 2H), 7.02-6.93 (m, 6H), 6.65 (d, J = 8.5 Hz, 2H), 6.62-6.53 (m, 6H), 4.57-4.49 
(m, 1H), 4.36 (dt, J = 8.2 5.2 Hz, 1H), 4.00 (dt, J = 6.4, 2.1 Hz, 2H), 2.96-2.85 (m, 3H), 2.85-
2.77 (m, 2H), 2.72 (dd, J = 15.6, 6.5 Hz, 1H), 1.71 ( p, J = 6.4 Hz, 2H), 1.47-1.35 (m, 2H), 1.37-
1.20 (m, 16H), 0.85 (t, J = 6.8 Hz, 3H) ppm; HRMS (ESI) m/z calc. for C45H55N3O9 781.3938, 
found 782.4013 [M+H]+; [ ] =α 20D  - 46.8° (C = 1.3, DMSO). 
 
Analytical data of compound 345 
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Peptide 345 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 796.1 [M+H]+, 818.4 [M+Na]+; Rt = 
10.15 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.20 (s, 1H), 9.10 (s, 1H), 9.09 (s, 1H), 8.34 (d, 
J = 7.4 Hz, 1H), 8.27 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 8.3 Hz, 1H), 7.73 (d, J = 8.9 Hz, 2H), 7.05 
(d, J = 8.5 Hz, 2H), 6.96 (t, J = 8.6 Hz, 4H), 6.65 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 
6.55 (d, J = 8.5 Hz, 2H), 4.56-4.44 (m, 1H), 4.37 (q, J = 7.0 6.7 Hz, 1H), 4.00 (t, J = 6.7 Hz, 
2H), 3.55 (s, 3H), 2.92-2.83 (m, 4H), 2.80 (dd, J = 14.8, 4.5 Hz, 1H), 2.67 (dd, J = 12.5, 9.0 Hz, 
1H), 1.71 (p, J = 6.1 Hz, 2H), 1.48-1.35 (m, 2H), 1.38-1.20 (m, 16H), 0.85 (t, J = 6.8 Hz, 3H) 
ppm; [ ] =α 20D  - 45.2° (C = 0.2, DMSO). 
 
Analytical data of compound 346 
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Peptide 346 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 858.4 [M+H]+, 880.4 [M+Na]+; Rt = 9.99 
min. 
 
Analytical data of compound 347 
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Peptide 347 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 825.1 [M+H]+, 847.4 [M+Na]+; Rt = 
10.04 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.18 (s, 1H), 9.08 (s, 1H), 9.07 (s, 1H), 8.29 (d, 
J = 8.1 Hz, 2H), 7.84 (d, J = 8.0 Hz, 1H), 7.73 (d, J = 8.9 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 6.98 
(d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.9 Hz, 2H), 6.65 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 
6.52 (d, J = 8.5 Hz, 2H), 4.95-4.87 (m, 1H), 4.56-4.49 (m, 1H), 4.46 (dt, J = 8.8, 4.67 Hz, 1H), 
4.00 (t, J = 6.6 Hz, 2H), 3.58 (s, 3H), 3.05 (s, 3H), 2.92-2.75 (m, 4H), 2.73-2.63 (m, 2H), 1.71 ( 
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p, J = 6.9 Hz, 2H), 1.44-1.37 (m, 2H), 1.34-1.23 (m, 18H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  
- 32.0° (C = 0.2, DMSO). 
 
Analytical data of compound 348 
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Peptide 348 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 863.3 [M+H]+, 885.6 [M+Na]+; Rt = 
10.39 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.10 (s, 1H), 9.07 (s, 1H), 9.06 (s, 1H), 8.28 (d, 
J = 8.4 Hz, 1H), 7.93 (d, J = 8.3 Hz, 1H), 7.89 (d, J = 7.9 Hz, 1H), 7.71 (d, J = 8.8 Hz, 2H), 7.59 
(d, J = 7.8 Hz, 1H), 7.04 (d, J = 8.5 Hz, 2H), 6.97-6.91 (m, 4H), 6.61 (d, J = 8.5 Hz, 2H), 6.57 
(d, J = 8.5 Hz, 2H), 6.51 (d, J = 8.5 Hz, 2H), 4.51 (dt, J = 10.5, 4.0 Hz, 1H), 4.39 (dd, J = 12.2, 
7.7 Hz, 1H), 4.34 (dd, J = 14.5, 6.9 Hz, 1H), 3.98 (t, J = 6.5 Hz, 2H), 3.50-3.38 (m, 1H), 2.88 
(dd, J = 14.4, 4.5 Hz, 1H), 2.83-2.74 (m, 3H), 2.73-2.63 (m, 2H), 1.73-1.45 (m, 6H), 1.44-1.34 
(m, 2H), 1.33-1.15 (m, 16H), 1.14-0.94 (m, 4H), 0.85 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 74.0 ° 
(C = 0.3, DMSO). 
 
Analytical data of compound 349 
O
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Peptide 349 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 12 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 907.2 [M+H]+, 929.4 [M+Na]+; Rt = 
10.35 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.16 (s, 1H), 9.07 (s, 1H), 9.07 (s, 1H), 8.29 (d, 
J = 7.8 Hz, 1H), 8.27 (d, J = 10.4 Hz, 1H), 8.09 (d, J = 8.2 Hz, 1H), 7.91 (d, J = 7.9 Hz, 1H), 
7.71 (d, J = 8.9 Hz, 2H), 7.18-7.11 (m, 1H), 7.03 (d, J = 8.5 Hz, 2H), 6.99-6.87 (m, 8H), 6.61 (d, 
J = 8.5 Hz, 2H), 6.57 (d, J = 8.5 Hz, 2H), 6.51 (d, J = 8.5 Hz, 2H), 4.51 (ddd, J = 10.3, 8.3, 4.1 
Hz, 1H), 4.46-4.38 (m, 2H), 4.25 (dd, J = 15.6, 6.2 Hz, 1H), 4.14 (dd, J = 15.3, 5.5 Hz, 1H), 3.98 
(t, J = 6.5 Hz, 2H), 2.90-2.83 (m, 2H), 2.83-2.77 (m, 2H), 2.74 (dd, J = 8.2, 5.4 Hz, 1H), 2.66 
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(dd, J = 13.7, 8.1 Hz, 1H), 1.73-1.65 (m, 2H), 1.43-1.34 (m, 2H), 1.34-1.19 (m, 16H), 0.85 (t, J = 
6.8 Hz, 3H) ppm; [ ] =α 20D  - 38.0° (C = 0.8, DMSO). 
 
Analytical data of compound 350 
O
N
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O H
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Peptide 350 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 12 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 893.1 [M+H]+, 915.4 [M+Na]+; Rt = 
10.35 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.74 (s, 1H), 9.14 (s, 1H), 9.07 (s, 1H), 9.04 (s, 
1H), 8.27 (d, J = 8.3 Hz, 1H), 8.21 (d, J = 7.9 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 8.8 
Hz, 2H), 7.69-7.63 (m, 1H), 7.06-7.02 (m, 5H), 6.94 (d, J = 8.5 Hz, 2H), 6.93 (d, J = 8.9 Hz, 
2H), 6.63 (d, J = 8.5 Hz, 2H), 6.57 (d, J = 8.5 Hz, 2H), 6.48 (d, J = 8.4 Hz, 2H), 4.67 (q, J = 
7.3Hz, 1H), 4.55-4.48 (m, 1H), 4.45 (dt, J = 8.5 4.6 Hz, 1H), 3.98 (t, J = 6.5 Hz, 2H), 2.97-2.74 
(m, 5H), 2.71-2.62 (m, 1H), 1.69 ( p, J = 6.4 Hz, 2H), 1.45-1.33 (m, 2H), 1.36-1.19 (m, 16H), 
0.85 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 27.1° (C = 0.8, DMSO). 
 
Analytical data of compound 351 
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Peptide 351 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 15 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 889.4 [M+H]+, 911.5 [M+Na]+; Rt = 
8.45 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.17 (s, 1H), 9.11 (s, 2H), 8.84 (s, 1H), 8.33 (d, J 
= 8.3 Hz, 1H), 8.06 (d, J = 7.5 Hz, 1H), 7.96 (d, J = 7.9 Hz, 1H), 7.85 (t, J = 5.77, 5.77 Hz, 1H), 
7.74 (d, J = 8.8 Hz, 2H), 7.61 (d, J = 15.7 Hz, 2H), 7.03 (d, J = 8.5 Hz, 2H), 6.97 (d, J = 8.5 Hz, 
2H), 6.95 (d, J = 1.2 Hz, 2H), 6.93 (s, 2H), 6.64 (d, J = 8.4 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 
6.54 (d, J = 8.5 Hz, 2H), 4.51 (ddd, J = 10.2, 8.0, 4.6 Hz, 1H), 4.42 (dt, J = 8.4, 8.4, 5.0 Hz, 1H), 
4.31 (q, J = 7.4, 7.4, 7.4 Hz, 1H), 4.04-3.96 (m, 5H), 2.98 (dq, J = 13.8, 13.8, 13.7, 6.8 Hz, 2H), 
2.91-2.80 (m, 6H), 2.79-2.63 (m, 2H), 1.94-1.77 (m, 2H), 1.76-1.65 (m, 2H), 1.47-1.36 (m, 2H), 
1.34-1.20 (m, 18H), 0.85 (t, J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-
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D6): δ = 171.4, 170.7, 170.7, 165.8, 161.0, 155.7, 155.6, 155.5, 135.4, 130.0, 129.9, 129.9, 129.8, 
129.1, 128.2, 127.3, 125.8, 121.5, 121.3, 120.7, 114.8, 114.7, 113.7, 67.5, 55.1, 54.5, 54.5, 54.1, 
45.5, 36.6, 35.7, 34.9, 31.1, 29.4, 28.8, 28.6, 28.5, 28.4, 25.3, 21.9, 13.8 ppm; HRMS (FAB, m-
NBA) m/z calc. for C51H64N6O8 888.4786, found 889.4825 [M+H]+; [ ] =α 20D  - 16.6° (C = 0.9, 
DMSO). 
 
Analytical data of compound 352 
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Peptide 352 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 9 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 756.4 [M+H]+, 778.4 [M+Na]+; Rt = 8.64 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.10 (s, 1H), 8.66 (s, 1H), 8.37 (d, J = 8.5 Hz, 1H), 
8.26 (d, J = 8.0 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.70 (d, J = 8.9 Hz, 2H), 7.25 (s, 1H), 7.02 (d, 
J = 8.4 Hz, 2H), 6.98 (d, J = 8.5 Hz, 1H), 6.94 (d, J = 8.9 Hz, 2H), 6.57 (d, J = 8.5 Hz, 2H), 6.54 
(d, J = 8.5 Hz, 1H), 4.55-4.47 (m, 2H), 4.40 (dd, J = 12.7, 8.2 Hz, 1H), 3.99 (t, J = 6.5 Hz, 2H), 
3.09 (dd, J = 15.1, 5.2 Hz, 1H), 2.96 (dd, J = 15.1, 7.9 Hz, 1H), 2.89 (t, J = 4.1 Hz, 1H), 2.85 (t, 
J = 4.3 Hz, 1H), 2.80-2.64 (m, 2H), 1.73-1.65 (m, 1H), 1.44-1.34 (m, 2H), 1.33-1.22 (m, 16H) , 
0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 38.3° (C = 0.3, DMSO). 
 
Analytical data of compound 353 
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Peptide 353 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 19 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 864.3 [M+H]+, 886.4 [M+Na]+; Rt = 
10.12 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.32 (d, J = 7.3 Hz, 1H), 8.28 (d, J = 8.4 Hz, 
1H), 7.84 (d, J = 8.1 Hz, 1H), 7.72 (d, J = 8.7 Hz, 2H), 7.45 (d, J = 3.5 Hz, 1H), 7.20 (d, J = 3.5 
Hz, 1H), 7.04 (d, J = 8.4 Hz, 2H), 6.94 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 8.9 Hz, 2H), 6.62 (d, J = 
8.3 Hz, 2H), 6.58 (d, J = 8.3 Hz, 2H), 6.47 (d, J = 8.3 Hz, 2H), 4.68 (dd, J = 14.5, 7.2 Hz, 1H), 
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4.55-4.43 (m, 2H), 3.98 (t, J = 6.4 Hz, 2H), 2.97-2.92 (m, 1H), 2.89 (dd, J = 13.9, 4.1 Hz, 2H), 
2.80 (dt, J = 14.5, 14.1 Hz, 2H), 2.67 (dd, J = 14.1, 8.3 Hz, 1H), 1.73-1.65 (m, 2H), 1.43-1.34 
(m, 2H), 1.32-1.20 (m, 2H), 0.83 (t, J = 6.6 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-
D6): δ =171.2, 170.9, 170.0, 165.6, 160.9, 157.5, 155.8, 155.6, 155.4, 137.5, 130.1, 130.0, 129.9, 
129.1, 128.4, 127.2, 126.8, 125.9, 114.8, 114.7, 114.6, 113.7, 113.7, 113.5, 67.5, 54.9, 54.3, 53.6, 
36.6, 36.4, 35.7, 31.1, 28.8, 28.6, 28.6, 28.4, 25.3, 21.9, 13.8 ppm; [ ] =α 20D  - 14.8° (C = 1.2, 
DMSO). 
 
Analytical data of compound 354 
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Peptide 354 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 638.3 [M+H]+, 660.4 [M+Na]+; Rt = 
5.77 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.88 (s, 1H), 8.86 (s, 1H), 8.43 (d, J = 7.3 Hz, 
1H), 8.24 (d, J = 7.9 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.26 (s, 1H), 7.21 (s, 1H), 6.97 (d, J = 8.5 
Hz, 2H), 6.65 (d, J = 8.5 Hz, 2H), 4.59 (dt, J = 8.0, 8.0, 5.7 Hz, 1H), 4.52 (dt, J = 8.4, 8.3, 5.7 
Hz, 1H), 4.40 (dd, J = 14.0, 7.4 Hz, 1H), 3.56 (s, 3H), 3.12-3.01 (m, 2H), 3.00-2.91 (m, 2H), 
2.91-2.79 (m, 2H), 2.06 (t, J = 7.5, 7.5 Hz, 2H), 1.50-1.33 (m, 2H), 1.32-1.09 (m, 14H), 0.85 (t, J 
= 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 172.5, 171.5, 170.1, 169.8, 156.0, 
133.8, 133.6, 133.6, 129.8, 129.6, 129.2, 126.6, 116.6, 115.0, 54.0, 51.7, 51.5, 51.3, 35.7, 35.0, 
31.2, 28.9, 28.8, 28.6, 28.5, 28.4, 26.8, 26.7, 24.9, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z 
calc. for C33H47N7O6 637.3588, found 638.3646 [M+H]+; [ ] =α 20D  - 1.5° (C = 1.1, DMSO). 
 
Analytical data of compound 355 
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Peptide 355 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 12 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 777.3 [M+H]+, 799.4 [M+Na]+; Rt = 
7.64 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.89 (s, 1H), 8.87 (s, 1H), 8.83 (s, 1H), 8.55 (d, J 
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= 7.8 Hz, 1H), 8.33 (t, J = 7.9, 7.9 Hz, 2H), 8.06 (t, J = 5.6, 5.6 Hz, 1H), 7.77 (d, J = 8.9 Hz, 
2H), 7.33 (s, 1H), 7.30 (s, 2H), 6.98 (d, J = 8.9 Hz, 2H), 4.72-4.65 (m, 1H), 4.61-4.51 (m, 2H), 
4.01 (t, J = 6.5, 6.5 Hz, 2H), 3.56-3.41 (m, 2H), 3.33-3.21 (m, 2H), 3.21-3.16 (m, 1H), 3.17-3.06 
(m, 3H), 3.06-2.92 (m, 3H), 1.82-1.59 (m, 2H), 1.46-1.36 (m, 2H), 1.35-1.20 (m, 14H), 0.85 (d, J 
= 7.0 Hz, 3H) ppm; HRMS (FAB, m-NBA) m/z calc. for C39H56N10O7 776.4333, found 777.4422 
[M+H]+; [ ] =α 20D  - 8.5° (C = 0.4, DMSO). 
 
Analytical data of compound 356 
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Peptide 356 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 13 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 777.3 [M+H]+; Rt = 7.57min; 1H NMR 
(400 MHz, DMSO-D6): δ = 8.87 (s, 1H), 8.86 (s, 1H) 8.80 (s, 1H), 8.55 (d, J = 7.7 Hz, 1H), 8.41-
8.26 (m, 2H), 8.06 (t, J = 5.5, 5.5 Hz, 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.32 (s, 1H), 7.30 (s, 2H), 
6.98 (d, J = 8.9 Hz, 2H), 4.73-4.65 (m, 1H), 4.60-4.51 (m, 2H), 4.01 (t, J = 6.5, 6.5 Hz, 2H), 
3.57-3.42 (m, 1H), 3.32-3.25 (m, 2H), 3.21-3.17 (m, 1H), 3.16-2.93 (m, 7H), 1.86-1.59 (m, 2H), 
1.46-1.36 (m, 2H), 1.35-1.22 (m, 14H), 0.84 (t, J = 7.0, 7.0 Hz, 3H) ppm; 13C NMR (100 MHz, 
DMSO-D6): δ = 170.5, 169.8, 169.7, 166.1, 161.2, 158.3, 133.8, 130.0, 129.2, 129.2, 125.4, 
116.7, 116.6, 116.5, 113.8, 70.0, 69.9, 67.6, 63.4, 52.5, 52.4, 51.9, 42.1, 42.1, 31.1, 28.8, 28.6, 
28.5, 28.4, 25.3, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for C39H56N10O7 776.4333, 
found 777.4413 [M+H]+; [ ] =α 20D  - 5.2° (C = 0.8, DMSO). 
 
Analytical data of compound 357 
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Peptide 357 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 754.3 [M+H]+; Rt = 8.93min; 1H NMR 
(400 MHz, DMSO-D6): δ = 9.14 (s, 1H), 8.81 (s, 1H), 8.55 (d, J = 7.5 Hz, 1H), 8.43 (d, J = 8.3 
Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.25 (d, J = 6.4 Hz, 2H), 7.21 (s, 2H), 
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7.19 (s, 1H), 7.04-6.93 (m, 4H), 6.54 (d, J = 8.5 Hz, 2H), 4.73 (dt, J = 9.1, 8.9, 5.3 Hz, 1H), 4.54-
4.41 (m, 2H), 4.02 (t, J = 6.5, 6.5 Hz, 2H), 3.57 (s, 3H), 3.14-2.99 (m, 3H), 2.96 (dd, J = 13.9, 
5.4 Hz, 1H), 2.86 (dd, J = 13.9, 4.3 Hz, 1H), 2.68 (dd, J = 14.0, 8.3 Hz, 1H), 1.84-1.58 (m, 2H), 
1.48-1.36 (m, 2H), 1.36-1.18 (m, 14H), 0.85 (t, J = 6.8, 6.8 Hz, 1H) ppm ; 13C NMR (100 MHz, 
DMSO-D6): δ = 171.5, 170.9, 169.8, 165.8, 161.1, 155.6, 136.8, 130.0, 129.2, 128.9, 128.1, 
127.1, 126.4, 125.5, 114.7, 113.7, 109.1, 67.6, 53.8, 53.5, 52.0, 51.7, 36.5, 31.1, 28.8, 28.6, 28.5, 
28.4, 25.3, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for C43H55N5O7 753.4101, found 
754.4174 [M+H]+; [ ] =α 20D  - 14.7° (C = 0.7, DMSO). 
 
Analytical data of compound 358 
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Peptide 358 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 624.2 [M+H]+, 646.4 [M+Na]+; Rt = 
5.89 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (1H), 8.85 (1H), 8.25 (d, J = 7.4 Hz, 1H), 
8.21 (d, J = 7.9 Hz, 1H), 8.12 (d, J = 7.9 Hz, 1H), 7.26 (s, 1H), 7.22 (s, 1H), 7.00 (d, J = 8.4 Hz, 
2H), 6.64 (d, J = 8.5 Hz, 2H), 4.60 (dt, J = 8.1, 8.0, 5.5 Hz, 1H), 4.52 (dt, J = 8.4, 8.3, 5.3 Hz, 
1H), 4.36 (dt, J = 8.1, 8.0, 5.5 Hz, 1H), 3.08 (dd, J = 15.6, 5.1 Hz, 1H), 1.45-1.35 (m, 2H), 1.33-
1.05 (m, 14H), 0.85 (t, J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-D6): δ = 172.5, 
172.5, 170.1, 169.7, 155.9, 133.6, 133.6, 129.9, 129.6, 129.3, 127.0, 116.6, 114.9, 109.2, 53.9, 
51.5, 51.4, 35.7, 35.0, 31.2, 28.9, 28.8, 28.6, 28.5, 28.4, 26.7, 26.7, 24.9, 21.9, 13.8 ppm; HRMS 
(FAB, m-NBA) m/z calc. for C32H45N7O6 623.3431, found 624.3506 [M+H]+; [ ] =α 20D  + 2.6° (C 
= 1.6, DMSO). 
 
Analytical data of compound 359 
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Peptide 359 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 747.2 [M+H]+, 769.4 [M+Na]+; Rt = 6.65 
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min; 1H NMR (400 MHz, DMSO-D6): δ = 8.85 (s, 1H), 8.81 (s, 1H), 8.54 (t, J = 6.5 Hz, 1H), 
8.37 (d, J = 6.9 Hz, 1H), 7.76 (s, 1H), 7.74 (s, 1H), 7.29 (s, 1H), 7.27 (s, 2H), 6.96 (d, J = 8.9 Hz, 
2H), 4.66 (td, J = 7.2, 5.2 Hz, 1H), 4.55 (dt, J = 8.1 5.0 Hz, 1H), 4.25 (t, J = 5.2 Hz, 1H), 3.99 (t, 
J = 6.4 Hz, 2H), 3.57-3.54 (m, 1H), 3.25-3.14 (m, 1H), 3.15-3.03 (m, 1H), 3.03-2.94 (m, 1H), 
1.74-1.65 (m, 2H), 1.44-1.34 (m, 2H), 1.34-1.20 (m, 16H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  
- 19.2° (C = 0.4, DMSO). 
 
Analytical data of compound 360 
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Peptide 360 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 822.3 [M+H]+; Rt = 8.32 min; 1H NMR 
(400 MHz, DMSO-D6): δ = 8.92 (d, J = 1.3 Hz, 1H), 8.53 (d, J = 7.3 Hz, 1H), 8.48 (d, J = 8.2 
Hz, 1H), 7.83 (d, J = 8.2 Hz, 1H), 7.77 (d, J = 8.9 Hz, 2H), 7.46 (d, J = 3.5 Hz, 1H), 7.34-7.21 
(m, 7H), 7.21-7.13 (m, 1H), 6.96 (d, J = 8.9 Hz, 2H), 6.92 (d, J = 8.5 Hz, 2H), 6.44 (d, J = 8.5 
Hz, 2H), 4.95-4.63 (m, 2H), 4.45 (dt, J = 8.4, 8.4, 4.3 Hz, 1H), 4.00 (t, J = 6.5, 6.5 Hz, 2H), 3.22-
2.98 (m, 3H), 2.97-2.83 (m, 2H), 2.70 (dd, J = 13.9, 8.4 Hz, 1H), 1.75-1.64 (m, 2H), 1.47-1.34 
(m, 2H), 1.34-1.13 (m, 16H), 0.82 (t, J = 7.0, 7.0 Hz, 3H) ppm; HRMS (FAB, m-NBA) m/z calc. 
for C45H55N7O6S 821.3935, found 822.3965 [M+H]+; [ ] =α 20D  - 6.6° (C = 0.3, DMSO). 
 
Analytical data of compound 361 
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Peptide 361 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 783.3 [M+H]+; Rt = 8.28 min. 
 
Analytical data of compound 362 
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Peptide 362 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 4 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 847.6 [M+H]+, 869.5 [M+Na]+; Rt = 6.94 
min. 
 
Analytical data of compound 363 
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Peptide 363 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 783.3 [M+H]+, 805.4 [M+Na]+; Rt = 7.79 
min. 
 
Analytical data of compound 364 
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Peptide 364 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 739.4 [M+H]+, 761.5 [M+Na]+; Rt = 8.01 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.07 (s, 1H), 8.42 (d, J = 7.1 Hz, 1H), 8.14 (d, J = 7.8 
Hz, 1H), 7.75 (d, J = 8.7 Hz, 2H), 7.28-7.12 (m, 7H), 7.06 (s, 1H), 6.97 (d, J = 8.9 Hz, 2H), 6.50 
(d, J = 8.4 Hz, 2H), 4.67-4.59 (m, 1H), 4.46-4.30 (m, 2H), 4.00 (t, J = 6.3 Hz, 2H), 3.04-2.94 (m, 
2H), 2.85-2.76 (m, 2H), 2.70-2.63 (m, 1H), 1.70 (p, J = 6.7, Hz, 2H), 1.44-1.35 (m, 2H), 1.34-
1.21 (m, 16H), 0.83 (t, J = 6.7 Hz, 3H) ppm; [ ] =α 20D  - 13.0° (C = 0.2, DMSO). 
 
Analytical data of compound 365 
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Peptide 365 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 740.3 [M+H]+; Rt = 8.09 min; 1H NMR 
(500 MHz, DMSO-D6): δ = 9.14 (d, J = 5.70 Hz, 1H), 8.39 (d, J = 7.6 Hz, 2H), 8.18 (t, J = 6.7, 
6.7 Hz, 1H), 7.83 (s, 1H), 7.76 (d, J = 8.7 Hz, 2H), 7.58 (d, J = 8.7 Hz, 1H), 7.35-7.08 (m, 4H), 
7.04-6.84 (m, 4H), 6.52 (d, J = 8.3 Hz, 2H), 4.64 (dd, J = 13.8, 8.0 Hz, 1H), 4.52-4.35 (m, 2H), 
4.01 (t, J = 6.4, 6.4 Hz, 2H), 3.16-3.01 (m, 2H), 3.01-2.80 (m, 3H), 2.66 (dd, J = 14.3, 8.9 Hz, 
1H), 1.86-1.60 (m, 2H), 1.49-1.36 (m, 2H), 1.36-1.15 (m, 16H), 0.85 (t, J = 6.8, 6.8 Hz, 3H) 
ppm; [ ] =α 20D  + 16.3° (C = 0.6, DMSO). 
 
Analytical data of compound 366 
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Peptide 366 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 9 %; Purity > 90% (LC_MS); LC-MS (C4, ESI_MS) 813.4 [M+H]+, 835.5 [M+Na]+; Rt = 8.47 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.12 (d, J = 5.5 Hz, 1H), 8.79-8.69 (m, 1H), 8.43 (d, J 
= 7.8 Hz, 1H), 8.22 (d, J = 8.2 Hz, 1H), 8.18-8.14 (m, 1H), 7.75 (d, J = 8.8 Hz, 2H), 7.57 (d, J = 
8.8 Hz, 1H), 7.24-7.12 (m, 7H), 6.97 (d, J = 8.9 Hz, 2H), 6.90 (d, J = 8.4 Hz, 2H), 6.49 (d, J = 
8.4 Hz, 2H), 4.71 (dt, J = 8.6 5.3 Hz, 1H), 4.57-4.45 (m, 1H), 4.39 (dt, J = 8.1 4.6 Hz, 1H), 4.00 
(t, J = 6.4 Hz, 2H), 3.47-3.38 (m, 2H), 3.25 (dd, J = 5.5, 2.4 Hz, 1H), 3.24-3.20 (m, 2H), 3.19-
3.13 (m, 1H), 3.07-2.94 (m, 3H), 2.85-2.74 (m, 2H), 2.70-2.62 (m, 1H), 1.70 ( p, J = 6.8 Hz, 2H), 
1.47-1.34 (m, 2H), 1.32-1.15 (m, 16H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 6.5° (C = 0.7, 
DMSO). 
 
Analytical data of compound 367 
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Peptide 367 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 809.3 [M+H]+; Rt = 8.80 min. 
 
Analytical data of compound 368 
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Peptide 368 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 90% (LC_MS); LC-MS (C4, ESI_MS) 667.2 [M+H]+, 689.4 [M+Na]+; Rt = 5.39 
min; 1H NMR (400 MHz, DMSO-D6): δ =  8.89 (s, 2H), 8.39 (d, J = 7.7 Hz, 1H), 8.34 (d, J = 
8.0 Hz, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.30 (s, 1H), 7.28 (s, 1H), 6.97 (d, J = 8.5 Hz, 2H), 6.60 (d, 
J = 8.5 Hz, 2H), 4.66 (dd, J = 13.2, 7.8 Hz, 1H), 4.52 (dt, J = 8.4, 8.3, 5.4 Hz, 1H), 4.38-4.27 (m, 
1H), 4.24 (t, J = 5.2, 5.2 Hz, 2H), 3.14-3.01 (m, 5H), 2.94 (dd, J = 15.0, 8.6 Hz, 1H), 2.78 (dd, J 
= 13.7, 4.0 Hz, 1H), 2.69-2.52 (m, 1H), 2.24-1.74 (m, 2H), 1.49-1.28 (m, 2H), 1.28-1.02 (m, 
14H), 0.84 (t, J = 6.7, 6.7 Hz, 3H) ppm; HRMS (FAB, m-NBA) m/z calc. for C34H50N8O6 
666.3853, found 667.3948 [M+H]+; [ ] =α 20D  - 1.5° (C = 0.2, DMSO). 
 
Analytical data of compound 369 (Two diastereoisomers) 
N
H
H
N
N
H
H
N
O
NH
N
O
NH
N
O
OH
O
OH
OH
 
 
Peptide 369 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 17 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 697.3 [M+H]+, 719.5 [M+Na]+; Rt = 
5.48 min; 1H NMR (400 MHz, DMSO-D6): δ =  8.68 (s, 1H), 8.65 (s, 1H), 7.24 (s, 1H), 7.16 (s, 
1H), 7.02 (d, J = 8.49 Hz, 2H), 6.65 (d, J = 8.55 Hz, 2H), 4.59 (t, J = 6.3, 6.3 Hz, 1H), 4.54 (dd, 
J = 8.4, 6.2 Hz, 1H), 4.43 (ddd, J = 8.7, 6.4, 4.7 Hz, 1H), 3.65-3.53 (m, 1H), 3.48-3.29 (m, 2H), 
3.22 (d, J = 5.6 Hz, 1H), 3.20-3.03 (m, 4H), 3.01-2.92 (m, 2H), 2.81 (dd, J = 13.9, 8.6 Hz, 1H), 
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2.14 (t, J = 7.9, 7.9 Hz, 2H), 1.60-1.38 (m, 2H), 1.34-1.10 (m, 14H), 0.84 (t, J = 6.9, 6.9 Hz, 3H) 
ppm; 13C NMR (100 MHz, DMSO-D6): δ = 176.5, 174.2, 172.4, 172.4, 171.6, 157.4, 135.1, 
135.1, 135.1, 135.1, 135.0, 131.4, 128.7, 128.7, 118.8, 118.4, 116.4, 116.4, 116.3, 71.9, 71.7, 
64.9, 64.8, 56.9, 56.8, 53.7, 53.6, 43.5, 43.3, 38.1, 38.1, 36.7, 33.0, 30.7, 30.6, 30.4, 30.3, 28.2, 
28.0, 28.0, 26.8, 23.7, 14.4 ppm; HRMS (FAB, m-NBA) m/z calc. for C35H52N8O7 696.3959, 
found 697.4041 [M+H]+. 
 
Analytical data of compound 370 
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Peptide 370 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 13 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 694.4 [M+H]+, 716.5 [M+Na]+; Rt = 
4.93 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.72 (d, J = 1.40 Hz, 1H), 8.71 (d, J = 1.39 Hz, 
1H), 7.24 (d, J = 1.27 Hz, 1H), 7.19 (d, J = 1.27 Hz, 1H), 7.02 (d, J = 8.60 Hz, 2H), 6.66 (d, J = 
8.6 Hz, 2H), 4.60 (dd, J = 7.4, 5.8 Hz, 1H), 4.55 (dd, J = 8.7, 5.7 Hz, 1H), 4.40 (dd, J = 8.1, 6.9 
Hz, 1H), 3.24-3.02 (m, 5H), 3.02-2.90 (m, 2H), 2.89-2.79 (m, 3H), 2.13 (t, J = 8.1, 8.1 Hz, 2H), 
1.67-1.39 (m, 6H), 1.35-1.12 (m, 14H), 0.84 (t, J = 6.9, 6.9 Hz, 3H) ppm; 13C NMR (100 MHz, 
DMSO-D6): δ = 174.5, 171.6, 170.4, 169.6, 155.4, 132.9, 132.9, 129.4, 129.0, 128.5, 126.7, 
116.6, 116.4, 114.3, 54.9, 51.6, 51.6, 38.3, 37.5, 36.2, 34.6, 31.0, 28.6, 28.6, 28.4, 28.2, 25.9, 
25.7, 25.1, 24.7, 23.7, 21.7, 12.4 ppm; HRMS (FAB, m-NBA) m/z calc. for C36H55N9O5 
693.4326, found 694.4418 [M+H]+; [ ] =α 20D  - 2.5° (C = 0.8, DMSO). 
 
Analytical data of compound 371 
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Peptide 371 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 8 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 667.3 [M+H]+, 689.3 [M+Na]+; Rt = 5.00 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.82 (s, 2H), 8.34 (d, J = 7.6 Hz, 1H), 8.25 (d, J = 7.7 
Hz, 1H), 8.10 (d, J = 7.8 Hz, 1H), 7.22 (s, 1H), 7.19 (s, 1H), 6.97 (d, J = 8.5 Hz, 2H), 6.64 (d, J 
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= 8.5 Hz, 2H), 4.56 (dt, J = 8.2 5.2 Hz, 1H), 4.50 (dt, J = 8.0, 4.2 Hz, 1H), 4.25-4.11 (m, 2H), 
3.07 (t, J = 5.4 Hz, 2H), 3.05-2.89 (m, 4H), 2.84 (dd, J = 15.2, 9.2 Hz, 2H), 2.04 (t, J = 7.4 Hz, 
2H), 1.41-1.33 (m, 2H), 1.30-1.14 (m, 14H), 1.13-1.08 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; 
[ ] =α 20D  - 1.6° (C = 0.5, DMSO). 
 
Analytical data of compound 372 
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Peptide 372 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 12 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 650.3 [M+H]+, 672.3 [M+Na]+; Rt = 
6.90 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.21 (br s, 1H), 9.14 (br s, 1H), 8.80 (s, 1H), 8.25 
(d, J = 8.2 Hz, 1H), 8.06 (d, J = 7.5 Hz, 1H), 7.94 (d, J = 7.9 Hz, 1H), 7.24 (s, 1H), 6.99 (d, J = 
8.4 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.5 Hz, 2H), 4.59 (dt, 
J = 7.9, 7.6, 5.4 Hz, 1H), 4.41-4.27 (m, 2H), 3.05 (dd, J = 15.4, 5.3 Hz, 1H), 2.96-2.85 (m, 2H), 
2.85-2.74 (m, 2H), 2.58 (dd, J = 13.8, 10.5 Hz, 1H), 1.99 (dt, J = 7.1, 6.9, 1.0 Hz, 1H), 1.39-1.29 
(m, 2H), 1.29-1.02 (m, 14H), 0.84 (t, J = 6.8, 6.8 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-
D6): δ = 172.5, 172.4, 171.6, 169.6, 155.8, 155.6, 133.5, 129.9, 129.8, 129.4, 127.8, 127.0, 116.6, 
114.9, 114.6, 54.2, 53.7, 51.2, 36.1, 35.7, 35.0, 31.1, 28.8, 28.8, 28.6, 28.5, 28.3, 27.0, 25.1, 21.9, 
13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for C35H47N5O7 649.3475, found 650.3561 [M+H]+; 
[ ] =α 20D  + 13.1° (C = 1.0, DMSO). 
 
Analytical data of compound 373 
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Peptide 373 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 23 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 664.3 [M+H]+, 686.3 [M+Na]+; Rt = 
7.00 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.24 (br s, 1H), 9.14 (br s, 1H), 8.92 (d, J = 1.2 
Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.26 (d, J = 7.3 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.27 (s, 1H), 
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6.99 (d, J = 8.5 Hz, 2H), 6.95 (d, J = 8.5 Hz, 2H), 6.64 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.5 Hz, 
2H), 4.60 (dt, J = 8.2, 8.2, 5.8 Hz, 1H), 4.43-4.27 (m, 2H), 3.55 (s, 3H), 3.05 (dd, J = 15.1, 5.6 
Hz, 1H), 2.95-2.81 (m, 3H), 2.78 (dd, J = 14.2, 3.5 Hz, 1H), 2.58 (dd, J = 13.9, 10.3 Hz, 1H), 
2.00 (t, J = 7.0, 7.0 Hz, 2H), 1.49-1.29 (m, 2H), 1.29-1.01 (m, 14H), 0.83 (t, J = 6.9, 6.9 Hz, 3H) 
ppm; 13C NMR (100 MHz, DMSO-D6): δ = 172.4, 171.6, 171.5, 169.7, 155.9, 155.6, 133.5, 
129.8, 129.0, 127.7, 126.6, 116.6, 114.9, 114.6, 54.3, 53.9, 51.7, 51.1, 36.1, 35.7, 35.0, 31.2, 28.8, 
28.8, 28.6, 28.5, 28.4, 26.8, 25.1, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for 
C36H49N5O7 663.3632, found 664.3681 [M+H]+; [ ] =α 20D  + 13.1° (C = 1.6, DMSO). 
 
Analytical data of compound 374 
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Peptide 374 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 18 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 757.4 [M+H]+, 779.4 [M+Na]+; Rt = 
6.07 min; 1H NMR (400 MHz, DMSO-D6): δ =  8.92 (s, 1H), 8.91 (d, J = 1.0 Hz, 2H), 8.29 (d, J 
= 7.9 Hz, 1H), 8.09 (t, J = 5.7 Hz, 1H), 8.02 (d, J = 7.3 Hz, 1H), 7.98 (d, J = 7.8 Hz, 1H), 7.65 
(s, 1H), 7.62 (s, 1H), 7.27 (s, 1H), 6.99 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 
8.5 Hz, 2H), 6.60 (d, J = 8.5 Hz, 2H), 4.55 (dt, J = 8.1 5.77Hz, 1H), 4.36-4.27 (m, 2H), 4.01 (t, J 
= 7.0 Hz, 2H), 3.09-2.99 (m, 2H), 2.98-2.89 (m, 2H), 2.86-2.73 (m, 4H), 2.59 (dd, J = 13.8, 10.5 
Hz, 1H), 2.03-1.97 (m, 1H), 1.88-1.80 (m, 2H), 1.38-1.30 (m, 2H), 1.28-1.13 (m, 14H), 1.13-1.03 
(m, 2H), 0.83 (t, J = 6.9 Hz, 3H) ppm; [ ] =α 20D  + 6.6° (C = 1.5, DMSO). 
 
Analytical data of compound 375 
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Peptide 375 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 20 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 697.4 [M+H]+, 719.4 [M+Na]+; Rt = 
5.85 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.90 (s, 2H), 8.31 (d, J = 8.0 Hz, 1H), 8.21 (dd, J 
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= 7.6, 2.9 Hz, 1H), 8.01 (t, J = 5.1 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.31 (s, 1H), 7.29 (s, 1H), 
6.98 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.4 Hz, 2H), 4.57-4.50 (m, 2H), 4.33 (ddd, J = 11.6, 7.7, 
3.9 Hz, 1H), 3.50-3.43 (m, 1H), 3.31-3.19 (m, 3H), 3.12-3.04 (m, 2H), 3.01-2.91 (m, 3H), 2.79 
(dd, J = 14.0, 3.8 Hz, 1H), 2.00 (dt, J = 7.2, 2.7 Hz, 2H), 1.37-1.29 (m, 2H), 1.27-1.13 (m, 14H), 
1.11-1.04 (m, 2H), 0.84 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  + 1.8° (C = 1.6, DMSO). 
 
Analytical data of compound 376 
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Peptide 376 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 32 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 740.4 [M+H]+, 763.4 [M+Na]+; Rt = 
6.25 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.94 (s, 1H), 8.90 (d, J = 1.2 Hz, 1H), 8.25 (d, J 
= 7.7 Hz, 1H), 8.07 (d, J = 8.2 Hz, 1H), 7.97 (t, J = 5.7 Hz, 1H), 7.93 (d, J = 7.8 Hz, 1H), 7.66 
(s, 1H), 7.63 (s, 1H), 7.21-7.13 (m, 6H), 7.00 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.4 Hz, 2H), 4.58-
4.52 (m, 1H), 4.52-4.47 (m, 1H), 4.33 (q, J = 7.4 Hz, 1H), 4.00 (dt, J = 6.8, 1.45 Hz, 2H), 3.05-
2.92 (m, 4H), 2.86-2.70 (m, 4H), 2.02 (t, J = 7.4 Hz, 2H), 1.88-1.79 (m, 2H), 1.36 ( p, J = 7.3 Hz, 
2H), 1.27-1.15 (m, 14H), 1.13-1.08 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 8.4° (C = 
3.3, DMSO). 
 
Analytical data of compound 377 
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Peptide 377 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 5 %; Purity > 90% (LC_MS); LC-MS (C4, ESI_MS) 638.4 [M+H]+, 660.4 [M+Na]+; Rt = 6.03 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (s, 1H), 8.78 (s, 1H), 8.48 (d, J = 7.8 Hz, 1H), 
8.30 (d, J = 7.8 Hz, 1H), 7.94 (d, J = 7.8 Hz, 1H), 7.31 (s, 1H), 7.27 (s, 1H), 6.98 (d, J = 8.5 Hz, 
2H), 6.60 (d, J = 8.5 Hz, 2H), 4.57 (dt, J = 7.7, 5.2 Hz, 1H), 4.52 (dd, J = 7.9, 2.1 Hz, 1H), 4.33 
(ddd, J = 11.8, 7.6, 4.3 Hz, 1H), 3.60 (s, 3H), 3.12 (dd, J = 15.4, 5.5 Hz, 2H), 3.03 (dd, J = 15.7, 
6.6 Hz, 2H), 2.93 (dd, J = 14.7, 7.3 Hz, 1H), 2.79 (dd, J = 13.9, 3.8 Hz, 1H), 2.00 (dt, J = 7.3, 
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2.7 Hz, 2H), 1.38-1.29 (m, 2H), 1.28-1.13 (m, 14H), 1.11-1.05 (m, 2H), 0.84 (t, J = 6.9Hz, 3H) 
ppm; [ ] =α 20D  - 5.0° (C = 0.4, DMSO). 
 
Analytical data of compound 378 
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Peptide 378 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 20 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 694.4 [M+H]+, 716.5 [M+Na]+; Rt = 
5.36 min; 1H NMR (400 MHz, DMSO-D6): δ =  8.94 (s, 2H), 8.37 (d, J = 7.5 Hz, 1H), 8.24 (d, J 
= 7.7 Hz, 1H), 8.10 (t, J = 5.5, 5.5 Hz, 1H), 7.99 (d, J = 7.7 Hz, 1H), 7.84 (br s, 2H), 7.32 (s, 
1H), 7.30 (s, 1H), 6.99 (d, J = 8.48 Hz, 2H), 6.61 (d, J = 8.44 Hz, 2H), 4.54 (dd, J = 13.2, 7.7 
Hz, 1H), 4.49 (dd, J = 13.4, 7.5 Hz, 1H), 4.37-4.28 (m, 1H), 3.18-2.91 (m, 6H), 2.89-2.71 (m, 
3H), 2.58 (dd, J = 14.2, 10.1 Hz, 1H), 2.01 (dt, J = 7.2, 7.0, 3.0 Hz, 2H), 1.55-1.45 (m, 2H), 1.45-
1.38 (m, 2H), 1.38-1.30 (m, 2H), 1.29-1.02 (m, 14H), 0.85 (t, J = 6.8, 6.8 Hz, 3H) ppm; 13C 
NMR (100 MHz, DMSO-D6): δ = 172.6, 172.0, 169.7, 169.5, 158.6, 155.7, 133.7, 133.6, 129.8, 
129.3, 129.2, 127.7, 116.7, 114.7, 54.4, 51.9, 51.7, 38.3, 38.0, 36.0, 35.0, 31.2, 28.9, 28.8, 28.6, 
28.6, 28.4, 26.9, 26.4, 25.7, 25.0, 24.3, 22.0, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for 
C36H55N9O5 693.4326, found 694.4382 [M+H]+; [ ] =α 20D  - 1.1° (C = 1.6, DMSO). 
 
Analytical data of compound 379 
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Peptide 379 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 16 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 731.4 [M+H]+, 753.4 [M+Na]+; Rt = 
5.40 min; 1H NMR (400 MHz, DMSO-D6): δ = 9.03 (s, 1H), 8.94 (s, 2H), 8.39 (d, J = 7.9 Hz, 
1H), 8.28 (d, J = 7.7 Hz, 1H), 8.16 (t, J = 5.6, 5.6 Hz, 1H), 7.99 (d, J = 7.4 Hz, 1H), 7.72 (t, J = 
1.5, 1.5 Hz, 1H), 7.66 (t, J = 1.4, 1.4 Hz, 1H), 7.33 (s, 1H), 7.29 (s, 1H), 6.96 (d, J = 8.5 Hz, 2H), 
6.59 (d, J = 8.5 Hz, 2H), 4.52 (dt, J = 8.1, 8.0, 5.3 Hz, 1H), 4.45 (dt, J = 8.0, 7.9, 5.9 Hz, 1H), 
4.35-4.25 (m, 1H), 4.13 (t, J = 7.1, 7.1 Hz, 2H), 3.43-2.88 (m, 6H), 2.77 (dd, J = 13.7, 4.5 Hz, 
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1H), 2.57 (dd, J = 14.0, 10.5 Hz, 1H), 2.10-1.96 (m, 2H), 1.96-1.86 (m, 2H), 1.40-1.28 (m, 2H), 
1.28-1.00 (m, 14H), 0.83 (t, J = 6.9, 6.9 Hz, 3H) ppm; 13C NMR (100 MHz, DMSO-
D6): δ = 172.7, 172.0, 169.9, 169.7, 155.6, 135.3, 133.7, 133.6, 129.7, 129.3, 129.2, 127.6, 121.7, 
120.1, 116.7, 116.6, 114.6, 54.5, 52.1, 51.7, 45.8, 35.9, 35.2, 35.0, 31.1, 29.3, 28.8, 28.8, 28.6, 
28.5, 28.4, 26.6, 26.3, 25.0, 21.9, 13.8 ppm; HRMS (FAB, m-NBA) m/z calc. for C38H54N10O5 
730.4279, found 731.4353 [M+H]+; [ ] =α 20D  - 3.0° (C = 1.3, DMSO). 
 
Analytical data of compound 380 
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Peptide 380 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 714.3 [M+H]+, 736.3 [M+Na]+; Rt = 6.15 
min. 
 
Analytical data of compound 381 
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Peptide 381 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 667.3 [M+H]+, 689.3 [M+Na]+; Rt = 5.92 
min 
 
Analytical data of compound 382 
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Peptide 382 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 4 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 623.4 [M+H]+, 645.4 [M+Na]+; Rt = 5.90 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.87 (s, 1H), 8.83 (s, 1H), 8.30 (d, J = 7.6 Hz, 1H), 
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8.16 (d, J = 7.7 Hz, 1H), 7.97 (d, J = 7.5 Hz, 1H), 7.49 (s, 1H), 7.29 (s, 1H), 7.28 (s, 1H), 6.98 (d, 
J = 8.5 Hz, 2H), 6.60 (d, J = 8.4 Hz, 2H), 4.54-4.47 (m, 1H), 4.45 (dt, J = 8.0, 5.4 Hz, 1H), 4.32 
(ddd, J = 11.6, 7.9, 4.0 Hz, 1H), 3.15-3.04 (m, 3H), 2.99-2.90 (m, 2H), 2.79 (dd, J = 14.3, 4.3 
Hz, 1H), 2.00 (dt, J = 7.5, 3.5 Hz, 2H), 1.39-1.29 (m, 2H), 1.26-1.12 (m, 14H), 1.10-1.05 (m, 
2H), 0.84 (t, J = 6.9 Hz, 3H) ppm; [ ] =α 20D  + 10.0° (C = 0.3, DMSO). 
 
Analytical data of compound 383 
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Peptide 383 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 8 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 624.3 [M+H]+, 646.3 [M+Na]+; Rt = 6.23 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.78 (s, 1H), 8.76 (s, 1H), 8.35 (d, J = 7.9 Hz, 1H), 
8.23 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.29 (s, 1H), 7.25 (s, 1H), 6.99 (d, J = 8.4 Hz, 
2H), 6.60 (d, J = 8.4 Hz, 2H), 4.55-4.46 (m, 2H), 4.37-4.30 (m, 1H), 3.14 (dd, J = 15.0, 4.8 Hz, 
1H), 3.10 (dd, J = 10.8, 5.0 Hz, 1H), 3.03 (dd, J = 16.8, 7.0 Hz, 1H), 2.99 (dd, J = 15.1, 8.2 Hz, 
1H), 2.95 (dd, J = 15.2, 8.0 Hz, 1H), 2.80 (dd, J = 13.9, 3.8 Hz, 1H), 1.99 (dt, J = 7.2, 2.9 Hz, 
2H), 1.38-1.29 (m, 2H), 1.28-1.11 (m, 14H), 1.11-1.05 (m, 2H), 0.84 (t, J = 6.8 Hz, 3H) ppm; 
[ ] =α 20D  + 1.5° (C = 0.6, DMSO). 
 
Analytical data of compound 384 
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Peptide 384 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 5 %; Purity > 90% (LC_MS); LC-MS (C4, ESI_MS) 663.4 [M+H]+, 685.4 [M+Na]+; Rt = 5.77 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.99 (d, J = 1.3 Hz, 1H), 8.98 (d, J = 1.3 Hz, 1H), 
8.95 (d, J = 1.3 Hz, 1H), 8.94 (d, J = 1.3 Hz, 1H), 8.54 (dd, J = 7.7, 4.6 Hz, 1H), 8.38 (t, J = 7.8 
Hz, 1H), 8.16 (dd, J = 12.2, 7.4 Hz, 1H), 7.39 (d, J = 2.7 Hz, 1H), 7.33-7.31 (m, 2H), 7.07-7.01 
(m, 2H), 6.80-6.71 (m, 2H), 4.64-4.52 (m, 2H), 4.34-4.27 (m, 1H), 3.26-2.93 (m, 7H), 2.22-2.08 
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(m, 2H), 2.03-1.88 (m, 1H), 1.73-1.62 (m, 1H), 1.54-1.46 (m, 2H), 1.29-1.18 (m, 16H), 0.87-0.81 
(m, 3H) ppm; [ ] =α 20D  - 7.7° (C = 0.4, DMSO). 
 
Analytical data of compound 385 
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Peptide 385 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 11 %; Purity > 85% (LC_MS); Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 700.3 [M-
+H]+, 722.1 [M+Na]+; Rt = 6.09 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.90-8.87 (m, 2H), 
8.36 (t, J = 7.6 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H), 7.99 (d, J = 8.3 Hz, 1H), 7.94 (d, J = 7.1 Hz, 
1H), 7.82-7.73 (m, 1H), 7.34 (d, J = 7.9 Hz, 1H), 7.29 (d, J = 5.7 Hz, 1H), 7.16-7.09 (m, 1H), 
6.98 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 7.4 Hz, 2H), 4.59 (dd, J = 8.0, 5.6 Hz, 1H), 4.56-4.49 (m, 
1H), 4.37-4.30 (m, 1H), 3.21-3.12 (m, 2H), 3.11-3.05 (m, 1H), 3.04-2.91 (m, 2H), 2.83-2.76 (m, 
1H), 2.03-1.97 (m, 2H), 1.38-1.30 (m, 2H), 1.28-1.14 (m, 14H), 1.11-1.04 (m, 2H), 0.86-0.82 (m, 
3H) ppm; [ ] =α 20D  + 3.1° (C = 0.6, DMSO). 
 
Analytical data of compound 386 
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Peptide 386 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 23 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 714.4 [M+H]+, 736.3 [M+Na]+; Rt = 
5.89 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.94 (s, 1H), 8.93 (s, 1H), 8.25 (dd, J = 7.3, 3.1 
Hz, 1H), 8.15 (dd, J = 12.4, 7.9 Hz, 1H), 7.61 (dd, J = 6.0, 3.1 Hz, 1H), 7.33-7.24 (m, 3H), 7.06 
(d, J = 8.5 Hz, 1H), 6.97 (d, J = 8.5 Hz, 2H), 6.59 (d, J = 8.5 Hz, 2H), 4.60 (dt, J = 7.7, 5.9 Hz, 
1H), 4.56-4.49 (m, 2H), 3.25 (dd, J = 13.8, 6.5 Hz, 1H), 3.17-2.99 (m, 3H), 2.86 (dd, J = 15.4, 
9.7 Hz, 2H), 2.04 (dt, J = 7.8, 2.1 Hz, 2H), 1.41-1.33 (m, 2H), 1.28-1.15 (m, 14H), 1.13-1.09 (m, 
2H), 0.85-0.81 (m, 3H) ppm; [ ] =α 20D  + 4.5° (C = 2.1, DMSO). 
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Analytical data of compound 387 
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Peptide 387 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 661.3 [M+H]+, 683.4 [M+Na]+; Rt = 6.43 
min. 
 
Analytical data of compound 388 
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Peptide 388 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 648.3 [M+H]+, 670.3 [M+Na]+; Rt = 5.67 
min. 
 
Analytical data of compound 389 
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Peptide 389 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 13 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 739.4 [M+H]+, 761.4 [M+Na]+; Rt = 
5.99 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.91 (dd, J = 5.4, 1.3 Hz, 1H), 8.36-8.30 (m, 
1H), 8.19 (dd, J = 12.0, 7.4 Hz, 1H), 7.59-7.54 (m, 2H), 7.36-7.29 (m, 3H), 7.25-7.21 (m, 2H), 
7.06-7.00 (m, 2H), 6.79-6.72 (m, 2H), 5.41 (dd, J = 14.4, 7.7 Hz, 1H), 4.58 (dt, J = 8.0, 5.3 Hz, 
1H), 4.34-4.26 (m, 1H), 3.52-3.42 (m, 2H), 3.33-3.20 (m, 2H), 3.19-3.10 (m, 2H), 3.03 (dd, J = 
15.0, 8.2 Hz, 1H), 2.20-2.07 (m, 2H), 2.05-1.93 (m, 1H), 1.74-1.65 (m, 1H), 1.53-1.42 (m, 2H), 
1.25-1.16 (m, 16H), 0.84-0.79 (m, 3H) ppm. 
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Analytical data of compound 390 
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Peptide 390 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 18 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 548.2 [M+H]+, 576.2 [M+Na]+; Rt = 
5.83 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.86 (d, J = 1.2 Hz, 1H), 8.85 (d, J = 1.2 Hz, 
1H), 8.24 (d, J = 7.7 Hz, 1H), 8.19 (d, J = 7.9 Hz, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.29 (s, 1H), 
7.26 (s, 1H), 4.66 (dt, J = 8.0, 5.2 Hz, 1H), 4.52 (dt, J = 8.4, 5.7 Hz, 1H), 4.26 (td, J = 7.8, 4.4 
Hz, 1H), 3.74 (dd, J = 10.9, 5.1 Hz, 1H), 3.63 (dd, J = 10.9, 3.8 Hz, 1H), 3.11 (dd, J = 15.4, 5.2 
Hz, 1H), 3.02 (dd, J = 15.2, 5.5 Hz, 1H), 2.96 (dd, J = 15.3, 8.1 Hz, 1H), 2.87 (dd, J = 15.2, 8.6 
Hz, 1H), 2.05 (t, J = 7.5 Hz, 2H), 1.42-1.34 (m, 2H), 1.30-1.15 (m, 14H), 1.15-1.10 (m, 2H), 0.83 
(t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 3.7° (C = 1.5, DMSO). 
 
Analytical data of compound 391 
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Peptide 391 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 13 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 591.3 [M+H]+, 613.3 [M+Na]+; Rt = 
4.92 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.92 (d, J = 1.1 Hz, 1H), 8.90 (d, J = 1.2 Hz, 
1H), 8.36 (d, J = 7.7 Hz, 1H), 8.26 (d, J = 8.0 Hz, 1H), 8.16 (d, J = 7.8 Hz, 1H), 7.30 (s, 1H), 
7.27 (s, 1H), 4.67 (dt, J = 8.4, 5.2 Hz, 1H), 4.52 (dt, J = 8.5, 5.3 Hz, 1H), 4.44 (td, J = 8.3, 4.2 
Hz, 1H), 4.28-4.16 (m, 2H), 3.83 (dd, J = 11.1, 4.9 Hz, 1H), 3.65 (dd, J = 11.1, 3.9 Hz, 1H), 
3.16-3.07 (m, 5H), 3.03 (dd, J = 15.3, 5.0 Hz, 1H), 2.96 (dd, J = 15.6, 8.7 Hz, 1H), 2.87 (dd, J = 
15.1, 9.4 Hz, 1H), 2.05 (t, J = 7.5Hz, 2H), 1.42-1.33 (m, 2H), 1.28-1.17 (m, 14H), 1.15-1.08 (m, 
2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 3.1° (C = 1.2, DMSO). 
 
Analytical data of compound 392 
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Peptide 392 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 18 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 719.5 [M+H]+, 741.5 [M+Na]+; Rt = 
5.27 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.95 (dd, J = 2.3, 1.4 Hz, 1H), 8.91 (dd, J = 7.5, 
1.3 Hz, 1H), 8.35 (dd, J = 7.4, 4.5 Hz, 1H), 8.25 (dd, J = 10.5, 7.7 Hz, 1H), 8.17 (dd, J = 13.3, 
7.5 Hz, 1H), 8.04 (t, J = 5.5 Hz, 1H), 7.37-7.24 (m, 4H), 7.11-6.97 (m, 2H), 6.74-6.66 (m, 2H), 
4.57-4.50 (m, 1H), 4.48-4.40 (m, 1H), 4.31-4.24 (m, 1H), 3.23-3.02 (m, 4H), 3.02-2.92 (m, 2H), 
2.81-2.71 (m, 2H), 2.22-2.03 (m, 1H), 2.03-1.88 (m, 1H), 1.73-1.59 (m, 1H), 1.57-1.31 (m, 4H), 
1.24-1.17 (m, 16H), 0.85-0.79 (m, 3H) ppm; [ ] =α 20D  - 6.2° (C = 1.5, DMSO). 
 
Analytical data of compound 393 
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Peptide 393 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 5 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 692.3 [M+H]+, 714.5 [M+Na]+; Rt = 5.41 
min. 
 
Analytical data of compound 394 
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Peptide 394 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 7 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 649.4 [M+H]+, 671.3 [M+Na]+; Rt = 5.97 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.94 (dd, J = 3.2, 1.2 Hz, 1H), 8.91 (dd, J = 6.4, 1.2 
Hz, 1H), 8.40-8.28 (m, 1H), 8.14 (t, J = 7.8, 7.8 Hz, 1H), 7.36 (s, 1H), 7.30 (s, 1H), 7.02 (d, J = 
7.0 Hz, 1H), 6.99-6.92 (m, 4H), 6.60 (d, J = 9.6 Hz, 1H), 4.58-4.50 (m, 2H), 4.26 (dd, J = 13.5, 
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8.2 Hz, 1H), 3.16 (dd, J = 8.7, 5.0 Hz, 2H), 3.13-3.04 (m, 3H), 3.02-2.93 (m, 3H), 2.25-2.05 (m, 
2H), 2.02-1.86 (m, 2H), 1.73-1.59 (m, 1H), 1.54-1.42 (m, 2H), 1.27-1.16 (m, 16H), 0.85-0.79 (m, 
3H) ppm; [ ] =α 20D  - 6.6° (C = 0.5, DMSO). 
 
Analytical data of compound 395 
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Peptide 395 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 13 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 655.4 [M+H]+, 677.5 [M+Na]+; Rt = 
4.93 min; 1H NMR (400 MHz, DMSO-D6): δ =  8.98 (s, 1H), 8.91 (s, 1H), 8.91 (s, 1H), 8.23 (d, J 
= 7.8 Hz, 1H), 8.18 (s, 1H), 8.16 (s, 1H), 8.13 (d, J = 7.0 Hz, 1H), 7.71 (t, J = 1.6 Hz, 1H), 7.65 
(t, J = 1.5 Hz, 1H), 7.32 (s, 1H), 7.28 (s, 1H), 4.62 (dt, J = 7.7, 5.5 Hz, 1H), 4.53 (dt, J = 8.5, 4.9 
Hz, 1H), 4.22-4.14 (m, 4H), 3.63 (dd, J = 10.7, 5.7 Hz, 1H), 3.58 (dd, J = 10.8, 5.4 Hz, 1H), 3.11 
(dd, J = 15.1, 5.2 Hz, 1H), 3.04 (dd, J = 10.9, 4.1 Hz, 1H), 2.99 (dd, J = 15.8, 7.1 Hz, 1H), 2.87 
(dd, J = 15.2, 9.2 Hz, 1H), 2.05 (t, J = 7.3 Hz, 2H), 1.98-1.90 (m, 2H), 1.43-1.31 (m, 2H), 1.28-
1.16 (m, 14H), 1.14-1.09 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 6.0° (C = 1.2, DMSO). 
 
Analytical data of compound 396 
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Peptide 396 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 23 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 562.2 [M+H]+, 584.4 [M+Na]+; Rt = 
5.61 min; 1H NMR (400 MHz, DMSO-D6): δ = 8.89 (s, 1H), 8.87 (s, 1H), 8.38 (d, J = 7.5 Hz, 
1H), 8.23 (d, J = 7.9 Hz, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.29 (s, 1H), 7.26 (s, 1H), 4.66 (dt, J = 
8.1, 5.5 Hz, 1H), 4.52 (dt, J = 8.2, 5.6 Hz, 1H), 4.34 (td, J = 7.6, 4.6 Hz, 1H), 3.73 (dd, J = 11.0, 
5.0 Hz, 1H), 3.61 (s, 3H), 3.61 (dd, J = 11.0, 4.3 Hz, 1H), 3.10 (dd, J = 15.3, 5.3 Hz, 1H), 3.02 
(dd, J = 15.3, 5.6 Hz, 1H), 2.95 (dd, J = 14.9, 8.1 Hz, 1H), 2.87 (dd, J = 15.4, 9.0 Hz, 1H), 2.05 
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(t, J = 7.4 Hz, 2H), 1.42-1.34 (m, 2H), 1.27-1.17 (m, 14H), 1.15-1.10 (m, 2H), 0.83 (t, J = 6.8 
Hz, 3H) ppm; [ ] =α 20D  - 6.0° (C = 2.2, DMSO). 
 
Analytical data of compound 397 
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Peptide 397 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 26 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 618.4 [M+H]+, 640.4 [M+Na]+; Rt = 
4.92 min; 1H NMR (400 MHz, DMSO-D6): δ =  8.91 (s, 2H), 8.18 (t, J = 7.8 Hz, 2H), 8.10 (d, J 
= 7.2 Hz, 1H), 8.06 (t, J = 5.6 Hz, 1H), 7.81 (s, 2H), 7.32 (s, 1H), 7.28 (s, 1H), 4.61 (td, J = 7.7, 
5.75 Hz, 1H), 4.53 (dt, J = 8.6, 5.3 Hz, 1H), 4.20 (q, J = 5.6, 5.3 Hz, 1H), 3.58 (dd, J = 5.3, 2.7 
Hz, 2H), 3.16-2.96 (m, 3H), 2.87 (dd, J = 15.3, 9.3 Hz, 1H), 2.05 (t, J = 7.4, Hz, 2H), 1.58-1.47 
(m, 2H), 1.47-1.40 (m, 2H), 1.36 (dd, J = 14.7, 7.2 Hz, 2H), 1.28-1.15 (m, 14H), 1.14-1.09 (m, 
2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 5.9° (C = 2.4, DMSO). 
 
Analytical data of compound 398 
N
H
H
N
N
H
O
O
O
OH
O
H
N
N
H
N
NHN
N
 
 
Peptide 398 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 8 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 624.2 [M+H]+, 646.3 [M+Na]+; Rt = 5.72 
min; 1H NMR (400 MHz, DMSO-D6): δ = 10.46 (s, 1H), 8.91 (s, 1H), 8.89 (s, 1H), 8.31 (ddd, J 
= 4.8, 1.9, 0.9 Hz, 1H), 8.24 (d, J = 7.6 Hz, 1H), 8.21 (d, J = 7.5 Hz, 1H), 8.14 (d, J = 7.7 Hz, 
1H), 8.03 (d, J = 8.4 Hz, 1H), 7.80-7.74 (m, 1H), 7.33 (s, 1H), 7.29 (s, 1H), 7.11 (ddd, J = 7.3, 
4.9, 1.0 Hz, 1H), 4.68 (dd, J = 13.5, 7.5 Hz, 1H), 4.57-4.51 (m, 2H), 3.76 (dd, J = 10.9, 5.3 Hz, 
1H), 3.65 (dd, J = 11.0, 4.9 Hz, 1H), 3.13 (dd, J = 15.1, 5.2 Hz, 1H), 3.04 (dd, J = 15.4, 6.1 Hz, 
1H), 3.00 (dd, J = 15.3, 6.7 Hz, 1H), 2.88 (dd, J = 15.4, 8.1 Hz, 1H), 2.05 (t, J = 7.5 Hz, 2H), 
1.44-1.33 (m, 2H), 1.28-1.16 (m, 14H), 1.14-1.10 (m, 2H), 0.83 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  
- 7.5° (C = 0.6, DMSO). 
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Analytical data of compound 399 
N
H
H
N
N
H
O
O
O
OH
O
NH2
N
H
N
NHN
 
 
Peptide 399 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 547.3 [M+H]+, 569.4 [M+Na]+; Rt = 5.60 
min. 
 
Analytical data of compound 400 
O N
H
H
N
N
H
O
O N
NH
O
O
OH
O
NH2
 
 
Peptide 400 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 553.2 [M+H]+, 575.3 [M+Na]+; Rt = 4.35 
min. 
 
Analytical data of compound 401 
O N
H
H
N
N
H
OH
O N
NH
O
O
OH
O  
 
Peptide 401 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 510.1 [M+H]+, 532.1 [M+Na]+; Rt = 
5.29 min. 
 
Analytical data of compound 402 
O N
H
H
N
N
H
OMe
O N
NH
O
O
OH
O  
 
Peptide 402 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 524.1 [M+H]+, 546.2 [M+Na]+; Rt = 
5.71 min. 
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Analytical data of compound 403 
O N
H
H
N
N
H
NH2
O N
NH
O
O
OH
O  
 
Peptide 403 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 509.1 [M+H]+, 532.2 [M+Na]+; Rt = 
5.03 min. 
 
Analytical data of compound 404 
O N
H
H
N
N
H
H
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O N
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O
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O
OH
OH
 
 
Peptide 404 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 583.2 [M+H]+, 605.3 [M+Na]+; Rt = 
4.93 min. 
 
Analytical data of compound 405 
O N
H
H
N
N
H
H
N
O N
NH
O
O
OH
N  
 
Peptide 405 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 2 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 582.2 [M+H]+, 604.2 [M+Na]+; Rt = 
5.03 min. 
 
Analytical data of compound 406 
O N
H
H
N
N
H
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O N
NH
O
O
OH
O
N N
 
 
Peptide 406 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 90% (LC_MS); LC-MS (C18, ESI_MS) 617.2 [M+H]+, 639.2 [M+Na]+; Rt = 
4.35 min. 
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Analytical data of compound 407 
O N
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Peptide 407 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 567.2 [M+H]+, 589.2 [M+Na]+; Rt = 
4.44 min. 
 
Analytical data of compound 408 
O N
H
H
N
O N
NH
O
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N
O
N
H
O
OH
OH
OH
 
 
Peptide 408 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 597.2 [M+H]+, 619.3 [M+Na]+; Rt = 
4.92 min. 
 
Analytical data of compound 409 
O N
H
H
N
O N
NH
O
H
N
O
N
H
O
OH
NH2
 
 
Peptide 409 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 3 %; Purity > 80% (LC_MS); LC-MS (C18, ESI_MS) 614.2 [M+H]+, 636.2 [M+Na]+; Rt = 
5.59 min. 
 
Analytical data of compound 410 
O N
H
H
N
O N
NH
O
H
N
O
OH
O
OH  
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Peptide 410 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 2 %, Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 524.2 [M+H]+, 546.2 [M+Na]+; Rt = 5.32 
min. 
 
Analytical data of compound 411 
O N
H
H
N
O N
NH
O
H
N
O
N
H
O
OH
S
N
 
 
Peptide 411 was synthesized and released from solid support according to GP 2 and GP 4. Yield 
= 1 %; Purity > 95% (LC_MS); LC-MS (C18, ESI_MS) 606.1 [M+H]+, 628.2 [M+Na]+; Rt = 
5.78 min. 
 
Analytical data of compound 412 
N
H
H
N
N
H
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O
O
H
N
OH
OH OH
 
 
Peptide 412 was synthesized and released from solid support according to GP 2 and GP 5. Yield 
= 10 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 665.3 [M+H]+, 687.3 [M+Na]+; Rt = 
6.89 min; 1H NMR (400 MHz, DMSO-D6): δ = 10.69 (s, 1H), 9.17 (s, 1H), 9.12 (s, 1H), 8.88 (s, 
2H), 8.21 (d, J = 8.0 Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.95 (d, J = 7.8 Hz, 1H), 7.26 (s, 1H), 
7.00 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 8.6 Hz, 2H), 6.62 (d, J = 8.3 Hz, 2H), 6.60 (d, J = 8.2 Hz, 
2H), 4.55 (dd, J = 13.5, 7.6 Hz, 1H), 4.37-4.31 (m, 1H), 4.26 (q, J = 7.8, Hz, 1H), 3.02 (dd, J = 
14.9, 5.5 Hz, 1H), 2.91 (dd, J = 15.1, 7.6 Hz, 1H), 2.79 (dd, J = 12.9, 5.5 Hz, 2H), 2.69 (dd, J = 
12.7, 9.1 Hz, 2H), 1.99 (t, J = 7.0 Hz, 2H), 1.39-1.30 (m, 2H), 1.29-1.12 (m, 14H), 1.11-1.03 (m, 
2H), 0.84 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  + 7.7° (C = 0.8, DMSO). 
 
Analytical data of compound 413 
N
H
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Peptide 413 was synthesized and released from solid support according to GP 2 and GP 5. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 721.4 [M+H]+, 743.3 [M+Na]+; Rt = 7.25 
min; 1H NMR (400 MHz, DMSO-D6): δ = 10.55 (s, 1H), 9.17 (s, 1H), 9.11 (s, 1H), 8.87 (s, 1H), 
8.22 (d, J = 8.17 Hz, 1H), 8.11 (d, J = 7.4 Hz, 1H), 7.94 (d, J = 8.1 Hz, 1H), 7.27 (s, 1H), 7.00 
(d, J = 8.6 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.5 Hz, 2H), 6.60 (d, J = 8.5 Hz, 2H), 
4.57 (q, J = 7.7 Hz, 1H), 4.38-4.29 (m, 2H), 3.02 (dd, J = 15.2, 5.6 Hz, 1H), 2.91 (dd, J = 15.4, 
7.6 Hz, 1H), 2.83-2.70 (m, 3H), 2.63-2.54 (m, 1H), 1.99 (t, J = 7.4 Hz, 2H), 1.38-1.29 (m, 2H), 
1.29-1.12 (m, 14H), 1.11-1.05 (m, 2H), 1.03 (s, 9H), 0.84 (t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  + 
11.2° (C = 0.4, DMSO). 
 
Analytical data of compound 414 
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Peptide 414 was synthesized and released from solid support according to GP 2 and GP 5. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 639.3 [M+H]+, 661.3 [M+Na]+; Rt = 6.00 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.89 (s, 1H), 8.85 (s, 1H), 8.28 (d, J = 3.7 Hz, 1H), 
8.26 (d, J = 3.0 Hz, 1H), 7.95 (d, J = 7.5 Hz, 1H), 7.29 (s, 1H), 7.26 (s, 1H), 6.99 (d, J = 8.5 Hz, 
2H), 6.60 (d, J = 8.5 Hz, 2H), 4.52 (td, J = 7.9, 5.6 Hz, 1H), 4.41 (dd, J = 14.2, 7.7 Hz, 1H), 
4.36-4.30 (m, 1H), 3.08 (dd, J = 6.0, 3.2 Hz, 1H), 3.06-3.02 (m, 2H), 2.92 (dd, J = 14.9, 7.5 Hz, 
2H), 2.79 (dd, J = 13.9, 3.8 Hz, 1H), 2.02-1.97 (m, 2H), 1.38-1.29 (m, 1H), 1.28-1.11 (m, 14H), 
1.10-1.04 (m, 2H), 0.84 (t, J = 6.9 Hz, 3H) ppm; [ ] =α 20D  + 0.6° (C = 0.5, DMSO). 
 
Analytical data of compound 415 
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Peptide 415 was synthesized and released from solid support according to GP 2 and GP 5. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 695.4 [M+H]+, 717.4 [M+Na]+; Rt = 6.22 
min; 1H NMR (400 MHz, DMSO-D6): δ = 9.13 (s, 1H), 8.87 (s, 1H), 8.85 (s, 1H), 8.34 (d, J = 
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7.7 Hz, 1H), 8.28 (d, J = 7.9 Hz, 1H), 7.94 (d, J = 7.5 Hz, 1H), 7.33 (s, 1H), 7.27 (s, 1H), 6.99 (d, 
J = 8.4 Hz, 2H), 6.60 (d, J = 8.5 Hz, 2H), 4.54 (dd, J = 13.5, 7.5 Hz, 1H), 4.45 (q, J = 7.2 Hz, 
1H), 4.37-4.30 (m, 1H), 3.10-3.06 (m, 1H), 3.05-3.01 (m, 2H), 2.97-2.89 (m, 2H), 2.79 (dd, J = 
13.9, 3.5 Hz, 1H), 2.02-1.97 (m, 1H), 1.39-1.29 (m, 2H), 1.29-1.11 (m, 16H), 1.07 (s, 9H), 0.84 
(t, J = 6.8 Hz, 3H) ppm. 
 
Analytical data of compound 416 
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Peptide 416 was synthesized and released from solid support according to GP 2 and GP 3. Yield 
= 5 %; Purity > 85% (LC_MS); LC-MS (C4, ESI_MS) 664.3 [M+H]+, 686.4 [M+Na]+; Rt = 5.73 
min; 1H NMR (400 MHz, DMSO-D6): δ =  8.90 (s, 1H), 8.30 (d, J = 7.8 Hz, 1H), 8.14 (d, J = 
7.5 Hz, 1H), 7.29 (d, J = 4.7 Hz, 2H), 6.93 (d, J = 7.2 Hz, 1H), 6.55 (d, J = 6.7 Hz, 1H), 4.57-
4.50 (m, 1H), 4.37 (dd, J = 14.9, 6.9 Hz, 1H), 4.26 (dd, J = 14.8, 7.9 Hz, 1H), 3.14 (dd, J = 13.6, 
6.6 Hz, 1H), 3.10-3.02 (m, 4H), 3.01-2.95 (m, 1H), 2.23-2.03 (m, 2H), 1.54-1.42 (m, 2H), 1.27-
1.14 (m, 16H), 0.82 (dt, J = 7.0, 2.4 Hz, 3H) ppm; [ ] =α 20D  - 8.0° (C = 0.2, DMSO). 
 
Analytical data of compound 417 
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Peptide 417 was synthesized and released from solid support according to GP 2 and GP 5. Yield 
= 5 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 720.4 [M+H]+, 742.4 [M+Na]+; Rt = 6.00 
min; 1H NMR (400 MHz, DMSO-D6): δ =  8.90 (s, 1H), 8.30 (d, J = 7.8 Hz, 1H), 8.14 (d, J = 
7.5 Hz, 1H), 7.29 (d, J = 4.7 Hz, 2H), 6.93 (d, J = 7.2 Hz, 1H), 6.55 (d, J = 6.7 Hz, 1H), 4.57-
4.50 (m, 1H), 4.37 (dd, J = 14.9, 6.9 Hz, 1H), 4.26 (dd, J = 14.8, 7.9 Hz, 1H), 3.14 (dd, J = 13.6, 
6.6 Hz, 1H), 3.10-3.02 (m, 4H), 3.01-2.95 (m, 1H), 2.23-2.03 (m, 2H), 1.54-1.42 (m, 2H), 1.27-
1.14 (m, 16H), 1.04 (s, 9H), 0.82 (dt, J = 7.0, 2.4 Hz, 3H) ppm; [ ] =α 20D  - 6.5° (C = 0.2, DMSO). 
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Analytical data of compound 418 
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Peptide 418 was synthesized and released from solid support according to GP 2 and GP 5. Yield 
= 6 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 563.3 [M+H]+, 585.3 [M+Na]+; Rt = 5.59 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.83 (s, 1H), 8.80 (s, 1H), 8.15 (s, 1H), 8.13 (s, 1H), 
8.11 (d, J = 1.9 Hz, 1H), 7.27 (s, 1H), 7.26 (s, 1H), 4.59 (dd, J = 13.1, 7.1 Hz, 1H), 4.52 (dt, J = 
8.1, 5.3 Hz, 1H), 4.15 (dd, J = 13.2, 5.8 Hz, 1H), 3.53 (d, J = 6.0 Hz, 1H), 3.06 (dd, J = 15.7, 5.9 
Hz, 1H), 3.02 (dd, J = 16.3, 5.3 Hz, 1H), 2.96 (dd, J = 14.9, 7.3 Hz, 1H), 2.86 (dd, J = 15.1, 8.5 
Hz, 1H), 2.05 (t, J = 7.4 Hz, 2H), 1.43-1.34 (m, 2H), 1.28-1.15 (m, 14H), 1.16-1.07 (m, 2H), 0.84 
(t, J = 6.8 Hz, 3H) ppm; [ ] =α 20D  - 8.7° (C = 0.4, DMSO). 
 
Analytical data of compound 419 
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Peptide 419 was synthesized and released from solid support according to GP 2 and GP 5. Yield 
= 4 %; Purity > 95% (LC_MS); LC-MS (C4, ESI_MS) 619.4 [M+H]+, 641.3 [M+Na]+; Rt = 5.85 
min; 1H NMR (400 MHz, DMSO-D6): δ = 8.83 (s, 1H), 8.14 (d, J = 7.8 Hz, 1H), 8.10 (d, J = 8.0 
Hz, 1H), 7.28 (s, 1H), 7.26 (s, 1H), 4.60 (dd, J = 13.4, 6.8 Hz, 1H), 4.52 (dt, J = 8.2, 5.3 Hz, 1H), 
4.18 (dd, J = 12.7, 6.4 Hz, 1H), 3.55 (d, J = 6.3 Hz, 2H), 3.06 (dd, J = 15.3, 5.6 Hz, 1H), 3.01 
(dd, J = 15.1, 5.0 Hz, 1H), 2.97 (dd, J = 15.9, 5.7 Hz, 1H), 2.86 (dd, J = 15.2, 8.9 Hz, 1H), 2.05 
(t, J = 7.4 Hz, 2H), 1.43-1.34 (m, 2H), 1.27-1.15 (m, 16H), 1.13 (s, 9H), 0.84 (t, J = 6.9 Hz, 3H) 
ppm; [ ] =α 20D  - 16.0° (C = 0.1, DMSO). 
 
General procedure for in vitro screening of peptides library (M) 
 
 
The in vitro screening of peptides was performed in 96 microtiter plate.  50 µL of 0.4 µM Rab 
GGTase and 4 µM NBD-FPP 1 was added to the well followed by 0.5 µL of inhibitor in 10 mM 
DMSO solution. The solution was mixed, shaken and incubated at 37°C for two minutes. 50 µL 
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of 4 µM Rab-7:REP-1 cocktail solution was added to the same well. The measurement was 
started immediately.  
 
Negative control for the bleaching of NBD-FPP 1 caused by inhibitors during in vitro 
screeing (NC) 
 
50 µL of 0.4 µM Rab GGTase and 4 µM NBD-FPP 1 was added to the well followed by 0.5 µL 
of inhibitor in 10 mM DMSO solution. The solution was mixed, shaken and incubated at 37°C for 
two minutes. 50 µL buffer (50 mM Hepes, 50 mM NaCl, 2 mM MgCl2, 5 mM DTE, 20µM GDP, 
0.01% Triton X-100, pH7.2) was added to the same well. The measurement was started 
immediately.  
 
Positive control of measurement (PC) 
 
50 µL of 0.4 µM Rab GGTase and 4 µM NBD-FPP 1 was added to the well followed by 0.5 µL 
of DMSO. The solution was mixed, shaken and incubated at 37°C for two minutes. 50 µL of 4 
µM Rab-7:REP-1 cocktail solution was added to the same well. The measurement was started 
immediately. 
 
Negative control for the bleaching of NBD-FPP 1 caused by DMSO during in vitro screeing 
(NCDMSO)  
 
50 µL of 0.4 µM Rab GGTase and 4 µM NBD-FPP 1 was added to the well followed by 0.5 µL 
DMSO. The solution was mixed, shaken and incubated at 37°C for two minutes. 50 µL buffer (50 
mM Hepes, 50 mM NaCl, 2 mM MgCl2, 5 mM DTE, 20µM GDP, 0.01% Triton X-100, pH7.2) 
was added to the same well. The measurement was started immediately.  
 
% of remaining enzyme activity was determined by the following equation: 
 
 
% of remaining enzyme activity = 
DMSONCPC
NCM
−
−
 
 
 
The IC50 was determined using non linear fitting curve based on the following equation with the 
program Grafit: 
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S
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where  y = enzyme inhibition = Vi/V0 (0 < y <100) 
                          x = inhibitor concentration  
              s = slope factor  
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AcOH    Acetic acid 
Ac2O    Acetic anhydride 
Aloc   Allyloxycarbonyl 
Boc    Tert-butyl carboxycarbonyl 
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Summary of the Dissertation 
 
 
The first half of this thesis is dedicated to dynamic and structural studies on the 
interaction between the C-terminus of the N-Ras protein with phospholipid membranes 
using solid-state NMR. In this work, three semi-synthetic N-Ras proteins were 
constructed by replacing the native palmitoyl chain with hexadecyl chain to give better 
stability. To facilitate the NMR study, the C-terminal N-Ras peptide was labeled in an 
alternating pattern with 13C and 15N to increase signal intensity and to suppress the 
background signals from the lipid matrix. Furthermore, the hexadecyl chain of the 
peptide was labeled with 2H to study the dynamic behavior of the lipid chain in the 
phospholipid membrane. The proteins were synthesized using the chemical biology 
approach, through ligation of chemically synthesized labeled C-terminal lipidated peptide 
with the non-labeled N-terminal water-soluble N-Ras protein. The ligation strategy was 
done through the Michael addition of cysteine at C-terminal of soluble N-Ras protein to 
MIC group of labeled lipidated peptide. This synthetic method gave moderate yield 
which were sufficient for the solid state NMR study.  
 
Different MAS NMR experiments such as Bloch-decay 13C experiment, CP 13C 
experiment, 13C-13C and 13C-1H correlation experiments were performed to establish the 
13Cα, 13Cβ, 13CO and 1Hα chemical shifts for the C-terminus of the membrane-bound N-
Ras protein. The chemical shifts for the C-terminus of the membrane-bound N-Ras 
proteins determined in the MAS NMR experiments provided the input parameters for the 
structural calculations. The program package TALOS was used for the empirical 
prediction of Φ and Ψ backbone structure of the membrane-binding domain of Ras from 
the isotopic chemical shifts.  
 
A simulated annealing protocol was used for structural calculations of the C-terminus of 
the membrane-bound lipidated Ras protein based on the torsion angle obtained from 
TALOS prediction. The computer simulation revealed that the global fold of the C 
terminus of the N-Ras protein in the membrane resembles a horseshoe. The membrane 
anchor of Ras has no regular α-helical or β-sheet motifs. The membrane topology of the 
protein is determined by hydrophobic interactions between the lipidated cysteine and 
hydrophobic side chains. The lipid-binding domain is linked to the GTP-binding N-
terminal region of the protein by a linker domain, which is putatively flexible. In contrast 
to H-Ras, there is currently no known structure (or no available structural studies) of the 
C-terminus of N-Ras. However, considering that there is 92 % sequence homology 
between H-Ras and N-Ras it can be assumed that these structures are very similar.  
 
Deuterium-labeled hexadecyl lipid chain at cysteine 181 of N-Ras protein was used to 
obtain the dynamic information of the N-Ras lipid chain’s interaction with phospholipid 
membranes. The dynamic results calculated from 2H NMR indicate that the chain inserts 
into the hydrophobic membrane interior with almost no energy cost, thereby largely 
retaining its configurational entropy and leaving the host matrix relatively unchanged. 
The dynamic properties of this lipid chain completely differ from that of the phospholipid 
membrane, registering a comparatively low order parameter and high motional amplitude 
inside the phospholipid membrane.  
 
The backbone and side chain molecular mobility of the seven isotopically labeled C-
terminal amino acids of Ras were studied by 13C MAS NMR spectroscopy. The order 
parameter of backbone and side chain was determined by 2D dipolar coupling chemical-
shift correlation experiment (DIPSHIFT). The order parameter of farnesylated cysteine 
186 is about 60% higher than that of hexadecylated cysteine 181. This observation 
suggested that the farnesyl modification of cysteine 186 is relatively rigid. In summary, 
the C-terminus of membrane-associated full length Ras protein shows a versatile 
dynamics. 
 
The second half of the thesis dealt with the identification of peptide inhibitors of Rab 
GGTase, which is an enzyme of Rab proteins. The lead compound of the peptide 
inhibitors is the natural product Pepticinnamin E. The synthesis of peptides library 
employing hydrazine linker has shown to be an efficient method to generate a large 
compound library in a short time. By using this traceless linker, around 380 derivatives of 
Pepticinnamin E were generated. Two oxidation cleavage methods were used to released 
the peptides from the solid support, namely, NBS/pyridine, and Cu(OAc)2/pyridine 
leading to different derivatives at C-terminus of peptides.   
 
Out of these 382 peptide inhibitors, 18 compounds have been found to be active against 
Rab GGTase, with IC50 values between 1 µM to 70 µM. From the structure activity 
relationship analysis, peptides which contain a long lipid chain at its N-terminus and a 
moiety with metal chelating ability at C-terminus were found to be the most active 
substrate to inhibit Rab GGTase activity.  
 
Three compounds, 59, 80 and 81, were found to have in vivo activity against Rab 
GGTase. These three peptides were subjected to selectivity screening to determine their 
potency against FTase, GGTase I and Rab GGTase. These three peptides have shown 
high inhibitory selectivity of Rab GGTase over FTase and GGTase I. Of which, 81, 
which consists of these two features mentioned above, has IC50 value of around 1 µM 
against the enzyme. The kinetic studies of 81 have revealed that the inhibitor is a non-
competitive inhibitor of Rab GGTase with respect to the lipid substrate and has a Kd 
value of around 600 nM.   
 
Zusammenfassung der Dissertation 
 
Der erste Teil der Dissertation widmet sich dem Studium von Struktur und Dynamik des C-
Terminus des N-Ras-Proteins in Phospholipid-Membranen mittels Festkörper-NMR-
Techniken. In dieser Arbeit wurden drei semi-synthetische N-Ras-Proteine konstruiert, bei 
denen die Palmitoylgruppe durch eine Hexadecyleinheit ersetzt wurde, um eine bessere 
Stabilität zu gewährleisten. Zur Verstärkung der NMR-Signale des Proteins und zur 
Unterdückung der Signale der Lipidmatrix, wurden mit  13C- und 15N-Isotopen angereicherte 
C-terminale N-Ras Peptide dargestellt. Darüber hinaus wurde die Hexadecylkette des Peptids 
mit 2H markiert, um Informationen über die Dynamik des Proteins in Wechselwirkung mit 
Phospholipid-Membranen zu erhalten. Im Sinne einer chemisch-biologischen Fragestellung 
wurden zunächst durch chemische Synthese isotopenmarkierte C-terminale Peptide dargestellt 
und diese dann biochemisch mit dem wasserlöslichen N-Ras Protein über eine MIC-Ligation 
verknüpft. Die hierbei erzielte moderate Ausbeute war ausreichend, um die folgenden NMR-
Studien durchzuführen. 
 
Um die chemischen Verschiebungen von 13Cα, 13Cβ, 13CO und 1Hα des C-Terminus von 
membran-gebundenen N-Ras zuzuordnen, wurden mittels direkt angeregte 13C-NMR 
Experiment, 13C-Kreuzpolarisationsexperimente, 13C-13C- und 13C-1H Korrelationations- 
experimente durchgeführt. Aus diesen Daten konnten mithilfe des TALOS-Programmpakets 
empirische Voraussagen der Phi (Φ)- und Psi (Ψ)-Rückgratstruktur der membranbindenden 
Domäne von N-Ras gemacht werden. 
 
Auf den TALOS-Voraussagen über den Torsionswinkel basierend, wurde ein Strukturmodell 
des membran-gebundenen lipidierten Ras-Poteins berechnet. Der C-Terminus des 
membrangebundenen Ras Proteins ähnelt in seiner Struktur einem Hufeisen. Der 
Membrananker von Ras verfügt nicht über reguläre α-helikale oder β-Faltblatt-Motive. Die 
Membrantopologie des Proteins ist bestimmt durch hydrophobe Wechselwirkungen zwischen 
dem lipidierten Cystein und hydrophoben Seitenketten. Die lipidbindende Domäne ist mit der 
GTP-bindenden N-terminalen Region des Proteins über eine Linker-Domäne verknüpft, die 
mutmaßlich flexibel ist. Im Gegensatz zu H-Ras existiert gegenwärtig noch keine Struktur des 
N-Terminus von N-Ras. Dennoch kann bei einer Sequenzhomologität von 92 % von einer 
hohen strukturellen Ähnlichkeit ausgegangen werden. 
 
Eine deuteriummarkierte Hexadecyl-Lipidkette an Cystein 181 von N-Ras wurde zur 
Gewinnung dynamischer Informationen über die Wechselwirkung von N-Ras-Lipidkette und 
Phospholipid-Membran eingesetzt. Aus 2H-NMR-Experimenten berechnete Ergebnisse zur 
Dynamik deuten darauf hin, dass sich die Kette in die Hostmembran einbaut, wobei die 
Konfigurationsentropie größtenteils erhalten bleibt und die Lipidmembran relativ unverändert 
bleibt. Die dynamischen Eigenschaften dieser Lipidkette unterscheiden sich jedoch 
vollständig von denen einer Phospholipid-Membran, da ein niedriger Ordnungsparameter und 
eine hohe Bewegungsamplitude innerhalb der Phospholipid-Membran berechnet wurden. 
 
Die molekulare Dynamik von Rückgrat und Seitenketten der sieben isotopen-markierten C-
terminalen Aminosäuren von Ras wurden mittels 13C-MAS-NMR untersucht. Hierbei wurde 
durch 2D DIPSHIFT-Experimente der Ordnungsparameter von Rückgrat und Seitenkette 
bestimmt. Für den Ordnungsparameter von farnesyliertem Cystein 181 wurde ein um etwa 
60 % höher Wert als für hexadecyliertes Cystein 186 gefunden, was für eine relative hohe 
Rigidität der Farnesylmodifikation von Cystein 186 spricht. Zusammenfassend lässt sich 
sagen, dass der C-Terminus von membranassoziiertem Ras-Protein eine vielseitige Dynamik 
aufweist. 
 
Die zweite Hälfte dieser Dissertation setzt sich mit der Identifikation von Peptidinhibitoren 
der Rab GGTase, einem Enzym der Rab-Proteine, auseinander. Als Leitstruktur für die 
Peptidinhibitoren dient der Naturstoff Pepticinnamin E. Es wurde gezeigt, dass die 
Festphasensynthese einer Peptidbibliothek unter Anwendung des Hydrazidlinkers eine 
effiziente Methode zur Herstellung einer großen Zahl von Substanzen in kurzer Zeit 
ermöglicht. Durch Nutzung dieses „spurlosen“ Linkers wurden etwa 380 Pepticinnamin-
Derivate dargestellt. Zur Abspaltung der Peptide von der festen Phase wurden zwei 
Oxidationsmethoden angewandt, die zu unterschiedlichen Derivaten am C-Terminus der 
Peptide führten: NBS/Pyridin und Cu(OAc)2. 
 
Bei 18 dieser 382 Peptidinhibitoren wurde eine inhibitorische Aktivität bei der Rab GGTase 
gefunden; in der Folge wurden IC50-Werte zwischen 1 µM und 70 µM für diese Peptide 
bestimmt. Eine Analyse der Struktur-Aktivitäts-Beziehung ergab, dass Peptide mit langer 
Lipidkette am N-Terminus und Metall-chelatisierenden Eigenschaften am C-Terminus die 
höchste inhibitorische Aktivität bei Rab GGTase aufweisen. So wurde für die Verbindung 81, 
die diese beiden strukturellen Bedingungen erfüllt, ein IC50-Wert von etwa 1 µM gegen das 
Enzym bestimmt. 
 
Drei Verbindungen, 59, 80 und 81, zeigten in vivo – Aktivität gegen Rab GGTase in der 
Zelle. In einem Selektivitäts-Screening zeigten diese Peptide eine hohe inhibitorische 
Selektivität gegen Rab GGTase im Vergleich zu FTase und GGTase I. Kinetische 
Untersuchungen mit 81 zeigen eine in Bezug auf das Lipidsubstrat nicht-kompetitive 
Inhibierung der Rab GGTase mit einem KD-Wert von etwa 600 nM.  
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